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 Abstract 
DNA still represent the main target of the traditional “cytotoxic 
chemotherapy” in the treatment of cancer. A particular interest has been awarded to 
the DNA Topoisomerases (topos), essential enzymes that regulate the topological 
state of DNA during cellular processes such as replication, transcription, 
recombination, and chromatin remodeling. The ability to interfere with these 
enzymes or generate enzyme-mediated damage is an effective strategy for cancer 
therapy and DNA topos (I and II) proved to be excellent targets of clinically 
significant classes of anticancer drugs. In this connection, I performed the synthesis 
of a series of benzo- and pyrido-thiopyrano indoles, characterized by a planar mojety 
and pendant protonable dialkylaminoalkyl side chains, as new potential DNA 
intercalators and Topoisomerases inhibitors. The antiproliferative activity of the 
novel derivatives, as well as their ability to intercalate into the DNA and eventually 
inhibit the Topoisomerases were evaluated along the course of the thesis by a 
research group of the Faculty of Pharmacy of the University of Padua.  
A more recent and alternative strategy for the treatment of cancer is 
represented by the so called “biological therapy”, which is based on the disproportion 
of the signaling pathways controlling growth and differentiation, between normal and 
cancer cells. In particular, the molecular basis of tumour angiogenesis, the process of 
new vessel formation, has been extensively studied, and the Vascular Endothelial 
Growth Factor (VEGF) pathway has emerged as one of the most important positive 
modulators of this process. The founding that expression of VEGF and of its 
receptors correlates with the degree of vascularization of many experimental and 
clinical tumours led to the rational design and development of agents targeting this 
pathway, both selectively and with a multi-target action involving other tyrosine 
kinases responsible for tumour pathogenesis. In this regard I synthesized a series of 
benzo- and pyrido-thiopyrano-fused pyrimidines as new potential VEGFR inhibitors. 
Then the ability of the novel derivatives to inhibit the kinase activity of the VEGFR-
2, as well as their cytotoxic effect were determined by the research group of the 
University of Padua. Moreover, as a part of the collaboration with the University of 
Valencia, I tested the anti-angiogenic activity of some of the synthesized compounds 
in the ex-vivo “rat aortic ring assay”.  
 My collaboration with the University of Valencia also regarded the 
partecipation to an extensive project on the study of the mechanism of action of 
Carvedilol and the Vasodilating Beta-Blockers. In particular I focused my studies on 
the evaluation of the relationship between adrenoceptors and angiogenic growth 
using the “rat aortic ring assay”, on the analysis of the changes in the ARs gene 
expression induced by Carvedilol and/or by other α/β ARs agonist, by RT-PCR, and 
finally on the analysis of intracellular signals coupled to α/β ARs (ERK 1/2 
activation), by western blotting. 
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1. Cancer: general aspects 
 
 
1.1 Statistics1-3 
 
The global burden of cancer continues to increase, largely because of the 
aging and growth of the world population, alongside an increasing adoption of 
cancer-causing behaviors, particularly smoking, in economically developing 
countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer 
cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 
56% of the cases and 64% of the deaths occurred in the economically developing 
world. 
 
Figure 1. Worldwide cancer incidence (red) and mortality (blue) rate in male and female 
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Figure 2. Estimated age-standardized incidence (A) and mortality (B) rate, per 100,000. All cancer 
excl. non-melanoma skin cancer: both sexes, all ages (GLOBOCAN 2008) 
 
 
 
A) 
B) 
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Cancer causes about a quarter of all deaths in developed countries, only 
slightly less than cardiovascular diseases. The incidence started to increase early in 
the 20th century owing partly to increasing longevity and reduction in deaths from 
other serious illnesses, which gives tumours more time to develop. One in three 
people will develop cancer at some time. Part of the increase is also undoubtedly due 
to environmental features of industrialized life, such as atmospheric pollution, 
smoking and diet. There are wide variations in the incidence and prevalence of 
cancer for different anatomical sites, sexes, ages, and racial, ethnic and geographical 
groups. 
Cancer incidence generally increases with age. For certain tumours in the 
very aged the prevalence can be very high, e.g. >50% for prostatic carcinoma in 
males over 80 years (although much remains asymptomatic), but less for breast 
cancer in females. However, some tumours are more common in childhood, such as 
leukaemia and tumours of the CNS. 
Breast cancer is the most frequently diagnosed cancer and the leading cause 
of cancer death among females, accounting for 23% of the total cancer cases and 
14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 
17% of the total new cancer cases and 23% of the total cancer deaths. 
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Different nationalities have strikingly different incidences for certain 
tumours. Stomach cancer is far more common in Japan and Chile than in the USA or 
Israel, while the incidence of colon cancer is particularly low in Asia and Africa. 
Jewish women, nuns and virgins have a low incidence of cervical cancer. Skin cancer 
is common in Australia. Prostate cancer is highest among Africans, lowest among 
East and South Asians. On the other hand, the prevalence of leukaemia is remarkably 
constant between nations. Although genetic factors may explain some of these 
variations, environmental associations are often found to be more important. 
Furthermore, it has been established that cervical cancer is strongly associated with 
the infection with human papilloma virus (HPV). 
Changes in incidence and mortality over time reflect a combination of 
changes in longevity, detection rates, treatment success and exposure to 
environmental risk factors. According to the GLOBOCAN 2008 predictions, despite 
the enormous efforts and the remarkable improvements in the overall cancer 
survival, e.g. breast cancer in women and gastrointestinal cancers in men and 
women, the future burden of cancer is expected to increase, coming to an incidence 
of about 20 million cases in 2030 (Figure 4) 
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Figure 4. Estimated predictions of global cancer incidence (red) and mortality (blue) from 2008 to 
2030. All ages, all cancer types and both sexes are considered. (GLOBOCAN 2008) 
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1.2 Cancer Pathology 
 
Cancer is the general term for a group of disorders caused by the abnormal 
and unrestricted growth of cells. The term derives from the crab-like histological 
appearance of an invasive tumour, which seems to extend claws or tentacles into 
surrounding tissue. Each primary tumour derives from a single aberrant cell 
following mutation. The term neoplasm („new growth‟) describes this tendency to 
excessive, uncontrolled growth. It is synonymous with the less technical „tumour‟ 
(swelling). Benign tumours enlarge but do not invade surrounding tissue. They are 
generally much less dangerous than malignant tumours, which do invade local 
tissues and also spread to distant sites (metastasis). The nomenclature of cancer is 
complex and inconsistent. It attempts to classify three characteristics, all of which 
have a bearing on prognosis and treatment:  
- the tissue of origin (in the histological sense)  
- the organ of origin  
- whether it is benign or malignant. 
Malignant tumours are predominantly carcinomas (epithelial origin, e.g. 
adenocarcinoma), sarcomas (connective tissue, e.g. osteosarcoma) or leukaemias 
(haematological). Some examples are reported in Table 1. 
 
- Aetiology: 
Any theory of the causation of cancer must account for both genetic and 
environmental factors. Almost certainly, cancers form a heterogeneous group of 
diseases with multifactorial causes. Individuals may have an inherited predisposition, 
but this may never be expressed unless an appropriate combination of environmental 
triggers is met. There are also several steps between initiation and clinical disease, 
and arrest at any of these will prevent the tumour from developing. The current 
consensus is that, although DNA changes are involved in all cancers, hereditary 
factors contribute only about 20% to the overall causation, while environmental 
factors contribute 80%. Despite the tremendous efforts to identify specific 
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carcinogenic factors, considerable doubt remains about the extent of their 
contribution. Chemicals seem to be the chief culprits. Actually smoking is by far the 
largest single contributor, although a wide variety of industrial carcinogens have also 
been positively identified. Dietary factors are increasingly seen to be important, 
although the specific carcinogenic constituents remain largely unknown. Drugs may 
also cause cancer in a number of ways. Hormones, especially the sex hormones (e.g. 
oestrogens), may encourage tumours in hormone-dependent tissues. Finally the 
possible contributions of immunological factors, trauma (e.g. local irritation) and 
psychosocial factors are unknown. 
 
Table 1. Classification and nomenclature of neoplasms, with common examples. 
Tissue and organ of origin 
Examples 
Benign Malignant 
Haematopoietic Polycythaemia - 
Lymphoreticular   
   Granulocytes - Myelocytic leukaemias 
   Limphocytes - Limphocitic leukaemias 
   Limphoyd tissue - Lymphomas, e.g. Hodgkin’s L. 
   Plasma cells - Myelomas 
Connective tissue/mesenchyme   
   Bone Osteoma Osteosarcoma 
   Fatty tissue Lipoma Liposarcoma 
   Mesothelium Mesothelioma Malignant Mesothelioma 
Epithelial tissue   
   Glandular Adenoma Adenocarcinoma 
   Squamous Squamous papilloma Squamous cell carcinoma 
   Melanocytes Moles Malignant melanoma 
Nervous tissue   
   Meninges Meningioma Meningiosarcoma 
Embryonic, germinal Teratoma Testicular teratoma, 
Choriocarcinoma, 
Nephroblastoma 
Usually, but not universally, malignant tumours end in ‘-carcinoma’, ‘-sarcoma’ or ‘-aemia’, while 
benign tumours usually end simply in ‘-oma’. For historic reasons there are a number of exceptions, 
e.g. melanoma and lymphoma are malignant (and so are usually explicitly so described), while 
neither anaemia nor granuloma is a tumour at all. 
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- Pathobiology: 
During the growth phase of an organism, cell proliferation clearly exceeds 
cell death, but subsequently cell numbers remain relatively stable throughout mature 
life. However, tissues retain the ability to proliferate in response to either 
physiological demands or losses (e.g. bone marrow, gut lining) or pathological ones 
(e.g. injury). Thus, in most tissues there is a reservoir of stem cells, which remain 
dormant until their division is needed to provide either replacement stem cells or 
more functional differentiated (end) cells. Cancer involves uncontrolled division and 
impaired differentiation, and because stem cells are both incompletely differentiated 
and still capable of division, neoplasms generally derive from stem cells. Stem cells 
need a signal to tell them when to divide and to stop, and the daughter cells need to 
know whether or not to differentiate. This is accommodated by their responding to a 
complex network of cytokines with growth stimulant or growth inhibitory properties. 
Some cells release autocrines that act on receptors on their own surfaces. Numerous 
growth factors specific for particular cell types are known, e.g. platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF), epoetin, thymopoietin, 
granulocyte colony stimulating factor (G-CSF). Some tumours also secrete their own 
transforming growth factors (TGF), which closely resemble EGF. Generally these 
are growth stimulants (mitogenic) and they may be secreted in excess in some 
cancers. Other factors are growth inhibitors and are presumed deficient in cancer. 
There are also more general, systemic endocrine stimulants such as somatotropin 
(growth hormone) and the adrenocorticoids.  
Insensitivity to local growth control mechanisms has long been recognized as 
a characteristic feature of neoplastic tissue. This breakdown in control may involve 
abnormal secretion of growth factors, an abnormality in growth factor receptors, or 
abnormal signaling between the cell surface receptors and nuclear receptors coding 
for growth or differentiation. It is now known that the genes coding for mitogenic 
proteins or their receptors can become expressed inappropriately (amplified). They 
are known as cellular oncogenes: 
• Human oncogenes are normally present but repressed. 
• When activated by the need for proliferation, they code for growth factors, or 
growth factor receptors, or other mitogenic promoters. 
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• These factors are essential for a cell‟s entry into the cell cycle and movement 
through it as a prelude to cell division. 
• Expression of oncogenes is strictly controlled and turned off when no further 
growth is required. 
• „Anti-oncogenes‟ (tumour suppressor genes) may be expressed to control 
excessive cell growth. 
 
However, neoplastic transformation may result in abnormal proliferation by one or 
more of the following mechanisms: 
• A carcinogen causes the inappropriate expression of a human oncogene, often 
by mutation of a controlling gene, e.g. a repressor or de-repressor gene. 
• Viral oncogenes mimic activated human oncogenes. 
• An anti-oncogene (or tumour suppressor gene) malfunctions through 
mutation, permitting neoplastic transformation. 
 
- Tumor Growth 
As a tumour grows, its bulk puts pressure on local structures such as nerves, 
blood vessels, the gut lumen, etc. with predictable symptomatic consequences. 
Benign tumours tend to be self-contained and have definite margins, so this is their 
main adverse effect. Conversely, malignant tumours, partly because of their 
insensitivity to the presence of other cells and also because of a lower adhesiveness 
to their basement membrane, are far more invasive. They expand in a very 
disorganized way, their margin is indistinct and they cause considerable disruption to 
their environment. This process is aided by the secretion of proteases (proteolytic 
enzymes such as matrix metalloproteinase) from tumour cells, which facilitate their 
passage through basement membranes and into the extracellular matrix of local 
connective tissue.  
Migration of neoplastic cells away from the primary tumour to distant sites is 
the key stage in malignancy. Most morbidity and almost all mortality from cancer is 
associated with metastatic deposits. This process probably starts very early in the 
natural history of a tumour, and perhaps has already begun in some 50% of all cases 
at diagnosis. There are two important stages: escape from the primary cell mass by a 
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loss of adhesion, as with invasion; and arrest at a distant site. The most important cell 
adhesion molecules (CAMs) are cell surface-transmembrane molecules known as 
cadhedrins. Possibly reduced activity of these, owing to gene down-regulation, 
allows some cells to escape. Migrating cells then become trapped by other adhesion 
receptors called integrins, which are normally involved in localizing cells involved in 
defence mechanisms, e.g. leucocytes. Metastases usually grow considerably faster 
than their parent primary tumour, partly because they are smaller and thus better 
perfused. In patients who have been exposed to previous chemotherapy they also 
tend to be more chemoresistant. 
  
1.3 Current therapies4-7 
 
The method of treatment will largely be determined by a realistic assessment 
of the therapeutic goal. The usual modes are: 
• Surgery (excision of primary tumour). 
• Radiotherapy. 
• Pharmacotherapy (cytotoxic chemotherapy, endocrine therapy, biological 
therapy, immunotherapy, gene therapy). 
 
Surgery is usually the most appropriate treatment for solid tumours in sites 
where it would neither threaten a vital function nor be too mutilating, and where 
reconstruction is possible. However, surgery may inadvertently facilitate metastatic 
spread, displacing tumour cells and liberating them into the local circulation or 
lymph. Radiotherapy is suitable as primary therapy in some local tumours when 
surgery is inappropriate. Radiotherapy may be administered externally as high-
energy ionizing radiation, or systemically by radioisotope administration, e.g. oral 
radioiodine [
131
I] for thyroid tumour, or implantation, e.g. intrauterine radiocaesium 
[
137
Cs] needles for cervical cancer. The ideal antineoplastic drug would have 
completely selective toxicity for neoplastic cells, just as antimicrobial agents are 
toxic to microbial but not human cells. Unfortunately, save for one minor exception 
(the utilization of crisantaspase by some leukaemic cells), human neoplastic cells do 
not differ in any qualitative biochemical way from normal cells.  
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Thus other, usually quantitative, differences between normal and neoplastic 
tissue have to be exploited. These occur in several broad areas: 
• Neoplastic tissues have different growth parameters, which are amenable to 
cytotoxic intervention. 
• The growth of some neoplasms is sensitive to natural hormones and other 
growth factors. 
• Cell signal transduction pathways are activated to a different (greater or 
lesser) degree in neoplastic cells; these processes can be selectively modified 
by biological agents including cytokines. 
• Genomic expression may be inappropriate in neoplastic cells, making them 
targets for gene therapy and biological agents that interfere with gene 
expression. 
• Neoplastic cells may express a different immunological phenotype, making 
them a target for immunological agents. 
 
It is usual to distinguish the traditional relatively unselective cytotoxic agents, 
which act on nucleoprotein within the nucleus, from newer biological agents that act 
primarily on cell signaling and cytokines within the cytoplasm or on the cell surface. 
The former kill cells, hence the name cytotoxic; the latter tend to be cytostatic, 
inhibiting further growth but not necessarily killing the cell. 
 
- Cytotoxic Chemotherapy 
Two theoretical principles underlie cytotoxic therapy: 
• Tumours are often more sensitive to agents that interfere with the 
biochemistry of cell division, a greater proportion of neoplastic cells being 
affected than those in normal tissue. 
• Tumour tissue usually does not recover as rapidly as normal tissue from such 
interference. 
 
There are two important aspects of the action of the cytotoxic drugs: the 
biochemical mode of action (pharmacological classification) and the cell cycle phase 
or phases when active (cytokinetic classification) (Table 2 and 3). Almost all 
cytotoxic drugs act within the nucleus to kill cells by interfering with the production 
or structure of nucleic acid, or occasionally protein. Cell death following exposure to 
cytotoxic action (and to radiation) is due to the triggering of apoptosis. 
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Table 2. Biochemical mode of action of some cytotoxic drugs 
Action Group Examples 
Alkylating agents (cross-link DNA) Alkyl sulphonate Busulfan 
 
Chloroethylamine Chlorambucil, Melphalan, 
Cyclophosphamide, Ifosfamide 
 Nitrosourea Lomustine, Carmustine 
 Heavy metal agent Cisplatin, Carboplatin, Oxaliplatin 
Antimetabolites (impair nucleotide 
base incorporation into DNA/RNA) 
Purine analogue Mercaptopurine, Tioguanine, 
Cytarabine, Fludarabine, Cladribine 
 
Pyrimidine analogue Fluorouracil, Capecitabine, 
Gemcitabine, Tegafur 
 Antifolate Methotrexate 
 
Thymidylate inhibitor Pemetrexed, ralitrexed 
Topoisomerase inhibitors Camptothecin Topotecan, Irinotecan 
 
Anthracycline antib. Doxorubicin, daunorubicin, 
epirubicin, mitoxantrone 
 
Podophyllotoxin Etoposide, teniposide 
Miscellaneous DNA-RNA inhibitors  Dactinomycin, hydroxycarbamide 
DNA scission  Bleomycin 
Mitotic spindle inhibitors (tubulin-
binding) 
Vinca alkaloid Vincristine, vinblastine 
 
Taxane Paclitaxel, docetaxel 
Precursor depleter 
Enzyme inhibitor Crisantaspase (asparaginase) 
Photosensitizer 
 Porfimer, temoporfin 
Uncertain action Corticosteroid
(a)
 Prednisolone 
(a) Only cytotoxic in very high doses, possibly by protein synthesis inhibition; lympholytic in 
leukaemias. Drugs may act by several mechanisms; it is not always certain which action is responsible 
for clinical effect. 
 
Table 3. Cytokinetic classification of cytotoxic drugs. 
Phases in which active Class Examples 
Resting (G0) plus all cycling cells Non-specific (Class I) Chlormethine 
   
Cycling cells only   
   • certain phases only Phase-specific (Class II) Antimetabolites, Vinca alkaloids, 
Podophyllotoxin, 
Hydroxycarbamide, Crisantaspase, 
Taxanes, Bleomycin 
   • all phases Cycle-specific (Class III) Alkylating agents, Anthracyclines, 
Platinum agents, Corticosteroids(?) 
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- Biological Therapies 
Following discoveries in molecular biology about the control of cell cycle 
events it became clear that certain signalling pathways controlling growth and 
differentiation were excessively activated in various tumours. Although these 
pathways are part of normal cell growth, and as such are to a certain extent present in 
all dividing cells including in the bone marrow, they are relatively more prominent in 
neoplastic cells. This is analogous to the partial selectivity conferred on cytotoxic 
drugs by the higher growth fractions or reduced recovery rates of tumour masses. 
However, with signalling the disproportion between normal and neoplastic cells 
seems to be considerably greater, resulting in greater potential selectivity. To further 
enhance the targeting, many of the agents developed are humanized monoclonal 
antibodies aimed at specific elements of these signalling processes. Other 
characteristics of tumours, such as their propensity to migrate and to encourage 
neovascularization, are also controlled by similar signalling mechanisms. Biological 
therapies offer an increasingly promising line of approach because of the possibility 
of attaining the holy grail of cancer therapy, i.e. agents that exclusively target 
neoplastic cells (Table 4). 
Table 4. Properties of some biological antineoplastic agents 
Molecular Target Class Receptor Drug Action Indication 
Interleukin  Aldesleukin Cytostatic Renal cell 
carcinoma 
Cytokin 
 Interferon α,β Cytostatic Lymphoma, 
leukaemia 
     
Growth factor Inhibitor VEGF Bevacizumab Cytostatic Colorectal 
     
Growth factor receptor blocker HER2 Trastuzumab Cytostatic Breast cancer 
 EGF Cetuximab Cytostatic? Colorectal 
 Retinoid X Bexarotene Cytotoxic Lymphoma 
     
Proteosome Inhibitor  Bortezomib Cytotoxic Myeloma 
     
Protein Kinase Inhibitor BCR-ABL Imatinib Cytotoxic Chronic myeloid 
Leukaemia 
     
Limphocytolytic  Rituxumab, 
alemtuzumab 
Cytotoxic Lymphoma, 
Leukaemia 
VEGF, vascular endothelial growth factor; EGF epidermal growth factor; HER2, human epidermal 
growth factor receptor 2; BCR-ABL, abnormal tyrosine kinase fusion protein, found in chronic 
myeloid leukaemia. 
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- Endocrine Therapy 
The growth of certain tissues, especially the sex organs, is hormone-
dependent. In effect these hormones play an analogous role to growth factors in 
cellular growth. By manipulating hormone levels the growth of tumours derived 
from such organs can be reduced, provided that they are still sufficiently 
differentiated to respond, i.e. they retain hormone receptors. The effect is cytostatic, 
suppressing further growth rather than killing cells. Thus, although endocrine therapy 
can rarely be curative it can provide valuable remissions or can be combined with 
other treatments to improve their effectiveness. 
 
- Immunotherapy 
Neoplastic transformation involves genetic changes. This change in the 
genotype, as well as being directly responsible for the changes in growth pattern, 
may cause tumour cells to differ immunologically from normal cells. For example, 
they may express abnormal or „nonself‟ surface antigens or fail to express „self‟ 
antigens. Indeed, many potential tumours may normally be aborted by immune 
mechanisms. The immune system could be manipulated either by actively 
stimulating it or by developing immunoactive substances such as antibodies or 
immune cells specific for tumour cells. One radical approach being investigated is to 
infect tumour cells with „oncolytic‟ viruses that selectively damage neoplastic cells 
rather than normal ones, owing to the defective defences and repair mechanisms of 
the former. A vaccine that activates a cell surface molecule on breast cancer cells, 
making them more susceptible to immune attack, is being investigated, while a 
vaccine against human papilloma virus (HPV), which is responsible for much 
cervical cancer, has recently become available. Other approaches are currently under 
study. 
 
- Gene therapy 
This involves a fundamental attempt to change the actual genes responsible 
for the neoplastic process. Cancer is among the first areas of application of this 
rapidly developing technology, both in facilitating immunotherapy and in changing 
the neoplastic genome. Cells are being experimentally implanted with a variety of 
different genes, based on the observation that neoplastic cells may have escaped 
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immunosurveillance because mutation has prevented them from expressing 
histocompatibility (HLA) antigens. Some tumour cells are implanted (transfected) 
with appropriate HLA gene sequences and then injected into the patient, to enable a 
specific immune response to be mounted against the tumour phenotype. More direct 
genetic manipulation involves either inserting normal tumour suppressor genes or 
disabling the oncogene responsible for the tumour. An ingenious gene therapy 
technique for drug delivery is to use a so-called „suicide gene‟ or „Trojan horse 
vector‟. Certain tumours overexpress specific abnormal gene products, e.g. AFP in 
liver cancer. The promoters for some of these genes have been isolated and coupled 
to promoters for genes expressing enzymes that activate a cytotoxic drug. These 
enzymes are then preferentially activated in tumour cells. Most of these therapies are 
still experimental. 
 
Table 5. Possible causes of resistance to cytotoxic chemotherapy. 
Extracellular Factors Drug interaction 
 Incorrect/inappropriate dosage schedule 
 Immune clearance of antigenic drugs 
 Poor access to tumour; sanctuaries 
 Poor penetration of tumour 
 Low tumour growth fraction, large G0 
compartment 
Intracellular biochemical factors  
   Quantitaive Reduced cellular uptake 
 Increased efflux pump activity 
 Reduced prodrug activation 
 Increased activity in affected pathway 
 Alternative pathway used (block bypassed) 
 Increased receptor specificity 
 Increased repair of DNA damage 
   Qualitative Production of dummy or excess substrate 
 Production of drug inhibitors 
 Drug inactivation 
 
- Drug Resistence 
Although the lack of biochemical specificity is one major drawback with 
cytotoxic chemotherapy, the development of resistance (i.e. an unusually low tumour 
responsiveness) is equally important. In general, resistance is due either to 
extracellular circumstances that limit drug access to the tumour, or to intracellular 
pharmacological or biochemical factors that antagonize cytotoxic action (Table 5).  
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Recent studies on the p53 gene have suggested that treatment resistance may 
in some cases be associated with defects in this gene, possibly because cytotoxic 
drug-induced apoptosis is prevented. 
Resistance to a range of structurally unrelated cytotoxic agents, multiple 
drugs resistance (MDR), is quite common and is an extremely serious constraint on 
chemotherapy. The recent discovery of a non-specific membrane efflux pump for 
toxins (known as p-glycoprotein or MDR protein) may provide a clue. This appears 
to pump drugs such as etoposide, vincristine and the anthracyclines out of cells. The 
mdr gene coding for this pump has been found in normal cells, and it is presumably 
expressed when protection is needed from environmental toxins. In multiresistant 
tumours it may be over-expressed. 
 
1.4 Focus of the synthetic work 
The work I performed during my thesis in the department of Pharmaceutical 
Chemistry of the Faculty of Pharmacy, University of Pisa, was devoted to the 
synthesis of new polycyclic systems with potential antitumor activity. The novel 
synthesized molecules, according to target and structure, can be divided in two main 
different classes. 
 The first class includes tetracyclic compounds, belonging to the “traditional” 
cytotoxic chemotherapy, which interact with DNA, by an intercalative 
binding mode, and eventually inhibit the DNA Topoisomerase I and/or II. 
(Chapter 2) 
 The second class includes compounds belonging to the “biological therapy” 
category. In this case the target was the growth signals that are over-activated 
in tumor cells, and in particular the vascular endothelial growth factor 
receptors (VEGFRs). (Chapter 3). 
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2.1 DNA Recognition 
 
2.1.1 Background and significance 
 
Double helical DNA consists of two complementary, antiparallel 
polydeoxyribonucleotide strands associated by specific hydrogen bonding 
interactions between nucleotide bases. The sugar phosphate backbone of paired 
strands defines the helical grooves, within which the edges of the heterocyclic bases 
are exposed. The biologically relevant B-form structure of the DNA double helix is 
characterized by a shallow, wide major groove and a deep, narrow minor groove 
(Figure 1). The chemical features of the molecular surfaces presented by a given 
DNA sequence in either groove are distinct, forming the basis for molecular 
recognition by small molecules and proteins. 
 
 
Figure 1. Structural features of the DNA double helix. (A) Molecular rendering of B-form DNA double 
helix. Sugar phosphate backbones of complementary nucleotide strands are shown in red and 
orange. (B) Chemical features and electropotential surfaces of Watson-Crick base pairings. 
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Understanding the functional significance of genome sequence variation and 
organization, as well as the complex molecular interplay between various genes and 
gene products, remain central questions for human medicine. Designed small 
molecules capable of sequence specific recognition of predetermined DNA 
sequences are powerful tools that can be directed toward interpreting the human 
genome, and these molecules may ultimately prove valuable as therapeutic agents.
1
 
Actually DNA-interacting small molecules are of exceptional importance in 
medicine, accounting for a significant portion of all anticancer drugs.
2,3
  
Since the clinical introduction of mustards in the 1940s and Sidney Farber‟s 
use of the natural product actinomycin D (1954), when the mechanism of actions was 
unknown, much progress has been made toward understanding small molecule-DNA 
recognition. It was the landmark elucidation of the DNA structure by Watson and 
Crick that allowed the seminal conceptualization of DNA intercalation by Lerman in 
1961
4
 and the elucidation of the origin of actinomycin‟s properties.5,6 In the 
subsequent 50 years, extensive studies have defined a number of small molecule 
DNA binding modes and recognition paradigms
7
. The cumulative understanding of 
ligand-DNA recognition and the availability of advanced tools have provided the 
foundation for the design of DNA and RNA targeting drugs, a strategy intuitively 
appealing in this postgenomic era. Actually a large percentage of the 
chemotherapeutic anticancer agents currently used belong to the category of DNA-
binding drugs
8
.  
Broadly speaking, small molecules that associate with DNA fall into two 
categories: those that intercalate between base pairs, and those that are found in the 
grooves, particularly the minor groove, of the double helix. Binding may involve the 
formation of covalent links between reactive groups in the ligand and the DNA, or 
recognition may be entirely through non-covalent interactions (Figure 2). Anyhow 
the effects of small organic compounds that non-covalently bind to nucleic acids are 
structural modifications that can lead to functional changes, often to the inhibition of 
transcription and replication processes, culminating in cellular death. Accordingly, 
DNA binding compounds have potential applications as anti-cancer and anti-viral 
agents.  
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Figure 2.
9
 Stereo views of the X-ray structure of three classical DNA-binding drugs (orange) in 
complex with their target DNA (blue), with the structures of the corresponding drug alongside. (A) 
Intercalator ellipticine 1 (PDB access code 1Z3F). (B) Minor groove binder distamycin 2 (PDB access 
code 2DND). (C) Covalent cross-linker cisplatin 3 (PDB access code 1AIO). 
C 
B 
A 
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2.1.2 Major and Minor groove binding 
Although not yet heavily represented with drugs in clinical use, minor groove 
binding molecules are thought to hold the most promise for de novo design
10-12
. The 
structural features found to be most critical to small molecule recognition are groove 
width, groove depth, floor functionality, and electrostatic potential, and are all 
sequence dependent. Minor groove widths vary from 3-4 Å for AT-rich tracts to over 
8 Å for GC tracts. Groove depth is more shallow for GC sequence than for AT tracts 
due to the presence of the G exocyclic C2-amine. A compensating feature of this 
groove floor functionality is the nucleophilic character of the G C2-amine (an 
alkylation site) and the additional opportunity it provides for recognition through H 
bonding. In contrast to intercalation, where compound binding induces a large 
change in DNA conformation, minor groove binding is characterized by little or no 
apparent DNA distortion and often occurs with induced changes in the bound 
compound conformation. Distamycin and netropsin exemplify a large class of minor 
groove binding molecules (Figure 3).  
 
Figure 3. Molecular structure of the minor groove binders Distamycin and Netropsin. 
 
They are characterized by repeating pyrrole subunits connected by amide 
bonds and usually terminate with one or more positively charged (protonated) 
nitrogen atoms. They were among the first compounds that displayed selectivity for 
AT sequences, and it is their characterization that provided the foundation for much 
of what we now understand about minor groove binding selectivity and affinity.
11-14
 
The origin of their binding selectivity, often referred to as “shape-selective binding”, 
entails preferential binding in the narrower, deeper AT-rich minor groove, where the 
stabilizing van der Waals contacts are optimized. Further stabilizing the complex 
Distamycin A Netropsin 
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formation are accommodated H bonds of the linking amides with the floor base pairs 
and stabilizing electrostatic interactions of the terminal protonated amines.
15
 
Although general aspects of recognition such as the matching of electrostatic 
potential and shape complementarity are well understood and can explain, for 
example, why netropsin binds better to AT-rich sequences than GC-rich ones, why 
this ligand prefers the sequence ATTTA over ATTAT
16
 is much harder to explain. A 
major reason for this is that the binding of ligands to the minor groove of DNA 
appears to be mainly entropy-driven
17
 and our ability to accurately predict entropic 
terms from simulation data remains limited.
18
  
Despite the extensive studies with distamycin, it was not until 1989 that the 
discovery was made that it can bind in a cooperative 2:1 as well as 1:1 complex with 
DNA
19
. The impact of this observation on synthetically designed agents (hairpin 
polyamides) has been remarkable. When this binding mode was recognized, the 
expanded groove width requirements could be combined with ongoing design 
modifications used to extend the binding recognition to a GC base pair (lexitropsins) 
to provide linked hairpin polyamides capable of reading specific DNA sequences
13
. 
Another well studied structure is that of the natural duocarmycins (e.g. 
Duocarmycin SA, Figure 4), exceptionally potent antitumor agents that derive their 
properties through a sequence selective minor groove alkylation
20
. 
 
 
Figure 4.
20
 Molecular structure of Duocarmycin SA and models Illustrating the alkylation of (+)-
duocarmycin SA (left) and (−)-duocarmycin SA (right) 
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Not only they have been shown to exhibit an AT-rich binding selectivity like 
that of distamycin (shape selective binding), but superimposed on this binding 
selectivity is a shape-dependent catalysis,
21,22
 which also occurs preferentially in the 
narrower, deeper AT-rich minor groove. This findings led to the design of synthetic 
analogs including adozelesin, bizelesin, and carzelesin which progressed into clinical 
trials.  
Other extensively studied structures include quinolinium quaternary salts
23
 
and Hoechst 33342,
24
 but few, if any, new classes of compounds in these categories 
have been identified and reported. Actually although some 300 structures of ligand-
DNA or RNA complexes have been deposited in structural databases since the 1 
January 2004, most of these consist of previously studied compounds in complex 
with other DNA sequences, or represent new derivatives of well-known leads. This is 
especially true for the major groove binders. 
 
DNA major groove binding has not been exploited with small molecules or 
natural products to the same extent as the minor groove. This is surprising since the 
major groove contains more H-bond donor and acceptor sites and consequently more 
information. It has been suggested that the wider major groove provides a much 
larger, shallower binding pocket less effective for small molecule binding than the 
narrower, deeper minor groove.
7
 Most such compounds bind by intercalation and 
make further H-bond contacts in the major groove. 
 
2.1.3 Intercalation 
Lerman‟s demonstration that acridine dye could insert or intercalate between 
DNA base pairs, spawned a vast literature on intercalators with a variety of 
molecular thicknesses including certain highly potent and effective drugs as well as 
certain carcinogenic compounds. The initial studies on aminoacridines led to the 
observation of physical changes in DNA including changes in DNA X-ray diffraction 
patterns, an increase in viscosity, and the lowering of the sedimentation coefficient. 
This physical distortion of DNA has become the hallmark of intercalation, of which 
the extension of the double helix and its local unwinding at the site of binding are 
most prominent.  
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The connection between intercalation and the structural nature of the DNA 
distortion provided the basis for the correlation between simple intercalation 
(misrecognized as a base pair) and mutagenic potential and brought to preeminence 
DNA targeted chemotherapy.  
An extensive range of natural and synthetic products bind to DNA with 
intercalation
25
 and even those ligands categorized as minor or major groove binders 
are often further stabilized by intercalation of a pendant chromophore or quinone. 
The structural features that drive intercalation and the selectivity of binding, although 
appearing fairly simple, are complex and have been the subject of extensive 
studies.
7,25,26
 The major driving forces are thought to be π-stacking and stabilizing 
electrostatic interactions, where the chromophore seeks maximum overlap with the 
flanking DNA base pairs (parallel intercalation). However, a number of 
perpendicular intercalators (e.g., anthracyclines) are known that thread end to end 
through DNA from the minor to major groove. Once the ligand is intercalated 
hydrogen-bonding, van der Waals and hydrophobic interactions, and steric hindrance 
effects, which all depends on the DNA sequence, can also be detected.  
“Classical” intercalators, which actually satisfy the mentioned properties, are 
fused-ring aromatic molecules with positive charges on an attached side chain and/or 
the ring system itself.
27,28
 Typical examples are illustrated in Figure 5. The planar 
ring system stacks well with base pairs in the intercalation complex.  
 
Figure 5. Examples of “Classical intercalators”: ligands with flat, aromatic structures demonstrated to 
fit between base pairs in double stranded DNA. 
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A particular class is represented by the “bisintercalators” (e.g. NSC 727357, 
Figure 5), dimers with two intercalating chromophores linked with a chain of 
appropriate length. These structures often show high dsDNA binding affinities, 
greater by several orders of magnitude than those of the corresponding monomers. 
Ligands with greater molecular thickness, but not necessarily characterized 
by fused rings, are referred to as “non classical” intercalators (Figure 6).29-34 The 
possibility that molecules other than flat, aromatic compounds might be capable of 
inserting between base pairs in DNA was originally considered by Huggins and 
Yang in 1962. Actually contrary to the notion that intercalation is synonymous with 
cytotoxicity, a large percentage of existing small molecule drugs as well as chemicals 
with a wide range of biological activities has now been shown to be capable of 
intercalation, i.e. vitamins, hormones, hormone antagonists, antipsychotics, 
antidepressants, antihistamines.
35
 
 
Figure 6. Examples of “Non-classical intercalators”: ligands less studied but found to fit between 
base pairs using molecular modeling. 
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The observation that certain non-classical intercalators which had a greater 
molecular thickness than the classical intercalators but fit remarkably well into 
intercalation sites, led to the hypothesis that intercalation was a natural mode of 
action of these compounds. Specifically, the proposal was made that small molecules 
in concert with chromosomal proteins regulate genes via intercalation.
35,38
 The 
argument was also made that while replication and transcription of genetic 
information are provided by the complementary hydrogen bonding of the base pairs, 
the intercalation sites between the base pairs provided an additional recognition 
system for biologically active natural products. 
 
• Intercalation Site: 
The most common form of double stranded DNA is the Watson and Crick B 
form in which the DNA is wound in a right-handed double helix. It is important to 
note that many other conformations of DNA exist, e.g. A, C, and Z, that results from 
different conformations of the D-deoxyribose sugars.
36
  
DNA can be unwound by rotating the phosphodiester bonds and modifying 
the conformation of the sugars. As the DNA is unwound, the base pairs separate and 
form a cavity. The shape and size of the cavity is dependent upon the degree of 
unwinding and the sequence of base pairs. When the cavity reaches approximately 4 
Å in width, it becomes possible to insert flat, aromatic small molecules between the 
base pairs. A maximally unwound intercalation site is approximately 8 Å in width 
and 12-14 Å in length and can accommodate small molecules with a variety of 
molecular shapes and sizes.
37
  
The exact geometry of intercalation sites, and for that matter DNA in general, 
is governed by many factors including pH, ionic strength, cations, degree of 
hydration, secondary and tertiary structure and chromosomal proteins (nuclear 
enzymes, receptors and transcription factors). The shape, size, conformational 
flexibility and physicochemical characteristics (e.g. hydrogen bonding) of an 
intercalating ligand can also affect the intercalation site. The primary factor that 
distinguishes one intercalation site from another is the sequence of the neighboring 
base pairs above and below the cavity which is limited to 10. While the three-
dimensional properties of double stranded DNA have been studied extensively, there 
has been relatively little discussion of the absolute stereochemistry of naturally 
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occurring DNA. Natural DNA possesses an unique asymmetry or chirality that arises 
from the stereochemistry of the sugar, i.e. d-deoxyribose. When unwound DNA was 
examined closely, it became increasingly obvious that the intercalation sites 
themselves were chiral. For example, the strongest potential hydrogen bonding 
groups on the DNA, i.e. the negatively charged oxygens of the phosphate groups on 
adjacent strands, are asymmetrically positioned. As a consequence, the best fitting 
molecules, as exemplified by estradiol and other non steroidal but chiral biologically 
active compounds, possess a unique stereochemistry that is complementary to the 
stereochemistry of intercalation sites in unwound DNA. 
A variety of techniques have been employed to study intercalation and 
include relatively simple studies employing temperature melting of DNA, 
equilibrium dialysis, changes in viscosity, dichroism and fluorescence 
measurements.
38
 More refined methods include mass spectrometry, solution NMR 
and X-ray crystallography accompanied by computer modeling. The latter is a 
mainstay of current studies of the interactions of small molecule, DNA and nuclear 
proteins where energy calculations can provide valuable information about the 
strength of ligand/macromolecule interactions. 
 
2.1.4 More complex binding mode 
 
In eukaryotic cells, DNA is stored in its supercoiled duplex form and is 
arranged in supramolecular structures that are stabilized by ancillary proteins. 
However, during activation toward processes such as replication and transcription, 
this stable storage complex is rearranged and the DNA may form structures that 
differ from the Watson-Crick-induced B-DNA duplex.  
The paradigm shift towards the targeting of intermediate DNA structures 
other than the form in which DNA is stored, and the concomitant design of 
compounds with specificity for certain DNA forms, may open up access to the 
targeting of certain types of biological activity. In addition, it is expected that 
sequence specificity will be achieved more straightforwardly, since the opening of 
the DNA duplex leads to increased exposure to new interactions of the otherwise 
buried bases.   
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Drug design based on the principle of DNA structure targeting, would yield 
control over the expression of a determined gene or locus at a desired cell state or 
stage.  
• DNA three-way junction (3WJ): 
A recent work reported a study on the recognition of a DNA three-way 
junction (3WJ) by a small supramolecular helical compound.
39,40
 The interaction 
mode observed involves a highly stable complex between the DNA junction and the 
„helicate‟, i.e. a compound that consists of three organic stranded ligands wrapped 
around two Fe
2+
 atoms, as shown in Figure 7.
41
 
 
 
Figure 7.
9
 Assembly of the [Fe2L3]
4+
 (L=C25H20N4) tetracationic supramolecular helicate (Fe
2+
 ions 
represented as spheres) and a stereo view of its complex with a DNA 3-way junction (PDB access 
code 2ET0).
38
 
 
The helicate combines the two positively charged centers with an extensive 
hydrophobic surface formed by four aromatic rings of each respective ligand. The X-
ray structure that was determined,
39
 shows that these properties constitute the driving 
force of the binding mode observed, which consists of electrostatic interactions 
between the iron ions and the phosphate backbone of the DNA and of π-π stacking 
between the central DNA bases and the two phenyl rings in the center of the ligand 
strands. 
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• Holliday (four-way) junction 
Recognition of a Holliday junction binder has been achieved with an acridine 
derivative (Figure 8). Like the three-way junction, it is another example of 
recognition of higher order B-DNA structures. The two acridine moieties function as 
intercalators, separated by a spacer that places them at the appropriate distance for 
insertion at two distant sites. The complex of the acridine derivative with a small 
DNA fragment has been characterized by X-ray crystallography, which shows that 
bisintercalation occurs at the two opposite branch points of an X-stacked, closed 
Holliday junction and that the linker aligns with the crossover region.
42
 
 
 
Figure 8. Stereo view of a Holliday junction (PDB access code 2GWA), complexed to the acridine 
derivative shown alongside.
42
 
 
• Quadruplex DNA  
Telomere recognition and regulation has been marked as an important 
potential target for cancer therapy,
43
 because the behavior of these regions differs in 
somatic and cancer cells. In the former, telomere length decreases with time and cell 
division is arrested upon reaching the Hayflick limit. In contrast, telomere lengths are 
actively maintained at a certain length in cancer cells. The extremes of telomeres 
contain repeated poly G sequences that rearrange into quadruplex structures, i.e. 
parallel bundles consisting of four DNA strands.
44
 This type of DNA structure has 
additionally been proposed to occur in certain regions of continuous DNA sequences, 
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for example in a poly G tract of the promoter region of the MYC oncogene.
45
 The 
search for suitable agents that target this type of DNA structure and the associated 
proteins has led to several candidates, some of which have been structurally 
characterized complexed with DNA (Figure 9). 
 
Figure 9.
9 
(A)The complex of a porphyrin molecule and a parallel quadruplex representing the c-MYC 
oncogene DNA (PDB access code 2A5R). (B) Intercalation-like binding of an acridine derivative into an 
antiparallel quadruplex (PDB access code 1L1H). 
 
The porphyrin TMPyP4 was shown to stack on top of a G tetrad of a parallel 
DNA quadruplex, mimicking the c-MYC oncogene
46
 (Figure 8A), suggesting that 
tetrad interactions are more feasible for parallel quadruplexes. A recent structure of a 
complex of an acridine derivative with an antiparallel quadruplex, does not 
contradict this notion: the structure reveals intercalation of the acridine between a G-
tetrad, covering three of the four bases, capped by a loop that connects two 
antiparallel DNA strands of the quadruplex.
47
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2.2 DNA Topoisomerases I/II  
 
 
2.2.1 DNA Topology 
 
DNA compaction is such that the entire genome of a single human cell (3x10
9
 
base pairs corresponding to approximately 1.8 m) needs to be squeezed into a 
nucleus with an average diameter of 6 µm. On the other hand DNA metabolism 
requires the two strands of the duplex to be separated for them to serve as templates 
for transcription, replication, recombination and repair. Actually the DNA molecule 
is extremely flexible and can exist in a different number of configurations.
48
  
 
Figure 10. Diagram of closed circular DNA. 
The topology and consequent torsional state of a DNA molecule can be well 
defined in a covalently closed double stranded DNA circle (Figure 10), where each 
strand is a ring invariably linked to the other an integer number of times (Linking 
number or Lk, Figure 11). 
  
 
Figure 11. Linking number definition 
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Quantitatively, the linking number is close to N/γ , where N is the number of 
base pairs in the molecule and γ is the number of base pairs per double-helix turn 
under given conditions. Under physiological conditions, the two complementary 
DNA strands form a right-handed helix with a pitch of 10.5 base pairs, each one of 
which is rotated by 36 degrees from its adjacent pair (B-DNA). Thus a relaxed DNA 
molecule presents a Linking number Lk0 = N/10.5 (e.g. a relaxed DNA molecule 
made of 105 base pairs will present a Lk = Lk0 = 10).
49,50
 
Deviations of Lk experimentally observed (for instance, in a supercoiled 
DNA plasmid) are expressed as: 
ΔLk = Lk − Lk0 
Normalization of ΔLk by the length of DNA is obtained with ΔLk/Lk0, which is 
known as the specific linking difference (also named superhelical density or σ). 
However, DNA is not usually expressed in a relaxed state but in supercoiling 
topological forms. Supercoiling can be structurally realized in two ways: by 
deforming the molecular axis and by altering the twist of the double helix. 
Quantitatively it can be expressed by the White‟s theorem:51 
Lk = Tw +Wr 
where Tw (Twist) is a measure of the helical winding of DNA and roughly equals the 
number of times each DNA strand turns around the central axis of the duplex; Wr 
(Writhe) is a measure of planar deviations of the duplex and is calculated by 
averaging the number of (+) and (−) crossings of the DNA axis over itself in multiple 
spatial projections.  
Any alteration of Lk translates to changes of Tw and Wr (ΔLk = ΔTw + ΔWr). 
Also, while leaving Lk constant, Tw and Wr deformations will always interconvert to 
alter the spatial configuration of DNA (Figure 12). 
                                                   2.2 DNA Topoisomerases I/II        
 
34 
 
 
Figure 12. Twist and Writhe definition. 
 
Therefore according to the different value of Lk, three main DNA topological states 
can be identified (Figure 13):
52
 
• Relaxed (Lk = Lk0 with Wr = 0 and Lk = Tw) 
• (+) Supercoiling (Lk > Lk0) In this case DNA is overwound, i.e. the number 
of base pairs per double-helix turn is less than 10.5, with consequent 
increment of the number of twists and thus of torsional stress. 
• (–) Supercoiling (Lk < Lk0) In this case the DNA is underwound, i.e. the 
number of base pairs per double-helix turn is more than 10.5 
 
 
Figure 13. Representation of the main DNA topological states. 
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Negative supercoiling provides the energy for localized, controlled melting of 
the DNA duplex to allow access of DNA polymerases, RNA polymerases, repair 
factors and recombinases to the internal nucleotide sequence. While negative 
supercoiling promotes many nucleic acid processes, DNA overwinding (i.e. positive 
supercoiling) inhibits them.
53,54
 
Whereas all the above parameters are both theoretically and experimentally 
amenable in naked circular DNA molecules few kilobase pairs in size, the challenge 
begins when we want to exercise with a huge circular bacterial chromosome or a 
much larger eukaryotic chromosome. Actually DNA strands are not topologically 
closed in linear DNA molecules and, in the case of large DNA circles (hundreds of 
kilobase pairs), Lk measurement is technically impracticable. This problem is 
overcome, however, by the general assumption that the large chromosomal DNA 
molecules are organized into a succession of topological domains. As in a DNA 
circle, each topological domain comprises a DNA segment somehow bounded by 
both ends, such that local alterations of Lk, Tw, or Wr do not affect (or at least do not 
immediately affect) the neighboring domains. In chromosomal DNA topology Tw 
and Wr deformations and their interconversions depend less than on the intrinsic 
properties of the double helix, but mainly on the multiple molecular interactions and 
tensions that concur in virtually any short segment of DNA.
55
  
Various physiological cellular processes, such as the DNA strand unwinding 
associated with the function of DNA and RNA polymerases, chromosome 
segregation during cell division, and chromatin assembly and remodeling, generate 
strong torsional forces along the DNA axis, resulting in positive supercoiling (Figure 
14). Notwithstanding, DNA is homeostatically maintained in an underwound state in 
all species, facilitating access to the genetic code. How do the cells manage to reset 
the topological status of the DNA and revert it to an underwound state was revealed 
with the discovery of DNA topoisomerases, first in Escherichia coli and afterwards 
in all species throughout evolution.
56 
 
                                                   2.2 DNA Topoisomerases I/II        
 
36 
 
 
Figure 14. Topological problems associated with an elongating replication fork. a The replication 
machinery is immobile; the DNA turns as it is passed through the machinery, and positive supercoils 
accumulate ahead of the advancing replication fork. b The replication machinery is allowed to rotate 
around the helical axis of the unreplicated DNA. This rotation allows the redistribution of positive 
supercoils ahead of the advancing fork into the region behind it, and leads to the intertwining of the 
pair of duplicated double helices.
57
 
 
2.2.2 DNA Topoisomerases  
 
DNA strand separation for transcription and replication, the flawless 
segregation of two identical copies of entire genomes in two daughter cells following 
replication, and the formidable genomic compaction in cells, exemplify the critical 
actions of DNA topoisomerases.  
- History and Classification: 
At about the same time of the discovery of the first DNA topoisomerase (the 
omega protein, ω, from E. coli) by Jim Wang in 1971, a second DNA topoisomerase, 
the calf-thymus swivelase, was identified by Champoux and Dulbecco in 1972. 
Whereas the ω protein was only able to relax negatively supercoiled DNA, the 
swivelase on the contrary could relax both positively and negatively supercoiled 
DNA.
58,59
  
                                                   2.2 DNA Topoisomerases I/II        
 
37 
 
From the introduction in 1975, of agarose gel electrophoresis a great variety 
of DNA topoisomerases has been described in all kind of organisms; The first were 
bacterial DNA gyrase in 1976,
60
 and eukaryotic decatenase in 1980.
61
 With these 
findings the distinction between Type I and Type II DNA topoisomerases has then 
been introduced, as it became clear that the reaction mechanism performed by the ω 
protein and swivelase on the one side, and by DNA gyrase and eukaryotic decatenase 
on the other side, was significantly different. Whereas the former introduced 
transient single-strand breaks into the DNA to change the linking number between 
the two strands of the DNA molecule (Type I), the latter introduced double-strand 
breaks, a clear requirement to decatenate double-strand DNA (Type II).
62
 The 
discovery of new DNA topoisomerases in the eighties and nineties then produced 
quite a complex nomenclature that was finally clarified when the sequencing of DNA 
topoisomerase genes revealed the first clear-cut evolutionary relationships between 
the DNA topoisomerases themselves.  
All the topoisomerase world can now be described in the framework of four 
families (Topo IA, Topo IB, Topo IIA, Topo IIB), with the exception of the stand-
alone Topo V, a DNA topoisomerase discovered by Alexei Slesarev in 1992 which is 
only present in one species, the archaeon Methanopyrus kandleri.
63
 
 
- General aspects of the mechanism of action: 
DNA topoisomerases regulate DNA over- and underwinding, and remove 
knots and tangles from the genetic material by creating transient breaks in the sugar 
phosphate backbone of the double helix. They achieve this through their unique 
ability to transiently cleave and reseal the phosphodiester backbone via a 
transesterification reaction (Figure 15). This reaction involves two sequential 
nucleophilic attacks:  
(i) an initial nucleophilic attack of an active-site tyrosyl oxygen of the enzyme on a 
DNA phosphate, followed by the formation of a covalent 3‟ phosphotyrosine bond 
and the simultaneous breakage of the phosphodiester bond.  
(ii) strand rejoining through the nucleophilic attack of the 5‟-hydroxyl group, 
generated in the first transesterification reaction, on the 3‟ phosphotyrosine link and 
subsequent restoration of the DNA backbone bond.
57
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Figure 15. Catalysis of transient breakage of DNA by DNA topoisomerases. Transesterification 
between an enzyme tyrosyl and a DNA phosphate group leads to the breakage of a DNA backbone 
bond and the formation of a covalent enzyme-DNA intermediate. Rejoining of the DNA backbone 
bond occurs by the reversal of the reaction shown. 
 
 
2.2.3 DNA Topoisomerase I 
 
Type I topoisomerases are enzymes that effect topological changes on DNA 
by transiently cleaving one DNA strand at a time. All Topo I use the above reported 
general chemistry to break the phosphodiester bond. A tyrosyl group of the enzyme 
attacks a phosphodiester bond on DNA and remains covalently attached to one side 
of the break while releasing a free hydroxylated strand. The attack of the 
phosphotyrosine bond by the hydroxyl end of the free strand restores a 
phosphodiester bond and releases the enzyme for the next catalytic cycle. As the 
energy of the phosphodiester bond is conserved in the protein-DNA covalent 
intermediate, the cleavage-religation step does not require ATP hydrolysis. To relax 
DNA, type I enzymes garner the energy stored as torsional stress in the supercoiled 
DNA. The way the stored energy in the DNA is transformed into changes in the 
protein as the reaction proceeds, is still not understood and remains one of the major 
future challenges in understanding not only type I topoisomerases, but all 
topoisomerases. Type I topoisomerases were further divided into two families, IA 
and IB, on the basis of the polarity of strand cleavage, and slight differences in the 
mechanism of relaxation.
64
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• Topoisomerase IA: 
Type IA enzymes have been found in bacteria, archaea and eukarya and all 
share a common mechanism known as „„enzyme-bridged strand passage‟‟ that was 
first proposed for the E. coli ω protein.65 Topo IA catalyse the cleavage of a single-
strand DNA, forming a transient 5‟-phosphotyrosine covalent complex. The other 
DNA end is not free to rotate but rather bound to the enzyme, thus allowing the 
passage of another DNA strand through the break prior of rejoining the DNA ends 
(Figure 16).
66,67
 
 
Figure 16. Enzyme-bridged DNA strand-passage model for type IA topoisomerases. The ribbon 
diagrams are based on the crystal structure of E. coli DNA topoisomerase I (PDB ID code 1ECL) and 
show the closed form of the enzyme before cleavage of the DNA (single strand of DNA modeled as a 
thick black line; A) and the open form after cleavage with both ends of the broken DNA strand 
associated with the enzyme (B).
67
 
 
 The overall reaction cycle is Mg
2+
 dependent and results in the modification 
of DNA topology strictly by steps of one.
68
 All Topo IA promote a partial relaxation 
of negatively, but not positively supercoiled DNA, most likely because these 
enzymes require an exposed single-strand region within the substrate DNA. In 
addition to DNA relaxation, Topo IA can catalyse the knotting, unknotting and 
interlinking of single-strand DNA circles as well as the knotting, unknotting and 
catenation/decatenation of nicked double-strand DNAs.
65
  
The core structure of type IA topoisomerases (Figure 17), typically of around 
67 kDa in molecular weight, has a characteristic toroidal fold formed by four 
domains. Sites of topo IA subclass enzyme, that are located outside the catalytic 
“pocket”, are also involved in DNA binding and the relaxation reaction of the DNA 
                                                   2.2 DNA Topoisomerases I/II        
 
40 
 
substrate. For example, E. coli topo I contains three zinc ions that bind in the C-
terminal region of the protein (residues 598-737), where three tetracysteine domains 
involved in binding and manipulations with DNA strands are located.
53,69
  
 
Figure 17. Structure of E. coli type I DNA topoisomerase. a) Domain organization of topo I. b) 
Structure of N-terminal fragment (67 kDa) determined by X-ray analysis.
53
 
 
A detailed model on how type IA enzymes perform complex topological 
rearrangements was proposed several years ago based on the structure of E. coli 
topoisomerase I,
70
 and have been further confirmed by recent single molecule 
experiments.
68,71
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The proposed mechanism of action involves several steps (Figure 18), and 
crystal structures for some of these intermediate steps have been obtained. The 
structures revealed that the enzyme and the DNA have to change conformation 
during the catalytic cycle in a coordinated manner.
69
  
 
Figure 18. Diagram showing the proposed mechanism of DNA relaxation by type IA topoisomerases. 
The mechanism involves several transient conformational intermediates both of the protein and the 
DNA.
69
 
 
The structure of the covalent complex of a type IA topoisomerase that shows 
the crucial interactions with the 5′ and 3′ ends of cleaved DNA has been only 
recently obtained (Figure 19). In the last year (2011) Zhang et al. reported the 
structure of Escherichia coli topoisomerase I N-terminal catalytic domain (residues 
2-695) in covalent complex with a substrate oligonucleotide stabilized by a mutation 
in the topoisomerase-primase (TOPRIM) motif that inhibits DNA rejoining.
72
 
 
Figure 19. Structure of the topoisomerase I and DNA covalent complex. (A) Ribbon representation of 
the overall structure with four domains shown in different colors. (B) Annealed difference map 
around the DNA fragments, calculated in the absence of bound DNA. (C) Closer view of the active 
site of the covalent intermediate.
72
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This structure of the covalent topoisomerase-DNA intermediate, previously 
elusive for type IA topoisomerases, shows distinct conformational changes from the 
structure of the enzyme without bound DNA and provides detailed understanding of 
the covalent catalysis required for strand cleavage to take place. The portion of 
cleaved DNA 5′ to the site of cleavage is anchored tightly with extensive 
noncovalent protein-DNA interactions as predicted by the “enzyme-bridged” model. 
Distortion of the scissile strand at the -4 position 5′ to the cleavage site allows 
specific selectivity of a cytosine base in the binding pocket (Figure 20).
72
 
 
 
Figure 20. Structural determinants for substrate binding and specificity. (A) Surface representation of 
the DNA binding groove. The cleavage site sits on the border between domain III and domain IV. (B) 
The phenol side chain of Y177 wedges between bases −4 and −5 and forms π-interactions among 
them. (C) The cavity formed at the −4 position can accommodate only a cytosine.72 
 
There are still many open questions regarding the atomic mechanism of type 
IA topoisomerases, but additional structural information on the intermediate steps in 
the reaction cycle, as the mentioned structure of the topoisomerase I covalent 
complex, may address these difficult questions and also provide potential target sites 
for the design of pharmaceuticals to stabilize reaction intermediate. 
 
 
 
 
                                                   2.2 DNA Topoisomerases I/II        
 
43 
 
• Topoisomerase IB: 
Type IB enzymes have been identified in eukaryotes, poxviruses and bacteria, 
but not in archaea. Eukaryotic type IB molecules are large, typically over 90 kDa in 
molecular weight, while viral and bacterial type IB molecules are relatively small, 
around 36 kDa. Despite their differences in size, all type IB molecules share a 
common fold around the active site region and a common catalytic mechanism. 
Structures of the fully functional enzyme in complex with DNA shows a C-shaped 
protein clamp around duplex DNA. The two regions that close the C-clamp consist 
of loops that meet in a non-covalent interaction to envelop the target DNA (Figure 
21).
73-75
 
 
 
Figure 21. Diagrams of the structures of eukaryotic and viral type IB topoisomerases. (A) Structure of 
human topoisomerase I in non-covalent complex with DNA [PDB 1A35]. The protein encircles the 
DNA by forming a clamp around it. The protein is composed of two domains: a core domain, shown 
in red and blue, and a C-terminal domain, shown in green. (B) Structure of variola virus 
topoisomerase I in covalent complex with DNA [PDB 2H7F]. The viral and bacterial type IB enzymes 
are composed of two domains: an N-terminal domain, shown in red, and a larger, C-terminal 
domain, shown in blue.
69
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Two different Topo IB are present in vertebrates, one localized in the nucleus 
and the other in the mitochondria.
76
 Eukaryotic Topo IB are large monomeric 
enzymes (around 90 kDa) with a highly conserved DNA binding domain and a C-
terminal catalytic domain, linked by a non conserved hydrophilic region. The C-
terminal domain contains the catalytic tyrosine while all other residues in the 
catalytic pentad reside in the core domain (Figure 22).
48
 
 
 
Figure 22. Schematic representation of the two human type IB enzymes. Top1mt has a much shorter 
N-terminal segment consisting primarily of a mitochondrial targeting sequence (MTS) and lacking the 
nuclear localization sequences (NLS) of Top1 (nuclear). The catalytic homologous residues are 
indicated with their position.
48
 
 
The mechanisms of cleavage/religation and DNA relaxation are identical for 
all the type IB enzymes. Unlike Topo IA, they can relax both positive and negative 
supercoils and catalyze topological cycles to a fully relaxed product. Although the 
cleavage step implies a chemistry similar to that of Topo IA, DNA relaxation does 
not require Mg
2+
 and the polarity of covalent complex formation is different (type IA 
enzymes covalently bind 5‟-phosphate, whereas type IB enzymes form a bond with 
3‟-phosphate with the hydrolyzed DNA strand). Relaxation occurs by a different 
mechanism (Figure 23), referred to as the „„controlled rotation mechanism‟‟, since 
the free 5‟-OH strand is free to rotate prior to religation (except for friction between 
the rotating DNA and the enzyme cavity).
48,57
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Figure 23. Topo IB-mediated DNA relaxation by controlled rotation.
48
 
 
The structures of both covalent and non-covalent intermediates of type IB 
enzymes are available, but the changes that occur in the protein as the DNA swivels 
inside the C-clamp are yet to be elucidated.  
Eukaryotic type IB topoisomerases have received additional attention as 
important chemotherapeutic targets. Actually while Topo IA is not yet a clinical 
therapeutic target, Topo IB enzymes are the target of important anticancer 
compounds such as camptothecins,
77
 indolocarbazoles
78
 and indenoisoquinolines.
79
 
Moreover the structures of ternary complexes of the enzyme, DNA and drugs,
80,81
 
reveal the drug interactions at the atomic level and this may be helpful in the 
development of better type IB poisons. 
 
2.2.4 DNA Topoisomerase II 
 
Type II DNA topoisomerases induce double-strand breaks in a DNA duplex 
and force the passage of another duplex through this break.
82
 The DNA cleavage, 
energy storage and religation reactions are chemically similar to those performed by 
Type I topoisomerases, with the formation of a phosphotyrosine link between DNA 
and the enzyme, except that the two strands of the DNA duplex are broken in a 
concerted reaction. In contrast to Topo I that can make transient links with either the 
5‟ end (Topo IA) or the 3‟ end (Topo IB) of the DNA breaks, all Topo II make 
transient links with the 5‟ end of the DNA breaks. All type II enzymes can catenate 
(or decatenate) and knot (or unknot) circular duplex DNA, and alter DNA 
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superhelicity by relaxing positively or negatively supercoiled DNA. DNA gyrase, a 
bacterial Topo IIA, appears unique as it is the only topoisomerase that can negatively 
supercoil a covalently closed DNA duplex. In contrast to Topo I, all type II 
topoisomerases are ATP-dependent and multimeric enzymes with a dyad 
symmetry.
64
 
 Lower eukaryotes and invertebrates encode only a single type II 
topoisomerase.
83
 In contrast, vertebrate species encode two closely related isoforms 
of the enzyme, topoisomerase IIA and topoisomerase IIB. These isoforms differ in 
their protomer molecular masses (170 versus 180 kDa, respectively) and are encoded 
by separate genes.
84-86
 Topoisomerase IIA and topoisomerase IIB display a high 
degree (~70%) of amino acid sequence identity and similar enzymological 
characteristics. One notable difference between the two isoforms is that 
topoisomerase IIA relaxes (i.e. removes) positive superhelical twists ~10 times faster 
than it does negative in vitro, while the B isoform is unable to distinguish the 
geometry of DNA supercoils during DNA relaxation.
87
 Topoisomerase IIA and 
topoisomerase IIB have distinct patterns of expression and separate cellular 
functions. Topoisomerase IIA is essential for the survival of proliferating cells, and 
protein levels rise dramatically during periods of cell growth. The enzyme is further 
regulated over the cell cycle, with protein concentrations peaking in G2/M. 
Topoisomerase IIA is associated with replication forks and remains tightly bound to 
chromosomes during mitosis. Thus, it is believed to be the isoform that functions in 
growth-related processes, such as DNA replication and chromosome segregation.
88-90
 
Topoisomerase IIB is dispensable at the cellular level but appears to be required for 
proper neural development. Expression of topoisomerase IIB is independent of 
proliferative status and cell cycle, and the enzyme dissociates from chromosomes 
during mitosis. Topoisomerase IIB cannot compensate for the loss of topoisomerase 
IIA in mammalian cells, suggesting that these two isoforms do not play redundant 
roles in replicative processes.
91-93
 Much of what we understand regarding the 
mechanism of action of type II enzymes comes from experiments with topoisomerase 
II from species that express only a single form of the protein. Consequently, 
eukaryotic type II topoisomerases will be referred to collectively as topoisomerase II. 
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• Topoisomerase II Structure 
Eucaryotic topos II comprise a highly conserved family of homodimeric 
enzymes with each subunit containing an N-terminal ATPase domain, a central DNA 
cleavage and ligation domain, and a variable C-terminal domain (CTD). The CTD is 
not required for enzyme activity but has interesting regulatory properties. For one 
thing, the CTD has been proposed to allow the enzyme to distinguish the handedness 
of DNA supercoils (Figure 24).
85,94-96
 
 
Figure 24. Topo II domain structure. Numbers refer to amino acid coordinates for S. cerevisiae Topo 
II. Y782 is the active site tyrosine.
96
 
 
Over the past two decades, several structures of type II topos have been 
determined.
73,85
 The model for most structural studies has been the type II 
topoisomerase from yeast (Figure 25).  
 
Figure 25. Structure of yeast topo II. Structures of Saccharomyces cerevisiae topo II (PDB 1PVG and 
1BGW) were computationally docked together to illustrate a possible representation of the enzyme. 
ATPase domains, shown in blue, form the N-gate. The central B’-subfragment forms the DNA gate 
(green). The C-terminal A’ portion (red) encloses a hole large enough to accommodate T-segment 
DNA, which is thought to exit through the C-gate. 
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However, eukaryotic type II topoisomerases are highly conserved, and the 
structural insights from the yeast enzyme are also likely to apply to the human 
enzyme. Although a structure has not been solved for a full-length type II 
topoisomerase, the available structures provide a near-complete picture of the 
architecture of topo II:  
- The ATPase region forms a heart-shaped dimer upon nucleotide binding and folds 
into two discrete domains: the N-terminal region bears the characteristic GHKL 
ATP-binding fold, while the C-terminal region comprises the transducer domain. The 
GHKL superfamily is named for its founding members DNA gyrase, Hsp90, 
histidine kinase and Mut L, and it forms the primary dimer interface of the ATPase 
region. The C-terminal transducer domain is situated below the ATP-binding fold 
and is thought to transduce ATP binding and hydrolysis signals to downstream 
regions of the enzyme, thus coordinating DNA cleavage/religation with DNA 
transport. ATP hydrolysis is used for conformational changes of the enzyme, and is 
not directly involved in DNA breakage or resealing.
97,98
 
- The core region of topo II also forms a heart-shaped dimer with a central cavity 
more than large enough to accommodate duplex DNA, which is thought to exit at the 
C-terminal dimer interface (C-gate) of the enzyme. The N-terminal portion of the 
topo II cleavage/core region contains what has been termed the TOPRIM 
(TOpoisomerase/PRIMase) domain. This region contains the conserved acidic 
residues believed to promote formation of the topo II/DNA phosphodiester linkage 
by coordinating Mg
2+
, which is essential for DNA cleavage. The core of topo II also 
includes a winged-helix domain (WHD) that contains the active site tyrosyl residue 
essential for DNA cleavage, and a „tower‟ domain, which was found to act as a 
supporting element for DNA. The recently determined topo II/DNA structure also 
provides support to previous biochemical evidence that the C-terminal domain (C-
gate) of topo II opens to allow expulsion of the transported DNA segment.
97,98
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• The Topoisomerase II catalytic reaction 
Human topoisomerase IIA and IIB function as homodimers and interconvert 
different topological forms of DNA by a “double-stranded DNA passage reaction”.  
Structural and biochemical evidence have led to the two-gate model for topo II-
mediated DNA tran sport (Figure 26).  
In this model, topo II utilizes the energy from ATP to transport one intact 
DNA duplex through an enzyme-mediated 4-bp staggered double-stranded break in a 
second duplex. In the first step of the reaction, the N-terminal ATPase domains (N-
gate) are separated, allowing topo II to bind a DNA duplex within the 
binding/cleavage core. This DNA has been termed the gate or „G-segment‟ because it 
serves as a gate through which another strand must pass. ATP binding to the N-
terminal GHKL domains triggers their dimerization and capture of a second DNA 
duplex. Closure of this N-gate induces a succession of conformational changes that 
promotes the cleavage and opening of the G-segment, followed by transport of the 
captured DNA (T-segment DNA) through the break. The T-segment then exits 
through the opened C-terminal dimerization interface (C-gate), and the DNA gate 
closes to allow G-segment religation.
48,98,99
 
 
Figure 26. Type IIA and IIB topoisomerases catalytic reaction. (They share the same mechanism but 
differ in overall tertiary structure).
99
 
                                                   2.2 DNA Topoisomerases I/II        
 
50 
 
The ability of topoisomerase II to cleave and ligate DNA is central to all of its 
catalytic functions. All topoisomerases utilize active site tyrosyl residues to mediate 
DNA cleavage and ligation. Since type II enzymes cut both strands of the double 
helix, each protomer subunit contains one of these residues (Tyr805 and Tyr821 in 
human topoisomerase IIA and topoisomerase IIB, respectively).  
Topoisomerase II initiates DNA cleavage by the nucleophilic attack of the 
active site tyrosine on the phosphate of the nucleic acid backbone (Figure 27).
84,100,101
 
 
 
Figure 27. Double-stranded DNA cleavage and ligation mediated by topoisomerase II. Scissile bonds 
are located four bases apart on opposite strands of the double helix. 
 
The resulting transesterification reaction results in the formation of a covalent 
phosphotyrosyl bond that links the protein to the newly generated 5‟-terminus of the 
DNA chain. It also generates a 3‟-hydroxyl moiety on the opposite terminus of the 
cleaved strand. The scissile bonds on the two strands of the double helix are 
staggered and are located across the major groove from one another. Thus, 
topoisomerase II generates cleaved DNA molecules with four-base 5‟-single-
stranded cohesive ends, each of which is covalently linked to a separate protomer 
subunit of the enzyme.  
The covalent enzyme-DNA linkage plays two important roles in the 
topoisomerase II reaction mechanism. First, it conserves the bond energy of the 
sugar-phosphate DNA backbone. Second, because it does not allow the cleaved DNA 
chain to dissociate from the enzyme, the protein-DNA linkage maintains the integrity 
of the genetic material during the cleavage event.
100,101
  The covalent topoisomerase 
II-cleaved DNA reaction intermediate is referred to as the „cleavage complex‟ and is 
critical for the pharmacological activities of the enzyme. Actually agents such as 
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etoposide and mAMSA inhibit the re-ligation step and trap Topo II as a complex in 
which the enzyme is covalently bound to DNA with broken strands.  
Although topoisomerase II acts globally, it cleaves DNA at preferred sites 
even if the mechanism is not apparent, and it is nearly impossible to predict de novo 
whether a given DNA sequence will support scission. Most likely, the specificity of 
topoisomerase II-mediated cleavage is determined by the local structure, flexibility, 
or malleability of the DNA.
102-103
  
Information regarding the roles of specific amino acid residues comes from 
structural studies on the catalytic core of yeast topoisomerase II generated in the 
absence of DNA or in a non-covalent complex with its nucleic acid substrate.
102
 
Cleavage is initiated when a general base deprotonates the active site tyrosine 
hydroxyl, allowing the oxyanion to attack the scissile phosphate. The DNA cleavage 
reaction requires a divalent metal ion, and Mg
2+
 appears to fulfill this function in 
vivo (Figure 28).
104
 Recent evidence indicates that human topoisomerase IIA utilizes 
a „two-metal-ion‟ mechanism, in which one of the metal ions interacts with the 
bridging 5‟-oxygen of the scissile bond. This interaction greatly accelerates rates of 
enzyme-mediated DNA cleavage and most likely is needed to stabilize the leaving 
3‟-oxygen. The role of the second metal ion is not known.105  
 
Figure 28. Mechanism of DNA cleavage and ligation mediated by topoisomerase II. 
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Topoisomerase II-DNA cleavage complexes normally are short-lived and 
readily reversible, and the DNA cleavage/ligation equilibrium of the enzyme greatly 
favors religation. Even if the two protomer active sites of the enzyme do not act in 
complete concert with one another there is a relatively high degree of coordination 
between them. To this point, once topoisomerase II cleaves the first strand, it is 
estimated that the enzyme cuts the second strand ~20-fold faster.
84,104-107
  
Following the passage of the other duplex, DNA ligation is initiated when a 
general acid extracts the hydrogen from the 3‟-terminal hydroxyl group. The acid 
may be a water molecule or an unidentified amino acid in the active site of 
topoisomerase II. The conversion of the terminal hydroxyl moiety to an oxyanion 
induces a nucleophilic attack on the phosphotyrosyl bond. This action represents the 
reverse of the cleavage event and regenerates an intact DNA chain as well as the 
active site of topoisomerase II.
100,101,108,109
 
The Topo II catalytic reaction requires two cofactors in order to carry out its 
catalytic double-stranded DNA passage reaction. First, it needs a divalent cation for 
all steps beyond enzyme-DNA binding, as reported above. Second, topoisomerase II 
uses the energy of adenosine triphosphate (ATP) to drive the overall DNA strand 
passage reaction. While ATP is not required for either DNA cleavage or ligation, the 
binding of this nucleoside triphosphate triggers the translocation of DNA through the 
double-stranded nucleic acid gate. Finally ATP hydrolysis is also necessary for 
enzyme recycling.
97,98,105
 
 
• Topoisomerase II Biological Functions: 
One of the central roles of DNA topoisomerases is to solve the topological 
problems associated with replication. Semi-conservative replication involves the 
unwinding of duplex DNA and copying of each strand. The positively supercoiled 
DNA in front of the replication fork can isomerize by migration of the positive 
supercoiling into wrapping of the two replicated strands (Figure 29). This structure, 
called a precatenane, is a substrate for Topo II-mediated DNA catenation. In the 
latter stages of replication, when two replication forks impinge on each other, there is 
no longer room for a type I topoisomerase to relax positive supercoils, and 
completion of replication leads to two interlinked catenanes. This catenated dimer 
requires Topo II for resolution.
57,98
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Figure 29. Roles of Topo II in replication. During replication, helicase action on DNA creates positive 
supercoils in front of the fork. This structure can isomerize into intertwinings of the daughter 
duplexes, generating precatenanes (a). At early steps in replication, when forks are widely separated, 
either Topo I or Topo II can function as a replication swivel. Topo I acts by relaxing positive supercoils 
whereas Topo II unlinks precatenanes. As the replication forks converge, there is a limited ability to 
generate positive supercoiling, and complete unlinking absolutely requires Topo II (b).
98
 
 
Although catenation of replicated chromosomes is presented as a problem, 
the generation of catenated sister chromatids may assist in the proper segregation of 
duplicated chromosomes. Although specialized protein complexes, called cohesions, 
are the main responsible for keeping sister chromatids together, cohesion can be 
maintained by multiple mechanisms, with catenanes representing one of them. 
Recent studies in mammalian cells support the hypothesis that Topo II has crucial 
functions at centromeric regions, although the molecular details remain to be 
elaborated. Support for a role for catenation in chromosome cohesion came from 
seminal studies on the regulation of yeast Topo II by the Small Ubiquitin-like 
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Modifier SUMO. Mutation of the SMT4, the isopeptidase that deconjugates SUMO, 
leads to precocious sister chromatid separation and the defect in cohesion was 
specific for regions near the yeast centromere. Biological functions of Topo II 
isoforms are actually modulated by a variety of protein-protein interactions that may 
affect enzyme activity, stability and localization.
57,98
 
A specific role for the enzymatic activity of a type II topoisomerase in 
transcriptional regulation was also established. A recent work demonstrated that 
Topo IIB associates with signal-dependent promoters as part of a complex that 
includes several proteins important for DNA repair, such as poly(ADP-ribose) 
polymerase, DNA-dependent protein kinase, and Ku70-Ku86, and that the enzymatic 
activity of Topo IIB was required for efficient transcriptional activation. Moreover, 
the result of other studies suggests that Topo IIB can also participate in repression of 
transcription, indicating important contexts in which Topo IIB influences regulation 
of gene expression.
57,98
  
Some aspects of Topo II function during the cell cycle are monitored by 
checkpoints. It has been hypothesized that a major role of checkpoints is to monitor 
the completino of decatenation. If so, then Topo II-dependent checkpoints may be 
crucial for normal chromosome segregation and genome stability.
98
  
Topoisomerase II is especially relevant in cancer because it is the target of 
many active anticancer agents. At present, most drugs targeting Topo II kill cells by 
generating enzyme-mediated DNA damage, rather than by inhibiting enzyme 
activity, as discussed below.
57 
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2.3 TOPOISOMERASES I/II INHIBITORS 
 
 
Topoisomerase-DNA cleavage complexes (ccs) are transient in nature and 
their cellular concentration is tightly regulated. Conditions that significantly alter the 
physiological concentration or lifetime of these breaks are responsible for DNA 
alterations that play a crucial role in inhibiting cell cycle progression. Although the 
biological functions of Topoisomerases are important for ensuing genomic integrity, 
the ability to interfere with the enzymes or generate enzyme-mediated damage is an 
effective strategy for cancer therapy. In this regard, DNA Topoisomerase I and II 
inhibitors represent an important class of anticancer agents, forming the basis of 
many chemotherapy combinations widely used in a broad spectrum of tumours.  
DNA Topoisomerases targeting drugs can be first divided on the basis of the 
mechanism used for altering the physiological function of the enzymes, in “poisons” 
and “pure inhibitors”:  
- “Poisons” stabilize the covalent DNA-Topos complex and thus generate DNA 
strand breaks. 
-  “Pure Inhibitors” do not induce an increase in cleavable complexes because they 
inhibit the enzyme activity acting on other steps of the catalytic cycle. 
 
2.3.1 Topoisomerase I inhibitors  
 
As previously described, topoisomerase I enzymes are essential in higher 
eukaryotes, as they are required to relax DNA supercoiling generated by 
transcription, replication and chromatin remodelling. DNA topoisomerases I are 
particularly vulnerable during their cleavage intermediate step (referred to as the 
cleavage complex). Despite their frequency throughout the genome, Topo I cleavage 
complexes are normally so transient that they are not detectable, but it is these 
complexes that are specifically and reversibly trapped by endogenous alterations to 
DNA (mismatches, abasic sites, nicks and adducts) and apoptotic alterations to 
chromatin, as well as by anticancer drugs such as camptothecin and its 
pharmaceutical derivatives.
110 
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Because Topo I inhibitors bind reversibly to Topo I ccs, and Topo I readily 
religates the cleaved DNA after drug removal, Topo I inhibitors do not directly 
damage DNA. It is Topo I itself that damages DNA in connection with DNA-helix-
tracking processes - primarily replication and transcription. As Topo I religation 
activity is slowed down by the drugs, replication and transcription complexes „catch 
up‟ and „collide‟ with the Topo I-DNA cleavage complexes, thereby generating 
irreversible Topo I covalent complexes as the 5′ end of the nicked DNA template 
becomes misaligned with its substrate (Figure 30). Therefore, it is DNA replication 
and/or transcription that convert the Topo I ccs, that are reversibly trapped by drugs, 
into irreversible Topo I covalent complexes and DNA damage. For this reason, Topo 
I inhibitors that trap Topo I ccs are commonly referred to as „Topo I poisons‟.110 
 
Figure 30. Conversion of TOP1 cleavage complexes into DNA damage by replication-fork collision and 
transcription.
110
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Camptothecin was first isolated from the bark of the Chinese tree, 
Camptotheca acuminata.
111,112
 It was discovered and developed by the US National 
Cancer Institute (NCI) at about the same time and by the same groups that were also 
working on paclitaxel (Taxol).
112
 Camptothecin carboxylate (Figure 31) was tested 
clinically in the mid 1970s and showed anticancer activity, but was discontinued 
because of its side effects.  
 
Figure 31. Camptothecin chemical structure and its conversion to the carboxylate inactive form. 
It was not until after the discovery that Topo I was the cellular target of 
camptothecin that the water-soluble derivatives of camptothecin -  topotecan and 
irinotecan (also known as CPT-11) - were successfully developed
113
 and recently 
approved by the US Food and Drug Administration. Topotecan for the treatment of 
ovarian and lung cancers; Irinotecan is “per se” a weak Topo I inhibitor, as its 
bispiperidine group has to be hydrolysed to yield the active metabolite SN-38, which 
shows a clinical efficacy in the treatment of colorectal cancer (Figure 32). 
 
Figure 32. Chemical structure of the Camptothecin derivatives Topotecan and Irinotecan.  
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New camptothecin derivatives are now in clinical trials. Among them, 
gimatecan given orally, and belotecan, i.v., have shown some activity in glioma. 
(Figure 33) 
 
Figure 33. Chemical structure of new camptothecin derivatives in clinical trials. 
The camptothecins are pharmacologically unique for several reasons. First, 
Topo I is their only target, as has been shown using yeast cells, which become totally 
resistant to camptothecin when the Topo I gene is removed.
114
 Second, changing the 
stereochemistry of camptothecin by inverting its chiral centre at position 20 
completely inactivates camptothecin. Third, camptothecins penetrate vertebrate cells 
readily and target Topo I within minutes of exposure; the cleavage complexes then 
reverse within minutes of camptothecin removal, thus allowing precise control of 
drug exposure and the trapping of Topo I ccs.
110
 
However camptothecins have also several limitations. First, Topo I ccs need 
to be maintained long enough to be converted into DNA damage which means that 
the drugs must be given as a prolonged infusion to maintain persistent cleavage 
complexes. Second, camptothecins produce side effects (such as leucopaenia) that 
limit the dose that can be safely administered and, therefore, the anti-tumour 
efficacy. The diarrhea that is induced by irinotecan can be severe and is probably due 
to „off-target‟ effects that are related to the bis-piperidine group that confers water-
solubility. Third, the α-hydroxylactone-ring of camptothecins is readily converted 
into a carboxylate (Figure 31), which is inactive against Topo I and binds tightly to 
serum albumin.
110
  
Two approaches have been taken to overcome the lactone ring instability. 
The first was to enlarge the ring by one carbon atom, which limits ring opening but 
also prohibits its reclosure.
115,116
 The corresponding compounds are synthetic and 
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named homocamptothecins (Figure 34). Diflomotecan is the clinical derivative. The 
second approach to stabilize the ring was to convert it from a 6- to a 5-membered 
ring. Complete stabilization of the ring has been successfully achieved with the 
synthesis of the α-keto derivatives exemplified by S39625117. This novel series 
provided a further test for the relationship between lack of ring opening and trapping 
of Topo Icc. 
 
Figure 34. Chemical structures of the homocamptothecin derivatives Diflomotecan and S39625. 
 
More recently, the search for non-camptothecin derivatives has led to the 
development of various Topo I inhibitors, including indolocarbazole, 
indenoisoquinoline, and phenanthridine derivatives (Figure 35).
118,119
 
  
 
Figure 35. Chemical structures of Non-camptothecin derivatives. 
Compared with camptothecins, they have the advantage of being chemically 
more stable, lacking the hydroxylactone moiety, and enabling the formation of 
persistent Topo I complexes, thus becoming good candidates for clinical 
development.
120
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2.3.2 Topoisomerase II inhibitors  
 
Many of the topological problems that arise in double-stranded DNA can be 
solved by the generation of either single or double strand breaks. However, where 
there is a clear requirement to alter DNA topology by introducing transient double 
strand breaks, only DNA topoisomerase II can carry out this reaction. DNA 
Topoisomerase II perform the remarkable feat of passing one double-stranded 
segment of DNA through a transient break in another, thus allowing to manipulate 
topological properties of DNA such as supercoiling, unknotting and decatenation as 
previously illustrated. Considering its crucial role in such important processes Topo 
II enzyme has been widely exploited for cancer therapy. 
Drugs targeting Topo II include both “poisons”, which comprise most of the 
clinically active agents, such as etoposide, doxorubicin and mitoxantrone , and “pure 
inhibitors”, such as bisdioxopiperazines (ICRF-187) or novobiocin, merbarone or the 
anthracycline aclarubicin. The “poisons” generate lesions that include DNA strand 
breaks and protein covalently bound to DNA, leading to increases in the levels of 
Topo II-DNA covalent complexes. The second class of compounds inhibits Topo II 
catalytic activity but does not generate increases in the levels of Topo II covalent 
complexes. Agents in this second class are thought to kill cells through the 
elimination of the essential enzymatic activity of Topo II and are therefore termed 
Topo II catalytic inhibitors. The generation of high levels of Topo II-DNA covalent 
complexes has profound effects on cell physiology. Topo II poisons effectively block 
transcription and replication.
48,121,122
  
DNA strand breaks are rapidly detected following treatment with Topo II 
poisons and most of the strand breaks are linked to proteins, as expected. Cells 
subsequently commit to apoptosis, and etoposide is an agent commonly used to study 
apoptotic processes. The pattern of responses observed with catalytic inhibitors of 
Topo II differs from the pattern observed with Topo II poisons, albeit with several 
important complications. Most catalytic inhibitors of Topo II are not specific, with 
the exception of bisdioxopiperazines. Although bisdioxopiperazines generate DNA 
damage responses following long-term exposure, they do not produce a DNA 
damage response following short-term exposure.
121,122
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- Topo II poisons: 
Topo II poisons can be further subdivided into intercalating and non-
intercalating poisons. The intercalators are a chemically diverse group, and include 
doxorubicin and other anthracyclines, mitoxantrone, mAMSA and a range of other 
compounds that are not currently in clinical use, such as amonafide and ellipticine. 
Non-intercalating Topo II poisons (Figure 36) include the epipodophyllotoxins 
etoposide and teniposide, and fluoroquinolones, which are mainly active against 
prokaryotic type II topoisomerases. As non-intercalating Topo II poisons do not 
interact strongly with DNA, it has been suggested that protein-drug interactions have 
key roles in the ability of Topo II poisons to trap Topo II covalent complexes.
121,122
 
 
Figure 36. Chemical structures of Topoisomerase II poisons. 
The precise mechanism of action of Topo II poisons remains an important 
unsolved question. Studies on the mechanism of camptothecins against 
topoisomerase I and other experiments with a mAMSA analogue suggest the 
presence of an intercalator at a protein-DNA interface, and a major effect of the 
inhibitor being a change in the geometry of the residues required for re-ligating the 
DNA strand break. It is likely that this type of model also extends to non-
intercalating Topo II poisons. For non-intercalating poisons, an initial drug-protein 
binary complex might be important for delivering the drug to a site where a stable 
ternary complex can be formed. Because Topo II poisons act at the point of cleavage 
and re-ligation, the relevant drug binding pocket might be formed by residues that 
form both the TOPRIM and winged-helix domains. The hypothesis is supported by 
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studies of fluoroquinolone action against prokaryotic Topo II enzymes. 
Fluoroquinolone-resistant mutations occur in both the TOPRIM and winged-helix 
domains, and rarely occur in other parts of the protein. Although this localization of 
mutations is consistent with a drug-binding pocket that consists of these two domains 
of the protein, direct localization of fluoroquinolones by structural approaches has 
not yet been accomplished.
121,122
 
 
- Topo II Catalytic inhibitors: 
Several classes of compounds that target Topo II without stabilizing Topo II 
covalent complexes have been described (Figure 37).  
 
Figure 37. Chemical structures of Topo II catalytic inhibitors. 
 
Topo II can be inhibited at several different points in the enzyme reaction 
cycle, with different biochemical and cellular consequences. One simple mode of 
inhibition is to inhibit a step early in the enzyme reaction cycle. For example, 
competitive inhibitors of ATP binding, such as novobiocin, prevent strand passage 
and do not generate enzyme-mediated DNA damage. Similar effects would occur 
with inhibitors that prevent the binding of Topo II to DNA such as aclarubicin. 
Agents that prevent DNA cleavage by Topo II such as merbarone would also be 
expected to act as simple catalytic inhibitors. Although merbarone clearly prevents 
DNA cleavage by Topo II, merbarone affects other targets besides Topo II. Finally 
Topo II can be inhibited after strand passage is completed but before ATP hydrolysis 
and dissociation of amino-terminal dimerization. Bisdioxopiperazines such as 
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dexrazoxane (ICRF-187) inhibit both ATP hydrolysis and maintain the Topo II 
structure as a closed clamp. Although these agents are frequently termed catalytic 
inhibitors, they leave Topo II trapped on DNA and might interfere with DNA 
metabolism in a manner that might be analagous to Topo II poisons. Nonetheless, as 
bisdioxopiperazines are specific for Topo II, they are the most commonly used 
catalytic inhibitors of Topo II in mammalian cells.
84,121,122
 
 
2.3.3 Dual Topoisomerases I and II Inhibitors 
Despite their efficiency in the clinic, current anticancer therapies with 
topoisomerase-directed agents are limited by some important negative consequences, 
with the most important ones arising from the observation that treatment with Topo 
II targeting drugs may result in secondary malignancies. Actually, there is evidence 
that Topo II-mediated strand breaks can trigger chromosomal translocations that lead 
to specific type of leukaemia.
123 
In addition, the emergence of drug-resistant tumour 
cells remains one of the major problems, and is a frequent cause of failure in long-
term clinical therapies. In this context, it has long been suggested that such resistance 
may be overcome, at least in part, by the ability of drugs to target both Topo I and 
Topo II simultaneously. Actually, new research strategies are now emerging, on the 
basis of the observation that drugs hitting a single target are inadequate for the 
treatment of diseases, like cancer, which involve multiple pathogenic factors.
124,125
 
Consequently, the clinical development of a single drug that has multiple biological 
properties, and is able to address multiple targets, may disclose new avenues also for 
the treatment of severe pathologies like cancer.  
In recent years, a number of compounds able to target both enzymes have 
been identified and described (Figure 38). The first and larger category includes 
compounds that bind to DNA by intercalation and includes Acridine (DACA), 
pyridocarbazole (intoplicine), and anthracycline derivatives (aclarubicine). A second 
class consists of hybrid molecules prepared by combining topoisomerase I with 
Topoisomerase II inhibitors, as the hybrids camptothecin-epipodophyillotoxin 
ellipticine-distamycin. A third class includes compounds like Tafluposide (F11782), 
obtained by structural modifications of compounds with selective activity against one 
or the other class of enzymes (Figure 38).
126
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Figure 38. Molecular structures of Dual Topoisomerase I and II inhibitors. 
 
Targeting both enzymes might increase overall anti-tumour activity, seeing 
that Topo I and Topo II have overlapping functions in DNA metabolism. It has also 
been suggested that the combination of a Topo I and a Topo II poison would help to 
prevent mechanism-based drug resistance, since alterations to the regulation of one 
Topo are often compensated by alterations in the other. For example, resistance to 
camptothecins may be due to down-regulation of Topo I, thereby leading to 
hypersensitivity to Etoposide as a consequence of a possible increase in Topo II 
expression to compensate for Topo I downregulation. However, the results from 
experimental trials with simultaneous or sequential exposure of tumour cells to 
Etoposide and to Topotecan or Irinotecan, demonstrated an antagonistic, rather than 
synergistic, behaviour including typically severe to life-threatening neutropenia and 
anemia. On the contrary, a single agent that jointly inhibit both Topos appears to 
combine the properties of the individual specific inhibitor, thus targeting a larger 
population of cells, and leading to a more promising anti-tumour activity.
126
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2.4 NEW DNA INTERCALATORS AND TOPOISOMERASES I/II 
INHIBITORS 
 
 
2.4.1 Recent findings 
 
The research unit I‟m working with, has extensively studied several 
polycyclic chromophores, structurally related to classes of DNA intercalating agents, 
that exhibited the ability to intercalate with DNA and in some cases to inhibit 
topoisomerases I/II. Among them were synthesized compounds (Figure 39) 
incorporating the purine (I), benzimidazole (II), and indole (III) moieties, and more 
recently it was developed an extensive study on the series of benzothiopyrano-indole 
derivatives with general formula (IV).
127-130
 
 
Figure 39. General structure of novel synthesized compounds incorporating the purine (I), 
benzimidazole (II), indole (III) and benzothiopyrano-indole (IV) unity.
130 
 
The described benzothiopyranoindoles showed an antiproliferative activity at 
low micromolar concentrations on HeLa (cervix adenocarcinoma) and HL-60 
(promyelocytic leukemia) human tumor cell lines (Table I). 
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Table I.
130 
                                  
Comp. X X’ R 
Cell lines IC50 (μM) 
HL-60 HeLa 
1a OCH3 H H > 20 > 20 
1b OCH3 OCH3 H > 20 > 20 
1c OCH3 Cl H > 20 > 20 
1d Cl H H > 20 > 20 
1e OCH3 H (CH2)2N(CH3)2 0.41 ± 0.08 1.30 ± 0.10 
1f OCH3 H (CH2)2N(C2H5)2 1.80 ± 0.06 2.70 ± 0.05 
1g OCH3 H (CH2)3N(CH3)2 1.90 ± 0.08 2.90 ± 0.3 
1h OCH3 H (CH2)3N(C2H5)2 2.40 ± 0.08 3.90 ±0.6 
1i OCH3 OCH3 (CH2)2N(CH3)2 0.66 ± 0.17 2.15 ± 0.50 
1l OCH3 OCH3 (CH2)2N(C2H5)2 1.10 ± 0.06 2.30 ± 0.40 
1m OCH3 OCH3 (CH2)3N(CH3)2 1.35 ± 0.10 2.60 ± 0.30 
1n OCH3 OCH3 (CH2)3N(C2H5)2 1.50 ± 0.12 2.50 ± 0.30 
1o OCH3 Cl (CH2)2N(CH3)2 1.17 ± 0.12 1.82 ± 0.87 
1p OCH3 Cl (CH2)2N(C2H5)2 0.71 ± 0.09 1.12 ± 0.20 
1q OCH3 Cl (CH2)3N(CH3)2 1.07 ± 0.24 1.85 ± 0.21 
1r OCH3 Cl (CH2)3N(C2H5)2 1.02 ± 0.18 1.68 ± 0.25 
1s Cl H (CH2)2N(CH3)2 1.31 ± 0.17 1.53 ± 0.24 
1t Cl H (CH2)2N(C2H5)2 3.21 ± 0.39 4.33 ± 0.80 
1u Cl H (CH2)3N(CH3)2 7.19 ± 0.69 14.05 ± 1.76 
1v Cl H (CH2)3N(C2H5)2 2.64 ± 0.60 2.91 ± 0.11 
Ellipticine    0.66 ± 0.02 0.29 ± 0.01 
 
 
The results showed the chromophore scaffold itself does not possess any 
significant antiproliferative effect. On the contrary the presence of a basic side chain 
(dialkylaminoalkyl) inserted at the 11-position on the indole nitrogen, seemed to be 
required for the cytotoxicity, allowing IC50 values ranging from 0.41 to 14.05 μM. 
The derivatives carrying the dimethylaminopropyl or diethylaminoethyl side chains, 
showed, within each class of analogues, a lower cytotoxic capacity, thus indicating 
that an increase in length and steric hindrance of the side chain seems to be 
detrimental for the antiproliferative activity. Actually, the most notable effect was 
shown by the compound 1e, carrying a dimethylaminoethyl side chain, along with a 
methoxy group in the 7 position and hydrogen in the 3 position, which was able to 
exert a cytotoxic effect higher than that of ellipticine on HL-60 cell line. 
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 Linear dichroism (LD) studies (Figure 40), revealed that compounds 1e-v 
were able to form a complex with DNA, which is consistent with an intercalative 
binding mode. Otherwise intercalation failed in the absence of the basic side chain 
(compounds 1a-d). Fluorimetric titrations in the presence of DNA characterized by 
different base compositions and synthetic polyDNAs interestingly demonstrated a 
high sequence specificity of the benzothiopyranoindoles for AT rich regions. These 
studies allowed us to identify two binding sites, S1 and S2. The binding parameters 
permitted the hypothesis that S1 participated in a binding event independent of base 
composition and mediated by the charged side chain, while S2 accounted for an 
intercalative complexation to AT rich regions, mediated by weak interactions. 
  
 
Figure 40. LD spectra for compounds 1a and 1e-h at [drug]/[DNA]=0.04 ; [DNA]=1.9x10
-3
M. Four 
other experiments gave similar results.
130
 
 
Molecular docking and high level quantum-mechanical calculations, 
including implicit solvent and a proper treatment of dispersion forces, allowed a 
further understanding at the molecular level of which specific interactions provide an 
optimal intercalative model, in agreement with the experimental data, for the ligand-
DNA complexes of the three most active compounds 1e, 1i, and 1p.  
This model showed a strong ion pair interaction between the protonated 
dimethylaminoethyl side chain and the phosphate backbone, with the side chain 
sitting in the DNA minor groove, and an extended π-π stacking interaction between 
the benzothiopyranoindole moiety and the two adjacent DNA base pairs (Figure 41). 
Hence, the crucial presence of the dialkylaminoalkyl side chain for achieving 
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significant cytotoxic effects was corroborated by the present model, which also 
suggested that the side chain may play the important role of favoring the complex 
formation by firmly anchoring the ligand to the DNA during the insertion of the 
benzothiopyranoindole moiety into the nucleic acid strands. 
 
 
Figure 41. Intercalation site of the two complexes between compounds 1e (orange, (a) and (b)) and 
1i (magenta, (c) and (d)) and hexamer d(TATATA)2 viewed in a projection plane orthogonal to the 
helix axis. Left: complexes with the protonated dimethylammonium group in the major groove ((a) 
and (c)). Right: complexes with the protonated dimethylammonium group in the minor groove ((b) 
and (d)). Nonpolar hydrogens were removed for clarity. H-bonds are represented with yellow dashed 
lines.
130
 
 
The ability of the new 11-substituted benzothiopyranoindoles to intercalate 
between DNA base pairs prompted further investigations into possible interference 
with the activity of the nuclear enzymes topoisomerases I and II. The derivatives 
showed the capacity to inhibit the relaxation of supercoiled plasmid DNA mediated 
by topoisomerase II in a dose-dependent manner (Figure 42), and interestingly, this 
ability appeared in accordance with the antiproliferative data. Moreover, for the most 
cytotoxic derivative 1e, a weak topoisomerase II poisoning effect (Figure  43) and 
the capacity to inhibit the topoisomerase I-mediated DNA relaxation (Figure 44), 
was also demonstrated. m-Amsacrine (m-AMSA), a well known topoisomerase II 
inhibitor, was used as reference.
130
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Figure 42. Effect on relaxation of supercoiled pBR322 DNA of human recombinant topoisomerase II. 
(A) Supercoiled DNA (DNA) was incubated with topoisomerase II in the absence (Topo II) and 
presence of 1i and 1e at indicated concentration (μM). Eight micromolar m-AMSA was used as 
reference. (B) SupercoiledDNA(DNA) was incubated with topoisomerase II in the absence (Topo II) 
and presence of 1a and 1e-h at 2.5 μM concentration; 8 μM m-AMSA was used as reference. The 
images are representative of three experiments. 
 
Figure 43. Effect of compound 1e on the stabilization of covalent DNA-topoisomerase II complex. (A) 
Supercoiled pBR322DNA(DNA) was incubated as reported in Experimental Section with 
topoisomerase II in the absence (Topo II) and presence of 1e at indicated concentration (μM); 8 
μMm-AMSA was used as reference. DNA samples were separated by electrophoresis on agarose gels 
containing 0.5 μg/mL ethidium bromide. (B) Experimental conditions as in (A), except where 
indicated (ATP). The images are representative of four experiments.  
 
Figure 44. Effect of compound 1e on relaxation of supercoiled pBR322 DNA by human recombinant 
topoisomerase I. Supercoiled DNA (DNA) was incubated with topoisomerase I in the absence (Topo I) 
and presence of 1e at indicated concentrations (μM). The image is representative of three 
experiments. 
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2.4.2 Novel Benzo- and Pyrido-thiopyranoindoles 
 
The successful results from the described benzothiopyranoindoles (1a-v) 
prompted the synthesis of novel derivatives in which I performed structural 
modifications suitable to further increase antitumor activity. In particular, on the 
same benzothiopyranoindole system, the methoxy group, which already seemed to 
positively influence the activity, was shifted from the 7 to the 3 position of the 
chromophore, and an additional methoxy group was eventually introduced into the 2 
position, allowing the synthesis of novel compounds of formula (2) (Figure 45). 
Furthermore, the pyridothiopyranoindole isosters (3) were also prepared; In 
this case the introduction into the chromophore of a protonable nitrogen atom, could 
provide an additional or alternative anchor point in the formation of the intercalation 
complex. All derivatives were functionalized with dialkylaminoalkyl chains, 
considering their crucial role for the biological activity. To this regard we decided to 
focus on the dimetylaminoethyl and diethylaminoethyl chains, as they characterized 
the most active compounds of the series (1). 
 
 
Figure 45. Chemical structure of the novel series of benzothiopyranoindoles 2 and 
pyridothiopyranoindoles 3. 
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- Benzothiopyranoindoles (2):  
 
 
                 
Figure 46. Chemical structure of the synthesized benzothiopyranoindoles (2a-h). 
 
The synthetic pathway leading to the benzothiopyranoindole derivatives 2a-h 
(Figure 46), required the preparation of the new tetracyclic systems 4a-d, 
characterized by the presence or the absence of a chlorine substituent in position 7 
(4c,d and 4a,b respectively) and with or without the additional methoxy group in 
position 2 (4b,d and 4a,c respectively). Compounds 4a-d were obtained following 
the synthetic procedure already described in literature,
131-135
 and illustrated in 
Scheme 1.  
Benzothiopyranone 5a and the 7-chloro substituted derivative 5c, were 
formylated with good yields to give 6a,b, by reaction with ethyl formate in the 
presence of sodium methoxide, in a 1:2:2 ratio respectively, in anhydrous toluene 
solution. Hydroxymethylen derivatives 6a,b, containing a methine active group, gave 
the desired 3-phenylhydrazono intermediates 7a-d, in particularly good yields, by 
coupling with the appropriately substituted diazonium salt using the Japp-
Klingemann reaction.
136
 The obtained compounds 7a-d were directly converted to 
the desired indoles 4a-d using the Fischer cyclization,
137
 by refluxing in ethanolic 
hydrogen chloride solution, with good to high yields (Spectroscopic and analytical 
data are reported in Chapter 4). 
 
 
 
 X X’’ R 
2a H H (CH2)N(CH3)2 
2b H H (CH2)N(C2H5)2 
2c Cl H (CH2)N(CH3)2 
2d Cl H (CH2)N(C2H5)2 
2e H OCH3 (CH2)N(CH3)2 
2f H OCH3 (CH2)N(C2H5)2 
2g Cl OCH3 (CH2)N(CH3)2 
2h Cl OCH3 (CH2)N(C2H5)2 
 
(2) 
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Scheme 1. 
 
 
Reagents and conditions: 
i) MeONa/MeOH, HCOOEt/anhydrous toluene, r.t., 24h N2 atm.  
ii) HCl 18%, NaNO2 aq. 0°C 
iii) AcONa/MeOH, 0°C, 0.5 h, r. t., 3 h  
iv) EtOH HCl, 80° 
 
 
Of particular interest in the reported procedure is the Japp-Klingeman 
reaction: an aqueous cooled solution of the appropriate p-anisidine diazonium salt is 
slowly dripped into a hydro-methanolic solution of derivative 6a or 6b, in the 
presence of sodium acetate; the immediate formation of an orange-red precipitate, 
corresponds to the desired arylhydrazone derivatives 7a-d, which are sufficiently 
pure to be used in the cyclization reaction that leads to the products 4a-d. The Japp-
Klingeman reaction probably proceeds with the formation of the intermediate 8, 
which through hydrolytic cleavage and loss of the formate ion, followed by the N=N 
double bond rearrangement, provides the desired arylhydrazone products. 
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8 
Intermediate 8 derived from direct binding between the anion of the 
compound containing the methine group and the diazonium cation, but it is also 
conceivable, as a first intermediate, the formation of an O-azo compound 9:  
 
9 
While the starting benzothiopyranone 5a is commercial, the 7-chloro substituted 
derivative 5c was synthesized according to the procedure illustrated below (Scheme 
2): 
Scheme 2. 
 
Reagents and conditions: 
i) 3-bromopropionic acid in NaHCO3 aq. and NaOH 10%, 100°C 3h  ii) H2SO4 r.t. 24h. 
 
 
The commercial 3-chloro-thiophenol was reacted with 3-bromopropionic acid 
in a sodium hydroxide solution, to obtain the 3-(2-carboxy-5-chloro-1-
phenylthio)propionic acid 10c; The subsequent cyclization to afford the 2,3-dihydro-
7-chloro-thiopyrano-4(4H)-one 5c was carried out by reaction of 10c with sulfuric 
acid for 24 hours at room temperature. 
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Tetracyclic derivatives 4a-d were then functionalized with the 
dimetylaminoethyl and diethylaminoethyl side chains, since in the previous study, 
they led to the most efficacious products, as already discussed. The alkylation of 
compounds 4a-d was carried out in anhydrous DMF using NaH to catalyze the 
reaction with the appropriate dialkylaminoalkyliodide hydroiodides (Scheme 
3).
138,139
 (The use of iodide derivatives, obtained by reacting the commercial chloride 
analogs with KI in ethanol, was made necessary because of the poor reactivity of the 
commercially available chloride compounds).  
Scheme 3. 
 
 
 
 
 
 
The new derivatives 2a-h, were purified by crystallization; then the treatment 
with anhydrous hydrochloric acid in ethanol, gave the corresponding hydrochlorides 
which were recrystallized with MeOH/Et2O. The final products were characterized 
by analytical and spectroscopic data that are consistent with the proposed structures 
(Chapter 4).  In particular the analysis of 2a-h IR spectra highlighted the absence of 
the band at approximately 3300 cm
-1
 relative to the NH stretching that characterized 
the tetracyclic starting products 4a-d. Likewise in the 2a-h 
1
H-NMR spectra the 
exchangeable singlet, observed around 12 ppm as characteristic of the indole NH 
proton of derivatives 4a-d, is lacking. The 
1
H-NMR spectra of the alkylated 
derivatives 2a-h also clearly shows the aliphatic protons signals, whose multiplicity 
is in agreement with the structure of the side chains introduced on the system 
(Section 4.2). 
4a X=H; X''=H 
4b X=H; X''=OCH3 
4c X=Cl; X''=H 
4d X=Cl; X''=OCH3 
 X X’’ R 
2a H H (CH2)N(CH3)2 
2b H H (CH2)N(C2H5)2 
2c Cl H (CH2)N(CH3)2 
2d Cl H (CH2)N(C2H5)2 
2e H OCH3 (CH2)N(CH3)2 
2f H OCH3 (CH2)N(C2H5)2 
2g Cl OCH3 (CH2)N(CH3)2 
2h Cl OCH3 (CH2)N(C2H5)2 
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- Pyridothiopyranoindoles (3): 
 
 
Figure 47. Chemical structure of the synthesized pyridothiopyranoindoles (V) 3a-f. 
 
The experimental procedure leading to the synthesis of the novel compounds 
3a-f (Figure 47), characterized by the pyridothiopyranoindole system, is similar to 
the procedure described above for the benzothiopyranoindole analogs.  
In this case, the key starting product is the carbonyl derivative 2,3-
dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 11, which was obtained by a procedure 
already described in literature.
140
 2-mercaptonicotinic acid, commercial product, is 
reacted with bromopropionic acid in a sodium hydroxide solution, to obtain the 
intermediate 3-(3-carboxy-2-pyridilthio) propionic acid 15. The subsequent 
cyclization to give the 2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 11 was 
carried out by heating derivative 15 in excess of acetic anhydride and in the presence 
of anhydrous sodium acetate at a temperature of 150° C (scheme 4).  
The pyridothiopyranone 11 was formylated with good yields to α-
hydroxymethylene derivative 12 by reaction with ethyl formate, following a protocol 
similar to that previously reported. An aqueous cooled solution of the appropriate 
diazonium salt was slowly dripped into a hydro-methanolic solution of the 
intermediate 12, in the presence of sodium acetate, to give the arylhydrazone 
derivatives 13a-c. The products did not required further purifications and were 
subject to indole Fisher cyclization, affording the pyridothiopyranoindole derivatives 
14a-c with low to good yields. 
 
 
 
 X’ X’’ R 
3a H H (CH2)N(CH3)2 
3b H H (CH2)N(C2H5)2 
3c Cl H (CH2)N(CH3)2 
3d Cl H (CH2)N(C2H5)2 
3e OCH3 OCH3 (CH2)N(CH3)2 
3f OCH3 OCH3 (CH2)N(C2H5)2 
 
(3) 
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Scheme 4. 
 
Reagents and conditions: 
i) 3-bromopropionic acid in aq. NaHCO3 and NaOH 10%, 60°C, 4h 
ii) AcONa/Ac2O, 160°C, 2h 
iii) MeONa/MeOH, HCOOEt/anhydrous toluene, r.t., 24h N2 atm. 
iv) HCl 18%, aq. NaNO2 0°C 
v) AcONa/MeOH, 0°C, 0.5 h, r.t., 3 h 
vi) EtOH HCl, 80° 
 
The tetracyclic derivatives 14a-c were then functionalized at position 6 with 
dimethylaminoethyl and diethylaminoethyl side chains, according to the same 
procedure previously described.
142
 The commercial dialkylaminoalkyl chlorides were 
converted again to the corresponding and more reactive iodides, which by 
condensation with 14a-c in anhydrous DMF at 100° C and in the presence of sodium 
hydryde, allowed to obtain the desired compounds 3a-f. (Scheme 5) 
 
 
 X’ X’’ 
a H H 
b Cl H 
c OCH3 OCH3 
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Scheme 5. 
 
 
 
 
 
 
The new derivatives 3a-f, were purified by crystallization and then the 
relative hydrochlorides were obtained. The characterization by analytical and 
spectroscopic data (Chapter 4.2), gave results that are consistent with the proposed 
structures. As for compounds of series 2, the most characteristic feature of the IR and 
1
H-NMR spectra of the products 3a-f is the absence of the typical NH indole signal. 
 
2.4.3 Biological evaluation 
The biological evaluation of all compounds synthesized in this thesis was 
conducted in collaboration with a research group of the Faculty of Pharmacy, 
University of Padua. In particular, the cytotoxic activity was first assessed and 
subsequently, the cellular mechanisms that may be involved were detailed.  
The antiproliferative activity is usually tested in vitro on human tumor cell 
lines, representative for different types of tissue: HeLa (cervical adenocarcinoma), 
A-431 (squamous cell carcinoma) and MSTO-211H (biphasic mesothelioma). The 
toxicity data are expressed as IC50 values, i.e. the concentration (µM) of compound 
able to produce 50% cell death with respect to the control culture using Ellipticine as 
a reference compound (Table II).  
 
 X’ X’’ R 
3a H H (CH2)N(CH3)2 
3b H H (CH2)N(C2H5)2 
3c Cl H (CH2)N(CH3)2 
3d Cl H (CH2)N(C2H5)2 
3e OCH3 OCH3 (CH2)N(CH3)2 
3f OCH3 OCH3 (CH2)N(C2H5)2 
 
 X’ X’’ 
14a H H 
14b Cl H 
14c OCH3 OCH3 
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Table II. Antiproliferative activity of the novel compounds 2a-h and 3a-f. 
 
 Y X X’ X” R HeLa A431 MSTO-211H 
2a CH H OCH3 H (CH2)2N(CH3)2 n.d. n.d. n.d. 
2b CH H OCH3 H (CH2)2N(C2H5)2 n.d. n.d. n.d. 
2c CH Cl OCH3 H (CH2)2N(CH3)2 n.d. n.d. n.d. 
2d CH Cl OCH3 H (CH2)2N(C2H5)2 n.d. n.d. n.d. 
2e CH H OCH3 OCH3 (CH2)2N(CH3)2 n.d. n.d. n.d. 
2f CH H OCH3 OCH3 (CH2)2N(C2H5)2 2.4±0.04 0.16±0.01 0.75±0.06 
2g CH Cl OCH3 OCH3 (CH2)2N(CH3)2 n.d. n.d. n.d. 
2h CH Cl OCH3 OCH3 (CH2)2N(C2H5)2 3.5±0.3 1.68±0.3 n.d. 
3a N H H H (CH2)2N(CH3)2 1.55±0.05 0.54±0.04 1.08±0.07 
3b N H H H (CH2)2N(C2H5)2 2.6±0.2 0.47±0.02 1.63±0.06 
3c N H Cl H (CH2)2N(CH3)2 n.d. n.d. n.d. 
3d N H Cl H (CH2)2N(C2H5)2 4.2±0.3 1.80±0.05 1.42±0.09 
3e N H OCH3 OCH3 (CH2)2N(CH3)2 1.7±0.1 0.71±0.10 0.35±0.03 
3f N H OCH3 OCH3 (CH2)2N(C2H5)2 6.9±1.2 2.7±0.7 0.62±0.01 
Ellipticine 0.320.01 0.430.02 0.460.08 
 
All tested compounds exert a significant antiproliferative activity on the 
considered cell lines, showing IC50 values ranging from 6.9 to 0.16 μM, in some 
cases comparable to those obtained for ellipticine. In particular HeLa seemed to be 
less sensitive than A431 and MSTO-211H cell lines, which actually displayed the 
best results. Considering the pyridothiopyranoindole analogues (3a-f) SAR 
indications on the side chain linked at the 11 position come out from our preliminary 
results: the derivatives characterized by the dimethylaminoethyl side chain (3a and 
3e) showed IC50 values lower than the analogues carrying the diethylaminoethyl 
group (3b and 3f). Moreover, the insertion of a chlorine in the 3 position appears 
detrimental for the antiproliferative effect on both HeLa and A-431 cells, while it 
does not affect the activity on MSTO-211H (compare 3b with 3d).  
Finally, the preliminary results obtained for the benzothiopyranoindoles 2a-h 
suggest also for these compounds a significant ability to inhibit cell growth, with 
IC50 values in the micromolar range. 
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To investigate the mechanism of action responsible for the cytotoxic activity 
of the new pyridothiopyranoindole derivatives 3a-f, linear flow dichroism (LD) 
experiments were performed in the presence of a solution of salmon tested DNA and 
two different concentration of test compounds. The results showed that all 
compounds are able to intercalate into DNA, as it appears in the LD spectra of the 
derivative solutions at two [DNA]/[drug] concentration ratios (Figures 48,49 relative 
to compounds 3e and 3f respectively). 
 
 
Figure 48. Linear flow dichroism spectra (LD) for DNA alone or in the presence of compound 3e at 
[DNA]/[Drug] ratios = 50 and 25. 
 
Figure 49. Linear flow dichroism spectra (LD) for DNA alone or in the presence of compound 3f at 
[DNA]/[Drug] ratios = 50 and 25. 
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The occurrence of a dichroic signal at wavelengths higher (330-450 nm) than 
that due to DNA bases (260 nm) indicates the ability of the pyridothiopyranoindole 
chromophore to form a molecular complex with DNA. Moreover, the negative sign 
of this induced signal suggests an orientation of the planar chromophore parallel to 
the plane of DNA bases, i.e. an intercalative mode of binding. Similar behaviours 
have been observed for the other pyridothiopyranoindoles and also for the 
benzothiopyranoindole derivatives. 
Considering that DNA Topoisomerases have been shown to be the molecular 
target of many anticancer drugs, including known DNA intercalators, such as 
adriamycin, m-AMSA and mitoxantrone, the effect of the new derivatives on the 
relaxation of supercoiled plasmid pBR322 DNA mediated by both Topoisomerase I 
and II was also investigated. The preliminary results (Figures 50a and 50b, related to 
compound 3e) indicate that unlike the benzothiopyranoindole analogs of series 1, the 
new pyridothiopyranoindoles do not inhibit the catalytic activity of both enzymes. 
Actually it was observed only a partial inhibition of Topoisomerase I, at a 
concentration of 50 M. 
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Figure 50a. Effect on relaxation of supercoiled pBR322 DNA mediated by Topo II. Supercoiled DNA 
(DNA) was incubated with Topo II in the absence (Topo II) and presence of 3e at indicated 
concentration (μM); 10 μM m-amsacrine (m-AMSA) was used as reference drug. 
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Figure 50b. Effect on relaxation of supercoiled pBR322 DNA by human recombinant Topo I. 
Supercoiled DNA (DNA) was incubated with Topo I in the absence (Topo I) and presence of 3e at 
indicated concentrations (μM). 
 
 
Further experiments were performed with the aim to verify the potential 
“poisoning” effect of the new pyridothiopyranoindoles. The occurrence of the 
cleavage complex can be evidenced by the enzyme-mediated formation of linear  
(Topo II) or nicked (Topo I) DNA from supercoiled. Experiments performed with the 
pyridothiopyranoindoles (3a-f) demonstrated the inability to induce any increase in 
Topoisomerase II-DNA covalent complexes, thus indicating that these derivatives 
are not Topo II poisons (Figure 51 as an example).  
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Figure 51. Effect on the stabilization of covalent DNA-Topo II complex. Supercoiled pBR322 DNA 
(DNA) was incubated with Topo II in the absence (Topo II) and presence of 3e at indicated 
concentration (μM); 10 μM m-AMSA was used as reference drug. DNA samples were separated by 
electrophoresis on agarose gel containing 0.5 μg/mL ethidium bromide. 
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As regard Topoisomerase I, preliminary results performed in the presence of 
3e show a poisoning effect on Topo I activity (Figure 52) and indeed, a 
concentration-dependent increase in nicked DNA can be observed in the presence of 
test compound. 
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Figure 52. Effect on the stabilization of covalent DNA-Topo I complex. Supercoiled pBR322DNA 
(DNA) was incubated with Topo I in the absence (Topo I) and presence of 3e at indicated 
concentration (μM); 0.5 μM camptotecine (CPT) was used as reference drug. DNA samples were 
separated by electrophoresis on agarose gel containing 0.5 μg/mL ethidium bromide 
 
The results obtained so far indicate the benzothiopyranoindole and the isoster 
pyridothiopyranoindole systems as excellent scaffold for the development of 
topoisomerases inhibitors. In particular, the benzothiopyranoindole derivatives are 
potential dual topoisomerase I and II inhibitors, while the pyridothiopyranoindole 
system seems to be suitable for obtaining efficacious topoisomerase I poisons. 
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3.1 Tyrosine Kinase receptors: VEGF/VEGFR family 
 
 
 
 
3.1.1 Tyrosine Kinase receptors (RTKs) 
 
 
Protein tyrosine kinases represent a wide family of homologous enzymes, 
both transmembranous and cytoplasmic, that catalyze the transfer of the γ-phosphate 
group from ATP to a hydroxy group of selected tyrosine residues in target protein 
substrates. Under physiological conditions, tyrosine phosphorylation represent a 
fundamental signal transduction mechanism that proceeds hierarchically in a ordered 
sequence of protein interactions, ensuring cross-talk between cells and regulating key 
aspects of cell life such as proliferation, differentiation, metabolism, and apoptosis.
1
 
Approximately 90 TK receptors have been identified, 58 of which are 
transmembrane receptor type (eg: EGFR, Epidermal Growth Factor Receptor) while 
32 are of the cytoplasmic “non receptor” type. Among the transmembrane receptor 
type, depending on their different structural features, approximately 20 RTK classes 
have been identified (Figure 1).
2 
 
 
 
Figure 1. Human Receptors Tyrosine Kinase.
2
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All RTKs have a similar molecular architecture, with a ligand binding region 
in the extracellular domain, a single transmembrane helix, a cytoplasmic region that 
contains the protein tyrosine kinase domain (TKD)  plus additional carboxy (C-) 
terminal and juxtamembrane regulatory regions, and an activation loop. The overall 
topology of RTKs, their mechanism of activation, and key components of the 
intracellular signaling pathways that they trigger are highly conserved in evolution 
from the nematode Caenorhabditis elegans to humans, which is consistent with the 
key regulatory roles that they play.
3
 
  
 
3.1.2 Mechanism of receptor activation 
 
The molecular mechanisms underlying activation of RTKs share common 
themes among the families but markedly differ in their details.  
 
- Ligand-induced dimerization of RTK extracellular regions: 
In general, ligand-binding activates RTKs by inducing receptor dimerization,
4
 
however it is important to note that a subset of RTKs forms oligomers even in the 
absence of an activating ligand.
5,6
 Whether the „inactive‟ state is monomeric or 
oligomeric, activation of the receptor still requires the bound ligand to stabilize a 
specific relationship between individual receptor molecules in an „active‟ dimer or 
oligomer. Early studies of RTKs and cytokine receptors suggested a conceptually 
straightforward mechanism for ligand-induced dimerization: a bivalent ligand 
interacts simultaneously with two receptor molecules and effectively cross-links 
them into a dimeric complex.
4
 However, additional paradigms are likely to emerge 
from more comprehensive studies of other RTK families.  
 
- Activation of intracellular kinase domains: 
Ligand-induced dimerization of the extracellular regions of RTKs leads to the 
activation of the intracellular tyrosine kinase domain (TKD) through different 
mechanisms. All TKDs presents a minor lobe (N-lobe),with the function to link ATP, 
allowing γ-phosphate transfer, and a larger lobe (C-lobe) which properly orients the 
γ-phosphate and allows protein substrate interaction. Crystal structures of the 
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activated forms of TKDs of RTKs are all very similar while the structures of inactive 
TKDs differ substantially from receptor to receptor, and this variation reflects the 
diversity in their regulatory mechanisms.
7,8
 Each TKD is uniquely cis-autoinhibited 
by a set of intramolecular interactions, that occlude the active site, blocking access of 
ATP and/or protein substrates.
9
 Release of cis-autoinhibition, following ligand-
induced receptor dimerization, is the key event that triggers RTK activation and it 
occurs through an auto-phosphorilation process: auto-phosphorylation of the 
activation loop,
7,8
 of key tyrosines in the juxtamembrane region
10,11 
or in the C-
terminal tail,
12
 or also trans-phosphorylation between dimers,
13
 disrupt the cis-
autoinhibitory configuration so that TKD can adopt the characteristic active 
configuration.  
 
- Linking RTK activation to cell signaling: 
Once the TKD is activated, additional tyrosines are then autophosphorylated 
in other parts of the cytoplasmic region of most RTKs in a precise order. The 
resulting phosphotyrosines serve as specific sites for the assembly of downstream 
signaling molecules that are recruited to the receptor and activated in response to 
ligand stimulation.
14,15
 These molecules contain Src homology-2 (SH2) or 
phosphotyrosine-binding (PTB) domains that specifically bind to phosphotyrosine 
and start different signaling cascades. They may be directly recruited to 
phosphotyrosines in the receptor, or they may be recruited indirectly by binding to 
docking proteins that are phosphorylated by RTKs with which they associate.
16,17
  
With multiple phosphotyrosines in most receptors and the involvement of 
numerous docking proteins, activated RTKs clearly can recruit and influence a large 
number of different signaling molecules. Therefore, an activated RTK can be thought 
of as a node in a complex signaling network that transmits information from the 
exterior to the interior of the cell. 
 
- RTKs as nodes in complex signaling networks: 
As the first SH2 domain-containing proteins, Ras exchange factors, MAP 
kinases, and other proteins involved in RTK signaling were being identified, the 
prevailing view was that these components comprise linear signaling pathways.
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A key example that appeared to support this hypothesis was the RTK-Grb2-
Sos-Ras/MAP kinase pathway;
 
Genetic experiments further supported this linear-
pathway view.
18
 However, several emerging facts clearly suggested that a more 
complicated and intertwined signaling network must exist for RTKs. First, RTKs 
such as EGFR have multiple autophosphorylation sites that can each recruit different 
SH2 and PTB domain-containing proteins; second, a given adaptor or scaffold 
protein can interact with multiple signaling molecules.
19,20
 Furthermore as 
biochemical analyses advanced, it became clear that all pathways previously thought 
to be linear are in fact highly interconnected into a complex and dynamic signaling 
network, with RTKs functioning as key regulatory nodes. Experimentally, this fact is 
underscored by very early experiments showing that activation of a given RTK by its 
ligand has dramatically different effects depending on the RTK‟s expression level 
and the kinetics of its activation.
21
 Moreover, it has become clear that positive and 
negative feedback loops, both within and between different levels, play key roles in 
regulating the „information flow‟ through the bow tie network, and can explain many 
emergent properties of the system.
22,23
 
 
 
3.1.3 Vascular Endothelial Growth Factor (VEFG) family 
 
The VEGF family and its receptors play an integral role in angiogenesis, 
lymphangiogenesis, and vasculogenesis. The human VEGF family consists of five 
members: VEGF (or VEGF-A), VEGF-B, VEGF-C, VEGF-D, and placental growth 
factor (PlGF). Moreover, alternative splicing of their corresponding pre-mRNAs 
generates multiple isoforms of VEGF, VEGF-B, and PlGF.
24,25
  
These growth factors are produced by many different cell types and typically 
act locally, in a paracrine manner. However, VEGFA is produced in endothelial cells 
and may act in an autocrine manner on VEGFRs expressed in the same cell.
26
  
All VEGF isoforms are hydrophilic and freely diffusible in simple buffered 
solutions. However, some isoforms contain heparan sulfate proteoglycan-binding 
domains that limit their diffusibility in vivo because of their affinity for anionic 
proteoglycans located on the plasma membrane of cells and in the extracellular 
matrix.
27
 Their release is mediated by extracellular proteases including plasmin and 
matrix metalloproteases.
28
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VEGFs are homodimers containing a cystine knot motif that is essential for 
establishing the tertiary structure.
29 
(Figure 2)  
 
 
Figure 2. Structure of a VEGF molecule (determined with synchrotron light at the SLS, Paul Scherrer 
Institute) 
 
- VEGF-A 
The discovery of VEGF (VEGF-A) represents the convergence of work by 
several groups beginning in the 1980s (Senger et al. in 1983, and Ferrara and Henzel 
in 1989).
30,31
 Different molecular weight of VEGF were determined (34 to 46 kDa) 
probably because of partial proteolysis, different degrees of N-glycosylation, or the 
production of isoforms related to alternative splicing of pre-mRNAs. X-ray 
crystallographic structure of human VEGF-A showed an antiparallel homodimer 
covalently linked by two disulfide bridges, with three other disulfide bridges for each 
monomer.
32
 VEGF-A, which contains an N linkage glycosylation site, consists of 
nine isoforms that result from alternative splicing of pre-mRNA transcribed from a 
single gene containing eight exons with the VEGF-165 as predominant isoform 
followed by the 189 and 121 residue molecules.
25,33
 VEGF-A, which can bind both 
VEGFR1 and VEGFR2, is a mitogen and survival factor for vascular endothelial 
cells. It also promotes vascular endothelial cell and monocyte motility, and 
selectively and reversibly permeabilizes the endothelium to plasma and plasma 
proteins, without leading to injury.
31,34,35
 Experiments with VEGF-A null mice, 
which die at embryonic Day 8.5, exhibit impaired vasculogenesis and blood-island 
formation indicating that VEGF-A participates in the earliest stages of embryonic 
vasculogenesis. Moreover, loss of a single VEGF-A allele in mice leads to vascular 
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deformities and embryonic death between Days 11 and 12.
36,37
 VEGF-A mRNA and 
protein are expressed in many tissues and organs (especially lung, adrenal, heart, and 
kidney) but also in a wide variety of human malignancies, thus representing an 
important anti-cancer target.
25
  
 
- VEGF-B 
VEGF-B consists of two isoforms that result from alternative splicing of pre-
mRNA synthesized from a single gene containing seven exons.
38
 VEGF-B186, is 
freely diffusible while VEGF-B167, the predominant isoform, binds to heparan 
sulfate proteoglycan and is not freely diffusible in vivo. Both VEGF-B isoforms exist 
as disulfide-linked homodimers. The highest levels of VEGF-B transcripts occur in 
brain, heart, kidney, and testes but it is also expressed in several human neoplasms.
39 
The function of VEGF-B is unclear: it seems to be required for normal heart function 
in adults but is not required for cardiovascular development or for angiogenesis. 
However, its expression in human tumors and its ability to activate VEGFR1 and 
neuropilin-1 indicate that VEGF-B represents a potential anti-cancer target.
40
 
 
- VEGF-C 
VEGF-C is synthesized as a prepro-protein that undergoes intricate 
proteolytic processing to generate the mature form of the growth factor, which exists 
as a homodimer lacking inter-subunit disulfide bonds. Human adult heart, ovary, 
placenta, skeletal muscle, and small intestine contain high levels of VEGF-C mRNA, 
but modest amounts were also found in other tissues.
 41
 The fully processed form of 
VEGF-C binds to both VEGFR2 and VEGFR3 and participates in 
lymphangiogenesis during embryogenesis and in the maintenance of differentiated 
lymphatic endothelium in adults.
42 
About half of VEGF-C null mice die between 
embryonic days 15.5 and 17.5 and none survive gestation, indicating the essential 
nature of this factor. VEGF-C is indispensable for embryonic lymphangiogenesis, 
while blood vessels develop normally in VEGF-C null mice. Moreover, VEGF-C is 
expressed by a significant fraction of human tumors, making it a potential anti-cancer 
target.
43
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- VEGF-D 
Like VEGF-C, VEGF-D is synthesized as a prepro-protein that undergoes 
intricate proteolytic processing to generate the mature form of the growth factor. 
Mature VEGF-D is a non-covalent homodimer and  binds to both VEGFR2 and 
VEGFR3.
44
 In contrast to VEGF-C null mice, VEGF-D null mice are viable and 
exhibit normal lymphangiogenesis during development and normal lymphatics in 
mature animals thus suggesting that VEGF-C and perhaps other factors can substitute 
for VEGF-D.
45 
Adult colon, heart, lung, skeletal muscle, and small intestine contain 
high levels of VEGF-D transcripts and as the other VEGFs, it also results up-
regulated in several tumors, representing a potential anti-cancer target.
46-48
 
 
- PlGF 
Placental growth factor is a homodimeric glycoprotein that shares 42% amino 
acid sequence identity with VEGF allowing the same inter- and intra-subunit 
disulfide bonds. The PlGF gene contains seven exons and expresses four isoforms 
(PlGF-131, -152, -203, and -224).
49,50
 PlGF isoform transcripts occur primarily in 
placenta but they could also be found in other healthy or tumoral tissues.
51-53
 PlGF 
null mice are viable and fertile, but they exhibit diminished vascularization of the 
retina and the corpus luteum.
54
 
 
 
• Regulation of VEGF gene expression 
 
 
The action of growth factors is regulated at several levels including gene 
expression, protein transcription, translation, secretion, translocation to the site of 
action, receptor activation, and inactivation by endocytosis and proteolytic 
degradation. With regard to the VEGFs gene expression, it was proved to be 
regulated by many factors including the hypoxia-inducible transcription factor (HIF), 
growth factors, hormones, oncogenes, and tumor suppressor genes. 
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- Hypoxia-inducible transcription factor (HIF):  
The cellular concentration of oxygen plays a key role in regulating the 
expression of 50–500 or more genes.55 When the oxygen concentration is low 
(hypoxia), the expression of many proteins including glucose transporters, enzymes 
of the glycolytic pathway, erythropoietin, and VEGF increases. The augmentation of 
these gene products constitutes an adaptive response to hypoxia. Actually glucose 
catabolism is the only metabolic pathway in vertebrates to generate substantial 
amounts of ATP in the absence of oxygen; erythropoietin increases red blood cell 
production leading to increased oxygen transport; increased VEGF production 
promotes angiogenesis, which in turn leads to increased red blood cell and oxygen 
delivery. The HIF family lies at the center of the adaptive response to hypoxia in 
embryos, growing animals, and adults.
56
  
HIF is a heterodimer composed of HIF-1α and HIF-1β. Oxygen regulates 
HIF-1α cell content and activity by mechanisms that involve: (i) hydroxylation of 
proline 564 (preferred) or proline 402 and (ii) hydroxylation of asparagine 803. 
Hypoxia decreases HIF-1α prolyl and asparaginyl hydroxylation that occur in 
normoxic conditions. As a result of diminished prolyl hydroxylation, HIF-1α is 
stabilized and forms a dimer with HIF-1β, thereby forming the transcription factor. 
As a result of diminished asparaginyl hydroxylation, HIF-1α, complexed with HIF-
1β, is able to interact with transcriptional co-activators such as p300 or CBP (CRE 
binding protein, where CRE is the cyclic AMP response element of genes), that are 
histone acetyltransferases which promote transcription of target genes. Hypoxia 
inducibility of genes is conferred by a hypoxia response element (HRE) that occurs 
in the promoter or enhancer of target genes.
56,57
  
Using a systems biology approach, Manalo et al. founded that hypoxia 
increased the gene expression of VEGFA, VEGF-C, PlGF, and PDGF-B, all of 
which are implicated in angiogenesis. VEGFA has a hypoxia response element 
(HRE), but the mechanism of induction of the other three of these growth factors is 
ill defined.
55
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- Growth Factors and Hormones: 
Although the role of hypoxia has been more thoroughly investigated, it is 
clear that growth factors and hormones also regulate VEGF gene expression.
24,25
 
 
Table 1. Selected growth factors and hormones that increase VEGF expression. 
Growth factor/hormone 
Basic fibroblast growth factor (bFGF) 
Epidermal growth factor (EGF) 
Follicle-stimulating hormone (FSH) 
Heparin-binding epidermal-like growth factor (HB-
EGF) 
Insulin 
Insulin-like growth factor-1 (IGF-1) 
Interferon-β (IFN-β) 
Interleukin-1 (IL-1) 
Interleukin-6 (IL-6) 
Luteinizing hormone (LH) 
Platelet-derived growth factor (PDGF) 
Progesterone 
Testosterone 
Transforming growth factor-β (TGF-β) 
Tumor necrosis factor-α (TNF-α) 
 
- Oncogenes: 
Mutations that result in the conversion of proto-oncogenes to oncogenes 
occur in a variety of cancers. It would not be surprising if these gain-of-function 
mutations lead directly or indirectly to angiogenesis because of increased pro-
angiogenic signaling and to decreased anti-angiogenic signaling. Mutations of the 
Ras proto-oncogene occur in a large fraction of human cancers.
58,59
 One function of 
Ras is to activate the Raf-Mek-Erk MAP kinase cascade which leads to the increased 
expression of VEGF. Several studies concluded that the amplification of Ras leads to 
increased VEGF expression in a variety of tumors. In addition to Ras and Raf other 
oncoproteins, including Myb, Myc, HER-1 (EGFR), HER-2, Fos, Bcl-2, were found 
to directly or indirectly stimulate angiogenesis.
60,61
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3.1.4 Vascular Endothelial Growth Factor Receptors (VEFGR) 
 
There are three receptor protein-tyrosine kinases for the VEGF family of 
ligands (VEGFR1, VEGFR2, and VEGFR3) and two non-enzymatic receptors 
(Neuropilin-1 and -2). Moreover, several of the VEGF family ligands bind to 
heparan sulfate proteoglycans (HSPG) that are found on the plasma membrane and in 
the extracellular matrix. The five VEGFs present different affinities to the three 
VEGFRs, initiating homo- and hetero-dimer formation (Figure 3 and Table 2).
62
 
 
 
 
 
Figure 3. VEGF binding specificities and VEGFR signalling complexes. 
Schematic outline of the five VEGFs, VEGFA, VEGFB, VEGFC, VEGFD and PlGF, binding with different 
affinities to three VEGFRs, initiating VEGFR homo- and hetero-dimer formation. JMD, 
juxtamembrane domain; KID, kinase insert domain; TMD, transmembrane domain; TKD1, ATP-
binding domain; TKD2, phosphotransferase domain. 
 
 
 
 
 
Receptor VEGFR1 VEGFR2 VEGFR3 Neuropilin-1 Neuropilin-2 
Ligands VEGF, VEGF-B, PlGF VEGF, VEGF-C, 
VEGF-D 
VEGF-C, 
VEGF-D 
VEGF, PlGF, 
VEGF-B, VEGF-
C, VEGF-D 
VEGF, VEGF-C, 
VEGF-D 
Functions Vasculogenesis, 
Angiogenesis and 
monocyte/macrophage 
motility 
Vasculogenesis, 
Angiogenesis, 
vascular 
permeability 
and endothelial 
cell motility 
Vascular and 
lymphatic 
development 
and 
maintenance 
Vascular 
maturation, 
branching, 
heart 
development 
Lymphangiogenesis 
 
Table 2. VEGF receptors, ligands and functions. 
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The VEGF receptor protein-tyrosine kinases consist of an extracellular 
component containing seven immunoglobulin-like domains, a single transmembrane 
segment, a juxtamembrane segment, an intracellular protein-tyrosine kinase domain 
that contains an insert of about 70 amino acid residues, and a carboxyterminal tail 
(Figure 4).
63
  
 
 
 
Figure 4. Organization of the VEGF receptor protein–tyrosine kinases. Numbers on the right of each 
receptor correspond to human tyrosine residue phosphorylation sites. The relative lengths of the 
receptor components are to scale.
63
 
 
 
These enzymes catalyze the following reaction: 
 
MgATP
1-
 + Protein-OH → Protein-OPO3
2-
 +MgADP + H
+
 
 
where -OH is a tyrosyl hydroxyl group. Moreover, there are two non-enzymatic 
VEGF family co-receptors (neuropilin-1 and neuropilin-2). 
 
- VEGFR dimerization and activation of the kinase: 
Binding of VEGF occurs to the N-terminal part of the extracellular domain of 
the receptor, and can take place in cis, e.g. by freely diffusible VEGF or by 
presentation of VEGF through co-receptors expressed on the same cell as the 
VEGFR, or in trans, e.g. by presentation through co-receptors expressed on adjacent 
cells.
64,65
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Dimerization of receptors to form homo- or hetero-dimers is necessary, but 
not sufficient, for receptor activation. Dimerization is stabilized by contact points 
between receptor extracellular domains in Ig-loop 7. VEGF binds to the second 
immunoglobulin domain of VEGFR1 and the second and third immunoglobulin 
domains of VEGFR2. Although it is likely that VEGF-C and VEGF-D bind to the 
second or second and third immunoglobulin domains of VEGFR3, this has 
apparently not been addressed.
66,67
  
According to the model for activation of receptor tyrosine kinases previously 
illustrated, dimerization is accompanied by changes in the intracellular domain 
conformation, which lead to autophosphorylation of tyrosine residues within the 
activation segment of the kinase domain, thus stimulating catalytic activity. 
Autophosphorylation of tyrosine residues at other locations generates docking 
sites for modular Src homology 2 (SH2) and phosphotyrosine binding (PTB) 
domains that recognize phosphotyrosine in sequence-specific contexts.  
There are at least two possible mechanisms for autophosphorylation: cis and 
trans. In a cis mechanism, a receptor monomer catalyzes its own phosphorylation. A 
trans mechanism occur, in case of phosphorilation between monomers of the same 
receptor, or in the case of intermolecular phosphorilations, between different 
receptors. A cis mechanism predicts that auto-phosphorylation will be enzyme 
concentration-independent while a trans mechanism will be enzyme-concentration-
dependent.
62,63
 
 
- VEGFR protein kinase core: 
The VEGFR2 protein-tyrosine kinase core has the characteristic bilobed 
architecture observed in all protein kinases (Figure 5). The active site is located in 
the cleft between the two lobes and consists of residues contributed by both lobes. 
There are two general types of conformational changes associated with 
protein kinases. The first involves the interconversion of inactive and active states. 
Inactivation-activation involves changes in the position of the αC helix in the N-lobe 
and the conformation of the activation segment in the C-lobe. The second type of 
conformational change occurs in the active state as the two lobes move relative to 
each other to open and close the cleft as the enzyme goes through its catalytic cycle: 
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ATP and protein substrate bind to the open conformation, catalysis occurs in 
the closed conformation, and ADP and phosphorylated substrate are released during 
progression to the open state that completes the cycle. The three-dimensional 
structures of the protein kinase cores of VEGFR1 and VEGFR3 have not yet been 
solved crystallographically, but they are expected to conform to the canonical 
structures of other protein kinases.
63
 
 
 
 
Figure 5. Structure of the protein kinase catalytic core of VEGFR2. The αC helix is colored blue, the 
catalytic loop is green, and the activation segment is magenta. The glycine-rich loop is hidden by 
Lys868.
 63
  
 
 
The smaller N-terminal lobe has a predominantly antiparallel β-sheet 
structure. A glycine-rich (GXGXXG) ATP-phosphate binding loop occurs in each of 
the VEGF receptors. The larger C-terminal lobe, which is predominantly α-helical in 
nature, contains the catalytic loop and the activation segment. Hanks and 
colleagues,
68
 identified 12 subdomains with conserved amino acid signatures and in 
particular the role of three amino acids was described. 
- Lys868: in the activated enzyme, Lys868 is an invariant residue that forms 
ion pairs with the α- and β-phosphates of ATP and with Glu885 of the αC helix. In 
the inactive enzyme, which lacks ATP bound, Lys868 binds instead to an activation 
segment phosphotyrosine and is far from Glu885.  
- Asp1028: orients the tyrosyl group of the substrate protein in a catalytically 
competent state.  
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- Asp1046: is part of a magnesium-binding loop, binds to Mg
2+
 that in turn 
coordinates the β and γ phosphate groups of ATP; Asp1046 also binds to the α-
phosphate. 
Within each lobe there‟s a polypeptide segment that can assume active and 
inactive orientations. In the small N-lobe, this segment is the αC helix which rotates 
and translates with respect to the rest of the lobe, making or breaking part of the 
catalytic site. C-lobe differs between active and inactive enzymes. In protein kinases 
that are in the inactive state, the activation loop is positioned to prevent protein 
substrate binding and phosphorylation of the activation segment stabilizes it in its 
active conformation.
63,69
 
 
 
 
Figure 6. Diagram of the inferred interactions between the human VEGF receptor 2 protein–tyrosine 
kinase catalytic core residues, ATP, and a protein substrate. Catalytically important residues that are 
in contact with ATP and protein substrate occur within the light khaki background. Secondary 
structures and residues that are involved in regulation of catalytic activity occur within the gray 
background. Hydrophobic interactions between the HRD motif, the DFG motif, and the aC helix are 
shown by black arrows while polar contacts are indicated by dashed lines. Pho refers to a 
phosphotyrosine within the activation segment. copyright Proceedings of the National Academy of 
Sciences USA.
63
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- VEGFR1 structure, expression and signaling: 
VEGFR1 (Flt-1, fms-like tyrosyl kinase-1, where fms refers to feline 
McDonough sarcoma virus) is a 180–185 kDa glycoprotein that is activated in 
response to binding of VEGFA, VEGFB and PlGF. The ligands bind to Ig loop 2, but 
loops 1 and 3 are also required for high-affinity binding.
62,70,71
  
VEGFR1 is expressed in vascular endothelial cells at relatively high levels 
throughout development and in the adult. In addition, a wide range of non-
endothelial cells, such as monocytes and macrophages, human trophoblasts, renal 
mesangial cells, vascular smooth muscle cells, dendritic cells and different human 
tumour cell types, express VEGFR1. VEGFR1 expression is regulated by hypoxia 
through a hypoxia-inducible enhancer element in the VEGFR1 promoter. Alternative 
splicing of VEGFR1 results in the generation of sVEGFR1 (soluble VEGFR1), 
encompassing the N-terminal six extracellular Ig-loops.
72-74
 
 
 
Figure 7. VEGFR1 tyrosine phosphorylation sites and signal transduction 
Schematic outline of activated and dimerized VEGFR1 with tyrosine (Y) phosphorylation sites and 
downstream signalling pathways. 3D, three-dimensional; JAK, Janus kinase; NFAT, nuclear factor of 
activated T-cells; PKB, protein kinase B; RACK1, receptor for activated C-kinase 1; SHP2, SH2-domain-
containing protein tyrosine phosphatase 2; STAT, signal transducer and activator of transcription. 
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Although VEGFR1 binds VEGFA with higher affinity than does VEGFR2 
(Kd =15 pM compared with 750 pM), VEGFR1 tyrosine kinase activity is only 
weakly induced by its ligands.
75
 Actually Gille et al.
76
 identified a repressor 
sequence in the juxtamembrane domain of VEGFR1. Moreover, structural properties 
of the activation loop of VEGFR1, including the lack of positive regulatory tyrosine 
residues, contribute to the poor kinase activity.
77 
 
By overexpression of VEGFR1 in insect cells or mammalian cells, several 
VEGFR1 tyrosine phosphorylation sites have been identified, namely Tyr
794
, Tyr
1169
, 
Tyr
1213
, Tyr
1242
, Tyr
1327
 and Tyr
1333
.
77
 Interestingly, the pattern of tyrosine 
phosphorylation of VEGFR1 depends on the ligand. In vitro phosphorilation studies 
showed that PlGF, but not VEGFA, induces phosphorylation of Tyr
1309
. Furthermore 
Tyr
794
 and Tyr
1169
 are involved in binding and activation of PLCγ , resulting in 
intracellular Ca
2+
 fluxes and generation of inositol 1,4,5-trisphosphate. Tyr
1213
 binds 
different SH2- containing proteins, such as PLCγ, GRB (growth-factor-
receptorbound protein) 2, Nck (non-catalytic region of tyrosine kinase adaptor 
protein) and SHP-2 (SH2-domain-containing protein tyrosine phosphatase 2), and, 
according to other studies, also the p85 subunit of PI3K. Clearly, further analyses are 
required to determine the biological role of VEGFR1-interacting signal 
transducers.
78-80
 
The exact role for VEGFR1 in endothelial cells is disputed. Several studies 
imply that VEGFR1 is dispensable for proliferation or migration of endothelial cells 
in vitro. On the other hand, VEGFR1-neutralizing antibodies have been employed to 
implicate VEGFR1 in endothelial cell reorganization and migration through RACK1 
(receptor for activated C-kinase 1). VEGFR1 may regulate endothelial cells via 
cross-talk with VEGFR2, through dimerization, through transphosphorylation 
independently of heterodimerization and through regulation of receptor expression 
levels.
81,82
  
VEGFR1–VEGFR2 heterodimers would form as a consequence of VEGFA 
binding, but not PlGF or VEGFB binding, since these latter ligands bind only to 
VEGFR1.
83
 Mouse models expressing recombinant variants of VEGFR1 have been 
instrumental in revealing its complex biology. VEGFR1−/− embryos die at 
embryonic day 9 due to increased proliferation of endothelial cells and a severe 
disorganization and dysfunction of the vascular system. Deletion of the intracellular 
VEGFR1 TK domain is, however, compatible with vascular development. This 
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suggests that in endothelial cells, VEGFR1 as well as sVEGFR1 may act as a VEGF 
decoy, serving to spatially control VEGFR2 signalling and formation of angiogenic 
sprouts. Importantly, mice expressing a TK-deficient VEGFR1 (VEGFR1 TK−/−) 
fail to mount an inflammatory response in pathologies such as cancer.
84,85
  
However the molecular mechanisms underlying the different functions of the 
two VEGFR1-specific ligands PlGF and VEGFB remain to be identified. 
 
- VEGFR2 structure, expression and signaling: 
VEGFR2 [also known as KDR in the human and Flk1 (fetal liver kinase-1) in 
the mouse] is a 210-230 kDa glycoprotein that binds VEGFA, with a 10-fold lower 
affinity than VEGFR1, but also VEGFC and VEGFD. Ligand binding involves 
extracellular Ig-like domains 2 and 3 of VEGFR2. Alternative splicing results in the 
generation of sVEGFR2, which is present in various tissues such as the skin, heart, 
spleen, kidney and ovary, and in plasma. sVEGFR2 binds VEGFC and prevents 
binding to VEGFR3, consequently inhibiting lymphatic endothelial cell 
proliferation.
67,86,87
 
VEGFR2 is expressed most prominently in vascular endothelial cells and 
their embryonic precursors, with highest expression levels during embryonic 
vasculogenesis and angiogenesis. VEGFR2 is also found in a range of non-
endothelial cells such as pancreatic duct cells, retinal progenitor cells, 
megakaryocytes and haemopoietic cells.
88
  
VEGFR2 expression is induced in conjunction with active angiogenesis, such 
as in the uterus during the reproductive cycle, and in pathological processes 
associated with neovascularization, such as cancer.
89 
 
VEGFR2 is known to transduce the full range of VEGF responses in 
endothelial cells, i.e. regulating endothelial survival, proliferation, migration and 
formation of the vascular tube (Figure 8).   
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Figure 8. VEGFR2 tyrosine phosphorylation sites and signal transduction 
Schematic outline of activated and dimerized VEGFR2. Upon VEGFA binding to extracellular Ig-like 
domains 2 and 3 of VEGFR2, signalling molecules bind to respective tyrosine phosphorylation sites in 
the intracellular domain of VEGFR2 and activate downstream mediators. Tyr
1054
 and Tyr
1059
 are 
crucial for VEGFR2 kinase activity. The complex network of intracellular signal transduction pathways 
results in biological responses such as proliferation, migration, survival and permeability, which are 
all required for the co-ordinated arrangement of endothelial cells in three dimensions to form and 
maintain vascular tubes. CDC42, cell division cycle 42; DAG, diacylglycerol; IP3, inositol 1,4,5-
trisphosphate; MEK, MAPK/ERK kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; SOS, Son of 
sevenless. 
 
 
VEGF induces dimerization of VEGFR2 that leads to receptor 
autophosphorylation and activation. Autophosphorylation occurs in trans: one kinase 
of the dimer catalyzes the phosphorylation of tyrosine residues in the second, and the 
second catalyzes the phosphorylation of tyrosine residues in the first. 
Autophosphorylation of tyrosine residues within the activation loop of the 
kinase domain stimulates catalytic activity while autophosphorylation of tyrosine 
residues at other locations generates docking sites for modular Src homology 2 
(SH2) and phosphotyrosine binding (PTB) domains that recognize phosphotyrosine 
in sequence-specific contexts.
 62
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Major phosphorylation sites in VEGFR2 are Tyr
951
 in the kinase insert 
domain, Tyr
1054
 and Tyr
1059
 within the kinase domain, and Tyr
1175
 and Tyr
1214
 in the 
C-terminal domain.
90,91
  
Phosphorylated Tyr
951
 serves as a binding site for the SH2-domain-containing 
TSAd (T-cell-specific adapter molecule), also denoted VRAP (VEGFR-associated 
protein). Tyr
951
 is phosphorylated during active angiogenesis, but not in quiescent 
endothelial cells.
90
  
Phosphorylation at Tyr
1054
 and Tyr
1059
, which are located in the kinase 
domain activation loop, leads to increased kinase activity. Actually Tyr
1059
 has been 
shown to bind Src, which in turn phosphorylates other residues, such as Tyr
1175
, as 
well as downstream signal transducers, such as the actin-binding protein IQGAP1 
(IQ-motifcontaining GTPase-activating protein 1) which has been implicated in the 
regulation of cell–cell contacts, proliferation and migration.92,93  
Phosphorylation of Tyr
1175
 creates a binding site for PLCγ, but it also binds 
the adapter proteins SHB (SH2- domain-containing adaptor protein B) and Sck [SHC 
(Src homology and collagen homology)-related adaptor protein]. SHB binds to FAK 
(focal adhesion kinase), which is tyrosine phosphorylated in VEGF-treated cells and 
contributes to endothelial cell attachment and migration. Tyr
1175
 has also been 
described to bind SHC or GRB2, which recruit the nucleotide-exchange factor SOS 
(Son of sevenless) to VEGFR2. This pathway may control Ras activation and 
mitogenicity in response to VEGF. VEGF-induced Ras activation has been 
implicated in the generation of pleiotropic lipid mediators, the prostaglandins, via 
cPLA2 (cytoplasmic phospholipase A2). An important pathway for VEGF regulated 
proliferation appears to be through Tyr
1175
-PLCγ - mediated activation of PKC 
(protein kinase C) and downstream induction of the ERK pathway leading to cell 
proliferation. The PKC isoforms PKCα, PKCβ and PKCδ have been shown to 
mediate VEGF-induced proliferation. PKC activation also results in activation of 
PKD (protein kinase D), which promotes nuclear translocation of HDAC (histone 
deacetylase) 5 and HDAC7, followed by phosphorylation of CREB (cAMP-
response-element-binding protein) as well as HSP (heatshock protein) 27.
94-98
  
Tyr
1214
 allows recruitment of Nck and the cytoplasmic tyrosine kinase Fyn to 
VEGFR2. A Nck–Fyn complex mediates phosphorylation of PAK (p21-activated 
protein kinase) 2 and subsequent activation of Cdc42 (cell division cycle 42) and 
p38MAPK. The docking protein GAB (GRB2-binding protein) 1 contains a binding 
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site for the p85 subunit of PI3K. VEGFinduced recruitment of GAB1 leads to PIP3 
(phosphatidylinositol 3,4,5-trisphosphate) generation, which in turn activates the 
small GTPase Rac, resulting in membrane ruffle formation and cell motility. PI3K in 
turn promotes activation of PKB (protein kinase B, also called Akt) through PDK 
(phosphoinositide-dependent kinase) 1 and PDK2. Akt phosphorylates BAD [Bcl 
(Bcell lymphoma)-2-associated death promoter] and caspase 9 and thereby inhibits 
their apoptotic activity.
99-101
 
In vivo models showed how VEGFR2−/− mice die at E8.5 from impaired 
development of haemopoietic and endothelial cells. VEGFR2 is therefore believed to 
be the main transducer of VEGFA effects on endothelial cell differentiation, 
proliferation, migration and formation of the vascular tube. Mice with a Y1173F 
knockin, as well as those PLCγ 1-deficient die between E8.5 and E9.5 from lack of 
endothelial and haemopoietic development. SHB is not required for vascular 
development, but SHB-deficient mice show defects in vessel functionality and 
impaired tumour growth. VEGFA-induced extravasation of proteins or white blood 
cells is mediated by VEGFR2 in vivo. Transient opening of endothelial cell–cell 
junctions in response to VEGF is well documented in vitro and involves dissolution 
of tight junctions and adherens junctions, as well as eNOS (endothelial nitric oxide 
synthase)-mediated generation of NO.
102-105
 
 
- VEGFR3 structure, expression and signaling: 
VEGFR3 (also denoted Flt4) is synthesized as a precursor protein of 195 
kDa, and is activated by the binding of VEGFC and VEGFD. Cloning of VEGFR3, 
identified alternative C-terminal splicing, giving rise to short and long VEGFR3 
isoforms, with the long one predominantly expressed.
106 
 
VEGFR3 has an essential role in lymphatic endothelial cells, but its 
expression is induced in endothelial cells in conjunction with active angiogenesis, 
such as in the tumour vasculature or in endothelial tip cells of angiogenic sprouts in 
the developing retina. VEGFR3 is also expressed in non-endothelial cells such as 
osteoblasts, neuronal progenitors, and macrophages, while whether VEGFR3 is 
expressed in tumour cells is disputed.
107-110
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Figure 9. VEGFR3 tyrosine phosphorylation sites and signal transduction. 
Schematic outline of activated and dimerized VEGFR3. Tyr1068 is crucial for VEGFR3 kinase activity. 
VEGFR3 occurs as a short and a long isoform. Tyr1337 and Tyr1363 are transphosphorylated only in 
the long isoforms by VEGFR3 in homodimers, but not by VEGFR2 in heterodimers. VEGFR3 may 
contribute to proliferation, migration and survival of lymphendothelial cells through ligand-
dependent or ligand-independent mechanisms. 
 
 
Binding of VEGFC/VEGFD to VEGFR3 leads to kinase activation and 
phosphorylation of at least five C-terminal tyrosine residues in VEGFR3 (Tyr
1230
, 
Tyr
1231
, Tyr
1265
, Tyr
1337
 and Tyr
1363
). Mutational analyses show that residues Tyr
1063
 
and Tyr
1068
, located in theVEGFR3 kinase domain activation loop, are fundamental 
for kinase activity.
111,112
 
Phosphorylated Tyr
1063
 has been shown to interact with the adaptor protein 
CRK I/II (C10 regulator of kinase), which activates the JNK (c-Jun N-terminal 
kinase) pathway, leading to cell survival.
 
 
Phosphorylation of Tyr
1230
 and Tyr
1231
 creates a docking site for SHC–GBR2, 
which promotes signalling in the ERK1/2 and PI3K/Akt pathways. The PI3K 
pathway is critical in the development of lymphatics by regulating lymphendothelial 
migration.
112
 Interestingly integrins can induce VEGFR3 phosphorilation and 
activation independently by VEGFC/D binding. There are several studies describing 
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heterodimers between VEGFR2 and VEGFR3, and the heterodimers appear to be 
functionally different from homodimers of each receptor.
113 
 
Studies on recombinant mice expressing mutated or truncated forms of 
VEGFR3 have shown that VEGFR3 has to be expressed and functional to allow 
lymphatic development. In contrast, blood vessel development is maintained in mice 
expressing a kinase-deficient VEGFR3.
114
 
 
- VEGF Co-Receptors: 
VEGF co-receptors are VEGF-binding cell-surface-expressed molecules that 
are devoid of intrinsic catalytic activity, but modulate the signal-transduction output 
downstream of VEGFRs. However, signals might be transmitted downstream of co-
receptors also independently of VEGFRs. 
Heparan Sulfate (HS):  
Heparan sulfate is a sulfated polysaccharide that is found on the surface of 
most cells or in the extracellular matrix as part of proteoglycans (HSPG). In this 
form, it‟s able to bind to a variety of protein ligands regulating a wide variety of 
biological activities. HS and the more abundantly sulfated, mast cell-derived heparin, 
modulate VEGF biology in several ways by binding not only VEGF, but also 
receptors and co-receptors such as Neuropilin-1 (NRP-1). HS serves as a reservoir 
for growth factors, and controlled release allows formation of growth-factor 
gradients.
115,116
 
Neuropilin-1 and -2:  
There are two neuropilin homologues, NRP-1 and NRP-2, which are 130 kDa 
transmembrane proteins with a large extracellular component, a transmembrane 
segment, and a small cytoplasmic tail lacking intrinsic catalytic function. Neuropilins 
are co-receptors for both the semaphorin and the VEGF family.
117 
 
Semaphorins are glycoproteins with neuronal guidance functions, implicated 
in modulating the development of the nervous and vascular systems. Of the seven 
classes, neuropilins recognize selected members of class III semaphorins.
118
  
NRP1 modulates VEGFR signalling, leading to enhanced migration and 
survival of endothelial cells in vitro. Furthermore, NRP1 has been implicated in 
VEGFR2-mediated permeability and in VEGFA-induced vessel sprouting and 
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branching. NRP2 mediates VEGFC-induced lymphatic sprouting in a VEGFR3-
dependent manner.
119,120
  
Treatment with a neutralizing anti-NRP1 antibody reduces angiogenesis and 
vascular remodelling in vivo and has an additive effect with anti-VEGFA antibody 
therapy in reducing tumour growth and tumour vessel organization. Treatment with a 
neutralizing anti-NRP2 antibody reduces lymphangiogenesis and functional 
lymphatics in tumours, while leaving established lymphatics unaffected. The reduced 
lymphatic function is accompanied by reduced metastatic spread.
121,122
 
 
Integrins:  
Integrins are transmembrane heterodimers that mediate cell matrix adhesion 
by specific binding to extracellular matrix components, such as collagen, fibronectin, 
vitronectin and laminin. VEGF induces complex formation between VEGFR2 and 
the αVβ3 integrin, which is important for full VEGFR2 activity, for activation of 
p38MAPK and FAK, and for recruitment of actin-binding vinculin to initiate 
endothelial cell migration.
123
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3.2 Anti-angiogenic cancer therapy: 
Tyrosine Kinase Inhibitors (TKIs) 
 
 
3.2.1 Angiogenesis in health and pathology 
 
 
Formation of new vessels is critical in a number of processes where tissues 
expand. The principles of blood vessel formation differ vastly depending on whether 
blood vessels form during embryogenesis (denoted vasculogenesis), during 
physiological processes such as wound healing or growth of the endometrium 
(denoted regulated angiogenesis), or during pathologies such as inflammation and 
cancer (pathological angiogenesis). 
In the embryo and yolk sac, early blood vessels develop by aggregation of 
angioblasts into a primitive network of simple endothelial tubes.
124
 In contrast, 
angiogenesis is the process of new blood vessel formation from pre-existing vascular 
networks by capillary sprouting. During this process, mature endothelial cells divide 
and are incorporated into new capillaries. Adult human vascular endothelial cells 
correspond to an estimated surface area of 1000m
2
, but only 1 in every 10,000 
endothelial cells is in the cell division cycle at any one time. However, there is an 
increased rate of endothelial cell mitosis and angiogenesis during wound healing and 
tissue repair, during ovarian corpus luteum formation, and during placental 
development establishing pregnancy.
24,62,125
  
Angiogenesis, is regulated by both endogenous activators and inhibitors 
(Table 3). There are about 30 known endogenous pro-angiogenic factors; among 
them three families of receptor protein-tyrosine kinases play pivotal roles, and in 
particular the VEGF/VEGFR (vascular endothelial growth factor/VEGF receptor) 
family, as previously described, is proved to be essential in vasculogenesis and 
angiogenesis.
62
 
 
 
 
 
                                     3.2 Anti-Angiogenic Cancer Therapy: TK-Inhibitors 
 
119 
 
Table 3. Selected endogenous pro- and anti-angiogenic factors. 
Endogenous pro-angiogenic factors Endogenous anti-angiogenic factors 
Acidic fibroblast growth factor (aFGF, FGF1) (A) Derived from the extracellular matrix 
Angiogenin       Anastellin 
Angiopoietin-1       Arresten 
Angiopoietin-2       Canstatin 
Basic fibroblast growth factor (bFGF, FGF2)       Chondromodulin-1 
Ephrin-A1       EFC-XV 
Ephrin-B1       Endorepellin 
Ephrin-B2       Endostatin 
Epidermal growth factor (EGF)       Fibulin fragments 
Granulocyte colony-stimulating factor (GCSF)       Thrombospondin-1 and -2 
Macrophage-granulocyte colony-stimulating factor 
(GM-CSF)       Tumstatin 
Hepatic growth factor (HGF, scatter factor) (B) Non-matrix derived factors 
Interleukin-8 (Il-8, CXCL8)       Angiostatin 
Leptin       Antithrombin III (cleaved) 
Placental growth factor (PlGF)       Hemopexin-like domain (PEX) 
Platelet-derived endothelial growth factor (PD-EGF)       Interferon-α, -β, -γ 
Platelet-derived growth factor-A (PDGF-A)       Interleukin-1, -4, -12, -18 
Platelet-derived growth factor-B (PDGF-B)       2-Methoxyestradiol 
Transforming growth factor-α (TGF-α)       Pigment epithelium-derived factor (PEDF) 
Transforming growth factor-β (TGF-β)       Plasminogen kringle-5 
Tumor necrosis factor (TNF-α)       Platelet factor-4 
Vascular endothelial growth factor (VEGF-A)       Prolactin fragments 
VEGF-B       Prothrombin kringle-2 
VEGF-C       Semaphorin-3F 
VEGF-D       Soluble VEGFR1 
       TIMP-2 
       Troponin I 
       TrpRS 
       Vasostatin 
 
 
Therefore angiogenesis appears as an intricate process that involves 
interactions between regulatory and effector molecules. According to a classic model 
of healthy neo vascualrization, angiogenesis can be divided into a phase of sprouting 
and a phase of resolution.
126
  
The phase of sprouting consists of six components: (i) increased vascular 
permeability and extravascular fibrin deposition, (ii) vessel wall disassembly, (iii) 
basement membrane degradation, (iv) cell migration and extracellular matrix 
invasion, (v) endothelial cell proliferation, and (vi) capillary lumen formation.  
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The phase of resolution consists of five components: (i) inhibition of 
endothelial cell proliferation, (ii) cessation of cell migration, (iii) basement 
membrane reconstitution, (iv) junctional complex maturation, and (v) vessel wall 
assembly including recruitment and differentiation of smooth muscle cells and 
pericytes, both of which are mural cells (mural, wall).
62
  
Several features distinguish vessels formed during physiological processes 
from those in pathologies, and research on tumor angiogenesis has assumed 
considerable biomedical importance during the past 40 years.  
Historically, Dr. Virchow was the first to identify a huge number of blood 
vessels in tumors in 1863.
127
 The term “angiogenesis” was first used in 1935 and 
described the formation of new blood vessels in the placenta.
128
 However, it was not 
until 1971 when Folkman hypothesized that inhibition of angiogenesis may be a 
potential way to inhibit cancer progression.
129
 Since then, the impact of the tumor 
microenvironment, and tumor angiogenesis in particular, has been studied in greater 
detail.  
The “angiogenic switch”, a rapid increase of blood vessel formation to 
support tumor growth, is triggered by (1) oncogene-mediated tumor expression of 
angiogenic proteins including VEGF, fibroblast growth factor (FGF), platelet derived 
growth factor (PDGF), endothelial growth factor (EGF), lysophosphatic acid (LPA), 
and angiopoietin (Ang), (2) metabolic and/or mechanical stress, (3) genetic 
mutations, (4) the immune response, and maybe most prominently (5) hypoxia. 
Tumor-angiogenesis therefore depends on tumor type, site, growth and stage of 
disease, and contributes to tumor growth, invasion, and metastasis.
130
  
Various forms of non-sprouting angiogenesis have been described in tumors. 
These include intussusceptive vascular growth, co-option, and vasculogenic mimicry 
(Figure 10a, b and C respectively).
131,132
  
 
Figure 10. Non-sprouting forms of angiogenesis described in tumors.
131
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During intussusceptive vascular growth, a column of interstitial cells is 
inserted into the lumen of a pre-existing vessel, thereby dividing the lumen and 
yielding two vessels. The column is invaded by fibroblasts and pericytes and 
accumulates extracellular matrix proteins. The advantage of this mechanism of 
growth over sprouting is that blood vessels are generated in a metabolically 
economic process because extensive cell proliferation, basement membrane 
degradation, and invasion of the surrounding tissue are not required.  
By yet another mechanism, developing tumors can surround vessels in the 
tissue or organ of origin and incorporate, or co-opt, these vessels. Co-option may be 
important when tumors arise in or metastasize to vascular organs such as the lung or 
brain. Tumor cells, along with endothelial cells, may together form the luminal 
surface of capillaries thus generating a mosaic vessel.  
In vasculogenic mimicry, first described in ocular melanoma, vascular 
channels develop as extracellular matrix- rich tubular networks. These tubular 
networks or channels lack endothelial cells but contain circulating red blood cells. 
The nature of the factors that determine which combinations of these angiogenic 
processes occur during tumor progression is unknown.
130-132
  
Tumor vessels exhibit abnormal morphology while normal vessels are 
organized in a hierarchical fashion with arterioles, capillaries, and venules that are 
readily distinguishable. An in vivo study with rats showed how capillaries in rapidly 
growing tumors are about five times the diameter of those in normal tissue and rarely 
differentiated into arterioles or venules. Three-dimensional microscopy of tumor 
vascular casts revealed an absence of normal arteriole, capillary, and venule structure 
with arteriolar-venular shunts, frequent blind endings, and incomplete and abnormal 
endothelial cell lining. Pericytes, which embed healthy capillaries, may be more 
loosely associated with tumor vessels, or may be completely lacking, and the 
vascular basement membrane may be discontinuous. Tumor vessels often develop 
into disorganized bundles containing numerous vascular sprouts while exhibiting 
irregular vessel lumen diameters. Owing to the abnormal organization and structure 
of tumor vessels, blood flow in tumors is chaotic.
62,130,133
  
Therefore the crucial role of blood vessels in cancer and the assumed absence 
of angiogenesis in (most) healthy conditions have primed tremendous efforts to 
develop different approaches to block proangiogenic signalling pathways. 
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3.2.2 Targeting VEGF/VEGFR as anti-angiogenic therapy 
 
Angiogenesis research is based on the assumption that preventing the growth 
of new blood vessels will impair the viability of tumor cells. The aim of 
antiangiogenic therapy is to stabilize the disease and keep tumorigenesis in check, 
rather than eradicating tumor mass, as in the case of the endpoints of chemotherapy 
and radiotherapy. Out of the several hundreds of molecules with anti-angiogenic 
activity in experimental models, about one hundred of these have entered clinical 
testing in cancer patients, and around 10 of these so far have become approved for 
clinical use. Despite the existence of many important pathways for the angiogenic 
process, VEGF ligands and receptors still constitute the main target for anti-
angiogenic therapy used in clinical practice. The current strategies to inhibit VEGF 
signaling can be divided into those that bind VEGF ligands and therefore block their 
interaction with the receptors (antibodies, peptides, ribozymes and soluble receptors), 
and those that target the receptors in a direct way (antibodies or small molecules 
tyrosine kinase inhibitors). Table 4 and Figure 11 summarizes some of the principal 
anti-angiogenic molecules that currently are being used in clinical trials to target 
VEGF signaling.
134,135
 
Table 4. Angiogenesis inhibitors in advanced clinical trials. 
Therapeutic agent Type of inhibitor Specific Targets Clinical development 
Bevacizumab mAb VEGF Approved in 2004 (CC), in 
2006 (NSCLC), in 2008 (BC), 
in 2009 (RCC,Glioblastoma) 
Ramucirumab mAb VEGFR-2 Phase II/III 
MF-1/MC-18F1 mAb VEGFR-1 Phase I 
CDP791 PEG di-Fab conjugate VEGFR-2 Phase II 
VEGF-trap/aflibercept Fusion protein VEGF-A and PlGF Phase II/III 
VEGF-AS Oligonucleotide VEGF-A, VEGF-C, VEGF-D Phase I 
SU11248/sunitinib RTKI VEGFR1-3, PDGFR, c-kit, Flt-3 Approved in 2006 (GIST 
and RCC) 
Bay43-9006/sorafenib RTKI VEGFR2-3, PDGFR, Raf-1, Flt-
3, c-kit 
Approved in 2005 (RCC), in 
2008 (HCC) 
Pazopanib RTKI VEGFR1-3, PDGFR, Flt-3, c-kit Approved in 2009 (RCC) 
AG013736 RTKI VEGFR1-3, PDGFR, c-kit Phase II/III 
ZD6474/vandetanib RTKI VEGFR1-3, EGFR, RET Phase II/III 
AZD2171/cediranib RTKI VEGFR1-3, c-kit Phase II/III 
Brivanib alanitate RTKI VEGFR2, FGFR-1 Phase II/III 
AMG706/motesanib RTKI VEGFR1-3, PDGFR, c-kit, RET Phase II/III 
ABT869/linifanib RTKI VEGFR1-3, PDGFR, flt-3 Phase II/III 
AV-951/tivozanib RTKI VEGFR1-3, PDGFR Phase II/III 
PTK787/vatalanib RTKI VEGFR1-3, PDGFR, c-kit Phase II 
AE941/Neovastat Shark cartilage 
component 
VEGF/VEGFR binding, MMP2, 
MMP9 
Phase II/III 
Abbreviations: BC, breast cancer; CC, colorectal carcinoma; HCC, hepatocellular carcinoma; mAb, monoclonal 
antibody; NSCLC, non small cell lung; RCC, renal cell carcinoma. 
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Figure 11. VEGF signaling inhibitors and their targets. The VEGF family of ligands (VEGFA, PlGF, 
VEGFB, VEGFC, and VEGFD) bind to their cognate receptors (VEGFR1; VEGFR2; VEGFR3). Several 
different VEGF antagonists interfere with binding of VEGF ligands on the extracellular domain 
(Bevacizumab, VEGF-Trap, Veglin, IMC-18F1, Ramuciumab/CDP791), or compete for ATP-binding to 
the intracellular kinase domain (axitinib, brivanib, cediranib, linifanib, pazopanib, sorafenib, 
sunitinib, tivozanib, vandetanib, vatalanib).
135
 
 
 
However with exception for drugs targeting VEGF ligands or receptors, the 
vast majority of novel anti-angiogenic molecules have failed to confirm the 
encouraging preclinical results when tested in clinical trials. Furthermore, the initial 
concept to radically „„starve‟‟ the tumor by stripping the blood supply has been 
modified, as aggressive angiogenesis inhibition may aggravate tumor metabolism 
and promote metastatic spread.
136,137
  
Moreover why some inhibitors work in one cancer type and not in another is 
not understood and highlights the complexity of angiogenesis when applied to an 
individual tumor and the pathways to target. It has become clear that the efficacy of 
angiogenesis inhibition depends on the cellular context, the dose and the timing of 
drug delivery.
134,135,138
 
 
                                     3.2 Anti-Angiogenic Cancer Therapy: TK-Inhibitors 
 
124 
 
- Limitations and challenges of the Antiangiogenic therapy: 
After the success of VEGF-pathway inhibitors in the clinic, with hundreds of 
clinical trials currently underway in multiple cancer indications and pathological 
stages, and dozens of other VEGF and other angiogenic-pathway-targeted agents 
now in experimental or clinical testing, an urgent issue is understanding why the 
majority of patients stop responding - or do not respond at all - to such drugs, and 
how such limitations can be overcome. Numerous mechanisms of resistance to 
antiangiogenic therapy have been proposed highlighting that over two decades of 
positive preclinical studies have yielded only modest incremental changes in the 
clinic.
134,139,140
  
In theory, targeting the host‘tumor-supporting‟ angiogenic processes has 
many benefits but it might also have limitations. Antiangiogenic therapies might 
initiate an array of stromal and microenvironmental defense mechanisms that 
contribute to eventual drug inefficacy and, more provocatively, may lead to a more 
aggressive and invasive tumor phenotype with an increased ability to metastasize.
139
 
There is no compelling clinical evidence that antiangiogenesis treatment will make 
disease worse or decrease survival,
141
 but it remains a major question as to why such 
robust gains in progression-free survival (PFS) seen in the majority of completed 
phase III trials with bevacizumab and chemotherapy, or VEGFR TKIs as 
monotherapy, have not frequently corresponded to robust gains in overall survival. 
However, the difference between the preclinical efficacy of anti-angiogenic 
agents and activity displayed in the clinic, likely reflects the preclinical model 
utilised, the cancer type being clinically treated, as well as differences in the dosages 
and schedules utilised in the preclinical and clinical setting (Figure 12).
140
 
Considering the gap between how antiangiogenics are usually tested in the 
clinic (late-stage metastatic) and in preclinical mouse models (localized primary 
tumors), future testing of antiangiogenic therapies should be conducted in clinically 
relevant animal models of all disease stages.  
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Figure 12. Variable efficacy of VEGF pathway-targeted therapies: exposing the gap between 
preclinical and clinical testing. The number of studies that have been completed in the clinic in each 
setting are inversely correlated with the number of preclinical publications that model each setting. 
Abbreviations: CRC, colorectal cancer; GBM, glioblastoma muliforme; GIST, gastrointestional stromal 
tumors; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; NSCLC, non-small-cell lung 
cancer; RCC, renal cell carcinoma.
140
 
 
Furthermore it is crucial that the complexity of the signaling pathways that 
promote or regulate angiogenesis is translated into the clinical situation when 
selecting patients for the appropriate antiangiogenic therapy. Therefore research on 
the genetic basis of the tumour response to anti-angiogenic treatment will have 
important implications for the development of angiogenesis based biomarkers and 
the optimization of anti-angiogenic therapy. Tumour vascular imaging and 
determination of short-term response may provide the necessary data to develop and 
validate such markers. In the future, tailored treatments based on dynamic 
assessment of response should result in individualized patient therapy and improved 
progression free and survival free outcomes, as well as being more cost effective and 
importantly reduce unnecessary toxicity in patients and promote a more cost 
effective treatment.
134 
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3.2.3 Receptor Tyrosin Kinase Inhibitors (RTKIs) 
 
- ANTIBODY THERAPY: 
The extracellular ligand binding domain of the RTK is well suited to the 
binding of antibodies. Antibody binding to either the receptor or the ligand can 
disrupt ligand/receptor interaction and activation of the receptor. The first antibody 
approved by the US FDA for use in cancer therapy was Rituximab in 1997, for B cell 
non-Hodgkin‟s lymphoma and B-cell leukemias. In 1998, Trastuzumab was 
approved for HER2 inhibition in breast cancer and more have followed during the 
past decade.
142
 
Although the exact mechanism of antibody therapy is not fully understood, it 
has been proven efficacious in the clinical setting. It was hypothesized that in 
addition to the growth inhibitory effect by binding their specific targets on the 
surface of tumor cells, these antibodies probably also provoked antibody-dependent 
cell mediated cytotoxicity (ADCC). Hence, a majority of the antibodies currently in 
clinical use are IgG1 subtype. Monoclonal antibodies seem to work best when 
combined with other modalities such as chemotherapy. Furthermore, these 
monoclonal antibodies are either chimeric (-ximab), humanized (-zumab), or fully 
human antibodies (-mumab) to minimize immune response.
143
  
 
EGFR FAMILY:  
Three monoclonal antibodies for the epidermal growth factor receptor 
(EGFR), Cetuximab, Panitumumab and Trastuzumab, have been approved by the 
FDA for clinical usage. Actually the EGFR is frequently activated or overexpressed 
in a large percentage of tumors and targeting EFGR was explored for the treatment 
of a number of human malignancies including lung, head and neck, and colon.
144-148
  
In colorectal cancer Cetuximab has been shown to provide survival benefit, 
when used alone or combined with Irinotecan. Moreover the addition of Cetuximab 
to chemotherapy improves survival in EGFR positive metastatic NSCLC 
patients.
147,148
 Trastuzumab, a humanized antibody against HER2/Neu, a member of 
the human EGFR superfamily, has been used successfully to treat breast cancers
149
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and significantly increased tumor response rate (RR) and overall survival (OS) time 
when combined with cytotoxic agents such as Paclitaxel or Carboplatin.
150,151
   
However, recent studies have demonstrated that anti-EGFR therapy is not 
effective in tumors bearing an activating K-RAS mutation, whose screening has 
quickly become a standard practice in the United States.
152,153
 In addition, although 
these three monoclonal antibodies have changed the natural history and outcomes of 
the three high incidence tumors (lung, breast and colon), the development of 
resistance to these agents poses a new challenge in the cancer treatment, and to 
overcome such resistance, several new monoclonal antibodies targeting EGFR 
family are in the pipeline (Matuzumab, Ertumaxomab, [188
Re
]-Nimotuzumab).
154-156
 
 
VEGFR FAMILY:  
As angiogenesis is essential to tumor growth, VEGF/VEGFR has been 
extensively studied, and nowadays the most clinically advanced angiogenesis 
inhibitor is Bevacizumab, an intravenously administered humanized monoclonal 
antibody against VEGF that also directly inhibits VEGFR on the tumor cells. In 
preclinical and clinical models, Bevacizumab demonstrated anti-tumor activity in a 
wide variety of human malignancies and at the present time, it has regulatory 
approval to treat metastatic colorectal, lung and breast cancers.
157-160
  
Other antibodies and other immunologic strategies targeting the VEGFR 
ligands are currently under study. On the other hand few agents to date have 
specifically inhibited one or more of the extracellular domains of a VEGFR. A 
PEGylated di-Fab fragment targeting specifically VEGFR-2, CDP791, was studied in 
a phase 1 clinical trial and showed tolerable toxicities with no observed DLTs (dose-
limiting toxicities).
161
 IMC-1121, a chimeric antibody against VEGFR-2, has also 
been evaluated in early clinical trials.
162
 Unfortunately, half of the patients exposed 
to IMC-1121 developed antichimeric antibodies and as such, clinical development of 
IMC-1121 was halted. Since favorable results from this drug were evident, the 
chimeric antibody was fully humanized to form IMC-1121B (Ramucirumab) which 
has gone on to be further investigated, and it is now the most clinically advanced 
direct and specific inhibitor of VEGFR-2. Efficacy from phase 1 and 2 studies is 
impressive and when compared to other agents in its class, Ramucirumab appears to 
be more effective at causing tumor responses or stability of tumor size for extended 
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periods in populations of patients that have been heavily pretreated. It is also 
noteworthy that Ramucirumab has activity after patients have been exposed to other 
antiangiogenic agents, perhaps indicating a more potent inhibition of angiogenesis 
when VEGFR-2 is blocked directly.
163
 
 
- SMALL MOLECULE RTK-INHIBITORS 
Although Bevacizumab has proved to be an effective drug, and studies testing 
growth factor receptors-targeting antibodies are promising, drug resistance often 
develops likely due to targeting a single tumorigenic pathway. Indeed extended 
blockade of a single growth factor may result in tumor revascularization, dependent 
on other proangiogenic factors. Small-molecule inhibitors have the advantage of 
being orally available as well as more promiscuous in target inhibition and also less 
expensive. Based on these therapeutic advantages, many tyrosine kinase inhibitors 
(TKIs) have been developed and subjected to clinical trials.
164,165
 
Unlike monoclonal antibodies (mAbs), TKIs can translocate through plasma 
membranes and interact with the cytoplasmic domain of cell surface receptors. Since 
the target kinase specificity among inhibitors can vary, different compounds have 
shown varying levels of efficacy and activity, according to the cancer type, as well as 
side effect profiles. Most of the RTKIs include compounds that bind to the kinase 
domain and compete for binding of the normal substrate, ATP. They target the ATP 
binding site in its active conformation, in which the activation loop is 
phosphorylated. Conceptually, the binding site of ATP can be divided into five 
regions (Figure 13).
166,167
 
 
Figure 13. Representation of the five main regions of the ATP binding site. 
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Adenine region: An hydrophobic region that accomodates the purine ring of ATP, 
which joins the lobes through the formation of two hydrogen bonds with the 
polypeptide chain, in which are involved the nitrogen atom N1 and the amino group 
in the 6 position, which behave as donor and acceptor of hydrogen. This region is 
also called the "hinge" region. In addition to these polar interactions, the purine ring 
also engages non-polar interactions with hydrophobic residues located at the N- and 
C-terminal lobes. The region of adenine‟s binding is not characterized by large 
amino acid variability and therefore the interaction with this site doesn‟t provide 
useful elements for selectivity towards specific protein kinases. 
Sugar Region: Where is located the riboside portion of ATP, whose 2'-OH group 
forms a hydrogen bond with a polar residue located at the beginning of the C-
terminal lobe. 
Phosphate region: This region accepts the triphosphate group and is mainly 
composed of a glycine-rich flexible loop, and an alpha helix structure that properly 
orients the phosphate group of ATP for catalysis. In most crystal structures of ATP-
kinase, a hydrogen bond between the α and β phosphate groups of ATP and a residue 
of lysine has been found. The γ-phosphate group instead interacts with an arginine 
residue. 
Buried region and solvent accessible region: ATP does not occupy these two regions, 
which constitute the main source of structural and sequence diversity among the 
members of the kinase superfamily. The buried region consists in a lipophilic pocket 
variable in shape and dimension, opposite to the sugar region. The shape of solvent 
accessible region depends, however, on the presence or absence of a glycine residue, 
which can cause a conformational change of the protein between the hinge region 
and the initial portion of the C-terminal tail.
166,167
 
RTKIs typically make hydrogen bonds to the Adenine region and 
hydrophobic interactions around the purine-like portion of the molecule (Figure 
14).
168
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Figure 14. Main hydrophobic and hydrogen interactions of the TKIs (PHA-680626 as an example) 
 
The high sequence similarity in the ATP-binding site among members of the 
kinase family, often results in inhibitors exhibiting poor selectivity and undesired 
side effects that limit the clinic use of these agents.
168
 These considerations led to the 
search for more selective inhibitors in an attempt to minimize the risk of side effects. 
However, the risk of a lower efficacy due to the redundancies in signaling pathways, 
has recently increased the interest in multitarget drug discovery (MTDD) based on 
the belief that modulating more than one target can provide superior efficacy and 
safety profiles compared to single target drugs.
169
 
Currently, there are two contrasting MTDD philosophies. The first involves 
combining agents that are selective for a single target to achieve an additive or 
synergistic effect. The second involves discovering agents that are simultaneously 
capable of addressing two or more targets. Many clinically useful drugs are now 
known to have multiple activities, but most of these multitarget drugs (MTDs) were 
discovered serendipitously and their mechanisms of action were only established 
retrospectively. The deliberate and prospective design of multikinase inhibitors 
(MKIs) with specific multiple activity profiles is an emerging trend in drug 
discovery. The aim for the medicinal chemist working in the MKI field should be to 
strike the right balance between the nonselectivity (promiscuity) that may be required 
for efficacy and the selectivity that is required for safety.
169,170
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• Selective Tyrosine Kinase Inhibitors (TKI) are usually inhibitors of the EGFR 
family, including compounds like Gefitinib, Erlotinib and Lapatinib (Figure 15). 
  
 
Figure 15. Chemical structures of the TKIs gefitinib, erlotinib and lapatinib. 
 
Erlotinib and Gefitinib are specific inhibitors of EGFR. Gefitinib was initially 
approved by FDA to treat NSCLC in the second line setting and later removed from 
market because of lacking survival benefit. Erlotinib remains the second line or third 
line treatment for NSCLC. Clinical data have shown that lung cancers showing 
EGFR mutations are sensitive to EGFR TKIs.
171-173
  
Lapatinib is a less specific tyrosine kinase inhibitor than erlotinib and 
gefitinib. It inhibits both EFGR and HER2/Neu. Currently, lapatinib is approved for 
treating HER2/Neu positive metastatic breast cancer. In addition, lapatinib can cross 
the brain-blood barrier and is effective in treating brain metastases.
174-176
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• Small molecule TKIs of the VEGFR family are generally multikinase inhibitors 
(MKIs). Among the drugs belonging to this class, approved or still in clinical trial 
(already summarized in Table 4) there are:
177,178
 
 
Sunitinib (Sutent
©
, SU11248; Pfizer) 
 
 
 
 
 
Sorafenib (Nexavar
©
, BAY 43-9006; Bayer and Onyx Pharmaceuticals) 
 
 
 
 
 
 
 
Sunitinib malate is an oral MTKI with 
antitumor and antiangiogenic activities. 
Sunitinib selectively inhibits members of the 
split-kinase domain RTKs, including all three 
isoforms of VEGFR, PDGF receptor 
(PDGFR)α, PDGFR-β, FLT3, KIT, colony-
stimulating factor 1 receptor, RET and 
RET/PTC subtypes 1 and 3. Sunitinib has 
received regulatory approval in 2006 by the 
FDA and by EMEA for the treatment of 
advanced renal cell carcinoma and imatinib-
resistant or imatinib-intolerant 
gastrointestinal stromal tumors (GISTs) and it 
is actually in phase III development across 
multiple tumor types. 
Sorafenib tosylate is a biaryl urea, orally 
available, multikinase inhibitor, which 
block VEGFR-2 and VEGFR-3, 
PDGFR-β, FLT3, RET, c-KIT, the 
serine/threonine kinases c-RAF and both 
wild-type and mutant
V599E
 BRAF. 
Sorafenib has been approved by FDA 
and EMEA for treatment of advanced 
unresectable HCC and it is the only 
approved targeted therapy for these 
patients, thus becoming the new 
reference standard. 
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Axitinib (AG013736; Pfizer) 
 
 
 
Cediranib (AZD2171; AstraZeneca) 
 
 
 
 
 
Pazopanib (Votrient
©
, GW-786034; GSK) 
 
 
 
Axitinib is a still investigational, second 
generation, orally available, angiogenesis 
inhibitor of multiple RTKs including VEGFR-
1, VEGFR-2, VEGFR-3, PDGFR and cKIT. It 
has a relatively high potency against VEGFR-
2 with respect to other inhibitors. In phase I 
and II trials single-agent axitinib demonstrated 
anti-tumor activity in multiple cancers, 
including advanced RCC, NSCLC, melanoma, 
colorectal and thyroid cancer. 
Cediranib maleate is a second generation, 
orally available, highly potent inhibitor 
of VEGFR-2 and, to a lesser degree, of 
VGFR-1, VEGFR-3, PDGFR-β, and 
cKIT. Cediranib has been tested in phase 
I and phase II clinical trials, either as a 
single agent or in combination with other 
agents in solid tumors and leukemias, 
showing a significant antitumor activity 
and a good tolerability profile. Cediranib 
is currently being evaluated in phase III 
trials (HORIZON II and HORIZON III) 
in combination with FOLFOX for the 
first-line treatment of metastatic 
colorectal cancer and in a phase II study 
as second-line treatment (HORIZON I). 
Pazopanib hydrochloride is a still investigational, 
second-generation, oral angiogenesis inhibitor of 
multiple RTKs such as VEGFR-1, -2 and -3, 
PDGFR, PDGFR-β and cKIT. Pazopanib has been 
approved by FDA on October 2009 for the 
treatment of patients with advanced RCC and is 
currently under clinical development for other 
solid tumors, including glioblastoma, gynecologic 
cancer and sarcomas.  
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Vandetanib (Caprelsa
©
,ZD6474; AstraZeneca) 
 
 
 
 
 
Vatalanib (PTK787/ZK 222584; Bayer Shering and Novartis) 
 
 
 
 
 
 
 
 
Vandetanib is an ATP mimetic small molecule, 
orally available, with inhibitory activity on 
different intracellular signaling pathways: 
VEGFR-2, EGFR and RET. The RET 
(rearranged during transfection) proto-oncogene 
encodes a trans-membrane TK for the glial cell 
line-derived neurotrophic factor family of 
ligands, which is involved in the regulation of 
cell growth, differentiation, and survival. 
Vandetanib demonstrates a significant clinical 
activity in patients with metastatic medullary 
thyroid carcinoma, a disease lacking effective 
medical therapy. Clinical activity of vandetanib 
in NSCLC is currently being tested in two large 
randomized phase III trials, in combination with 
docetaxel and with pemetrexed. 
Vatalanib succinate (PTK787/ZK 222584) is an oral 
angiogenesis inhibitor selected through high-throughput 
screening, for its ability to block VEGF receptors, 
PDGF-β and cKIT. The clinical antitumor activity of 
vatalanib is currently under evaluation, even if two phase 
III clinical trials in advanced colorectal carcinoma using 
vatalanib in combination with chemotherapy showed a 
non-significant benefit in terms of PFS and OS. 
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3.3 New VEGFR Inhibitors 
 
 
3.3.1 Structure-Activity Relationship (SAR) among TKIs targeting VEGFR 
By means of receptor-based virtual screening studies, several molecules have 
been docked into the crystallized structure of the VEGFR protein, leading to the 
identification of different classes of derivatives,
179
 among which I pointed out my 
attention on those reported below. 
 
- ANTHRANILAMIDES 
A representative class of VEGFR inhibitors is that of the anthranilamides, 
designed on the hypothesis that an intramolecular hydrogen bond between the aniline 
moiety and the benzanilide carbonyl group would favour a conformation with a high 
degree of similarity to that of the previously discovered phthalazine class (Figure 
16).
180
 Lead optimization studies within the anthranilamide series resulted in the 
identification of AAL993 as a highly potent and selective inhibitor of VEGFRs, with 
IC50 values of 130, 23 and 18 nM for VEGFR-1, -2 and -3, respectively. AAL993 
shows good pharmacological properties and excellent bioavailability, in both rodents 
and dogs.
181,182
 
 
        Phthalazine                    Anthranilamides 
 
Figure 16. Evolution of the phthalazine class (PTK787 as an example) of VEGFR inhibitors to the 
anthranilamides, and the structure of AAL993 as a representative example of the latter. 
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The X-ray crystal structure of AAL993 in complex with the catalytic domain 
of di-phosphorylated VEGFR-2 revealed that this molecule binds to and stabilizes 
the inactive conformation of the protein. The binding to the inactive conformation 
provides a reliable explanation for the observed selectivity of such compound. In 
fact, unlike the highly conserved ATP-binding (or active) conformation of TK, the 
inactive states of these enzymes often adopt distinct conformations.
182 
 
The analisys of the AAL993-VEGFR-2 complex, showed how the inhibitor 
binds to the protein through three hydrogen bonds between: a) the pyridine N atom 
and the backbone NH of Cys 919 in the hinge region of the protein, b) the 
anthranilamide C=O group and the backbone NH of Asp 1046 of the conserved DGF 
motif, and c) the anthranilamide NH and side chain carboxylate of Glu 885 of the αC 
helix. The trifluoromethylphenyl moiety of AAL993 is accommodated within a 
lipophilic pocket defined by hydrophobic amino acids, while the phenyl ring of the 
anthranilamide moiety is sandwiched between the hydrophobic side chain 
components of Val 914 and Lys 868 (Figure 17).
183
 
 
 
Figure 17 A-B. A) Model of VEGFR-2 kinase domain based on the X-ray crystal structure (PDB entry 
1YWN). The location of AAL993 in the ATP binding site is illustrated by the light green surface. Also 
indicated are the activation loop, the catalytic loop, the aC helix, the Gly-rich loop, and the two Tyr 
residues of the activation loop that were found to be autophosphorylated. B) Close-up view of 
AAL993 (stick representation; C atoms in orange) docked into the ATP binding site of VEGFR-2. 
Residues of the kinase domain (C atoms in light green) that mediate key H-bonding interactions are 
labeled. The trifluoromethylphenyl moiety of AAL993 is buried inside a hydrophobic pocket, which is 
depicted as a surface. Nitrogen atoms are shown in blue, oxygen in red, sulfur in yellow, and fluorine 
in green.
183 
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Some additional anthranilamide derivates have been patented by Novartis, 
including ABP309 (Figure 18), which was shown to be an active second-generation 
VEGFR inhibitor. In ABP309, the pyridine moiety of the previous derivates, which 
is hydrogen bonded to the enzyme hinge region, has been substituted by a pyridone 
group.
184
 ABP309 is active against VEGFR-2, with an IC50 value of 37 nM, while is 
less potent against VEGFR-1 and VEGFR-3 (IC50 of 810 and 330 nM, respectively); 
it inhibits tumor growth in murine xenografts with a 56% inhibition in a DU-145 
prostate model when orally dosed at 50 mg/Kg.  
Potent anthranilamide VEGFR inhibitors differently substituted at either the 
amide or the amino moiety were also published by Shering, and one of the more 
recent classes is represented by the pyridone 15 (Figure 18), endowed with a 59 nM 
IC50 value against VEGFR-2.
185
 
 
Figure 18. Chemical structures of anthranilamide derivates characterized by the pyridone group 
(ABP309 and the more recent 15).  
 
- PYRIMIDINE DERIVATIVES 
Many derivatives characterized by a variously substituted pyrimidine ring, 
either isolated or fused to form different heterocyclic structures, have been reported 
as interesting VEGFR inhibitors. 
• Pyrrolo-pyrimidines 
AEE788 (16) is a 7H-pyrrolo[2,3-d]pyrimidine synthetized by Novartis as a 
dual inhibitor of EGFR and VEGFR, which shows IC50 values of 2, 77, 59 nM 
towards EGFR-2, VEGFR-2 and VEGFR-1, respectively, in enzymatic assays. In a 
cell based ELISA assay it is not particularly active towards VEGFR-2 (IC50 = 960 
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nM), but it inhibits the proliferation of VEGF-stimulated HUVECs (human umbilical 
vein endothelial cell) and the VEGF-induced angiogenesis in a murine model. Orally 
administrated, AEE788 shows favourable pharmacokinetic properties and antitumor 
activity in different animal models of cancer. Antiangiogenic activity has been 
evaluated by measurement of tumor vascular permeability and interstitial leakage 
spacing with dynamic contrast enhanced magnetic resonance imaging 
methodology.
186
 The drug has been evaluated in different phase I clinical trials in 
patients with advanced solid tumors and with recurrent glioblastoma, and is currently 
in phase II trials.  
 
• Pyrazolo-pyrimidines 
Pyrazolo[1,5-a]pyrimidines with a 3-thienyl substituent have been reported 
by Merck researchers as potent inhibitors of VEGFR-2; optimization of the first 
series of compounds led to derivative (17), bearing a basic side chain on the 6-aryl 
ring that improves the pharmacokinetic properties. This molecule is selective for 
VEGFR-2, with an IC50 value of 7 nM, and inhibits VEGF-stimulated mitogenesis in 
HUVECs, with IC50 of 20 nM measured in the endothelial cell mitogenesis assay.
187
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• Thieno- and furo-pyrimidines 
Thieno-pyrimidines have been presented by Pfizer as potent dual inhibitors of 
VEGFR-2 and EGFR. Compound (18a) possesses IC50 values of 2 and 7 nM towards 
the two TKs, respectively; interestingly, the similar thieno-pyridine (18b) is 250-fold 
more selective towards VEGFR-2, showing IC50 values of 5 and 1250 nM against 
VEGFR-2 and EGFR, respectively.
188
 
 
 
Diaminofuro[2,3-d]pyrimidine (19) is a dual inhibitor of VEGFR-2 and 
PDGFR-β. The anti-angiogenic activity was assessed in the CAM (chicken embryo 
chorioallantoic  membrane) assay, where (19) showed a 40 nM IC50 value. Moreover, 
the compound is more active than metotrexate in a B16 melanoma mouse model, and 
was also able to decrease lung metastases. Molecular modelling studies show that the 
4-aminopyrimidine moiety of ATP and (19) were initially superimposed and both the 
Z- and the E-isomers of (19) could bind to the ATP domain of VEGFR-2. The 4-NH2 
along with the ring N3 of (19) make hydrogen bonds with the backbone carbonyl of 
Glu 917 and the backbone NH of Cys 919 in the hinge region, respectively; 
moreover, the 2-NH2 forms an additional H-bond with Cys 919.
189
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• Pyrimido-pyrimidinones 
RO4383596 (20a), produced by Hoffmann-La Roche, is a multitargeted 
molecule that inhibits VEGFR-2, FGFR and PDGFR with IC50 values of 44, 29, 33 
nM, respectively, while being between 10- and 3000-fold less potent against other 
TKs. In cell assays, it potently inhibits VEGF-stimulated HUVEC proliferation (IC50 
= 68 nM), while in vivo, oral administration at a dose of 25 mg/kg twice a day yields 
a good pharmacokinetic profile and leads to 81 % inhibition of corneal angiogenesis 
in mouse corneal pocket assay.
190 
Compound (20b) RO4396686, shows a biological 
behaviour similar to (20b) and significantly inhibits tumor growth at doses as low as 
50 mg/kg as tested in an H460a xenograft tumor model.
191
 
 
• Pyrido-pyrimidones 
TKI-28 (21) is a multitargeted TK inhibitor that shows IC50 in the low 
nanomolar range against VEGFR-2 (27 nM), EGFR, PDGFR-β, c-Kit and c-Src, 
while being inactive against VEGFR-1. The compound was found to possess anti 
angiogenic effects, with inhibition of EGF-, VEGF- and PDGF-stimulated cell 
proliferation, as well as decreased cell migration and tube formation in human 
microvascular endothelial cells (HMECs), suggesting TKI-28 as a very promising 
anti-cancer and anti-angiogenic agent.
192
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• Isolated pyrimidine ring derivatives 
The most active compound (22), bearing a 4-fluoro-2-methylindole on the 
oxygen atom at C-6 of the pyrimidine ring, has an IC50 value of 24 nM in enzymatic 
assays and shows antiproliferative activity against three different cancer cell lines, 
with IC50 values in the range 230-380 nM.
193
 
 
 
 
2,4-Disubstituted pyrimidines have been reported by Merck researchers as 
VEGFR-2 inhibitors; in particular, the 3,5- dimethylaniline derivative (23) inhibits 
the kinase with IC50 values of 6 and 19 nM in enzymatic and in cell assays, 
respectively.
194
 
 
 
The substituted cyano-pyrimidine JNJ-17029259 (24), reported by Johnson 
and Johnson Pharmaceuticals, is a potent, orally available and selective inhibitor of 
the VEGFR family, showing IC50 values of 90, 21 and 12 nM towards VEGFR-1, -2, 
and -3, respectively, about ten-fold lower activity towards PDGFR-β, FGFR and Flt-
3, and no significant activity towards a huge panel of other tyrosine and 
serine/threonine kinases. Moreover, JNJ-17029259 inhibits VEGF-induced HUVEC 
proliferation and migration with a 52 nM IC50 value and possesses an interesting 
antiangiogenic activity as evaluated in the aortic ring assay (IC50=50 nM). The 
compound exhibits activity in delaying the growth of a variety of solid tumors in 
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xenograft models, administered alone or in combination with conventional 
chemotherapeutic agents, such as paclitaxel and doxorubicin.
195
 
 
 
 
3.3.2 New Benzo- and Pyrido-thiopyrano fused pyrimidines 
 
The research program performed in the laboratory where I worked for my 
thesis has always been devoted to the preparation and evaluation of new 
antiproliferative agents,
196-200
 and a part of my thesis was dedicated to the synthesis 
of several polycyclic chromophores, as novel potential tyrosine kinase inhibitors. 
Moving from the structures of the aniline substituted pyrimidines above 
reported, I synthesized a series of benzothiopyrano-fused pyrimidines (26a-i) 
characterized by an aniline group in the 2-position (general formula I, Figure 19). 
Actually it was hypothesized that these new products might share the 
pharmacophoric requirements suitable for anchoring to the ATP binding site, in 
particular the NH group and the pyrimidine N1 and N3 atoms. It seemed also 
plausible to investigate if the thiopyrane sulfur atom might be directly implicated in 
additional H-bonding interactions with critical residues at the catalytic cleft; as it has 
been reported for the previously described thiophene-containing scaffold.  
With the aim to perform critical SAR studies, the analogue derivatives 2-aryl 
(compounds 25a-i) and 2-benzylamino (compounds 27a-i) were also synthesized. In 
addition, the influence of electron donor or electron withdrawing substituents (OCH3, 
Cl), into the system or on the pendant aryl group was also assessed.  
                     3.3 New VEGFR Inhibitors  
 
143 
 
Figure 19. General formula I of  2-substituted-benzothiopyrano-fused pyrimidines. 
 
Comp. Z X R1 Comp. Z X R1 Comp. Z X R1 
 
*
25a - H H 
*
26a NH H H 27a NHCH2 H H 
25b - H OCH3 26b NH H OCH3 27b NHCH2 H OCH3 
25c - H Cl 26c NH H Cl 27c NHCH2 H Cl 
*
25d - OCH3 H 26d NH OCH3 H 27d NHCH2 OCH3 H 
25e - OCH3 OCH3 26e NH OCH3 OCH3 27e NHCH2 OCH3 OCH3 
25f - OCH3 Cl 26f NH OCH3 Cl 27f NHCH2 OCH3 Cl 
25g - Cl H 26g NH Cl H 27g NHCH2 Cl H 
25h - Cl OCH3 26h NH Cl OCH3 27h NHCH2 Cl OCH3 
25i - Cl Cl 26i NH Cl Cl 27a NHCH2 H H 
*
The 2-phenyl unsubstitited derivative 25a, as well as the unsubstituted anilino derivative 26a, were 
already described in literature,
213,214
 while the 8-methoxy-2-phenyl-5H-benzo[3',2':5,6]thiopyrano 
[4,3-d]pyrimidine 25d, was previously prepared and published by our group of investigation.
200
 
 
The synthetic pathway employed in the preparation of compounds 25a-i, 26a-
i and 27a-i involved, as a first step, the preparation of the already described 7-
methoxy-2,3-dihydro-1-benzothiopyran-4(4H)-one 5b
201
 (see Scheme 2, Chapter 2) 
and the 7-chloro-2,3-dihydro-1-benzothiopyran-4(4H)-one 5c
201
 (Scheme 1), while 
the 7-unsubstituted thiochroman-4-one 5a is commercially available.  
 
Scheme 1. 
 
Reagents and conditions: 
i) 3-bromopropionic acid in NaHCO3 aq. and NaOH 10%, 100°C 3h   
ii) MSA 75°C 2h (5b); H2SO4 r.t. 24h (5c) 
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An excess of 3-bromopropionic acid in a saturated solution of sodium 
hydrogen carbonate was added to a solution of the appropriate 3-substituted 
thiophenol in a 10% potassium hydroxide aqueous solution. The reaction mixture 
was stirred at 100°C for 3 hours, cooled and acidified with concentrated hydrochloric 
acid to pH 4. The solid precipitate was collected and washed with water to give the 
pure thiopropionic acids 10b and 10c in a very good yield; these latters by 
treatment with methansulphonic acid or H2SO4 concentrated respectively, gave crude 
7-substituted 2,3-dihydro-1-benzothiopyran-4(4H)-ones 5b,c, which were purified by 
crystallizzation. 
The procedure leading to the synthesis of compounds 25a-i and 27a-i takes 
advantage of the 1,3-bielectrophile reactivity of 3-dimethylaminomethylen 
derivatives, like the intermediates 33a-c, in the reaction with appropriate 
binucleophile, in a basic medium (Scheme 2).
202-205
  
 
Scheme 2. 
 
 
Reagents and conditions: 
i) DMF DMA, refluxing toluene ii) EtONa, refluxing ethanol. 
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To this purpose, the preparation of the key compounds 33a-c was 
accomplished, with good yields, using as starting compounds the thiopyranones 5a-c, 
by reaction with an excess of dimethylformamide dimethylacetal (DMF-DMA) in 
refluxing toluene.
206
 The 2-phenyl substituted pyrimidines 25a-i and their 
benzylamino analogs 26a-i were subsequently obtained by reacting 3-
dimethylaminomethylen derivatives 33a-c, with the appropriate binucleophile 
benzamidines (36a-c)
*
 and benzylguanidines (37a-c)
*
, in an ethanolic refluxing 
solution, in the presence of sodium ethoxide. The crude target compounds were 
obtained as unique products in good overall yields (tlc analysis),  and purified by 
cristallization. However, any attempt to synthesize the 2-anilino substituted 
compounds 26a-i, by reacting 3-dimethylaminomethylen derivatives 33a-c with the 
appropriate phenylguanidines, failed. (Scheme 2). 
* The benzamidines 36a-c and benzylguanidines 37a-c, were synthesized 
according to the following procedure: (Scheme 3) 
Scheme 3. 
 
Reagents and conditions: 
i) MeONa, MeOH, NH4Cl ii) 2-methyl-2-thiopseudourea sulphate, H2O, r.t. for 7h, 100°C for 16h 
 
The p-substituted benzamidine hydrochlorides 36a-c were obtained by 
reaction of the appropriate benzonitrile derivative with a solution of sodium 
methoxide, by stirring at room temperature for 48 hours; then an equimolar amount 
of NH4Cl was added and the obtained suspension was allowed to stir for 24 hours. 
The desired benzamidines were obtained with good yields and purified by 
recrystallization with water.
207
 The p-substituted benzylguanidines 37a-c were 
synthesized by condensation of methylthiopseudourea sulfate with the appropriate 
benzylamine in aqueous solution, following a procedure described in literature.
208
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The preparation of compounds 26a-i was therefore accomplished by a 
different synthetic route:
209 
3-dimethylaminomethylen derivatives 33a-c were 
allowed to react with guanidine hydrochloride to give the 2-aminopyrimidine 
derivatives 34a-c, which, by reaction under nitrogen atmosphere with the 
appropriately p-substituted phenyliodide in anhydrous dioxane in the presence of 
K2CO3, N',N'-dimethylethylendiamine and CuI afforded the desired compounds 26a-
i (scheme 4).  
 
Scheme 4. 
 
Reagents and conditions: 
i) guanidine hydrochloride, EtONa, refluxing ethanol. 
ii) p-substituted phenyliodide, K2CO3, N',N'-dimethylethylendiamine, CuI, dioxane. 
 
The reaction mixture was heated at 100° C and stirred for 24 hours; after 
cooling, the suspension obtained was added of 2.5ml of concentrated NH3 and a 
saturated NaCl solution. The mixture was extracted with ethyl acetate and the 
organic layer was evaporated under reduced pressure giving a residue, which, 
purified by flash chromatography, using petroleum ether 60-80°C/ethyl acetate 5:5 as 
the eluting system, afforded the 2-anilino derivatives 26a-i. 
The structures proposed for the 2-substituted-benzothiopyrano-fused 
pyrimidines target compounds 25a-i, 26a-i and 27a-i were confirmed on the basis of 
analytical and spectral data (Section 4.3) which relied on those of similar compounds 
already reported.
203
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Subsequently, a series of pyridothiopyrano-pyrimidines analogs of general 
formula II was accomplished (Figure 20). 
 
Figure 20. General formula II of  2-substituted-pyridothiopyrano-fused pyrimidines. 
        
 
 
Similarly to the procedure above reported, the synthetic pathway utilized in 
the preparation of compounds 28a-c, 29a-c, and 30a-c involved, as a first step, the 
preparation of the key 2,3-dihydrothiopyran[2,3-b]pyridine-4(4H)-one 11 (Scheme 
5).
210
 
Scheme 5. 
 
Reagents and conditions: 
i) 3-bromopropionic acid in aq. NaHCO3 and NaOH 10%, 60°C, 4h 
ii) AcONa/Ac2O, 160°C, 2h 
 
 
The reaction of 2-mercaptopyridin-3-carboxylic acid with 3-bromopropionic 
acid in aqueous potassium hydroxide solution gave in very good yield (98%) the 3-
(3-carboxy-2-pyridylthio)propionic acid 15, which by treatment with anhydrous 
sodium acetate and acetic anhydride, afforded the crude desired compound 11, whose 
purification was made by filtration on silica gel 60/0.040-0.063 mm) 
chromatographic column, using petroleum ether 60-80° C/ethyl acetate 7:3 as the 
eluting system.  
 
Comp. Z R1 
28a - H 
28b - OCH3 
28c - Cl 
29a NH H 
29b NH OCH3 
29c NH Cl 
30a NHCH2 H 
30b NHCH2 OCH3 
30c NHCH2 Cl 
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2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 11,
205
 by reaction with an 
excess of dimethylformamide dimethylacetal (DMF-DMA) in refluxing toluene, 
afforded the intermediate 3-dimethylaminomethylen derivative 35,
210
 with good 
yields (Scheme 6). 
As for the benzothiopyrano analogs, the preparation of the 2-aryl- (28a-c) and 
2-benzylamino- (30a-c) substituted derivatives was accomplished by reacting 3-
dimethylaminomethylen derivative 35, under nitrogen atmosphere, with the 
appropriate p-substituted benzamidine (36a-c) or benzylguanidine (37a-c), in an 
ethanolic refluxing solution, in the presence of freshly prepared sodium ethoxide, for 
six hours (Scheme 6). After cooling, the suspension was concentrated under reduced 
pressure and the residue obtained was washed with water and collected, to give the 
crude desired compounds 28a-c and 30a-c, which were purified by recrystallization 
from ethanol. 
Scheme 6.  
 
Reagents and conditions: 
i) DMF DMA, refluxing toluene ii) EtONa, refluxing ethanol. 
 
* The benzamidines 36a-c and benzylguanidines 37a-c, were synthesized according 
to the procedure previously described (Scheme 3). 
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On the other hand, for the synthesis of the 2-anilino derivatives 29a-c we 
adopted the same synthetic route
209 
of the 2-anilino-benzothiopyrano analogs 26a-i. 
The 3-dimethylaminomethylen derivative 35 was allowed to react with 
guanidine hydrochloride obtaining the 2-aminopyrimidine derivative 38, which, by 
reaction under nitrogen atmosphere with the appropriately p-substituted phenyliodide 
in anhydrous dioxane in the presence of K2CO3, N',N'-dimethylethylendiamine and 
CuI afforded the target compounds 29a-c (Scheme 7). The reaction mixture was 
heated at 100°C and allowed to stir for 24 hours. After cooling, the suspension 
obtained was added with 2.5 ml of concentrated NH3 and with a saturated solution of 
NaCl. The mixture was extracted with ethyl acetate, the solution obtained was 
evaporated under reduced pressure giving a residue, which, purified by flash 
chromatography using petroleum ether 60-80°C/ethyl acetate 5:5 as the eluting 
system, afforded the target 2-anilino-5H-pyrido[3',2':5,6]thiopyrano[4,3-
d]pyrimidine derivatives 29a-c. 
Scheme 7. 
 
Reagents and conditions: 
i) guanidine hydrochloride, EtONa, refluxing ethanol 
ii) p-substituted phenyliodide, K2CO3, N',N'-dimethylethylendiamine, CuI, dioxane 
 
The structures proposed for the 2-substituted-pyridothiopyrano-fused 
pyrimidines target compounds 28a-c, 29a-c and 30a-c were confirmed on the basis 
of analytical and spectral data (Section 4.3) which relied on those of similar 
compounds already reported.
205
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- Recent Modifications: 
With the aim to further investigate the importance of the -NH group of the 2-
anilino substituted derivatives, I also performed the synthesis of the omologous N-
methyl anilino derivative 31. 
 
The synthetic procedure adopted is similar to the one we used for the 2-
anilino derivatives 29a-c: the 3-dimethylaminomethylen derivative 35, with 
methylguanidine hydrochloride gave the corresponding 2-N-methylaminopyrimidine 
39, which, by reaction with phenyliodide in anhydrous dioxane in presence of 
K2CO3, N',N'-dimethylethylendiamine and CuI afforded the target compound 31. 
(Scheme 8)  
Scheme 8. 
 
Reagents and conditions: 
i) methyl guanidine hydrochloride, EtONa, refluxing ethanol 
ii) phenyliodide, K2CO3, N',N'-dimethylethylendiamine, CuI, dioxane 
The reaction mixture was worked up following the usual protocols; 
compound 31 was purified by flash chromatography using petroleum ether 60°-
80°/ethyl acetate 70:30 as the eluting system and its structure was confirmed by 
analitycal data and 
1
H-NMR spectrum. This latter was characterized by a downfield 
(=3.54 ppm) singlet assigned to the N-methyl group, in addition to the absence of 
the D2O exchangeable NH signal in the  = 9.5-9.9 ppm range. 
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Moreover, considering that many VEGFR inhibithors described in literature 
present a m-substituted aniline inserted on the system of various fused 
pyrimidines,
211
 new benzothiopyrano- (26l-q) and pyridothiopyrano- (29d-f and 30d-
f) fused pyrimidines of general formula III, characterized by meta substituents on the 
2-aryl moiety, were also prepared (Figure 21). In addition to m-OCH3 and m-Cl 
phenyl- substituents, the m-Br phenyl group, which was already found to be effective 
for the activity of described VEGFR inhibitors,
212
 was eventually inserted. 
Figure 21. General formula III of  2-[(m-substituted)-aryl] benzo- and pyrido-thiopyrano 
fused pyrimidines. 
 
 
 
 
The synthesis of the novel 2-anilino derivatives, both the benzo- (26l-q) and 
the pyrido- (29d-f) thiopyrano, was achieved according to the same experimental 
procedures illustrated in Scheme 4 and 7 respectively (using the appropriate m-
substituted phenyliodide). For the synthesis of the novel 2-benzylamino-
pyridothiopyrano fused pyrimidines 30d-f, we followed the same route described in 
Scheme 6. The structures of the new benzo- and pyrido-thiopyrano pyrimidines were 
confirmed by analitycal data and 
1
H-NMR spectrum (Sectiion 4.3). 
* The benzylguanidines 37d-f, were synthesized according to the procedure reported 
below (Scheme 9) and previously illustrated in Scheme 3. 
 Scheme 9. 
 
Reagents and conditions: 
i) MeONa, MeOH, NH4Cl ii) 2-methyl-2-thiopseudourea sulphate, H2O, r.t. for 7h, 100°C for 16h 
Comp. Y Z X R2 
26l CH NH H OCH3 
26m CH NH H Cl 
26n CH NH H Br 
26o CH NH OCH3 OCH3 
26p CH NH OCH3 Cl 
26q CH NH OCH3 Br 
29d N NH H OCH3 
29e N NH H Cl 
29f N NH H Br 
30d N NHCH2 H OCH3 
30e N NHCH2 H Cl 
30f N NHCH2 H Br 
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- Biological evaluation: preliminary results    
 
As for the compounds described in Chapter 2, the biological activity of the 
novel derivatives here reported, was evaluated along the course of my thesis by a 
research group of the University of Padova.  
The ability to inhibit the kinase activity of the VEGFR-2 (also known as 
kinase insert domain receptor, KDR), which is considered to exert a pivotal role in 
neo-angiogenesis, was determined by a biochemical assay performed with a 
recombinant human kinase insert domain receptor. The preliminary results relative to 
the 2-substituted-5H-benzo[3',2':5,6]thiopyrano [4,3-d]pyrimidines 25a-i, 26a-q and 
27a-i are reported in Tables 5-7 and Figures 22a-c. 
 
Table 5.     Table 6. 
 
 
 
 
 
Table 7.  
 
 
 
 
 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
27a NHCH2 H H H n.d 
27b NHCH2 H OCH3 H 17 
27c NHCH2 H Cl H n.d 
27d NHCH2 OCH3 H H n.d 
27e NHCH2 OCH3 OCH3 H 13 
27f NHCH2 OCH3 Cl H n.d 
27g NHCH2 Cl H H n.d 
27h NHCH2 Cl OCH3 H 35 
27i NHCH2 Cl Cl H n.d 
 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
25a - H H H n.d 
25b - H OCH3 H 31 
25c - H Cl H n.d 
25d - OCH3 H H n.d 
25e - OCH3 OCH3 H 11 
25f - OCH3 Cl H n.d 
25g - Cl H H n.d 
25h - Cl OCH3 H 41 
25i - Cl Cl H n.d 
 
 
* The tested compounds were applied 
at a concentration of 7µM, and the 
results are expressed as percentage of 
inhibition with respect to the control 
SU5416 (KDR inhib. (%) = 67). 
Comp. Z X R1 R2 
KDR 
inhib. (%) 
26a NH H H H 83 
26b NH H OCH3 H 73 
26c NH H Cl H 71 
26d NH OCH3 H H 58 
26e NH OCH3 OCH3 H 60 
26f NH OCH3 Cl H 22 
26g NH Cl H H 21 
26h NH Cl OCH3 H 18 
26i NH Cl Cl H 80 
26l NH H H OCH3 92 
26m NH H H Cl 13 
26n NH H H Br 17 
26o NH OCH3 H OCH3 n.d 
26p NH OCH3 H Cl n.d 
26q NH OCH3 H Br n.d 
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Figure 22a. Percentage of the KDR tyrosine kinase activity inhibition of  2-phenyl (25b), 2-anilino 
(26b) and 2-benzylamino (27b) substituted derivatives. 
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Figure 22b. Percentage of the KDR tyrosine kinase activity inhibition of 2-phenyl- 25e, 2-anilino- 26e, 
and 2-benzylamino- 27e, 8-methoxy-substituted derivatives. 
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Figure 22c. Percentage of the KDR tyrosine kinase activity inhibition of 2-phenyl- 25h, 2-anilino- 26h, 
and 2-benzylamino- 27h, 8-chloro-substituted derivatives. 
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The results obtained from the enzymatic assays allowed a generally high 
percentage of inhibition for the most part of the 2-anilino substituted derivatives 
(compounds of series 26), while both the addition of a methylene group (compounds 
of series 27) and the deletion of the amino spacer group (compounds of series 25) 
reduced the tyrosine kinase inhibition, thus clearly indicating a crucial role for the 
length of the side chain.  
In addition an important role of the substituents on both the chromophore and 
the aryl moiety was observed. As regards the 2-anilino-substituted derivatives 26, 
when the aryl moiety is unsubstituted (26 a,d,g), or bears a p-methoxy group (26 
b,e,h), the inhibition values are progressively reduced by the presence in the 8 
position of the chromophore of methoxy or chlorine substituents. Conversely, when a 
p-chloro aryl group is present (26 c,f,i) the highest value is shown by the 8-chloro 
substituted compound 26i. In the group of m-substituted aniline derivatives, the 
preliminary results, referred to the 8 unsubstituted compounds 26 l-n, indicate the 
methoxy group (comp. 26l) as the most suitable, while a halogen (both Cl and Br) 
seems to be detrimental.  
What is concerning the 2-phenyl (25 a-i) or 2-benzylamino (27 a-i) 
substituted derivatives, the now available results indicate the 8-chloro substituted 
analogues 25h and 27h as the most active, and, what is puzzling, they show 
inhibition values higher than that of 26h. 
Finally, the drastic decrease in the KDR inhibition (2%) showed by the N-
methyl substituted anilino derivative 31 clearly indicated the key role played by the -
NH group on the 2 position. 
 
The achievements recorded by the evaluation of some of the isosteric 
pyridothiopyrano derivatives (Table 8 and Figure 23), showed that the introduction 
of the pyridine heteroatom resulted successful, leading to an improvement in the 
enzymatic inhibition. Actually the 2-anilino substituted counterparts (compounds of 
series 29) confirmed to be endowed of a notable activity and among the tested 
compounds, the 2-(p-methoxy-anilino) substituted derivative (29b) produced the 
maximal (98%) inhibition of the tyrosine kinase activity. 
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Table 8. KDR inhibition induced by 2-substituted-5H-pyrido[3',2':5,6]thiopyrano[4,3-
d]pyrimidine derivatives 28a-c, 29a-f and 30a-f espresse as (%) with respect to the control 
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Figure 23. Percentage of the KDR tyrosine kinase activity inhibition of 2-(p-OCH3-phenyl)- 28b, 2-(p-
OCH3-anilino)- 29b, and 2-(p-OCH3-benzylamino)- 30b, substituted derivatives. 
 
As a continuation of our research programme, the antiproliferative activity 
of several compounds was also assayed on HeLa (cervix adenocarcinoma), A-431 
(epidermoid carcinoma) and MSTO-211H (biphasic mesothelioma) cell lines. The 
results are expressed as IC50 values, i.e. the concentration (µM) of compound able to 
produce 50% cell death with respect to the control culture, using SU5416 
(Semaxanib) as reference compound (Table 9). 
Comp Z R1 R2 
KDR 
inhib. (%) 
28a - H H n.d 
28b - OCH3 H 20 
28c - Cl H n.d 
29a NH H H 92 
29b NH OCH3 H 98 
29c NH Cl H 60 
29d NH H OCH3 88 
29e NH H Cl 21 
29f NH H Br 53 
30a NHCH2 H H 10 
30b NHCH2 OCH3 H 38 
30c NHCH2 Cl H 11 
30d NHCH2 H OCH3 n.d 
30e NHCH2 H Cl n.d 
30f NHCH2 H Br n.d 
SU5416    67 
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Comp. Y Z X R1 R2 KDR HeLa A-431 MSTO-211H 
25a CH - H H H n.d >20 >20 >20 
25b CH - H OCH3 H 31 >20 >20 >20 
25c CH - H Cl H n.d >20 >20 >20 
25d CH - OCH3 H H n.d >20 6.51.2 11.91.1 
25e CH - OCH3 OCH3 H 11 >20 >20 >20 
25f CH - OCH3 Cl H n.d >20 >20 >20 
25g CH - Cl H H n.d >20 >20 >20 
25h CH - Cl OCH3 H 41 >20 >20 >20 
25i CH - Cl Cl H n.d >20 >20 >20 
26a CH NH H H H 83 10.22.1 >20 11.71.3 
26b CH NH H OCH3 H 73 0.70.5 0.960.25 1.080.04 
26c CH NH H Cl H 71 15.62.2 >20 11.51.5 
26d CH NH OCH3 H H 58 20.1 >20 15.01.6 
26e CH NH OCH3 OCH3 H 60 0.830.14 0.960.2 1.080.2 
26f CH NH OCH3 Cl H 22 >20 >20 >20 
26g CH NH Cl H H 21 >20 >20 >20 
26h CH NH Cl OCH3 H 18 2.10.2 5.80.4 20 
26i CH NH Cl Cl H 80 1.50.4 2.20.4 1.60.3 
26l CH NH H H OCH3 92 n.d n.d n.d 
26m CH NH H H Cl 13 n.d n.d n.d 
26n CH NH H H Br 17 n.d n.d n.d 
26o CH NH OCH3 H OCH3 n.d n.d n.d n.d 
26p CH NH OCH3 H Cl n.d n.d n.d n.d 
26q CH NH OCH3 H Br n.d n.d n.d n.d 
27a CH NHCH2 H H H n.d >20 >20 >20 
27b CH NHCH2 H OCH3 H 17 >20 >20 >20 
27c CH NHCH2 H Cl H n.d >20 >20 >20 
27d CH NHCH2 OCH3 H H n.d >20 >20 >20 
27e CH NHCH2 OCH3 OCH3 H 13 >20 >20 >20 
27f CH NHCH2 OCH3 Cl H n.d >20 >20 >20 
27g CH NHCH2 Cl H H n.d >20 >20 >20 
27h CH NHCH2 Cl OCH3 H 35 >20 >20 >20 
27i CH NHCH2 Cl Cl H n.d >20 >20 >20 
28a N - H H H n.d n.d n.d n.d 
28b N - H OCH3 H 20 >20 >20 >20 
28c N - H Cl H n.d >20 >20 >20 
29a N NH H H H 92 n.d n.d n.d 
29b N NH H OCH3 H 98 0.0840.022 0.120.02 0.130.02 
29c N NH H Cl H 60 n.d n.d n.d 
29d N NH H H OCH3 88 n.d n.d n.d 
29e N NH H H Cl 21 n.d n.d n.d 
29f N NH H H Br 53 n.d n.d n.d 
30a N NHCH2 H H H 10 n.d n.d n.d 
30b N NHCH2 H OCH3 H 38 2.70.2 >20 8.60.2 
30c N NHCH2 H Cl H 11 5.40.7 8.30.8 7.80.3 
30d N NHCH2 H H OCH3 n.d n.d n.d n.d 
30e N NHCH2 H H Cl n.d n.d n.d n.d 
30f N NHCH2 H H Br n.d n.d n.d n.d 
SU5416      67 38.50.5 37.20.4 27.31.8 
Table 9. 
                     3.3 New VEGFR Inhibitors  
 
157 
 
Considering the antiproliferative activity of the benzothiopyrano collection 
of compounds 25, 26 and 27, the crucial role for the length of the side chain was 
confirmed, as only the series of 2-anilino substituted derivatives 26 showed a 
noteworthy cytotoxic effect. In addiction, a notable effect might also be attributable 
to the p-methoxy substituent on the pendant phenyl ring, being 26 b,e the most active 
derivatives. The p-chlorine substitution seems detrimental, with the exception of 26i 
in which a good activity curiously appeared by introducing a chlorine atom on the 8-
position. 
The introduction of the pyridine heteroatom in the chromophore system led 
to an important improvement in cytotoxic activity, with IC50 values in the nanomolar 
range (29b). The crucial role for the length of the side chain was confirmed and the 
activity was now expanded to the benzyl substituted homologues (30b,c). 
Our preliminary results seem to indicate a relationship between the 
inhibition of the enzymatic activity of the VEGFR-2 and the observed cytotoxic 
effects, as the lowest IC50 values are usually related to the highest inhibition % (26b, 
26e, 29b). However, the exceptions to this general trend, e.g the lack of any 
antiproliferative activity of compound 25h (KDR inhib. 41%), or otherwise the 
notable activity exerted by compound 30c (KDR inhib. 11%), suggest the 
involvement of additional signalization pathways, that remain to be clarified. In this 
context, the evaluation of the enzymatic inhibition of other Tyrosine Kinases has 
been planned. 
 
- Evaluation of the anti-angiogenic activity in vitro: 
As a part of the collaboration with the University of Valencia, where I 
performed angiogenic biological studies, I planned to verify if the 2-anilino 
substituted derivatives (26b,e and 29b), which already proved to block the VEGFR-2 
tyrosine kinase activity, were actually able to inhibit the angiogenic process in vitro.  
To this purpose I tested the activity of the selected compounds in the ex-vivo 
“rat aortic ring assay”. Aortic explants were incubated for 7 days with compounds 
26b, 26e, and 29b, at different concentrations (10µM; 5µM; 1µM; 100nM) using 
DMSO as control, and the activity was compared with that exerted by the SU5416. 
The samples were daily monitored and on the 7
th
 day, a final time fluorescence cell 
staining was performed (Figure 24). 
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Figure 24. Anti-angiogenic activity of compounds 26b, 26e, 29b at [10µM]; [5µM]; [1µM]; [100nM] 
compared with DMSO and SU5416 at the same concentration. Images are visualized using a Nikon 
fluorescence microscope Eclipse E800 equipped with Nikon camera, with the 4x objective, after 
fluorescence cell staining at day 7
th
 of the experiment. All experiment were conducted in duplicate 
and at least on two different animals. 
 
The inhibition of the angiogenic sprouting by the selected compounds was 
confirmed in our aortic ring assay, and the use of different concentrations allowed us 
to identify the range in which the inhibition took place. In particular, the 
benzothiopyrano derivatives 26b and 26e, started to inhibit the process at 
concentrations ranging from 1 to 5µM, showing a profile similar to that of SU5416. 
The pyridothiopyrane derivative 29b, which totally inhibited the VEGFR-2 in the 
enzymatic assay, produced now a complete inhibition of the angiogenesis at a 
concentration lower than 1µM.  
 
 
 
 
DMSO 26e SU5416 26b 29b 
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- Future perspectives: 
Considering the remarkable results showed by the synthesized benzothio- and 
pyridothio-pyrano derivatives, further modifications have been planned in order to 
identify the pharmacophoric groups and improve the biological activity.  
In this context, the synthesis of isosters benzopyrane derivatives of general 
formula V  is currently in progress. 
 
Moreover, the introduction of a lipophylic group, as an additional pendant 
phenyl ring, into the (5) position of the chromophore has also been hypothesized. 
 
 
Finally, considering the crucial role of the 2-amino-pyrimidine portion of the 
molecule, it could be interesting to directly introduce it into the scaffold as 
exemplified below. 
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4.1 General Methods 
 
Unless otherwise noted, all solvents and reagents for organic synthesis were 
obtained from commercial suppliers and were used without further purification. 
Reactions requiring anhydrous conditions were carried out under a dry N2 
atmosphere using anhydrous, freshly distilled solvents. 
Reactions were monitored by thin-layer chromatography (TLC) carried out 
on Merck 0.2 mm precoated silica gel aluminium sheets (60 F-254). Silica gel 60 
(230-400 mesh) was used for column chromatography. Evaporations were made in 
vacuo (rotating evaporator). Magnesium sulfate was always used as the drying agent. 
Yields refer to chromatographically and spectroscopically (
1
H-NMR) homogeneous 
materials. 
Nuclear magnetic resonance spectra (
1
H-NMR) were recorded in DMSO-d6 
solution on a Varian Gemini 200 spectrometer operating at 200 MHz, using (CH3)4Si 
(TMS) as the internal standard. Infrared spectra were recorded with a Nicolet-Avatar 
360 FT-IR spectrophotometer in Nujol mulls. Melting points were determined using 
a Reichert Köfler hot-stage apparatus and are uncorrected. Elemental analyses were 
performed by our Analytical Laboratory and agreed with theoretical values to within 
± 0.4%. 
The evaluation in-vitro of the anti-angiogenic activity of the selected 
compounds, was performed at the Faculty of Pharmacy, University of Valencia, 
according to the general procedure described in section 5.5.  
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4.2 New Intercalating agents Topoisomerase I/II Inhibitors 
 
 
3-[(3-chlorophenyl)thio]propionic acid (10c)  
3-Bromopropionic acid (6.8 g, 44.5 mmoles) in 40 ml of water and 3.74 g (44.5 
mmoles) of sodium hydrogen carbonate were added to a solution of 3-chloro 
thiophenol (5.00g, 34.6 mmoles) in 28 ml of 10% potassium hydroxide acqueous 
solution. The reaction mixture was stirred at 100°C for 3 hours, cooled and acidified 
with concentrated hydrochloric acid to pH 2. The solid precipitate product was 
collected by filtration and washed with water to give 4.749 g (63.0 % yield) of pure 
10c.  
M.p. 65-67°C 
 
7-chloro-2,3-dihydro-4H-1-benzotiopyran-4-one (5c) 
3-[(3-chlorophenyl)thio]propionic acid 10c, (7,684 g, 35.5 mmoles) in 70 ml of of 
concentrated H2SO4 were allowed to stir at room temperature for 12 hours. Then, the 
reaction mixture was poured into ice and water. The yellow-orange solid that 
precipitated was collected by filtration to obtain 4,414 g of 5c which was crystallized 
from petroleum ether 30-60° (63,0 % yield).  
M.p. 50-55° C 
 
General procedure for the synthesis of compounds:
130 (2)
 
3-hydroximethylen-2,3-dihydro-1-benzothiopyran-4(4H)-one (6a)  
3-hydroximethylen-7-chloro-2,3-dihydro-1-benzothiopyran-4(4H)-one (6b) 
A solution of ethyl formate, 0.83 ml (10.30 mmoles), in 4 ml of anhydrous toluene is 
added dropwise to a solution of freshly prepared sodium methoxide (10.30 mmoles) 
in 4 ml of the same solvent. The mixture, cooled in ice and under anhydrous 
nitrogen, is allowed to react with a solution of the commercial 5a or the synthesized 
5c (5.15 mmoles) in 8 ml of anhydrous toluene. The resulting solution is left stirring 
at room temperature for 24 hours, checking the progress of the reaction by TLC 
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(petroleum ether 60°-80° / AcOEt = 7: 3). The suspension obtained is extracted with 
water and acidified with hydrochloric acid 18% till pH 5, producing a yellow oil (6a) 
or precipitate (6b): the oil is extracted with petroleum ether 30-60° C, dried with 
magnesium sulfate, and  concentrated to give pure 6a (52% yield); The precipitate is 
collected by filtration, giving up to 0.455g (46% yield) of product 6b.  
 
General procedure for the synthesis of compounds (7a-d):
130 (2)
 
3-(4-methoxyphenyl)hydrazono-2,3-dihydro-1-benzothiopyran-4(4H)-one (7a)  
3-(3,4-dimethoxyphenyl)hydrazono-2,3-dihydro-1-benzothiopyran-4(4H)-one   
(7b)  
3-(4-methoxyphenyl)hydrazono-7-chloro-2,3-dihydro-1-benzothiopyran-4(4H)-
one (7c) 
3-(3,4-dimethoxyphenyl)hydrazono-7-chloro-2,3-dihydro-1-benzothiopyran-
4(4H)-one (7d) 
 
To a solution of 5.31 mmoles of compound 6a or 6b in 30mL of methanol is added 
an aqueous saturated solution of 16.50 mmoles of sodium acetate. After cooling at 
0°C, a solution of the suitable diazonium salt, obtained from the appropriately 4-
methoxy- or 3,4-dimethoxy-substituted aniline (7.09 mmoles) in 18% 
hydrochloridric acid (7.5 mL) and sodium nitrite (7.09 mmoles), is added dropwise 
in slight excess. An orange precipitate immediately appears, and the mixture is 
stirred for 30 min at 0° C and then for 3h at room temperature. The solid is collected 
and washed with water to give crude compounds 7a-d, which are directly used in the 
subsequent reaction. 
7a M.p. 94-95° C ; 7b M.p. n.d ; 7c M.p. 167-170° C ; 7d M.p. 110-112° C 
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General procedure for the synthesis of compounds (4a-d): 
3-methoxy-1-benzothiopyrano[3,2-b] indol-10(11H)-one (4a)  
2,3-dimethoxy-1-benzothiopyrano[3,2-b] indol-10(11H)-one (4b) 
3-methoxy-7-chloro-1-benzothiopyrano[3,2-b] indol-10(11H)-one (4c) 
2,3-dimethoxy-7-chloro-1-benzothiopyrano[3,2-b] indol-10(11H)-one (4d) 
A solution of 4 mmoles of the suitable p-substituted phenylhydrazono derivative 7a-
d in 20 mL of ethanolic hydrogen chloride solution is refluxed for 2 hours and the 
progress of the reaction is monitored by TLC (CH2Cl2/ MeOH = 9: 1). After cooling 
the yellow/light-brown precipitate was collected and washed with ethanol to give 
crude indoles 4a-d, which were purified by crystallization with DMF (Table 1). 
Table 1. 
4a M.p.: > 300°C,   Formula: C16H11NO2S 
1H-NMR (DMSO-d6, ppm): 3.84 (s, 3H, OCH3); 7.16 (d, 1H, Ar-H); 7.33 (s, 1H, Ar-
H); 7.61-7.76 (m, 3H, ArH); 8.01 (d, 1H, ArH); 8.59 (d, 1H, ArH); 12.39 (s, 1H, 
NH exch.) 
4b M.p.: > 300°C,   Formula: C17H13NO2S 
1H-NMR (DMSO-d6, ppm): 3.87 (s 6H, 2,3-OCH3); 7.02 (s, 1H, 4-H); 7.32 (s, 1H, 1-H); 
7.62 (t, 1H, Ar-H); 7.65 (t, 1H, Ar-H); 7.99 (d, 1H, Ar-H); 8.59 (d, 1H, Ar-H); 12,32 (s, 1H, 
N-H exch.) 
4c M.p.: > 300°C,   Formula C16H10NO2SCl 
1H-NMR (DMSO-d6, ppm) 3.86 (s, 3H, OCH3); 7.15-7.20 (dd, 1H, Ar-H); 7.33 (d, 1H, Ar-
H); 7.53 (d, 1H, Ar-H); 7.64-7.69 (dd, 1H, ArH); 8.25 (d, 1H, Ar-H); 8.594 (d, 1H, ArH); 
12.47 (s, 1H, NH exch.) 
4d M.p.: > 300°C,   Formula: C17H12NO2SCl 
1H-NMR (DMSO-d6, ppm) 3.89 (s, 6H, 2,3-OCH3); 7.03 (s, 1H, 4-H); 7.33 (s, 1H, 1-H); 
7.64-7.69 (dd, 1H, 8-H J8-9 = 8.8 Hz J8-6 = 2.0 Hz); 8.22 (d, 1H, 6-H J6-8 = 2.0 Hz); 8.57 (d, 
1H, 9-H J9-8 = 8.9 Hz); 12.39 (s, 1H, N-H exch.) 
 
General procedure for the synthesis of dyalkylaminoalkyliodide 
hydroiodides
129,138 (2)
 
 
34.80 mmoles of the appropriate dialkylaminoalkylchloride hydrochloride and 76.40 
mmoles of potassium iodide are intimately mixed and heated to reflux in 100 ml of 
absolute EtOH at 120° C for 3 hours. The resulting suspension is filtered hot to 
remove inorganic salts (KCl). After cooling, the dyalkylaminoalkyliodide 
hydroiodides precipitate and are collected by filtration, and dried over P2O5. 
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General procedure for the synthesis of the final compounds: 
11-dialkyilaminoalkylbenzo[3’,2’:5,6]thiopyrano[3,2-b]indol-10(11H)-ones(2a-d) 
 
0.579 mmoles of the appropriate compound 4a-d are added in small portions to a 
stirred suspension of sodium hydride in 60% dispersion in mineral oil (0.086 g, 2.15 
mmoles) in 6 mL of anhydrous DMF, under nitrogen atmosphere. The reaction 
mixture is stirred at room temperature for 2 h and then supplemented with 0.279 
mmoles of the appropriate dialkylaminoalkyl iodide hydroiodide and left at room 
temperature for 24 h, monitoring the progress by TLC (CH2Cl2/ MeOH = 9: 1). The 
reaction mixture is diluted with water and left to stand at room temperature 
overnight. The crude products precipitated are collected and purified by 
crystallization from ethanol (Table 2 and 3). 
 
Table 2. 
 
 X X” R Yeld % M.p °C Molecular formula 
2a H H (CH2)2N(CH3)2 25 107-109 C20H20N2O2S 
2b H H (CH2)2N(C2H5)2 55.4 103-105 C22H24N2O2S 
2c Cl H (CH2)2N(CH3)2 30 98-101 C20H19N2O2SCl 
2d Cl H (CH2)2N(C2H5)2 32 95-97 C22H23N2O2SCl 
2e H OCH3 (CH2)2N(CH3)2 23 120-122 C21H22N2O3S 
2f H OCH3 (CH2)2N(C2H5)2 36 105-107 C23H26N2O3S 
2g Cl OCH3 (CH2)2N(CH3)2 22 170-172 C21H21ClN2O3S 
2h Cl OCH3 (CH2)2N(C2H5)2 28 135-136 C23H25ClN2O3S 
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Table 3. 
 
 X X’’ R 1H nmr (δppm) 
2a H H (CH2)2N(CH3)2 2.11 (s, 6H, N(CH3)2; 2.20 (t, 2H, CH2CH2N); 3.87 (s, 3H, OCH3); 
4.84  (t, 2H, CH2CH2N);  7.21-7.27 (dd, 1H, Ar-H); 7.32 (d, 1H, 
Ar-H); 7.58-7.79 (m, 3H, Ar-H); 7.98 (d, 1H, Ar-H); 8.59 (d, 1H, 
Ar-H) 
2b H H (CH2)2N(C2H5)2 0.79 (t, 6H, N(CH2CH3)2); 2.39-2.49 (q, 4H, N(CH2CH3)2); 2.69 
(t, 2H, CH2CH2N); 3.86 (s, 3H, OCH3); 4.88  (t, 2H, CH2CH2N);  
7.19-7.24 (dd, 1H, Ar-H); 7.30 (d, 1H, Ar-H); 7.57-7.78 (m, 3H, 
Ar-H); 7.97 (d, 1H, Ar-H); 8.58 (d, 1H, Ar-H) 
2c Cl H (CH2)2N(CH3)2 2.10 (s, 6H, N(CH3)2; 2.19 (t, 2H, CH2CH2N); 3.86 (s, 3H, OCH3); 
4.82  (t, 2H, CH2CH2N);  7.24 (d, 1H, Ar-H); 7.31 (d, 1H, Ar-H); 
7.64 (d, 2H, Ar-H); 8.20 (s, 1H, Ar-H); 8.54 (d, 1H, Ar-H) 
2d Cl H (CH2)2N(C2H5)2 0.78 (t, 6H, N(CH2CH3)2); 2.44-2.51 (q, 4H, N(CH2CH3)2); 2.70 
(t, 2H, CH2CH2N); 3.87 (s, 3H, OCH3); 4.88  (t, 2H, CH2CH2N);  
7.27-7.33 (m, 1H, Ar-H); 7.53 (d, 1H, Ar-H); 7.62-7.72 (m, 2H, 
Ar-H); 7.8.20-8.26 (dd, 1H, Ar-H); 8.54-8.60 (dd, 1H, Ar-H) 
2e H OCH3 (CH2)2N(CH3)2 2.81 (s, 6H, N(CH3)2; 2.56 (t, 2H, CH2CH2N); 3.89 (s, 3H, OCH3; 
3.99 (s, 3H, OCH3); 5.20 (t, 2H, CH2CH2N); 7.36 (s, 1H, 4-ArH); 
7.49 (s, 1H, 1-ArH); 7.64 (t, 1H, 7-ArH); 7.77 (s, 1H, 8-ArH); 
8.00 (d, 1H, 6-ArH); 8.60 (d, 1H, 9-ArH) 
2f H OCH3 (CH2)2N(C2H5)2 0.89 (t, 6H, N(CH2CH3)2); 2.61-2.64 (q, 4H, N(CH2CH3)2); 2.83 
(t, 2H, CH2CH2N); 3.87 (s, 3H, OCH3; 3.94 (s, 3H, OCH3); 4.95 (t, 
2H, CH2CH2N); 7.28 (s, 1H, 4-ArH); 7.60 (s, 2H, 1-, 8-ArH); 7.69 
(t, 1H, 7-ArH); 7.94 (d, 1H, 6-ArH); 8.58 (d, 1H, 9-ArH) 
2g Cl OCH3 (CH2)2N(CH3)2 2.21 (s, 6H, N(CH3)2; 2.63 (t, 2H, CH2CH2N); 3.87 (s, 3H, OCH3; 
3.93 (s, 3H, OCH3); 4.91 (t, 2H, CH2CH2N); 7.20 (s, 1H, 4-ArH); 
7.22 (s, 1H, 1-ArH); 7.60 (d, 1H, 8-ArH); 8.11 (s, 1H, 6-ArH); 
8.52 (d, 1H, 9-ArH) 
2h Cl OCH3 (CH2)2N(C2H5)2 0.79 (t, 6H, N(CH2CH3)2); 2.42-2.48 (q, 4H, N(CH2CH3)2); 2.71 
(t, 2H, CH2CH2N); 3.88 (s, 3H, OCH3; 3.93 (s, 3H, OCH3); 4.89 (t, 
2H, CH2CH2N); 7.23 (s, 1H, 4-ArH); 7.26 (s, 1H, 1-ArH); 7.63 (d, 
1H, 8-ArH); 8.15 (s, 1H, 6-ArH); 8.52 (d, 1H, 9-ArH) 
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3-(3-carboxy-2-pyridilthio) propionic acid (15)
140 (2)
 
3-Bromopropionic acid (11.83 g, 77.72 mmoles) in 50 ml of water and 6.50 g (77.72 
mmoles) of sodium hydrogen carbonate is added dropwise to a solution of 2-
mercaptonicotinic acid (10.00g, 64.40 mmoles) in 60 ml of 10% potassium 
hydroxide acqueous solution. The reaction mixture is stirred at 60°C for 4 hours, 
cooled and acidified with concentrated hydrochloric acid to pH 2. The solid 
precipitate product was collected by filtration and washed with water to give 18.60 
g (99 % yield) of pure 15. 
M.p. 205-208°C. 
 
2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one (11)
 140 (2)
 
A solution of 3-(3-carboxy-2-pyridylthio)propionic acid 15 (8.0 g, 35.2 mmoles) and 
anhydrous sodium acetate (5.376 g, 64 mmoles) in 72 ml of acetic anhydride was 
refluxed at 160°C for 1.5 hours. After cooling, the reaction mixture was diluted with 
water, basified with 30% ammonium hydroxide solution to pH 8-9 and, after filtering 
off the dark material, extracted with ethyl acetate. The combined extracts were 
washed with water, dried an evaporated to give 4.6 g of crude 11 as an orange oil. 
Purification was made by filtration on a silica gel 60/0.040-0.063 mm) 
chromatographic column, using petroleum ether 60-80°C/ethyl acetate 7:3 as the 
eluiting system. The product recovered from the less mobile fractions (tlc) gave 0.87 
g (25% yield) of pure 11. 
M.p. 66-67°C 
 
3-hydroxymethylen-2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one(12)
141 (2)
 
A solution of ethyl formate, 3 ml (36 mmoles), in 10 ml of anhydrous toluene is 
added dropwise to a solution of freshly prepared sodium methoxide 0.828g (36 
mmoles) in 10 ml of the same solvent. The mixture, cooled in ice and under 
anhydrous nitrogen, is allowed to react with a solution of product 11 (3 mg, 18 
mmoles) in 20 ml of anhydrous toluene. The resulting solution is left stirring at room 
temperature for 24 hours, checking the progress of the reaction by TLC (petroleum 
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ether 60°-80° / AcOEt = 7: 3). The suspension obtained is extracted with water and 
acidified with hydrochloric acid 18% till pH 5, producing a yellow precipitate, which 
is collected by filtration,  giving up to 3,360 g (95% yield) of product 12. 
M.p. 184-187° C 
 
General procedure for the synthesis of: 
2,3-dihydro-3-phenylhydrazonothiopyrano[2,3-b]pyridin-4(4H)-ones (13a-c)
141(2)
 
To a solution of 1.5 g (7.77 mmoles) of compound 12 in 50mL of methanol is added 
an aqueous saturated solution of 2.05 g (25.00 mmoles) of sodium acetate. After 
cooling at 0°C, a solution of the suitable diazonium salt, obtained from the 
appropriately substituted aniline (10.36 mmoles) in 18% hydrochloridric acid (13 
mL) and sodium nitrite (0.715 g, 10.36 mmoles), is added dropwise in slight excess. 
An orange precipitate immediately appears, and the mixture is stirred for 30 min at 
0° C and then for 3hours at room temperature. The solid is collected and washed with 
water to give crude compounds 13a-c, which are directly used in the subsequent 
reaction. 
13a M.p. 176-180° C ; 13b M.p. 126-130° C ; 13c M.p. n.d  
 
General procedure for the synthesis of: 
pyrido[3’,2’:5,6]thiopyrano[3,2-b]indol-5(6H)-ones (14a-c) 141 (Chapter 2) 
A solution of 4 mmoles of the suitable substituted phenylhydrazono 
derivative 13a-c in 20 mL of ethanolic hydrogen chloride solution is refluxed for 2 
hours monitoring the progress of the reaction by TLC (CH2Cl2/ MeOH = 9: 1). After 
cooling, the yellow/light-brown precipitate was collected and washed with ethanol to 
give crude indoles 14a-c, which were purified by crystallization with DMF (Table 4). 
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Table 4. 
14a M.p.: > 300°C,   Formula: C14H8N2OS 
1H-NMR (DMSO-d6, ppm): 7.25 (t, 1H, ArH), 7.55 (t, 1H, ArH), 7.62-7.74 (m, 3H, Ar-H), 
8.88-8.95 (m, 2H, ArH), 12.67 (s, 1H, NH exch.) 
14b M.p.: > 300°C,   Formula: C14H7ClN2OS 
1H-NMR (DMSO-d6, ppm): 7.32-8.96 (m, 6H, ArH), 12.86 (s, 1H, NH exch.) 
14c M.p.: > 300°C,   Formula: C16H12N2O3S 
1H-NMR (DMSO-d6, ppm): 3.88 (s 6H, 2,3-OCH3); 7.03 (s, 1H, 4-H); 7.38 (s, 1H, 1-H); 7.65-
7.71 (dd, 1H, 8-H J8-9 = 7.8 Hz J8-7 = 4.8 Hz); 8.86-8.90 (m, 2H, 7-, 9-H); 12.42 (s, 1H, N-H 
exch.) 
 
General procedure for the synthesis of the final compounds:  
6-dialkyilaminoalkyilpyrido[3’,2’:5,6]thiopyrano[3,2-b]indol-5(6H)-ones (3a-f) 
 
0.200 mmoles of the appropriate compound 14a-c are added in small portions to a 
stirred suspension of sodium hydride in 60% dispersion in mineral oil (0.053 g, 2.22 
mmoles) in 10 mL of anhydrous DMF, under nitrogen atmosphere. The reaction 
mixture is stirred at room temperature for 2 h and then supplemented with 0.945 
mmoles of the appropriate dialkylaminoalkyl iodide hydroiodide and left at room 
temperature for 24 h, monitoring the progress by TLC (CH2Cl2/ MeOH = 9: 1). The 
reaction mixture is diluted with water and left to stand at room temperature 
overnight. The crude products precipitated (3a-f) are collected and purified by 
crystallization from ethanol (Table 5 and 6). 
Table 5. 
 
 X’ X” R Yeld % M.p °C Molecular formula 
3a H H (CH2)2N(CH3)2 65 138-140 C18H17N3OS 
3b H H (CH2)2N(C2H5)2 80 100-103 C20H21N3OS 
3c Cl H (CH2)2N(CH3)2 21 160-163 C18H16N3OSCl 
3d Cl H (CH2)2N(C2H5)2 31 120-125 C20H20N3OSCl 
3e OCH3 OCH3 (CH2)2N(CH3)2 20 235-239 C20H22N3O3SCl 
3f OCH3 OCH3 (CH2)2N(C2H5)2 25 241-246 C22H26N3O3SCl 
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Table 6. 
 
 X’ X’’ R 1H nmr (δppm) 
3a H H (CH2)2N(CH3)2 2.20 (s, 6H, N(CH3)2; 2.64 (t, 2H, NCH2CH2 J = 6.9 Hz); 4.97 
(t, 2H, NCH2CH2 J = 6.8 Hz); 7.33 (t, 1H, 9-H J9-10 = 7.8 Hz); 
7.59-7.75 (m, 2H, 3-H, 8-H); 7.82 (d, 1H, 7-H J7-8 = 8.6 Hz); 
7.99 (d, 1H, 10-H J10-9 = 7.8 Hz); 8.87-8.95 (m, 2H, 2-H 4-H) 
3b H H (CH2)2N(C2H5)2 0.80 (t, 6H, N(CH2CH3)2 J = 7.0 Hz); 2.39-2.51 (m, 4H,  
N(CH2CH3)2); 2.76 (t, 2H, NCH2CH2); 4.94 (t, 2H, NCH2CH2 J 
= 6.7 Hz); 7.33 (t, 1H, 9-H J = 7.5 Hz); 7.60-7.74 (m, 2H, 3-
H, 8-H); 7.81 (d, 1H, 7-H J = 8.6 Hz); 8.00 (d,1H, 10-H J10-9 = 
8.0 Hz); 8.89-8.93 (m, 2H, 2-H 4-H) 
3c Cl H (CH2)2N(CH3)2 2.20 (s, 6H, N(CH3)2; 2.63 (t, 2H, NCH2CH2 J = 6.5 Hz); 4.96 
(t, 2H, NCH2CH2 J = 6.5 Hz); 7.59-7.65 (dd, 1H, 8-H J8-7 = 9.0 
Hz J8-10 = 1.6 Hz); 7.68-7.74 (dd, 1H, 3-H J3-4 = 8.2 Hz J3-2 = 
8.2 Hz); 7.88 (d, 1H, 7-H J7-8 = 9.0 Hz); 8.15 (d,1H, 10-H J10-8 
= 1.6 Hz); 8.87-8.94 (m, 2H, 2-H 4-H) 
3d Cl H (CH2)2N(C2H5)2 0.73 (t, 6H, N(CH2CH3)2 J = 7.0 Hz); 2.38-2.47 (q, 4H,  
N(CH2CH3)2); 2.71 (t, 2H, NCH2CH2 J = 6.6 Hz); 4.90 (t, 2H, 
NCH2CH2 J = 6.6 Hz); 7.57-7.63 (dd, 1H, 8-H J8-7 = 9.1 Hz J8-
10 = 2.1 Hz); 7.66-7.73 (dd, 1H, 3-H J3-4 = 8.0 Hz J3-2 = 8.2 
Hz); 7.84 (d, 1H, 7-H J7-8 = 9.1 Hz); 8.12 (d,1H, 10-H J10-8 = 
2.1 Hz); 8.85-8.92 (m, 2H, 2-H 4-H) 
3e OCH3 OCH3 (CH2)2N(CH3)2 2.21 (s, 6H, N(CH3)2; 2.60 (t, 2H, NCH2CH2); 3.87 (s, 3H, 3-
OCH3); 3.93 (s, 3H, 2-OCH3); 4.92 (t, 2H, NCH2CH2); 7.22 (s, 
1H, 4-H); 7.33 (d, 1H, 9-H J = 8.4 Hz); 7.63-7.70 (m, 1H, 8-
H); 8.82-8.88 (m, 2H, 1-H, 7-H)) 
3f OCH3 OCH3 (CH2)2N(C2H5)2 1.30 (t, 6H, N(CH2CH3)2 J = 7.2 Hz); 3.16-3.52 (m, 6H, 
N(CH2CH3)2,  NCH2CH2); 3.86 (s, 3H, 3-OCH3); 3.98 (s, 3H, 
2-OCH3); 5.20 (t, 2H, NCH2CH2); 7.36 (s, 1H, 4-H); 7.63 (d, 
1H, 9-H); 7.66-7.70 (m, 1H, 8-H); 8.82-8.88 (m, 2H, 1-H 7-
H) 
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4.3 New Small Molecules Tyrosine Kinase Inhibitors 
 
 
3-[(3-methoxyphenyl)thio]propionic acid (10b)
201 (3)
 
 
3-Bromopropionic acid (2,716 g, 18.0 mmoles) in 14 ml of water and 1.508 g (18.0 
mmoles) of sodium hydrogen carbonate were added to a solution of 3-
methoxythiophenol (1.76 ml, 14.0 mmoles) in 12 ml of 10% potassium 
hydroxide acqueous solution. The reaction mixture was stirred at 100°C for 3 hours, 
cooled and acidified with concentrated hydrochloric acid to pH 4. The solid 
precipitate product was collected by filtration and washed with water to give 14.52 
g (82.11% yield) of pure 10b.  
M.p.58-60°C 
 
7-methoxy-2,3-dihydro-4H-1-benzothiopyran-4-one (5b)
 201 (3)
 
 
A solution of 3-[(3-methoxyphenyl)thio]propionic acid 10b, (2.5 g, 18.0 
mmoles) in 50 ml of methanesulfonic acid were heated to 75°C for 30 minutes. 
After cooling, the reaction mixture was poured into ice and extracted with AcOEt 
(x3). The organic layer was worked with 10% KOH and then extracted with H2O 
(x3). The combined extracts were washed with water, dried and crystallized from 
petroleum ether 60-80 ° to obtain 0.609 g (26.60 % yield) of product 5b.  
M.p. 55-56°C 
 
General procedure for the synthesis of: 
3-dimethylaminomethylen-2,3-dihydrobenzothiopyran-4(4H)-ones (33a-c)
206 (3)
 
An excess of dimethylformamide dimethylacetal (2.60 mL, 19.3 mmoles) was added 
to a stirred solution of the appropriate 2,3-dihydrobenzothiopyran-4(4H)-ones 5a-c 
(7.73 mmoles) in anhydrous toluene (10 mL) and the mixture was refluxed for 12 
hours. After cooling, the solution obtained was evaporated under reduced pressure, 
giving a solid residue which was treated with ethyl ether, collected and purified by 
crystallization from toluene-petroleum ether 60-80°C (quantitative yield). 
33a M.p. 93-94° C 33b M.p. 118-120° C 33c M.p. 67-70°  
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General procedure for the synthesis of: 
4-Substituted-benzamidines hydrochloride (36a-c)
207 (3) 
 
The appropriate benzonitrile derivative (15 mmoles) was added, to a stirred solution 
of sodium methoxide (0.034 g, 1.50 mmoles of sodium in 15 ml of anhydrous 
methanol). The reaction mixture was stirred, at room temperature, for 48 hours, then 
0.800 g of NH4Cl (15.0 mmoles) were added and the suspension was allowed to stir 
for 24 hours. The obtained suspension was evaporated under reduced pressure and 
the residue was purified by trituration with ethyl ether to give compounds 36a-c. 
 
General procedure for the synthesis of the final products:  
2-aryl-5H-benzo[3',2':5,6]thiopyrano [4,3-d]pyrimidines (25a-i) 
 
The appropriate benzamidine hydrochloride 36a-c (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(0.059 g, 2.55 mmoles of sodium in 8 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then the opportune 
dimethylaminomethylene derivative 33a-c (0.187 g, 0.85 mmoles) was added and the 
reaction mixture was refluxed for 6 hours. After cooling, the suspension was 
concentrated under reduced pressure. The residue obtained was washed with water 
and collected, to give crude pyrimidines 25a-i, which were purified by 
recrystallization from ethanol. (Tables 7 and 8) 
 
 X R1 Yield M.p. Molecular Formula 
*25a H H  
25b H OCH3 30 108-110 C18H14N2OS 
25c H Cl 24 114-116 C17H11ClN2S 
*25d OCH3 H 94 82-85 C18H14N2OS 
25e OCH3 OCH3 40 186-188 C19H16N2O2S 
25f OCH3 Cl 35 142-144 C18H13ClN2OS 
25g Cl H 14 117-119 C17H11ClN2S 
25h Cl OCH3 13 142-144 C18H13ClN2OS 
25i Cl Cl 14 165-167 C17H10Cl2N2S 
Table 7. 
* 
Already described 
213,214 (3)
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Table 8. 
 
 X R1 
1H nmr (δppm) 
25b H OCH3 3.85 (S, 3H, 4'-OCH3); 4.16 (s, 2H, CH2S); 7.10 (d, 2H, 2',6'-ArH, J = 
8.8 Hz); 7.43-7.49 (m, 3H, 7-, 8-, 9-ArH); 8.45 (dd, 2H, 3',5'-ArH, J 
= 8.6 Hz); 8.52-8.55 (dd, 1H, 10-ArH) ; 8.81 (s, 1H, 4-ArH) 
25c H Cl 4.20 (s, 2H, CH2S); 7.42-7.51 (m, 3H, 7-, 8-, 9-ArH); 7.63 (d, 2H, 2',6'-ArH); 
8.49-8.56 (m, 3H, 3',5'-, 10-ArH); 8.89 (s, 1H, 4-ArH) 
25d OCH3 H 3.84 (s, 3H, OCH3); 4.16 (s, 2H, CH2S); 6.96-7.03 (m, 2H, 9-H 7-H); 7.52-
7.56 (m, 4H, ArH); 8.46-8.50 (m, 2H, ArH); 8.78 (s, 1H, 4-H) 
25e OCH3 OCH3 3.85 (S, 6H, 8-OCH3, 4'-OCH3); 4.14 (s, 2H, CH2S); 6.96-7.02 (m, 2H, 7-, 9-
ArH); 7.09 (d, 2H, 2',6'-ArH, J = 8.6 Hz); 8.41-8.49 (m, 3H, 3',5'-, 10-ArH) ; 
8.73 (s, 1H, 4-ArH) 
25f OCH3 Cl 3.86 (S, 3H, 8-OCH3); 4.17 (s, 2H, CH2S); 6.96-7.03 (m, 2H, 7-, 9-ArH); 7.61 
(d, 2H, 2',6'-ArH); 8.46-8.51 (m, 3H, 3',5'-, 10-ArH) ; 8.79 (s, 1H, 4-ArH) 
25g Cl H 4.22 (s, 2H, CH2S); 7.46-7.51 (dd, 1H, 9-ArH J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 
7.54-7.57 (m, 3H, 2'-, 4'-, 6'-ArH); 7.62 (d, 1H, 7-ArH, J = 2.0 Hz); 8.47-
8.57 (m, 3H, 3'-, 5'-, 10-ArH); 8.88 (s, 1H, 4-ArH) 
25h Cl OCH3 3.86 (S, 3H, 8-OCH3); 4.21 (s, 2H, CH2S); 7.11 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 
7.47-7.52 (dd, 1H, 9-ArH, J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.63 (d, 1H, 7-ArH, J 
= 2.2 Hz); 8.45 (d, 2H, 3',5'-ArH, J = 8.8 Hz); 8.53 (d, 1H, 10-ArH, J = 8.4 
Hz); 8.90 (s, 1H, 4-ArH) 
25i Cl Cl 4.24 (s, 2H, CH2S); 7.46-7.52 (dd, 1H, 9-ArH J9-10 = 8.4 Hz, J9-7 = 2.0 Hz); 
7.61-7.65 (m, 3H, 2',6'-, 7-ArH); 8.49 (m, 3H, 3',5'-, 10-ArH); 8.90 (s, 1H, 
4-ArH) 
 
General procedure for the synthesis of: 
4-substituted-benzylguanidines sulfate (37a-f)
208 (3)
  
The appropriate 4-substituted benzylamine (20.0 mmoles) was added, drop to drop, 
to a stirred solution of 2-methyl-2-thiopseudourea sulfate (2.782 g, 14.8 mmoles in 8 
ml of water), cooling the reaction flask into a ice bath. The reaction mixture was 
stirred, at room temperature, for 7 hours and then refluxed for 16 hours. After 
cooling, the obtained suspension was evaporated under reduced pressure and the 
residue was purified by recrystallization from water. 
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General procedure for the synthesis of the final products: 
2-benzylamino-5H-benzo[3',2':5,6] thiopyrano[4,3-d]pyrimidines (27a-i) 
The appropriate benzylguanidine sulfate 37a-f (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(0.059 g, 2.55 mmoles of sodium in 8 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then the appropriate 
dimethylaminomethylene derivative 33a-c (0.187 g, 0.85 mmoles) was added and the 
reaction mixture was refluxed for 6 hours. After cooling, the suspension was 
concentrated under reduced pressure. The residue obtained was washed with water 
and collected, to give crude pyrimidines 27a-i, which were purified by 
recrystallization from ethanol. (Table 9 and 10) 
 
 
Table 9. 
 
 X R1 Yield M.p. Molecular Formula 
27a H H 20 144-146 C18H15N3S 
27b H OCH3 25 160-162 C19H17N3OS 
27c H Cl 31 152-154 C18H14ClN3S 
27d OCH3 H 12 167-169 C19H17N3OS 
27e OCH3 OCH3 25 140-142 C20H19N3O2S 
27f OCH3 Cl 29 170-172 C19H16ClN3OS 
27g Cl H 14 158-160 C18H14ClN3S 
27h Cl OCH3 13 165-167 C19H16ClN3OS 
27i Cl Cl 12 185-187 C18H13Cl2N3S 
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Table 10. 
 
 X R1 
1H nmr (δppm) 
27a H H 3.92 (s, 2H, CH2S); 4.56 (d, 2H, CH2NH, J = 6.4 Hz) 7.16-7.39 (m, 8H, 7-, 8-, 
9-, 2'-, 3'-, 4'-, 5', 6'-ArH) 7.81 (t, 1H, CH2NH exch. J = 6.3 Hz); 8.19 (d, 1H, 
10-ArH, J = 7.6 Hz); 8.26 (s, 1H, 4-ArH) 
27b H OCH3 3.70 (S, 3H, -OCH3); 3.92 (s, 2H, CH2S); 4.48 (d, 2H, CH2NH, J = 6.2 Hz) 
6.85-(d, 2H, 2',6'-ArH, J = 8.4 Hz); 7.26-7.39 (m, 5H, 7-, 8-, 9-, 3',5'-ArH); 
7.71 (t, 1H, CH2NH exch., J = 6.3 Hz); 8.20-8.25 (m, 2H, 10-, 4-ArH) 
27c H Cl 3.92 (s, 2H, CH2S); 4.53 (d, 2H, CH2NH, J = 6.0 Hz); 7.28-7.39 (m, 7H, 7-, 8-, 
9-, 2',6'-, 3',5'-ArH); 7.82 (t, 1H, CH2NH exch., J = 5.9 Hz); 8.17 (d, 1H, 10-
ArH, J = 7.2 Hz); 8.26 (s, 1H, 4-ArH) 
27d OCH3 H 3.80 (S, 3H, 8-OCH3); 3.91 (s, 2H, CH2S); 4.54 (d, 2H, CH2NH, J = 6.4 Hz); 
6.87-6.92 (m, 2H, 7-, 9-ArH); 7.19-7.33 (m, 5H, 2'-, 3'-, 4'-, 5', 6'-ArH); 7.72 
(t, 1H, CH2NH exch. J = 6.3 Hz); 8.13 (d, 1H, 10-ArH, J = 8.8 Hz); 8.19 (s, 1H, 
4-ArH) 
27e OCH3 OCH3 3.70 (S, 3H, 4'-OCH3); 3.80 (S, 3H, 8-OCH3); 3.90 (s, 2H, CH2S); 4.46 (d, 2H, 
CH2NH, J = 6.0 Hz) 6.85-(d, 2H, 2',6'-ArH, J = 8.4 Hz); 6.90 (d, 1H, 9-ArH, J = 
9.8); 6.92 (s, 1H, 7-ArH); 7.27 (d, 2H, 3',5'-ArH, J = 8.4 Hz); 7.62 (t, 1H, 
CH2NH exch., J = 6.0 Hz); 8.15 (d, 1H, 10-ArH, J = 9.8 Hz); 8.18 (s, 1H, 4-
ArH) 
27f OCH3 Cl 3.80 (S, 3H, OCH3); 3.91 (s, 2H, CH2S); 4.52 (d, 2H, CH2NH, J = 6.4 Hz); 
6.85-6.93 (m, 2H, 7-, 9-ArH); 7.36-7.42 (m, 4H, 2',6'-, 3',5'-ArH); 7.74 (t, 
1H, CH2NH exch., J = 6.3 Hz); 8.11 (d, 1H, 10-ArH); 8.19 (s, 1H, 4-ArH) 
27g Cl H 3.96 (s, 2H, CH2S); 4.55 (d, 2H, CH2NH, J = 6.2 Hz) 7.19-7.39 (m, 6H, 9-, 2'-, 
3'-, 4'-, 5', 6'-ArH); 7.51 (d, 1H, 7-ArH, J = 1.8 Hz); 7.86 (t, 1H, CH2NH exch. 
J = 6.4 Hz); 8.17 (d, 1H, 10-ArH); 8.27 (s, 1H, 4-ArH) 
27h Cl OCH3 3.33 (S, 3H, 4'-OCH3); 3.95 (s, 2H, CH2S); 4.48 (d, 2H, CH2NH, J = 6.2 Hz) 
6.86 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 7.28 (d, 2H, 3',5'-ArH, J = 9.0 Hz); 7.37-
7.42 (dd, 1H, 9-ArH, J9-10 = 8.9 Hz, J9-7 = 2.0 Hz); 7.51 (d, 1H, 7-ArH, J9-7 = 
2.0 Hz); 7.76 (t, 1H, CH2NH exch. J = 6.2 Hz); 8.21 (d, 1H, 10-ArH, J = 8.9 
Hz); 8.27 (s, 1H, 4-ArH) 
27i Cl Cl 3.97 (s, 2H, CH2S); 4.54 (d, 2H, CH2NH, J = 6.4 Hz) 7.34-7.40 (m, 5H, 2',6'-, 
3',5'-, 9-ArH); 7.51 (d, 1H, 7-H, J = 2.2 Hz); 7.87 (t, 1H, CH2NH exch. J = 6.4 
Hz); 8.17 (d, 1H, 10-ArH, J = 8.8 Hz); 8.28 (s, 1H, 4-ArH) 
 
 
              4.3 New Small Molecules Tyrosine Kinase Inhibitors (Experimental Section) 
 
 
192 
 
General procedure for the synthesis of: 
2-amino-5H-benzo[3',2':5,6]thiopyrano[4,3-d]pyrimidines (34a-c) 
Guanidine hydrochloride (0.160 g, 1.70 mmoles) was added, at room temperature, 
under a nitrogen atmosphere, to a stirred solution of sodium ethoxide (0.059 g, 2.55 
mmoles of sodium in 8 mL of anhydrous ethanol). The resulting suspension was 
stirred at room temperature for 15 minutes, then the opportune 
dimethylaminomethylene derivative 33a-c (0.85 mmoles) was added and the reaction 
mixture was refluxed for 6 h. After cooling, the resulting suspension was 
concentrated under reduced pressure and the residue obtained was washed with water 
and collected to give crude pyrimidine 34a-c, which were purified by 
recrystallization from ethanol. 
34a M.p. 166-169° C  34b M.p. 172-175° C 
34c M.p. 180-182°C yield. 75% 1H-NMR (dimethyl-d6 sulfoxide):  3.95 (s, 2H, CH2S); 6.71 
(s, 2H, NH2 exch.) 7.35-7.41 (dd, 1H, 9-ArH J9-10 = 8.2Hz J9-7 = 2.2 Hz); 7.51 (d, 1H, 7-ArH J7-9 = 
2.0 Hz); 8.17 (d, 1H, 10-H J10-9 = 8.0 Hz); 8.24 (s, 1H, 4-ArH) Anal. Calcd. for C11H8ClN3S: C, 
52.90; H, 3.21; N, 16.83; Found: C, 52.75; H, 3.24; N, 16.85  
 
 
 
General procedure for the synthesis of the final compounds: 
2-anilino-5H-benzo[3',2':5,6] thiopyrano[4,3-d]pyrimidines (26b-q) 
The opportune 2-amino-5H-benzo[3',2':5,6]thiopyrano[4,3-d]pyrimidine 34a-c 
(0.417 mmoles) was added, at room temperature, under nitrogen atmosphere, to 
0.079 g of CuI (0.417 mmoles) and 0.115 g of anhydrous K2CO3 (0.833 mmoles). 
Then, the appropriate p- and m-substituted aryl iodide (0.694 mmoles) and 0.04 ml of 
DMEDA (0.417 mmoles) and 2.5 ml of dioxane were added. The reaction mixture 
was heated at 100°C and allowed to stir for 24 hours. After cooling, the mixture was 
added with 2.5 ml of concentrated NH3 and with a saturated solution of NaCl (10-15 
ml). The reaction mixture was extracted with ethyl acetate, the solution obtained was 
evaporated under reduced pressure giving a residue which was purified by flash 
chromatography using petroleum ether 60-80°C/ethyl acetate 5:5 as the eluting 
system, to give compounds 26a-q (Tables 11 and 12). 
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Table 11. 
* Already described.
210
 
 
 X R1 R2 Yeld % M.p °C Molecular formula 
*26a H H H    
26b H OCH3 H 16 164-165 C18H15N3OS 
26c H Cl H 23 226-228 C17H12ClN3S 
26d OCH3 H H 13 174-176 C18H15N3OS 
26e OCH3 OCH3 H 12 195-197 C19H17N3O2S 
26f OCH3 Cl H 35 214-216 C18H14ClN3OS 
26g Cl H H 70 222-224 C17H12ClN3S 
26h Cl OCH3 H 10 205-207 C18H14ClN3OS 
26i Cl Cl H 20 170-172 C17H11Cl2N3S 
26l H H OCH3 16.0 136-137 C18H15N3OS 
26m H H Cl 10.0 159-160 C17H12ClN3S 
26n H H Br 12.0 178-179 C17H12BrN3S 
26o OCH3 H OCH3 11.0 137-138 C19H17N3O2S 
26p OCH3 H Cl 10.0 139-140 C18H14ClN3OS 
26q OCH3 H Br 8.0 126-127 C18H14BrN3OS 
 
 
Table 12. 
 
 X R1 R2 
1H nmr (δppm) 
26b H OCH3 H 3.74 (S, 3H, 8-OCH3); 4.00 (s, 2H, CH2S); 6.91 (d, 2H, 2',6'-ArH J = 
9,0 Hz); 7.35-7.44 (m, 3H, 7-, 8-, 9-ArH); 7.69 (d, 2H, 3',5'-ArH J = 
9.0 Hz); 8.26-8.29 (dd, 1H, 10-ArH); 8.42 (s, 1H, 4-ArH); 9.47 (s, 
1H, NH exch.) 
26c H Cl H 4.03 (s, 2H, CH2S); 7.34-7.45 (m, 5H, 3',5'-, 7-, 8-, 9-ArH); 7.85 (d, 
2H, 2',6'-ArH J = 9.0 Hz); 8.29 (d, 1H, 10-ArH); 8.49 (s, 1H, 4-ArH); 
9.86 (s, 1H, NH exch.) 
26d OCH3 H H 3.83 (S, 3H, 8-OCH3); 4.01 (s, 2H, CH2S); 6.91-6.99 (m, 3H, 7-, 9-, 
4'-ArH); 7.30 (t, 2H, 3',5'-ArH); 7.81 (d, 2H, 2',6'-ArH); 8.24 (d, 1H, 
10-ArH); 8.40 (s, 1H, 4-ArH); 9.61 (s, 1H, NH exch.) 
26e OCH3 OCH3 H 3.74 (S, 3H, 4'-OCH3); 3.83 (S, 3H, 8-OCH3); 4.00 (s, 2H, CH2S); 
6.88-6.98 (m, 4H, 2',6'-, 7-, 9-ArH); 7.69 (d, 2H, 3',5'-ArH, J = 9.0 
Hz); 8.22 (d, 1H, 10-ArH, J = 9.0 Hz); 8.35 (s, 1H, 4-ArH); 9.40 (s, 
1H, NH exch.) 
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26f OCH3 Cl H 3.83 (S, 3H, OCH3); 4.02 (s, 2H, CH2S); 6.94-6.99 (dd, 2H, 7-, 9-
ArH); 7.35 (d, 2H, 3',5'-ArH, J = 9.0 Hz); 7.84 (d, 2H, 2',6'-ArH, J = 
8.8 Hz); 8.23 (d, 1H, 10-ArH, J = 8.2 Hz); 8.42 (s, 1H, 4-ArH); 9.79 
(s, 1H, NH exch.) 
26g Cl H H 4.06 (s, 2H, CH2S); 6.97 (t, 1H, 4'-ArH); 7.36 (t, 2H, 3',5'-ArH);7.44-
7.49(dd, 1H, 9-ArH J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.57 (d, 1H, 7-ArH); 
7.80 (d, 2H, 2',6'-ArH); 8.27 (d, 1H, 10-ArH J = 8.6 Hz); 8.49 (s, 1H, 
4-ArH); 9.73 (s, 1H, NH exch.) 
26h Cl OCH3 H 3.74 (S, 3H, 4'-OCH3); 4.05 (s, 2H, CH2S); 6.91 (d, 2H, 3',5'-ArH, J = 
9.0 Hz); 7.43-7.48 (dd, 1H, 9); 7.56 (d, 1H, 7-ArH); 7.67 (d, 2H, 
2',6'-ArH, J = 8.8 Hz); 8.25 (d, 1H, 10-ArH); 8.44 (s, 1H, 4-ArH); 
9.52 (s, 1H, NH exch.) 
26i Cl Cl H 4.06 (s, 2H, CH2S); 7.36 (d, 2H, 3',5'-ArH, J = 8.8 Hz); 7.41-7.47 (dd, 
1H, 9-ArH J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.57 (d, 1H, 7-ArH, J = 2.2 
Hz); 7.83 (d, 2H, 2',6'-ArH, J = 9.0 Hz); 8.26 (d, 1H, 10-ArH, J = 8.6 
Hz); 8.50 (s, 1H, 4-ArH); 9.89 (s, 1H, NH exch.) 
26l H H OCH3 3.77 (s, 3H, OCH3); 4.04 (s, 2H, CH2-S); 6.52-6.57 (dd, 1H, Ar-H, J = 
2.2 Hz, J = 7.8 Hz); 7.21 (t, 1H, Ar-H, J = 8.2 Hz); 7.32-7.46 (m, 4H, 
Ar-H); 7.63 (s, 1H, 2'-H); 8.32 (d, 1H, Ar-H, J = 6.0 Hz); 8.49 (s, 1H, 
4-H); 9.71 (s, 1H, NH exch.) 
26m H H Cl 4.05 (s, 2H, CH2-S); 7.00 (d, 1H, Ar-H, J = 9.0 Hz); 7.30-7.47 (m, 4H, 
Ar-H); 7.73 (d, 1H, Ar-H, J = 9.0 Hz); 8.07 (s, 1H, 4-H); 8.29 (d, 1H, 
Ar-H); 8.53 (s, 1H, 2'-H); 9.95 (s, 1H, NH exch.) 
26n H H Br 4.05 (s, 2H, CH2-S); 7.13 (d, 1H, Ar-H, J = 7.6 Hz); 7.28 (t, 1H, Ar-H, 
J = 8.1 Hz); 7.32-7.53 (m, 3H, Ar-H); 7.77 (d, 1H, Ar-H, J = 8.6 Hz); 
8.23 (s, 1H, 4-H); 8.30 (d, 1H, Ar-H, J = 6.4 Hz); 8.53 (s, 1H, 2'-H); 
9.94 (s, 1H, NH exch.) 
26o OCH3 H OCH3 3.76 (s, 3H, 3'-OCH3); 3.84 (s, 3H, 8-OCH3);  4.02 (s, 2H, CH2-S); 
6.51-6.56 (dd, 1H, Ar-H); 7.19 (t, 1H, Ar-H); 7.33 (d, 1H, Ar-H); 
7.61 (s, 1H, Ar-H); 8.25 (d, 1H, Ar-H); 8.41 (s, 1H, Ar-H); 9.62 (s, 
1H, NH exch.) 
26p OCH3 H Cl 3.84 (s, 3H, OCH3); 4.03 (s, 2H, CH2-S); 6.96-7.00 (m, 3H, Ar-H); 
7.32 (t, 1H, Ar-H); 7.72 (d, 1H, Ar-H); 8.05 (s, 1H, Ar-H); 8.23 (d, 
1H, Ar-H); 8.45 (s, 1H, Ar-H); 9.87 (s, 1H, NH exch.) 
26q OCH3 H Br 3.83 (s, 3H, OCH3); 4.14 (s, 2H, CH2-S); 6.93-6.99 (m, 2H, Ar-H); 
7.11 (d, 1H, Ar-H); 7.26 (t, 1H, Ar-H); 7.69-7.78 (m, 2H, Ar-H); 8.22 
(d, 1H, Ar-H); 8.44 (s, 1H, Ar-H); 9.84 (s, 1H, NH exch.) 
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3-(3-carboxy-2-pyridylthio)propionic acid (15) and 2,3-dihydrothiopyrano[2,3-
b]pyridine-4(4H)-one (11): See section 4.2 
 
2,3-dihydro-3-dimethylaminomethylen-thiopyrano[2,3-b]pyridin-4(4H)-one (35) 
An excess of dimethylformamide dimethylacetal (1 ml, 7.5 mmoles) was added to a 
stirred solution of 2,3-dihydrothiopyrano[2,3-b]pyridin-4(4H)-one 34 (0.500 g, 3.03 
mmoles) in anhydrous toluene (5 ml) and the mixture was refluxed for 16 hours. 
After cooling, the solution obtained was evaporated under reduced pressure, giving a 
residue which was treated with ethyl ether, collected and purified by recrystallization 
from toluene-petroleum ether 60-80°C to give 0.490 g of compound 35 (73.5% 
yield). 
M.p. 100-101° C 
 
General procedure for the synthesis of the final compounds:  
2-aryl-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine derivatives (28a-c) 
 
The appropriate benzamidine hydrochloride 36a-c (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(0.059 g, 2.55 mmoles of sodium in 8 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then the 
dimethylaminomethylene derivative 35 (0.187 g, 0.85 mmoles) was added and the 
reaction mixture was refluxed for 6 hours. After cooling, the suspension was 
concentrated under reduced pressure. The residue obtained was washed with water 
and collected, to give crude pyrimidines 28a-c, which were purified by 
recrystallization from ethanol. (Table 13 and 14) 
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Table 13. 
 
 R1 Yeld % M.p °C Molecular formula 
Analysis % 
Calc./Found 
C H N 
28a H 52 158-160 C16H11N3S 69.31 
68.98 
3.97 
3.61 
15.16 
14.99 
28b OCH3 12 185-187 C17H13N3OS 66.43 
66.25 
4.26 
4.19 
13.67 
13.52 
28c Cl 10 240-241 C16H10ClN3S 61.64 
61.33 
3.23 
3.01 
13.48 
13.08 
 
 
 
Table 14. 
 
 R1 
1H nmr (δppm) 
28a H 4.36 (s, 2H, CH2S); 7.40-7.46 (d, 1H, ArH); 7.53-7.57 (m, 3H, ArH); 8.48-8.57 (m, 
3H, ArH); 8.81-8.85 (dd, 1H, ArH); 8.92 (s, 1H, 4-ArH) 
28b OCH3 3.85 (s, 3H, OCH3); 4.34 (s, 2H, CH2S); 7.10 (d, 2H, 2',6'-ArH, J = 9.00 Hz); 7.40-
7.46 (dd, 1H, 9-ArH); 8.46 (d, 2H, 3',5'-ArH, J = 9.00 Hz); 8.53-8.57 (m, 2H, 8-, 
10-ArH); 8.86 (s, 1H, 4-ArH) 
28c Cl 4.35 (s, 2H, CH2S); 7.40-7.48 (m, 3H, 9-ArH, 3',5'-ArH); 7.90 (d, 2H, 2',6'-ArH); 
8.56-8.60 (m, 2H, 8-, 10-ArH); 8.86 (s, 1H, 4-ArH) 
 
 
 
 
 
 
 
 
 
 
 
 
 
              4.3 New Small Molecules Tyrosine Kinase Inhibitors (Experimental Section) 
 
 
197 
 
General procedure for the synthesis of the final compounds:  
2-Benzylamino-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidines (30a-f) 
The appropriate benzylguanidine sulfate 37a-f (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(0.059 g, 2.55 mmoles of sodium in 8 ml of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then the 
dimethylaminomethylene derivative 35 (0.187 g, 0.85 mmoles) was added and the 
reaction mixture was refluxed for 6 hours. After cooling, the suspension was 
concentrated under reduced pressure. The residue obtained was washed with water 
and collected, to give crude pyrimidines 30a-f, which were purified by 
recrystallization from ethanol (Table 15 and 16). 
 
Table 15. 
 
 R1 R2 Yeld % M.p °C Molecular formula 
Analysis % 
Calc./Found 
C H N 
30a H H 15.0 133-135 C17H14N4S 65.73 
65.26 
4.14 
4.06 
19.16 
19.12 
30b OCH3 H 11.0 175-176 C18H16N4OS 64.24 
64.18 
4.79 
4.71 
16.65 
16.49 
30c Cl H 25.0 171-173 C17H13ClN4S 58.80 
58.71 
3.39 
3.30 
17.14 
17.03 
30d H OCH3 47.5 125-127 C18H16N4OS 64.26 
64.21 
4.79 
4.81 
16.65 
16.59 
30e H Cl 19.5 161-162 C17H13ClN4S 59.91 
59.03 
3.84 
3.85 
16.44 
16.38 
30f H Br 14.5 179-180 C17H13BrN4S 53.00 
52.87 
3.40 
3.37 
14.54 
14.57 
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Table 16. 
 
 R1 R2 
1H nmr (δppm) 
30a H H 4.09 (s, 2H, CH2S); 4.56 (d, 2H, CH2NH, J = 6.00 Hz); 7.19-7.36 (m, 6H, 
2',6'-ArH, 3',5'-ArH, 4'-ArH, 9-ArH,); 7.92 (t, 1H, CH2NH, J = 6.20 Hz); 8.31 
(s, 1H, 4-ArH); 8.41-8.47 (m, 2H, 8-ArH, 10-ArH) 
30b OCH3 H 3.70 (s, 3H, OCH3); 4.09 (s, 2H, CH2S); 4.48 (d, 2H, CH2NH, J = 6.4 Hz); 
6.76 (d, 2H, 2',6'-ArH, J = 9.0 Hz); 7.26-7.36 (m, 3H, 3',5'-ArH, 9-ArH); 
7.82 (t, 1H, CH2NH, J = 6.2 Hz); 8.31 (s, 1H, 4-ArH); 8.45-8.48 (dd, 2H, 8-
ArH, 10-ArH) 
30c Cl H 4.09 (s, 2H, CH2S); 4.54 (d, 2H, CH2NH); 7.29-7.37 (m, 5H, 2',6'-ArH, 3',5'-
ArH, 9-ArH,); 7.94 (t, 1H, CH2NH, J = 6.20 Hz); 8.32 (s, 1H, 4-ArH); 8.41-
8.47 (m, 2H, 8-ArH, 10-ArH) 
30d H OCH3 4.10 (s, 5H, OCH3, CH2-S); 4.53 (d, 2H, CH2NH); 6.77 (d, 1H, Ar-H); 6.94 (s, 
2H, Ar-H); 7.21 (t, 1H, CH2NH); 7.30-7.36 (m, 1H, Ar-H); 8.32 (s, 1H, Ar-H); 
8.42-8.47 (m, 2H, Ar-H) 
30e H Cl 4.10 (s, 2H, CH2-S); 4.55 (d, 2H, CH2NH); 7.29-7.41 (m, 5H, Ar-H); 7.94 (t, 
1H, CH2NH); 8.31 (s, 1H, Ar-H); 8.32-8.48 (m, 2H, Ar-H) 
30f H Br 4.10 (s, 2H, CH2-S); 4.54 (d, 2H, CH2NH); 7.23-7.42 (m, 5H, Ar-H); 
7.55 (s, 1H, Ar-H); 7.94 (t, 1H, CH2NH); 8.32 (s, 1H, Ar-H); 8.42-
8.47 (m, 2H, Ar-H) 
 
2-amino-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine (38) 
Guanidine hydrochloride (0.160 g, 1.70 mmol) was added, at room temperature, 
under a nitrogen atmosphere, to a stirred solution of sodium ethoxide (0.059 g, 2.55 
mmol of sodium in 8 mL of anhydrous ethanol). The resulting suspension was stirred 
at room temperature for 15 minutes, then 2,3-dihydro-3-
dimethylaminomethylenethiopyrano[2,3-b]pyridin-4(4H)-one 35 (0.187 g, 0.85 
mmol) was added and the reaction mixture was refluxed for 6 h. After cooling, the 
resulting suspension was concentrated under reduced pressure and the residue 
obtained was washed with water and collected to give crude pyrimidine 38, which 
was purified by recrystallization from ethanol (60% yield). 
M.p. 195–197°C 
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General procedure for the synthesis of the final compounds:  
2-anilino-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine derivatives (29a-f) 
 
0.090 g of 2-amino-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine 38 (0.417 
mmoles) were added, at room temperature, under nitrogen atmosphere, to 0.079 g of 
CuI (0.417 mmoles) and 0.115 g of anhydrous K2CO3 (0.833 mmoles). Then, the 
appropriate m-substituted aryl iodide (0.694 mmoles), 0.04 ml of DMEDA (0.417 
mmoles) and 2.5 ml of dioxane were added. The reaction mixture was heated at 
100°C and allowed to stir for 24 hours. After cooling, the reaction mixture was added 
with 2.5 ml of concentrated NH3 and with a saturated solution of NaCl (10-15 ml). 
The mixture was extracted with ethyl acetate, the solution obtained was evaporated 
under reduced pressure giving a residue which was purified by flash chromatography 
using petroleum ether 60-80°C/ethyl acetate 5:5 as the eluting system, to give 
compounds 29a-f (Table 17 and 18). 
Table 17. 
 
 R1 R2 Yeld % M.p °C Molecular formula 
Analysis % 
Calc./Found 
C H N 
29a H H 27 161-162 C16H12N4S 65.73 
65.69 
4.14 
4.08 
19.16 
19.08 
29b OCH3 H 32 184-185 C17H14N4OS 63.33 
63.12 
4.38 
4.31 
17.38 
17.32 
29c Cl H 60 190-193 C16H11ClN4S 58.80 
58.71 
3.39 
3.33 
17.14 
17.08 
29d H OCH3 35.0 154-155 C17H14N4OS 63.33 
62.96 
4.38 
4.34 
17.38 
17.31 
29e H Cl 20.0 146-148 C16H11ClN4S 58.80 
58.18 
3.39 
3.34 
17.14 
17.09 
29f H Br 17.5 193-194 C16H11BrN4S 51.76 
51.68 
2.99 
2.93 
15.09 
14.98 
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 R1 R2 
1H nmr (δppm) 
29a H H 4.19 (s, 2H, CH2S); 6.96 (t, 1H, 4'-ArH); 7.27-7.43 (m, 3H, 9-ArH, 3',5'-
ArH); 7.78 (d, 2H, 2',6'-ArH, J = 8.2 Hz); 8.50-8.54 (m, 3H, 4-ArH, 8-ArH, 
10-ArH); 9.76 (s, 1H, NH exch.) 
29b OCH3 H 3.74 (s, 3H, OCH3); 4.18 (s, 2H, CH2S); 6.92 (d, 2H, 2',6'-ArH, J = 9.0 Hz); 
7.36-7.42 (dd, 1H, 9-ArH); 7.67 (d, 2H, 3',5'-ArH, J = 8.8 Hz); 8.47-8.52 (m, 
3H, 4-ArH, 8-ArH, 10-ArH); 9.57 (s, 1H, NH exch.) 
29c Cl H 4.20 (s, 2H, CH2S); 7.34-7.42 (m, 3H, 9-ArH, 3',5'-ArH); 7.82 (d, 2H, 2',6'-
ArH, J = 8.8 Hz); 8.50-8.53 (m, 3H, 4-ArH, 8-ArH, 10-ArH); 9.92 (s, 1H, NH 
exch.) 
29d H OCH3 3.76 (s, 3H, OCH3); 4.20 (s, 2H, CH2-S); 6.53-6.58 (dd, 1H, Ar-H); 7.21 (t, 
1H, Ar-H); 7.32-7.44 (m, 2H, Ar-H); 7.55 (s, 1H, Ar-H); 8.51-8.56 (m, 3H, 
Ar-H); 9.77 (s, 1H, NH exch.) 
29e H Cl 4.21 (s, 2H, CH2-S); 7.00 (d, 1H, Ar-H); 7.30-7.44 (m, 2H, Ar-H); 7.70-7.74 
(m, 2H, Ar-H); 7.99 (s, 1H, Ar-H); 8.49-8.57 (m, 2H, Ar-H); 9.99 (s, 1H, NH 
exch.) 
29f H Br 4.21 (s, 2H, CH2-S); 7.13 (d, 1H, Ar-H); 7.28 (t, 1H, Ar-H); 7.37-7.43 (dd, 
1H, Ar-H); 7.69-7.79 (m, 2H, Ar-H); 8.14 (s, 1H, Ar-H); 8.49-8.57 (m, 2H, 
Ar-H); 9.98 (s, 1H, NH exch.) 
 
2-amino-N-methyl-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine (39) 
0.298 g of methylguanidine hydrochloride (2.72 mmoles) was added, at room 
temperature, under a nitrogen atmosphere, to a stirred solution of sodium ethoxide 
(0.163 g, 7.09 mmoles of sodium in 10 mL of anhydrous ethanol). The resulting 
suspension was stirred at room temperature for 15 minutes, then 2,3-dihydro-3-
dimethylaminomethylenethiopyrano[2,3-b]pyridin-4(4H)-one 35 (0.300 g, 1.36 
mmoles) was added and the reaction mixture was refluxed for 3 h. After cooling, the 
resulting suspension was concentrated under reduced pressure and the residue 
obtained was washed with water and collected to give crude pyrimidine 39, which 
was purified by recrystallization from ethanol. 
Yield: 48% ;  M.p.: 205-207°C ; 1H-NMRδ: 2.86 (d, 3H, CH3-NH); 4.10 (s, 2H, CH2S); 
7.20 (d, 1H, 9-ArH); 7.30-7.36 (q, 1H, NH-CH3); 8.31 (s, 1H, 4-ArH); 8.45-8.48 (m, 
2H, 10-ArH, 8-ArH) 
Table 18. 
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2-N-methyl-N-phenyl-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine (31) 
0.100 g of 2-Amino-N-methyl-5H-pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine 39
 
 
(0.435 mmoles) were added, at room temperature, under nitrogen atmosphere, to 
0.083 g of CuI (0.435 mmoles) and 0.120 g of anhydrous K2CO3 (0.869 mmoles). 
Then, 0.177 g of iodobenzene (0.869 mmoles) and 0.04 ml of DMEDA (0.435 
mmoles) and 2.5 ml of dioxane were added. The reaction mixture was heated at 
100°C and allowing to stir for 24 hours. After cooling, the mixture was added with 
2.5 ml of NH3 concentrated and with a saturated solution of NaCl (10-15 ml). The 
reaction mixture was extracted with ethyl acetate, the solution obtained was 
evaporated under reduced pressure giving a residue which was purified by flash 
chromatography using petroleum ether 60-80°C/ethyl acetate 70:30 as the eluting 
system to give compounds 31.  
Yield 39% ; M.p.: 129-131°C ; 1H-NMR δ: 3.54 (s, 3H, CH3-N); 4.15 (s, 2H, CH2S); 7.26-
7.42 (m, 6H, 9-2',6'-, 3',5'-, 4'-ArH ); 8.33-8.38 (dd, 1H, 10-ArH); 8.38 (s, 1H, 4-
ArH); 8.44-8.48 (dd, 1H, 8-ArH) 
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5.1 Adrenoceptors (Introduction) 
 
5.1.1 Structure 
 
Of the several large families of receptors, by far the largest, most versatile 
and most ubiquitous is that of the seven-transmembrane (7TM) receptors, also 
referred to as G-protein coupled receptors (GPCRs) (Figure 1). There are 
approximately 1000 genes encoding such receptors in the human genome, and these 
receptors virtually regulate all known physiological processes in mammals. Their 
central importance and relevance to the current clinical practice of medicine is 
reflected in the plethora of drugs targeting these receptors. There are two main 
requirements for a protein to be classified as a GPCR. The first requirement relates to 
seven sequence stretches of about 25 to 35 consecutive residues that show a 
relatively high degree of calculated hydrophobicity. These sequences are believed to 
represent seven α-helices that span the plasma membrane in a counter-clockwise 
manner, forming a receptor, or a recognition and connection unit, enabling an 
extracellular ligand to exert a specific effect into the cell.
1,2
  
 
Figure 1. Structure and amino acid sequence of a human β2-AR.
3
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The second principal requirement is the ability of the receptor to interact with 
a G-protein which determines a specific response
1-4
. G proteins are heterotrimeric 
proteins, consisting of three subunits (, , ), that function as molecular switches: 
when they bind guanosine triphosphate (GTP), they are 'on', while binding guanosine 
diphosphate (GDP), they are 'off'. As the endogenous agonist activates the G protein, 
by interacting with the specific amino acids domain, it induces a conformational 
change that allows the receptor to function as a guanine nucleotide exchange factor 
(GEF) that exchanges GDP for GTP on the Gα subunit. In the traditional view of 
heterotrimeric protein activation, this exchange triggers the dissociation of the Gα 
subunit, from the Gβγ dimer and the receptor. Both Gα-GTP and Gβγ can then activate 
different signaling cascades (or second messenger pathways) and effector proteins, 
while the receptor is able to activate the next G protein.
5,6
 
The Adrenoceptors (ARs) belong to this 7TM receptors or GPCRs family and 
they are the cell membrane proteins through which Noradrenaline and Adrenaline act 
as important neurotransmitters and hormones in the periphery and in the central 
nervous system. The interaction of the endogenous catecholamines with the ARs 
activate different signaling pathways allowing the regulation of prime physiological 
processes such as blood pressure, heart rate, strength of cardiac contraction or airway 
reactivity, and other metabolic or central nervous system processes. The crucial 
transductional role exerted by the ARs in such important events, converted them into 
one of the main therapeutic target for the treatment of cardiovascular diseases, like 
hypertension (HT) or heart failure, of respiratory diseases like asthma, and of other 
important pathologies such as benign prostatic hypertrophy, nasal congestion, 
obesity, or pain and many others.
1,2
 
 
5.1.2 History and Classification 
 
The first step leading to the discovery of the ARs was made in the 
cardiovascular system: the observation by Dale (1905) that the pressor effect of 
adrenaline was reversed by ergotoxine into a depressor effect. An explanation for 
this phenomenon was not apparent until 43 years later (1948), when Ahlquist noted 
two patterns in the relative ability of several sympathomimetic agonists to cause 
pharmacological responses in a series of organs and proposed the division of ARs 
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into two types, α and β. This was subsequently confirmed by the identification of 
selective antagonists for these two sites: Phentolamine and Ergotamine for α-ARs; 
Dichloroisoprenaline and Propranolol for β-ARs. Nineteen years later, it was shown 
that certain agonists and antagonists could distinguish β-AR-mediated responses 
among tissues such as cardiac muscle and bronchial smooth muscle, implying the 
existence of β-AR subtypes (β1 in cardiac muscle and β2 in the bronchi). The 
existence of subclasses of α-ARs became evident from the results obtained by Starke 
and coworkers (1972-1975), who showed that pre- and post-junctional α-ARs 
differed with respect to the relative potencies of some agonists: low concentrations of 
Clonidine and Oxymetazoline selectively activate the prejunctional α-ARs, whereas 
Phenylephrine and Methoxamine selectively activate the postjunctional α-ARs. 
Similarly, the relative potency of antagonists supported this differentiation: 
Phenoxybenzamine was about 30 times more potent in blocking post-junctional than 
pre-junctional α-ARs and Yohimbine preferentially blocked pre-junctional α-ARs. 
Langer (1974) suggested that α-ARs mediating responses of effector organs should 
be referred to as α1 and those mediating a reduction of the transmitter release during 
nerve stimulation as α2. Later, it was found that α-ARs pharmacologically very 
similar to the pre-junctional α2-ARs are also found post-junctionally. Consequently, 
the nomenclature of α1- and α2-ARs, depending exclusively on the relative potencies 
of certain α-agonists and antagonists, was accepted. In the late 1980s, the 
development of more selective drugs and the use of molecular cloning technology 
showed that there are more AR subtypes than previously suspected.
7,8
  
Nine different subtypes have now been cloned and pharmacologically 
characterized
7,9 
(Figure 2). In the present work we focused on the six subtypes α1A, 
α1B, α1D; β1, β2 and β3. 
 
Figure 2. General Adrenoceptor classification. 
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5.1.3 α1-Adrenoceptors (α1-ARs) 
 
- Classification: 
α1-ARs were first divided into two subtypes, α1A and α1B, based on the 
differential affinity of the receptors for 5-Methyl Urapidil (5-MU), WB-4101 and the 
irreversible antagonist Chloroethylclonidine (CEC): α1A-ARs showed high affinity 
for 5-MU and WB- 4101 and were insensitive to Chloroethylclonidine, and α1B-ARs 
were sensitive to CEC and had low affinity for 5-MU and WB-4101. The receptors 
cloning techniques led to the hypothesis of a new subtype, called α1C, which later 
turned out to be the α1A. In the same period, an attempt to clone the α1A-AR, allowed 
the identification of a different subtype, called α1D. After some controversies at the 
present time, a consensus has been reached, such that the subdivision of α1-ARs into 
three subtypes is generally accepted: α1A (formerly α1C), α1B, and α1D (formerly 
α1A/D). In humans, α1A-, α1B-, and α1D-ARs are encoded by distinct genes located on 
chromosomes 8, 5, and 20, respectively.
7-9
 
 
- Signalization pathway: 
All the three 1-ARs subtypes are G Proteins Coupled Receptors (GPCRs), 
which mediate the endogenous Adrenaline and Noradrenaline signals. 1-ARs are 
preferentially associated with the Gq/11 protein whose effector is the β isoform of 
phospholipase C (PLCβ), the enzyme allowing hydrolysis of  phosphatidylinosotol 
4.5-bisphosphate (PIP2) into 1,4,5-inositol triphosphate (IP3) and diacylglycerol 
(DAG). The IP3 diffuses through the cytosol to the endoplasmic reticulum, where it 
interacts with the IP3 receptor (IP3R), a Ca
2+
 channel formed by four proteins,
10,11 
which requires the binding of four IP3 molecules to be opened.
12,13
 The opening of 
IP3R allows Ca
2+
 release from the endoplasmic reticulum to the cytoplasm where the 
Ca
2+
 concentration resulted increased also by the opening of membrane voltage 
dependent Ca
2+
 channels, and the subsequent Ca
2+ 
entry
 
from the extracellular 
medium.
14,15
 On the other hand, the DAG promotes the Protein Kinase C (PKC) 
activation which can phosphorylate different substrates allowing the regulation of 
Ca
+2
 levels, and other important processes including gene-transcription.
16,17
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Thus α1-AR activation, results in an increase in intracellular Ca
2+
 levels 
through a signaling pathway which basically includes the AR-α1, Gq/11 protein, the 
PLCβ, IP3 and the IP3R, and is this increase in Ca2+ levels the responsible for many 
essential activities such as the smooth muscle contraction: Ca
2+
 binds to calmodulin 
and the Ca
2+
-calmodulin complex removes the autoinhibition of myosin light chain 
kinase, that once activated, phosphorylates the 20-kd light chain of myosin on serine 
19 and activates the myosin ATPase. The phosphorylated myosin cyclically binds to 
actin filaments producing force or shortening, or both.
8,9
 
 
 
Figure 3. -AR signalization pathways (image from Qiagen, sample and assay technology). 
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Although the Gq/11 is the preferential isoform, each α1-AR subtype shows 
significant differences in the effectiveness of signal generation.
18
 Actually after 
stimulation with the same agonist, differences in the formation of IP3 (α1A> α1B ≥ 
α1D) as well as for the intracellular Ca
2+
 levels (α1A> α1B> α1D) were reported,
19
 and 
each subtype showed a specific PLCβ coupling efficiency. Furthermore along the 
years evidence of many other signaling pathways (Gi, Go, Gs, G12/13, even Gh) were 
also proved, as well as the recruitment of other effector systems (MAPK, PLA2, 
PLD, increased cAMP, exchangers Na
+
-H
+
 and Na
+
-Ca
+2
, and activation/inhibition 
of K
+
 channels), showing the involvement of several mechanisms that sometimes 
lack of evidence in the relationship with the observed response. 
 
- Localization and physiological role: 
As for the cellular localization is concerned, GPCRs have been thought to 
exist predominantly on the cell surface where they are accessible to water-soluble 
ligands. However, recent data have suggested that the cellular localization of GPCRs 
is more complicated than previously envisioned. Results obtained over the last 
several years have shown that there are major differences in the subcellular 
distribution of the α1-AR subtypes. The use of peptide antibodies 
immunocytochemistry, fluorescent proteins, and other techniques showed that the 
α1B subtype is localized predominantly on the cell membrane; the α1A was found to 
be expressed in intracellular compartments as well as on the cellular surface, while 
most of the α1D-AR immunoreactivity was detected intracellularly and was 
perinuclear.
20
 A different localization results in a different activity. While α1A and 
α1B subtype follow the “classic” GPCR pathway, according to recent studies, the α1D-
AR doesn‟t follow this model because it possesses constitutive activity. GPCR 
constitutive activity is defined as the activity showed by the receptor in the absence 
of an agonist, which corresponds to a receptor intrinsic or spontaneous activity.
21
 In 
addition to the cellular localization, the α1-ARs role widely varies depending on the 
cell type (Figure 4). 
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Figure 4. α1-ARs distribution throughout the cardiovascular system. 
 
Vascular smooth muscle:  
Many studies conducted in rat
22,23
 and human
24
 arteries, found differences in 
the mRNA levels of the three 1-ARs subtypes, in relation with the vessel. The 1A 
subtype mediates contraction of caudal, renal and distal mesenteric artery
22,25 
and 
also of the remote sections of the arterial tree, where a rapid basal vascular tone 
regulation is required to ensure caliber adjustments and therefore the control on the 
blood flow according to the physiological needs.
25
 1D subtype is mainly expressed 
in aorta, and femoral, iliac and proximal mesenteric arteries, where it plays an 
important role by preventing abrupt changes in the caliber of vessels, maintaining 
stability in the blood flow.
22,26
 On the other hand, 1B subtype was found to be 
expressed in all vessels, even if in smaller proportion respect to the other subtypes.
27
 
There is little evidence about the role of 1B subtype in vascular contraction, but it 
seems to be involved although to a lesser extent.
28,29
 
 
Hearth: 
The major subtypes in rat or mouse heart are 1B ≥ 1A
30,31 
with some 
differences with respect to the human heart, where 1A subtype stands out as the 
main one.
31,32 
The knock-out mouse models provided information on the role of each 
subtype in regulating cardiac function and remodeling. It was proved the 1A and 1B 
involvement in cardiac development, contractility, hypertrophy and adaptive 
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remodeling,
33,34 
while the activity of the minority subtype 1D, seemed to be related 
to the coronary contractility, as it resulted the main subtype present in these vessels.
35
 
 
Kidney: 
All the three 1-ARs are also located in the kidney, with 1B ≥ 1A but their 
functional role is still discussed.
31
 Both 1A and 1D seems to control renal artery 
contraction (distal and proximal respectively), thus regulating blood flow to the 
kidney.
37
 On the other hand, it is known that a prolonged sympathetic stimulation 
increases H2O and Na
+
 reabsorption (antidiuretic effect) producing hypertension.
38
 
Numerous studies indicate the 1B subtype as mediator of this process, especially in 
the development of hypertension, while its maintenance could depend on the 2-
ARs.
39
 
 
Other tissues: 
1-ARs have also been described in many other tissues: in the vas deferens, 
with 1A and 1D ≥ 1B,
40
 in the prostate and in the urinary bladder muscle, with 
similar proportions,
9,41
 in the liver, where the 1B subtype seems to be involved, 
among other functions, in the glucose metabolism,
42
 in the cerebral cortex, 
hippocampus, salivary and pituitary glands, lung and spleen, with different 
proportions.
30,31 
They are distributed along the central nervous system, but the 
subtype specific role is not yet clear due to the lack of selective agonists able to cross 
the blood-brain barrier. Nevertheless it is known that 1-ARs are involved in the 
regulation of several important functions such as the motor activity, and the fine 
motor skills. Transgenic animal studies have also associated the 1B subtype with 
neurodegeneration, locomotor dysfunction, with the effects of several drugs of abuse, 
as well as with exploratory capacity and memory modulation.
43,44
 Some authors have 
also described the presence of 1-ARs in cells of the immune system such as 
lymphocytes and / or peripheral circulating monocytes, finding a minimal expression 
of 1B ≥ 1D subtypes.
45
 It was proved that the lymphocyte activation can modify the 
expression of 1-AR receptors but their specific role is still not clear.
46
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5.1.4 β-Adrenoceptors (β-ARs) 
 
- Classification: 
Three distinct β-AR subtypes have been cloned so far: β1, β2, and β3.
47
 These 
subtypes are encoded by three different genes located on human chromosomes 10 
(β1), 5 (β2), and 8 (β3). β1- and β2-ARs are pharmacologically well known since the 
classical papers by Lands et al.
48 
The existence of a third β-AR subtype (β3-AR), 
which was previously shown to mediate lipolysis in rat adipocytes, was also proved 
in blood vessels where it mediates vasodilation.
49,50
 Considering the incapacity by 
the β-blocker Propranolol to inhibit the potent action of CGP-12177 (β3-agonist) in 
heart, the existence of a fourth β-AR subtype (β4) was postulated. Konkar et al. 
(2000) noted that the β1-AR met all the criteria of the hypothetic β4 and proposed the 
existence of two isoforms for the β1-AR.
51
 Today we consider that the β1-AR may 
adopt different active conformations, and that the product of the gene encoding for 
the β1-AR, may exhibit a phenotype of low affinity for Propranolol and other drugs, 
depending on different cell types. This phenotype is sometimes referred to as β4, 
sometimes as atypical β1-AR.
52
 
  
- Signalization pathway: 
All β-AR subtypes signal by coupling to the stimulatory Gs protein leading to 
activation of adenylyl cyclase (AC) and accumulation of the second messenger 
cAMP, followed by the activation of protein kinase A (PKA), which is able to 
phosphorylate different proteins. The resulting effect will vary depending on the cell 
type and the function of the phosphorylated protein. The cAMP itself is also involved 
in several processes mediated by mechanisms independent from the PKA activation 
(Figure 6). Furthermore, depending on subtype and/or location, β-AR can be coupled 
to another G-protein (Gi), which determines the inhibition of the adenylyl cyclase, 
producing the opposite effect to the Gs-protein. In physiological conditions, 1 
subtype is uniquely coupled to the Gs protein, while 2 subtype can activate both Gs 
and Gi pathways (Figure 5).
53
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Figure 5. Opposite effect of Gs and Gi proteins.  
 
 
Figure 6. -ARs signalization pathways. (image from Qiagen, sample and assay technology) 
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- Localization and physiological role: 
Since its discovery, -ARs were classified according to the effect on the 
different organs, with 1 subtype responsible for heart contraction and 2 subtype 
responsible for relaxation of smooth muscle in vessels, airways and uterus.
54
 New 
techniques and later studies, found that the three -ARs subtypes, were widely 
expressed throughout the body with different and sometimes opposite functions. 
 
Figure 7. -ARs distribution throughout the cardiovascular system. 
 
Vascular smooth muscle:  
All the three -ARs subtypes are located in the vascular smooth muscle, but 
the 2 subtype is undoubtedly the main one, even if with some exceptions related to 
the district: in large conductance vessels, such as aorta, mesenteric, splenic and 
pulmunary artery, the 2 is the most expressed, whereas in small vessels such as 
coronary arteries and mesenteric resistance arteries, the 1 subtype is predominant.
55
 
The resulting physiological effect is the vascular smooth muscle relaxation, mediated 
by the “classic” Gs/AMPc/PKA pathway, which lead to a decrease in intracellular 
Ca
2+
 concentration, preventing Ca
2+
-calmodulin binding and thus favoring vascular 
relaxation. The presence of 3-AR subtype in vascular smooth muscle cells has also 
been described.
56 
They are able to start the “classic” Gs/AMPc/PKA pathway, 
leading to vascular relaxation, but their specific role is related to the vasodilator 
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effect mediated by the production of NO.
57 
Actually the NO can activate the 
guanylate cyclase (GC) enzyme, producing guanosine monophosphate (cGMP), thus 
leading to the activation of the cGMP dependent protein kinase (PKG), which 
reduces the intracellular Ca
+2
 concentration, resulting in muscle relaxation.
57,58
 
Considering the presence of all the -ARs subtypes in endothelial cells, it was 
suggested that in large vessels, also the 1 and 2 subtypes could mediate vascular 
relaxation via NO (NO/cGMP /PKG), whereas in small arteries the vasodilation 
would be NO-independent (AC/cAMP /PKA) due to a preferential localization of the 
-ARs in smooth muscle cells.57,59 
 
Hearth: 
All the three -ARs subtypes are distributed in the hearth, with different 
proportions: 1 (70-80%), 2 (20 - 30%) and 3 (with a small percentage).
60
 The 
adrenergic stimulation of both 1 and 2 subtype, usually starts the “classic” Gs 
mediated pathway, leading to the activation of protein kinase A (PKA). Unlike what 
happened in vascular smooth muscle cells, activated PKA in cardiomyocytes, 
phosphorylates Ca
2+
 channels inducing Ca
2+
 release from the sarcolemma thus 
favoring the muscle contraction process.
61
 Therefore 1 subtype has primary 
responsability for muscle contraction and heart rate control, while the involvement of 
2 subtype seems reduced  because they are initially sequestered in caveolae.
62
 On 
the other hand, 1 and 2 subtypes are also involved in acceleration of both atrial and 
ventricular relaxation. Actually these receptors are able to couple to second 
messengers (PKA/Fosfolambam) responsible for phosphorylating proteins that lead 
to lower intracellular Ca
+2
 levels, and the inactivation of the proteins required for the 
contraction process, with consequent muscle relaxation.
63,64
 Furthermore, different 
pathways are activated in response to an excessive adrenergic stimulation. An 
increased intracellular Ca
+2
 level, in case of a long-term 1 stimulation, induces the 
activation of the CaMKII apoptotic pathway, leading to heart deterioration.
65,66
 A 
sustained stimulation of the 2 subtype, allows the coupling to the Gi protein, 
producing inhibition of the adenylyl cyclase (AC) and therefore opposing to the Gs 
mediated effect.
67,68
 Moreover it was recently demonstrated the relationship between 
the activation of the Gi protein, mediated by 2-AR, and other signaling pathways 
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such as the PI3K/Akt pathway and the MAPK pathway (ERK1/2 and p38), which 
produce antiapoptotic and therefore cardioprotective effects.
69,70
 Minority hearth 
subtype 3, produces negative inotropism, probably as a safety-valve during intense 
adrenergic stimulation, but its effect is not yet entirely clear.
71
 
 
Kidney: 
In kidney the predominant subtype is 1 > 2. The 2 subtype seems to be 
located at the nerve endings associated with the vessels supplying the kidney, 
producing vasodilation in the large renal vessels and in the tubules to a lesser extent. 
The 1 subtype prevails in structures such as the glomerulus and the distal tubules.
72
 
It was reported that  agonists inhibit K+ excretion, stimulate fluids reabsorption 
and/or promote the NaCl reabsorption, according to their location in the tubules or 
the loop of Henle and other areas.
73
 Furthermore it is known that 1 stimulation 
produces an increase in renin release and thus triggers the formation of agiotensin II, 
while lack of 1- and 2-ARs significantly reduces renin release.
74
 The minority 3-
AR didn‟t allow any marked effect.75 
 
Limphocytes: 
In lymphocytes, the presence of -ARs, has long been studied since it was 
first described.
76
 The majority and most studied 2 subtype, is involved in regulating 
the cytokines production, or cell proliferation and differentiation, and has proven its 
participation in the progression of autoimmune diseases like rheumatoid arthritis or 
multiple sclerosis.
77
 It was also suggested that the 2-AR could be the connection 
between nervous and immune system.
78
 Furthermore, it was observed a correlation in 
-AR density between cardiomyocytes and lymphocytes, suggesting their use as a 
tool to monitor possible changes induced by drugs or diseases, in organs with 
difficult access, with the aim to improve the treatment efficacy.
79
 Recently it was 
also found a small proportion of the 3-AR subtype (2> 1 >> 3).
80
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Lungs: 
-ARs play an important role in the epithelium of the airways, with the 2-
AR prevailing, and responsible for the lungs smooth muscle relaxation. Therefore 2-
ARs are involved in obstructive pulmonary diseases, and they represent a common 
therapeutic target.
81,82
 The 1 subtype was found to be less expressed in this tissue.
83
 
 
Other tissues: 
The 2 subtype is the main one in uterus where is responsible for the 
relaxation of smooth muscle; 2 selective agonists are used in the prevention of 
preterm birth.
84 -ARs are located in other tissues such as the esophagus, where 1 
prevails,
85
 in the smooth muscle of gastrointestinal tract, where 3 regulates 
motility,
86
 and in adipose tissue where 3 subtype also appears to be the most 
involved in lipolysis and thermogenesis.
87
 Moreover -ARs mediate smooth muscle 
relaxation of the urine bladder (the most important is the 3 subtype), of the urethra 
(predominantly 2) and of prostate where 3 seems to predominate.
88
 -ARs are also 
located in different parts of the brain, such as the hippocampus or the cortex (1) and 
the cerebellum (2),
83
 where they are involved in behavior changes related to stress, 
anxiety or depression among other mental disorders.
89
 Finally we can also find them 
in the skeletal muscle, where the majority subtype 2 is responsible for muscle 
hypertrophy via PI3K/Akt.
90
 
 
5.1.5 Adrenoceptors regulation: GRK 
 
The binding of agonist to heptahelical receptors results in the dissociation of 
heterotrimeric G proteins into Gα and Gβγ subunits, which go on to regulate various 
effectors. One consequence of Gβγ subunit release is the recruitment of G protein-
coupled receptor kinases (GRKs 1-7) that  preferentially phosphorylate agonist-
occupied or activated receptors and enhance the affinity of the receptor for cytosolic 
β-arrestins, which promote G protein uncoupling (Figure 8).95 The rapid ARs 
attenuation mediated by GRKs and β-arrestin, occurs within seconds or minutes after 
receptor activation and is not necessarily associated with receptors degradation. 
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Receptor interaction with GRKs and β-arrestin, not only allows G protein receptor 
uncoupling (desensitization), but can also promote the rapid receptors 
internalization.
92
 Both the rapid desensitization and sequestration processes, can be 
quickly reversed by agonist removal. Otherwise, prolonged or continuous GPCR 
stimulation (several hours), produces a decrease in the total number of receptors 
(down-regulation), that is very slowly or no reversible after agonist removal.
93,94
  
There are several mechanisms related to the receptor internalization (Figure 
8). A lot of GPCRs are sequestered by endocytosis through the formation of clathrin-
coated vesicles, as this is a process promoted by a highly conserved mechanism 
mediated by β-arrestin receptor interaction. However, there is strong evidence for the 
existence of different mechanisms of endocytosis according to specific cell type and 
receptor. For example, the β2-AR can be endocytosed by clathrin-coated vesicles but 
also through the formation of cell membrane invaginations called 
caveolae.
95
Anyhow, once internalized, either through clathrin vesicles or through 
caveolae, the receptor can follow two different paths: it can be retained into the 
endosome, allowing a temporary inactivation (sequestration, desensitization) but 
with the possibility of a successive recruitment (resensitization); Otherwise it can be 
transferred to a lysosome for degradation by proteolysis and in this case a decrease in 
the number of receptors is observed (down-regulation).
96
  
 
Figure 8. Desensitization, Sequestration and Recycling/Downregulation of GPCR, mediated by GRK 
and β-arrestin.
97
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Increased GRK activity and β-arrestin binding were traditionally believed to 
force the equilibrium of these receptors toward desensitization. However, these 
proteins are now known to also actively promote cellular signaling independent of G 
protein activation, as the Mitogen-Activated Protein Kinases (MAPK) pathway.
98,99
 
Actually GRKs not only control and regulate GPCRs activity, but they are also 
involved in many physiological processes and therefore linked to several diseases 
such retina degeneration (GRK1), cardiovascular diseases, such as hypertension and 
heart failure (GRK2, GRK3 and GRK5), autoimmune diseases, such as rheumatoid 
arthritis and multiple sclerosis, opioids addiction, different types of cancer, 
psychiatric disorders, or left ventricle overload.
100-102
 
 
 
5.1.6 The Mitogen-Activated Protein Kinases (MAPK)  
 
Mitogen-activated protein kinases (MAPK) pathways represent a vast 
network that regulates a variety of physiological processes such as cell growth, 
differentiation or programmed cell death (apoptosis). A MAPK deregulation is 
involved in several pathological conditions including inflammation, oncogenic 
transformation and tumor cell invasion.
103
  
To date, three MAPK pathways have been thoroughly characterized: the 
External Kinase-Response (ERK), the p38, and  the c-Jun N-terminal Kinase-/ 
Stress-Activated Protein Kinase (JNK/SAPK). The ERK pathway is activated by a 
variety of mitogens and phorbol esters, whereas p38 and JNK are primarily activated 
by environmental stress and inflammatory cytokines.
103
  
Generally MAPK activation is achieved through kinase cascades, which 
include a MAPK kinase (MAPKK or MEK) and a MAPKK kinase (MAPKKK or 
MEKK).
104
 These cascades serve as information relays, connecting cell-surface 
receptors to specific transcription factors and other regulatory proteins, thus allowing 
extracellular signals to regulate the expression of specific genes. It was revealed that 
the different MAPK subgroups are activated through distinct and only partially 
overlapping kinase cascades.  
For example, ERK activation occurs in the phosphorylations sequence Raf 
(MAPKKK) → MEK (MAPKK) → ERK (MAPK), but it was observed that MAPK 
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signaling cascades may also be initiated through a “scaffolding protein” as β-arrestin 
(Figure 9).
105
 Actually the number of possible targets for a single member of a 
signaling network is huge, and in order to maintain integrity and specificity of the 
signal, the cell makes use of molecular scaffolds. These complexes bind specific 
members of a signaling network, giving preferential access as needed, thus ensuring 
the fidelity of a particular signaling response.
98
 For example, stimulation of a GPCR 
may promote the formation of a complex formed by β-arrestin (which act as a 
scaffold protein) and MAPK pathway components, thus promoting the activation of 
the latter.
106
 Therefore it was proved that β-arrestin not only promotes GPCR 
internalization, as already mentioned, but can also act as scaffolding multiprotein, 
approaching elements of specific signaling pathways, and thus regulating a multitude 
of signaling molecules, including protein kinase ERK, JNK, p38 and Akt.
98
  
A recent study on ERK activation after angiotensin II type 1A receptor 
(AT1AR) stimulation by angiotensin II in HEK293 cells, suggested that two 
components allowing different spatio-temporal patterns were affecting the ERK 
phosphorylation: the former, G protein dependent, and the latter, β-arrestin 
dependent (in this case β-arrestin2).107 A similar work with another GPCR, the β2-
AR, showed a similar pattern of ERK phosphorylation: using a Gi protein inhibitor 
and β-arrestin1 and 2 silencers, they detected two components in ERK 
phosphorylation after β2-AR stimulation, an early component Gi protein dependent 
and a late component β-arrestin1 and 2 dependent.108 Therefore it was proved that the 
GPCR activation promotes MAPK phosphorylation using two different mechanisms 
acting at different times (Figure 10). 
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Figure 9. (a) G-protein-coupled receptor (GPCR) activation of mitogen-activated protein kinase 
(MAPK) cascades proceeds by the sequential activation of a MAPK kinase kinase (MAPKKK), a MAPK 
kinase (MAPKK) and a MAPK. (b) β-Arrestin acts as a scaffold for GPCR activation of both the ERK and 
the JNK3 cascades. 
 
 
 
Figure 10. Biphasic pattern of ERK activation after GPCR stimulation.
93
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5.2 Angiogenesis (Introduction) 
 
 
The growth of blood vessels, known as Angiogenesis, is essential for many 
life processes, such as the organ growth in the embryo, the female reproductive 
cycle, or the repairing of wounded tissue in the adult. It‟s not surprising that an 
imbalance in the growth of blood vessels may contribute to the pathogenesis of 
numerous disorders. Inadequate vessel maintenance or growth causes ischemia in 
diseases such as myocardial infarction, stroke, and neurodegenerative or obesity-
associated disorders, whereas excessive vascular growth or abnormal remodeling 
promotes many ailments including cancer, inflammatory disorders and eye diseases. 
Studies conducted during the past four decades have identified key mechanisms of 
the angiogenic process, leading to the development of potent anti-angiogenic drugs 
and pro-angiogenic agents (therapeutic angiogenesis).
109-111
 
 
 
5.2.1 Blood Vessel Structure 
 
The circulatory system may be broken down into those vessels that deliver 
oxygenated blood to tissues, the arteries, arterioles, and capillaries, and those vessels 
that return blood with carbon dioxide for gas exchange, the veins and venules. The 
basic structure of all these vessels can be divided into three layers: the Intima the 
Media and the Adventia (Figure 11).  
The Intima typical consists of a single layer of endothelial cells and an 
underlying 0.08µ thick basal lamina consisting largely of type 4 collagen, laminin, 
fibronectin, and some proteoglycans.  
The Media Consists mostly of circularly-arranged smooth muscle cells and 
sheets of elastin. The muscle cells contract and relax, whereas the elastin allows 
vessels to stretch and recoil. The number of concentric layers and thus media 
thickness increases with increasing artery diameter. 
The Adventia is the outermost layer and primarily consists of type I collagen 
fibers with some elastin and fibroblasts. 
It‟s the composition and the size of these three layers themselves that 
differentiates arteries from veins and indeed even one artery from another artery or 
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one vein from another vein. Actually arteries have the thickest media layer, because 
they are exposed to the highest pressures of any vessels, while veins walls are thinner 
with a large lumen and a thicker adventia layer. In terms of relative size and function, 
arteries can be divided into three groups: elastic arteries are closest to the heart and 
they have the greatest amount of elastin in the thick tunica media, enabling them to 
expand and recoil, accommodating pressure changing. Muscular arteries deliver 
blood to specific body organs; They have relatively more smooth muscle which 
enables them to actively constrict and relax. Arterioles are the smallest arteries, 
where occurs the steepest drop in blood pressure; The larger arterioles have all three 
layers, but their tunica media mainly consists of smooth muscle. Finally capillaries, 
the link between arteries and veins, consist of just a thin tunica intima, making them 
ideally suited for their role (the exchange of materials between the blood and the 
interstitial fluid).
112
  
 
Figure 11. Blood vessel structure 
 
5.2.2 Blood Vessel formation 
 
Several mode of vessel formation have been identified (Figure 12).
113
 In the 
developing mammalian embryo, angioblasts differentiate into endothelial cells, 
which assemble into a vascular labyrinth - a process known as vasculogenesis (Fig. 
12b). Distinct signals specify arterial or venous differentiation. Subsequent sprouting 
ensures expansion of the vascular network, the process known as angiogenesis (Fig. 
12a). Arteriogenesis then occurs, in which endothelial cell channels become covered 
by pericytes or vascular smooth muscle cells (VSMCs), which provide stability and 
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control perfusion. Tissues can also become vascularized by other mechanisms, but 
the relevance of these processes is not well understood. As already discussed in 
chapter 3, pre-existing vessels can split by a process known as intussusception, 
giving rise to daughter vessels (Fig. 12c). In other cases, vessel co-option occurs, in 
which tumour cells hijack the existing vasculature (Fig. 12d), or tumour cells can line 
vessels - a phenomenon known as vascular mimicry (Fig. 12e). Putative cancer stem-
like cells can even generate tumour endothelium (Fig. 12f).
113-115
 
 
 
Figure 12. Modes of vessel formation. There are several known methods of blood vessel formation in 
normal tissues and tumours. a–c, Vessel formation can occur by sprouting angiogenesis (a), by the 
recruitment of bone-marrowderived and/or vascular-wall-resident endothelial progenitor cells 
(EPCs) that differentiate into endothelial cells (b), or by a process of vessel splitting known as 
intussusception (c). d–f, Tumour cells can co-opt preexisting vessels (d), or tumour vessels can be 
lined by tumour cells (vascular mimicry; (e)) or by endothelial cells, with cytogenetic abnormalities in 
their chromosomes, derived from putative cancer stem cells (f). Unlike normal tissues, which use 
sprouting angiogenesis, vasculogenesis and intussusception (a–c), tumours can use all six modes of 
vessel formation (a–f).
113
  
 
 
5.2.3 Molecular basis of vessel branching 
 
The formation of vessels is a complex process, requiring a finely tuned 
balance between numerous stimulatory and inhibitory signals, such as integrins, 
angiopoietins, chemokines, junctional molecules, oxygen sensors, endogenous 
inhibitors and many others.
110
  
An exciting recent development is the discovery of the links between vessels 
and nerves and, in particular, how axon-guidance signals such as Ephrins, 
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Semaphorins, Netrins and Slits allow vessels to navigate to their targets or control 
vessel morphogenesis.
109,110
  
After birth, angiogenesis still contributes to organ growth but, during 
adulthood, most blood vessels remain quiescent and angiogenesis occurs only in the 
cycling ovary and in the placenta during pregnancy. However, ECs retain their 
remarkable ability of dividing rapidly in response to a physiological stimulus, such as 
hypoxia for blood vessels and inflammation for lymph vessels.
109,110
  
In a healthy adult, quiescent endothelial cells have long half-lives and are 
protected against insults by the autocrine action of maintenance signals such as 
VEGF, NOTCH, angiopoietin-1 (ANG-1) and fibroblast growth factors (FGFs). 
Because vessels supply oxygen, endothelial cells are equipped with oxygen sensors 
and hypoxia-inducible factors - such as prolyl hydroxylase domain 2 (PHD2) and 
hypoxia-inducible factor-2α (HIF-2α), respectively - which allow the vessels to re-
adjust their shape to optimize blood flow.  
Quiescent endothelial cells form a monolayer of phalanx cells with a 
streamlined surface, interconnected by junctional molecules such as VE-cadherin and 
claudins.These endothelial cells are ensheathed by pericytes, which suppress 
endothelial cell proliferation and release cell-survival signals such as VEGF and 
ANG-1. Endothelial cells and pericytes at rest produce a common basement 
membrane.  
When a quiescent vessel senses an angiogenic signal, such as VEGF, VEGF-
C, ANG-2, FGFs or chemokines, released by a hypoxic, inflammatory or tumour 
cell, pericytes first detach from the vessel wall (in response to ANG-2) and liberate 
themselves from the basement membrane by proteolytic degradation, which is 
mediated by matrix metalloproteinases (MMPs) (Fig. 13a).  
Endothelial cells loosen their junctions, and the nascent vessel dilates. VEGF 
increases the permeability of the endothelial cell layer, causing plasma proteins to 
extravasate and lay down a provisional extracellular matrix (ECM) scaffold. In 
response to integrin signalling, endothelial cells migrate onto this ECM surface. 
Proteases liberate angiogenic molecules stored in the ECM such as VEGF and FGF, 
and remodel the ECM into an angio-competent environment.
113-115
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Figure 13. The consecutive steps of blood vessel branching, with the key molecular players involved 
denoted in parenthesis.
113
 
 
 
To build a perfused tube and prevent endothelial cells from bodily moving 
towards the angiogenic signal, one endothelial cell, known as the tip cell, becomes 
selected to lead the tip in the presence of factors such as VEGF receptors, neuropilins 
(NRPs) and the NOTCH ligands DLL4 and JAGGED1 (Fig. 13a).  
The neighbours of the tip cell assume subsidiary positions as stalk cells, 
which divide to elongate the stalk (stimulated by NOTCH, NOTCH-regulated 
ankyrin repeat protein (NRARP), WNTs, placental growth factor (PlGF) and FGFs) 
and establish the lumen (mediated by VE-cadherin, CD34, sialomucins and VEGF) 
(Fig. 13b). Tip cells are equipped with filopodia to sense environmental guidance 
cues such as ephrins and semaphorins, whereas stalk cells release molecules such as 
EGFL7 into the ECM to convey spatial information about the position of their 
neighbours, so that the stalk elongates. A hypoxia-inducible program, driven by HIF-
1α, renders endothelial cells responsive to angiogenic signals. Myeloid bridge cells 
aid fusion with another vessel branch, allowing the initiation of blood flow. For a 
vessel to become functional, it must become mature and stable.
113-115
   
a) After stimulation with angiogenic factors, the quiescent vessel 
dilates and an endothelial cell tip cell is selected (DLL4 and 
JAGGED1) to ensure branch formation. Tip-cell formation requires 
degradation of the basement membrane, pericyte detachment 
and loosening of endothelial cell junctions. Increased permeability 
permits extravasation of plasma proteins (such as fibrinogen and 
fibronectin) to deposit a provisional matrix layer, and proteases 
remodel pre-existing interstitial matrix, all enabling cell migration. 
For simplicity, only the basement membrane between endothelial 
cells and pericytes is depicted, but in reality, both pericytes and 
endothelial cells are embedded in this basement membrane. 
b) Tip cells navigate in response to guidance signals (such as 
semaphorins and ephrins) and adhere to the extracellular matrix 
(mediated by integrins) to migrate. Stalk cells behind the tip cell 
proliferate, elongate and form a lumen, and sprouts fuse to 
establish a perfused neovessel. Proliferating stalk cells attract 
pericytes and deposit basement membranes to become stabilized. 
Recruited myeloid cells such as tumour-associated macrophages 
(TAMs) and TIE-2-expressing monocytes (TEMs) can produce pro-
angiogenic factors or proteolytically liberate angiogenic growth 
factors from the ECM.  
c) After fusion of neighbouring branches, lumen formation allows 
perfusion of the neovessel, which resumes quiescence by 
promoting a phalanx phenotype, re-establishment of junctions, 
deposition of basement membrane, maturation of pericytes and 
production of vascular maintenance signals. Other factors promote 
transendothelial lipidtransport.  
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Endothelial cells resume their quiescent phalanx state (Fig. 13c), and signals 
such as platelet-derived growth factor B (PDGF-B), ANG-1, transforming growth 
factor-β (TGF-β), ephrin-B2 and NOTCH cause the cells to become covered by 
pericytes. Protease inhibitors known as tissue inhibitors of metalloproteinases 
(TIMPs) and plasminogen activator inhibitor-1 (PAI-1) cause the deposition of a 
basement membrane, and junctions are re-established to ensure optimal flow 
distribution. Vessels regress if they are unable to become perfused.
113-115
 
Although the described model offers a framework to explain the activity of 
numerous pro- and antiangiogenic molecules, there are other angiogenic pathways, 
with documented effects on vessel growth in vivo, whose roles in vessel branching 
have not or have only incompletely been characterized. Examples include several 
transcriptional regulators, Wnt ligands and their frizzled receptors,
116
 other members 
of the FGF, PDGF, and TGF-ß superfamilies, or the VEGF homolog PlGF that 
transmits angiogenic signals through VEGFR1.
117
 Recently, the implication in 
vascular remodeling of catecholamines and their receptors (ARs) has also been 
hypothesized. 
 
 
5.2.4 Angiogenesis and Adrenoceptor’s role 
 
As previously described, ARs are prototypical members of the GPCR 
superfamily and traditionally, a linear signaling cascade of ligand-receptor-G-
protein-second-messenger-effector has been the accepted view of GPCR signal 
transduction. The ARs stimulation by catecholamines is proved to regulate diverse 
physiological processes, including heart-beating rate and contraction strength, 
vascular and bronchial smooth muscle tone, energy metabolism and central neuronal 
activities. Nevertheless great progresses have been made in the understanding of AR 
biology and medicine during the past four decades and their linear signaling 
paradigm gave way to a complex multidimensional „signalome‟, allowing subtype 
specific signaling, promiscuous G-protein coupling, time-dependent switching of 
intracellular signaling pathways, intermolecular interactions within or between AR 
subfamilies, and G-protein independent signaling pathways.
69 
  
5.2 Angiogenesis (Introduction) 
  
 
229 
 
The consideration of such a complex model paved the way for new possible 
implication for the ARs, and their role in vascular remodeling has recently been start 
to investigate. As a latter-day matter, there are only little evidence and further studies 
are required to disclosure the mechanisms underlying the obtained results, sometimes 
in contradiction with each other: 
 
- 1-adrenoceptors: 
α1-ARs have been widely considered as vasoconstrictor receptors, however, 
their role in the endothelial response has been uncompletely analyzed.
118,119
 It is 
known that catecholamines exert trophic activity on vascular smooth muscle cells 
(VSMCs) and evidence of this effect comes from both in vitro
120
 and in vivo
121,122
 
studies. Actually it was proved that 1-ARs can act like growth factors in vascular 
smooth muscle cells and fibroblasts, by producing reactive oxygen species
123
 or by 
autocrine production of growing factors.
120,124
 In particular, in an experimental model 
of hypoxia,
125
 the presence of α1D-ARs subtype in endothelial cells resulted 
significantly upregulated, and it seemed that the stimulation of 1D-ARs subtype, 
induced by picomolar concentration of Phenylephrine, may exert trophic effects on 
vascular endothelium. In fact Phenylephrine, at a concentration lower than those able 
to induce a vasoconstrictor response (0,03 nM), was able to promote the outgrowth 
of tubular structures from fragments of mature human vessels. The finding that only 
the selective α1D-AR antagonist BMY-7378 completely antagonized this kind of 
effect strongly supported the hypothesis of a selective involvement of the α1D-AR 
subtype. In agreement with previous results,
126
 it was found that the activation of this 
endothelial receptor was associated with NO synthase stimulation, because tube 
outgrowth was impaired by exposure to the NO synthase inhibitor L-NAME.
125
 
Moreover quinazoline-based 1-AR antagonists (doxazosin, terazosin and prazosin) 
suppressed angiogenesis, in vitro (HUVEC model) and in a number of in vivo 
models.
127
 Conversely, stimulation of α1-ARs with Phenylephrine, inhibited 
endothelial cell proliferation and DNA synthesis, ERK and retinoblastoma protein 
(Rb) phosphorylation, cell migration and tubule formation.
128 
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- β-adrenoceptors: 
Little is known about the role of β-ARs in Angiogenesis. Norepinephrine has 
been demonstrated to increase VEGF expression through the mediation of all β-ARs 
subtypes,
129-131
 depending on cell types, although β-adrenergic stimulation of VEGF 
expression may not necessarily be of major significance in regulating physiological 
angiogenesis.
132
 If on the one hand it was evidenced that chronic bradycardia, 
induced with β1-AR selective blockade, promotes a greater arteriolar growth in the 
surviving myocardium of  post-infarcted heart,
133 
other clinical trials revealed that β-
AR blocking with Propranolol, a non-selective β-adrenergic antagonist, resulted in 
angiogenic inhibition.
134
 A unique role seems to be exert by the β2-AR subtype: the 
overexpression of β2-ARs in mice enhanced the adaptive pro-angiogenic response to 
ischaemia,
135 
and the gene removal of this receptor altered the intracellular signal 
transduction pathways, allowing impaired angiogenesis.
136
 Furthermore a recent 
study demonstrated that hypoxia upregulates β3-AR expression in the retina of OIR 
mice and that β3-AR upregulation is associated with the onset of angiogenesis.
137
 If 
the last findings seems to indicate an involvement of β-AR in angiogenesis, we can 
only count on few experimental proves and the related mechanisms still remain to be 
clarified.    
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5.3 Carvedilol and the vasodilating β-blockers 
(Introduction) 
 
 
β-blocker therapy plays a major role in the treatment of several 
cardiovascular diseases, such as hypertension, coronary artery disease, and heart 
failure. They are recommended by the American Heart Association/American 
College of Cardiology and the European Society of Cardiology as standard therapy 
for patients who have acute myocardial infarction (MI), as secondary prevention in 
those with a history of MI, and for patients with heart failure.
138
 As antihypertensive 
agents, β-blockers are recommended as initial agents in patients with ischemic heart 
disease or heart failure and are suggested as an add-on treatment with other 
antihypertensive agents in a variety of clinical situations.
139
  
 
5.3.1 β-blockers history 
 
The β-blocker story really began with Ahlquist‟s distinction of the different 
actions of α- and β-receptors.140 In 1958, in the Lilly laboratories (Indianapolis), one 
compound, Dichloroisoproterenol (DCI), was found to block the relaxant effect of 
adrenaline and, subsequently, that it also inhibited the bronchodilator, vasodilator, 
and inhibitory actions of adrenaline. Moran and Perkins, then reported the blockade 
of the cardiac-stimulant effects of adrenaline by DCI.
141
 However, at that time, 
possible clinical applications were not appreciated. Later, Nobel Prize winner James 
Black developed the first β-blocker called Pronethalol. This compound showed 
attractive clinical effects of cardiac β-blockade without peripheral effects on α-
receptors, but was withdrawn from the market because of its association with tumors 
in rodents. In 1964, Propranolol became the successor, and was used for the 
treatment of a wide variety of cardiovascular diseases.
142
  During his research, Black 
modified Ahlquist‟s original dual α- and β-receptor theory into a more complicated 
classification with more receptor subdivisions - in particular β1- and β2-receptors - 
and his work suggested the possibility of further refining the selectivity of β-
blockers. Subsequently, additional β-blockers were developed.143 
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5.3.2 β-blockers definition 
 
β-Adrenergic antagonists (β-blockers) bind selectively to the β-ARs 
producing a competitive and reversible antagonism of the effects of β-adrenergic 
stimuli on various organs (Table 1).  
 
Table 1 Effects mediated by β 1- and β 2-adrenoceptors 
Tissue Receptor Effect 
Heart   
         SA node β 1, β2 Increase in heart rate 
         AV node β 1, β2 Increase in conduction velocity 
         Atria β 1, β2 Increase in contractility 
Ventricles β 1, β2 
Increase in contractility, conduction velocity and 
automaticity of idioventricular pacemakers 
   
Arteries β2 Vasodilation 
Veins  β2 Vasodilation 
Skeletal muscle β2 
Vasodilation, increased contractility 
Glycogenolysis, K
+
 uptake 
   
Liver β2 Glycogenolysis and gluconeogenesis 
Pancreas (β cells) β2 Insulin and glucagon secretion 
Fat cells β1 Lipolysis 
Bronchi β2 Bronchodilation 
Kidney β1 Renine release 
Gallbladder and ducts β2 Relaxation 
Urinary bladder detrusor β2 Relaxation 
Uterus β2 Relaxation 
Gastrointestinal β2 Relaxation 
Nerve terminals β2 Promotes noradrenaline release 
Parathyroid glands β 1, β2 Parathormone secretion 
Thyroid gland β2 T4           T3 conversion 
  SA: Sinu-Atrial; AV: Atrio-Ventricular 
 
Their pharmacological effects can be explained from the knowledge of the 
responses elicited by these receptors in the various tissues and the activity of the 
sympathetic tone.
144,145
 Thus, β-blockers have relatively little effect on heart rate and 
contractility in an individual at rest, but slow heart rate and decrease cardiac 
contractility when the sympathetic nervous system is activated, i.e., during exercise 
or stress. 
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5.3.3 β-blockers classification 
 
β-blockers can be broadly classified into (I) non-selective, those producing a 
competitive blockade of both β1- and β2-adrenergic receptors and (II) those with 
much higher affinity for the β1 than for the β2 receptors, usually called β1-selective 
(Table 2).
144-147
  
 
Table 2 Pharmacological classification of commonly used β-adrenergic antagonists (β-blockers) 
β-blocker ISA Lipid solubility 
Peripheral 
Vasodilation 
i.v. Average daily oral dose 
I. Non-selective (β 1 + β 2) adrenergic antagonists 
Carteolol + Low   2.5–20 mg once/twice 
daily 
Nadolol 0 Low   40–320 mg once daily 
Penbutolol + Moderate   20–80 mg once/twice 
daily 
Pindolol ++ High   10–40 mg twice daily 
Propranolol 0 High  + 40–180 mg twice daily 
Sotalol 0 Low  +  
Timolol 0 High   5–40 mg twice daily 
 
II. Selective β 1-adrenergic antagonists 
Acebutolol + Moderate   200–800 mg 
once/twice daily 
Atenolol 0 Low  + 25–100 mg once daily 
Betaxolol 0 Moderate   5–20 mg once daily 
Bisoprolol 0 Moderate   2.5–10 mg once daily 
Celiprolol + Moderate +  200–600 mg once daily 
Esmolol 0 Low  + Only i.v. 
Metoprolol 0 High  + 50–100 mg once/twice 
daily 
Nebivolol 0  +  2.5–5 mg once daily 
 
III. α1- and β-adrenergic antagonists 
Bucindolol + Moderate +  25–100 mg twice daily 
Carvedilol* 0 Moderate +  3.125–50 mg twice 
daily 
Labetalol + Low +  200–800 mg twice 
daily 
ISA: Intrinsic Sympathomimetic Activity; i.v.: Intravenous Administration possible; * In some studies 
there was lack of evidence for peripheral α1-adrenoceptor blockade during long-term treatment of 
heart failure with carvedilol. 
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Selectivity is, however, dose-dependent and decreases or disappears when 
larger doses are used. Paradoxically, some β-blockers can exert a weak agonist 
response (intrinsic sympathomimetic activity, ISA), and can stimulate and block the 
β-AR. Several β-blockers have peripheral vasodilator activity mediated via α1-AR 
blockade (carvedilol, labetalol) (III), β2-adrenergic receptor agonism (Celiprolol) or 
via mechanisms independent of the AR blockade (Bucindolol, Nebivolol). In 
addition, β-blockers can be classified as lipophilic or hydrophilic.138  
 
5.3.4 Molecular structure 
 
β-blockers share a common structure including an aromatic cycle and a short 
lateral chain with an amino function and an hydroxyl group. All these elements can 
be found in the chemical structure of endogenous catecholamines. According to 
Clark (1982), catecholamines bind the β-AR with hydrogen bonds between the 
receptor and their hydroxyl and amine functions (Figure 14).
148 
 
 
 
Figure 14. Schematic representation of ligand-binding on a β-adrenergic receptor. The aliphatic chain 
of catecholamine binds to one receptor site (R) with hydrogen bonds. The clinical structure of 
antagonists allows their binding to the binding site without any possible interaction with the 
activation site. 
 
The aromatic part of the molecule can activate the catalytic site of the 
adrenergic receptor by hydrogen bonds of the hydroxyl groups of the catecholamine 
aromatic ring.  
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In the case of β-blocker compounds, their chemical structure allows the 
binding to the receptor thanks to the similar structure of catecholamines but without 
the ability of activating the catalytic site since no hydrogen bond can occur at this 
site with these compounds (Figure 15).  
 
 
Figure 15. Schematic representation of ligand-binding on a beta-adrenergic receptor. The hydroxyl 
residues of the aromatic ring bind to the pact of the receptor that induces its activation. 
 
 
For some β-blockers, however, their chemical structure may allow some 
interaction with the catalytic sites and induce some agonist activity. These 
compounds are then antagonists with the so-called ISA. In fact, the compounds 
behave as partial agonists. The basic conditions of binding to the β-receptor for a β-
blocker are the presence of the amine function, which has to be a secondary amine, 
and a non-substituted hydroxyl function. Modifications of the aromatic ring 
substitutes and of the lateral chain will influence the partial agonist activity, the 
affinity, and the selectivity for β1- versus the β2-adrenergic receptor.
149
 
 
 
5.3.5 Pharmacological activity 
 
The pharmacological activity of the different β-blockers is diverse, not yet 
completely understood and probably with important differences between agents. 
- Anti-ischaemic action: β-blockers decrease myocardial oxygen demand by 
reducing heart rate, cardiac contractility, and systolic blood pressure. In addition, 
prolongation of diastole caused by a reduction in heart rate may increase myocardial 
perfusion.
150
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- Improvement of cardiac function: (i) decreasing left ventricular size and 
increasing ejection fraction, (ii) reducing heart rate, prolonging diastolic filling and 
coronary diastolic perfusion time, (iii) decreasing myocardial oxygen demands, (iv) 
improving myocardial energetics by inhibiting catecholamine-induced release of free 
fatty acids from adipose tissue, (v) upregulating β-adrenergic receptors and (vi) 
reducing myocardial oxidative stress.
144,151,152
 
- Antihypertensive action: associated with a decrease in cardiac output, inhibition 
of the release of renin and production of angiotensin II, blockade of presynaptic α-
ARs that increase the release of norepinephrine from sympathetic nerve terminals 
and decrease of central vasomotor activity.
144-147
 
- Vasodilating action: (i) blocking α1-adrenergic receptors (Labetalol, Carvedilol), 
(ii) through the partial β2-agonist activity (Pindolol, Celiprolol), and (iii) by NO 
production (Nebivolol). (Impact of such vasodilating properties on efficacy and 
tolerance remains to be demonstrated)
138,143
 
- Antiarrhythmic effect: the result of direct cardiac electrophysiological effects 
(reduced heart rate, decreased spontaneous firing of ectopic pacemakers, slowed 
conduction and increased refractory period of AV node)
153
 
- Other mechanisms: (i) inhibition of cardiac apoptosis mediated via the activation 
of the β-adrenergic pathway154 (ii) inhibition of platelet aggregation, reduction of the 
mechanical stress imposed on the plaque, preventing plaque rupture
144
 (iii) 
resensitization of the β-adrenergic pathway and changes in myocardial gene 
expression, i.e., an increase in sarcoplasmic reticulum calcium ATPase, mRNA and 
α-myosin heavy chain mRNA, and a decrease in β-myosin heavy chain mRNA 
levels
155
 (iv) Finally, some β-blockers exhibit antioxidant properties and inhibit 
vascular smooth muscle cell proliferation.
147
 
 
 
5.3.6 Focusing on the new Vasodilating Beta-Blockers (VBB) 
 
First generation of β-blockers, such as Propranolol, block both β1- and β2-
receptors. Through β1-receptor blocking these compounds induce the well known 
inhibitory effects on the function of the sinus and atrio-ventricular nodes and on 
myocardial contraction (negative chronotropic, dromotropic, and inotropic effect). 
By blocking the β2-receptors, they cause contraction of smooth muscle with a risk of 
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bronchospasm in predisposed individuals.
156,157
 Second-generation agents, such as 
Atenolol, Metoprolol, and others, have relative low selectivity, when given in low 
doses, for the β1-receptors and they are preferable in patients with chronic lung 
disease or in chronic smokers. Finally, third-generation agents, such as Labetalol and 
Carvedilol, have additional vasodilatory properties due to α1-adrenergic blockade 
capacity.
158
 Data on vasodilating β-blockers, suggest that these agents have generally 
more favorable effects, when compared with older, non-vasodilating members of this 
class.
159
  
Traditional β-blockers, which act by reducing cardiac output, can induce 
compensatory peripheral vasoconstriction to maintain blood pressure, thus increasing 
peripheral resistance, and the risk of chronic hypertension.
160
 Furthermore, an 
increase in systemic vascular resistance diminishes blood flow to peripheral tissues, 
such as the skeletal muscles, and may lead to adverse effects on lipid and glucose 
metabolism, which in turn contribute to the development of endothelial dysfunction 
and diabetes.
160,161
 These evidences led the European Society of Hypertension / 
European Society of Cardiology to recommend that β-blockers should not be 
preferred in hypertensives with multiple metabolic risk factors.
162
  
However, it must be kept in mind that most of the studies on the field 
included “traditional” agents, and that many effects of the various β-blockers differ 
greatly between the various compounds, according to the individual physicochemical 
and pharmacological properties of each of them.
163
 Actually, vasodilatory β-blockers 
decrease blood pressure largely through reducing systemic vascular resistance, while 
maintaining cardiac output.
160,164
 The benefits of peripheral vasodilation contribute to 
reduce cardiac afterload and preload, lack of adverse effects on lipid and glucose 
metabolism, and possible reversal of adverse arterial remodeling.
164,165
 These neutral 
or beneficial metabolic effects and the more favorable hemodynamic profile allowed 
by the vasodilating β-blockers, could overcome concerns about efficacy, metabolic 
and symptomatic adverse effects, and tolerability, specific of the traditional β-
blockers, resulting in a wide clinical use of drugs as Carvedilol or the newest 
Nebivolol.
143
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5.3.7 Carvedilol 
 
Carvedilol is a third-generation, vasodilating non-cardioselective β-blocker 
which lacks intrinsic sympathomimetic activity (ISA). In addition to its β-blocking 
effects, it has blocking effects at vascular α1-receptors, antioxidant, and calcium 
antagonist properties.
157
 Experimental models demonstrate that Carvedilol blocks α1-
, β1-, and β2- adrenergic receptors
166 
without exhibiting high levels of inverse agonist 
activity.
167
 The lack of inverse agonist activity and ISA reduces the side-effects and 
makes the compound better tolerated than the older β-blockers. 
 
- ADME (Absorption, Distribution, Metabolism, Excretion):  
Carvedilol is rapidly absorbed after an oral dose, reaching peak plasma drug 
concentrations within 1 to 2 hours. Absorption is delayed an additional 1 to 2 hours 
when the drug is administered with food.
168
 The plasma half-life of Carvedilol ranges 
from 7 to 10 hours in most subjects; thus, the drug requires twice-daily dosing. In 
plasma, 98% of the drug is bound to plasma proteins, predominantly to albumin.
168 
Carvedilol is almost exclusively metabolized by the liver and its metabolism is 
affected by genetic polymorphism of cytochrome P-450 2D6 activity. Drugs that 
inhibit cytochrome P-450 2D6 activity, such as Quinidine, Paroxetine, Fluoxetine, 
and Propafenone, may also increase plasma Carvedilol concentrations. Thus, patients 
taking these drugs may be at particularly high risk of hypotension due to excessive α-
adrenoceptor blockade. Some of the metabolites of carvedilol have β-AR antagonist 
activity, and one 4-hydroxyphenyl metabolite is approximately 13 times as potent as 
carvedilol in this regard. Approximately 60% of these metabolites are secreted with 
bile and excreted with the faeces.
147
 
 
- Hemodynamic effects: 
In contrast with traditional β-blockers, Carvedilol seems to lower blood 
pressure by decreasing peripheral vascular resistance, without affecting cardiac 
output;
169
 due to the α1-adrenergic blockade, which accounts for its vasodilatory 
effects, the hemodynamic effect of Carvedilol is similar to those of ACE inhibitors 
and CCBs.
147
 Hypertension is associated with the development of left ventricular 
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hypertrophy (LVH) and LVH is strongly related to subsequent cardiovascular 
morbidity and mortality.
170,171
 Carvedilol may have a more beneficial effect on LVH 
compared with the conventional β-blockers, due to its vasodilating properties 
although clinical evidences are still lacking.
160 
 
- Effects on Insulin sensitivity (IS) and glycerol control: 
A considerable number of clinical studies have proved that thiazide diuretics 
and β-blockers deteriorate insulin sensitivity and thus increase the propensity of 
hypertensive patients to new-onset diabetes, whereas ACE-inhibitors, Calcium 
channel blockers, and Angiotensin II receptor blockers, have rather neutral or 
beneficial effects on these parameters.
172
 However, recent findings clearly support a 
less detrimental effect of vasodilating compared with older β-blockers on glycemic 
control and insulin sensitivity and suggest that among the class of β-blockers, 
Carvedilol should be preferred in subjects with components of the metabolic 
syndrome, impaired glucose tolerance or type 2 diabetes.
173-176
 
 
- Effects on Lipid metabolism: 
Several studies have shown that β-blockers increase triglyceride levels and 
decrease high-density lipoprotein (HDL) levels.
177,178
 In contrast to older β-blockers, 
carvedilol seems to have a neutral or beneficial effect on lipoprotein lipase activity 
and levels of triglycerides and HDL.
176
 
 
- Effects on Kidney and Renal function: 
Hypertension is a well-established risk factor for chronic kidney disease,
179
 
and hypertensive renal disease is the second major cause of end-stage renal disease in 
the developed societies (US Renal Data System 2005). As hypertension-induced 
nephrosclerosis proceeds, renal blood flow and glomerular filtration rate decrease, 
and filtration fraction increases long before plasma creatinine level begins to rise. 
Non-vasodilating β-blockers further decrease renal blood flow and increase filtration 
fraction. In contrast to traditional β-blockers, several trials have demonstrated a 
beneficial effect of Carvedilol on kidney function including an increase in renal 
blood flow and a reduction in microalbuminuria.
180,181
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• Carvedilol unique behavior: 
It is well documented that β-blockers comprise a highly heterogeneous class 
of agents, allowing different pharmacologic, hemodynamic, and metabolic effects. 
Some evidence recently suggested Carvedilol may possess unique survival 
advantages over other β-AR antagonists.175 The mechanisms of such advantages are 
currently unknown but have been variously ascribed to ancillary properties of 
Carvedilol, including antioxidant,
182
 anti-inflammatory,
183 
antiproliferative,
184
 and 
antiarrhythmic abilities,
185
 as well as to its capacity to serve as an α1-adrenergic 
receptor antagonist,
186
 and to its particular cellular signalization pathway,
187
 which is 
currently under investigation. 
Antioxidant properties: a large body of experimental and clinical evidence 
has demonstrated that Carvedilol is advantageous in comparison with other β-
blockers, because of its potent antioxidant activity. Oxidative stress has generally 
been considered of cardinal importance in the pathogenesis of cardiovascular 
diseases and recent studies demonstrated that Carvedilol prevents CYP depletion in 
the cardiovascular system and attenuated nitrate tolerance via antioxidant effects.
188
 
Anti-inflammatory properties: pro-inflammatory, anti-inflammatory and 
fibrogenic cytokines are all involved in the process of post-infarction myocardial 
remodeling. Treatment with Carvedilol 1) reduced the pro-inflammatory cytokines 
and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with 
the amelioration of the elevated left ventricular diastolic pressure. 2) increased anti-
inflammatory cytokine, IL-10 protein expression. 3) reduced matrix 
metalloproteinases-2 and matrix metalloproteinases-9 activity 4) reduced myocardial 
collagens 5) did not modify fetal gene re-expression. According to these results one 
mechanism underlying the beneficial effects of Carvedilol on post-infarction 
myocardial remodeling may be modulation of the balance between pro- and anti-
inflammatory cytokines as well as fibrogenic cytokines and extracellular matrix 
(ECM) remodeling.
189
 
Antiproliferative properties: Carvedilol also resulted to inhibit cell 
proliferation and migration of VSMCs, elicited by various vasoactive agents such as 
endothelin-1 and platelet-derived growth factor,
184,190
 which lead to a pronounced 
protection of myointimal proliferation in vivo,
184
 and might also be involved in 
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preventing progression of cardiovascular remodeling observed in physiological 
conditions, such as myocardial infarction. It was hypothesized that the mechanism of 
the antimitogenic effects was not solely mediated through β-AR antagonists. 
Alternatively, elevation of [Ca
2+
]i seemed to be an important intracellular signal 
stimulating mitogenesis. Clinical trials indicated that Carvedilol inhibit ICa.L and may 
also inhibit agonist (endothelin-1 and vasopressin)-induced Ca
2+
 entry unrelated to 
ICa.L in VSMCs. These inhibitory effects of carvedilol on [Ca
2+
]i mobilization could 
not be observed in cases of Metoprolol, a β1-selective blocker, and classical 
dihydropyridine Ca
2+
 antagonists (Nifedipine and Nicardipine). These unique actions 
of Carvedilol may contribute to the antihypertensive and antimitogenic effects of 
Carvedilol in cardiovascular systems.
191
 
Antiarrhythmic properties: In patients after myocardial infarction and 
dilated cardiomyopathy, arrhythmias are a major cause of death. In theory, the 
prolongation of the cardiac refractory period makes the heart less susceptible for 
cardiac arrhythmias. Otherwise, prolonging the refractory period has the possibility 
of both anti-arrhythmic and pro-arrhythmic potential, particularly where Na
+
 channel 
blockade increases both the refractory period and the vulnerable period. Many class 
III anti-arrhythmic drugs prolong the cardiac action potential and thereby the 
refractory period by blocking IKr , the rapid component of the delayed rectifier K 
current. Potassium currents generated by several native K
+
 channels in 
cardiomyocytes, i.e. IKr (the rapid component of the delayed rectifier K
+
 current), IKs 
(the slow K
+
 component of the delayed rectifier K
+
 current) and Ito (the transient 
outward K
+
 current), have also been blocked by Carvedilol, resulting in a 
prolongation of cardiac action potential.
192
 
Carvedilol signalization pathway: Carvedilol is a non selective β-
blocker and selective α1 blocker (a study revealed a high affinity for α1D- and α1B-
ARs, which is comparable to that for β1-AR
193
), but thinking about the linear AR 
blockade as the only responsible for such a complex profile seems to be reductive. 
Carvedilol displays several and different properties, but the cellular mechanisms 
underlying this profile, which results in a unique clinical efficacy, are still under 
study. The recent considerations about the adrenergic receptor, as a complex 
multidimensional „signalome‟, as previously discussed,69 might help to explain the 
different properties displayed by Carvedilol and other agents belonging to the same 
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class. In this regard it has recently been appreciated that, in addition to signaling 
through G proteins, ARs can also use the multifunctional adaptor proteins β-arrestins 
1 and 2 to activate cellular pathways.
91,98
 As already mentioned, β-arrestins exist as 
bifunctional cellular mediators: even as they terminate G protein signaling by 
binding GRK-phosphorylated receptors, they can function as scaffolds for signaling 
networks such as mitogen-activated protein kinases (MAPK) including ERK 1/2, 
cJun N-terminal kinase (JNK3), and p38 kinase, as well as phosphatidylinositol 3 
kinase (PI3K) and Akt. In a recent screening of among 16 β-AR antagonists,187 a 
diverse spectrum of efficacies was observed for both Gs-dependent and β-arrestin-
dependent cellular signaling. Additionally, Carvedilol allowed the unique signaling 
profile of negative efficacy for Gs-dependent AC activation but positive efficacy for 
β-arrestin-dependent ERK 1/2 activation. Moreover, Carvedilol stimulated β2-AR 
phosphorylation, β-arrestin translocation to the receptor, and receptor internalization, 
all of which are characteristic of β-arrestin-mediated cellular processes. Thus, 
Carvedilol seemed to act as a „„biased‟‟ ligand194 signaling via β-arrestin-dependent 
ERK 1/2 activation in the absence of G protein activation, and this bias may explain 
the unique clinical effectiveness of carvedilol in heart failure and other 
cardiovascular diseases. 
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Traditionally α1- or β-AR blockers have been used successfully. Although 
their short-term efficacy is still unquestionable, recent studies questioned their use 
for pathologies requiring long-term treatment, such as high blood pressure. Actually 
the last few years saw the introduction in therapy of the so called “beta blockers 
vasodilators” (VBB), which combine the activity on β-ARs with other mechanisms 
of action, as α1-blocking or nitric oxide releasing activity as has been previously 
described. These new VBB, as Carvedilol or the newest Nebivolol, replaced the 
classic ones in heart failure therapy and now are the first choice treatment since they 
showed more benefits than selective β1-blockers. However, despite of the wide 
clinical use, the VBB pharmacological profile is still unclear. Their selectivity for 
different α1- or β-AR subtypes, as well as their relationship with the kinases that 
modulate ARs expression (GRKs), the nitric oxide releasing activity, the 
cardioprotective activity, or with the modulation of angiogenesis and mitochondrial 
oxygen consumption are still under study. Therefore, the group work I‟m 
collaborating with, always engaged and with a long lasting experience on the 
cardiovascular system, recently started an in-depth study into the activity of the 
VBB. In this context, I tried to define the pharmacological profile of α1 and/or β 
agonists/antagonists, focusing my attention on Carvedilol, a non selective β-blocker 
and selective α1-blocker, with different approaches: 
- Evaluation of the relationship between adrenoceptors and angiogenic growth by 
culturing aorta explants in a three-dimensional extracellular matrix (Matrigel®) 
for 7 days in the presence or absence of 1 and  agonists, and/or with Carvedilol. 
- Analysis and quantification of the mRNA expression levels of α1- and β-ARs (α1A, 
α1B, α1D ; β1, β2, β3) and of the G protein–coupled receptor kinases (GRK2, GRK3 
and GRK5), by real-time Quantitative RT‐PCR. 
- Analysis by Western Blot of intracellular signals coupled to α1/β-ARs: ERK 1/2 
activation in HEK293 cells stably transfected with the three different α1-AR 
subtypes (α1A, α1B, α1D), and treated with Carvedilol or other α1 or β agonists. 
                                                                             5.5 Matherial and Methods 
 
244 
 
5.5 Matherials and Methods 
 
 
5.5.1 Animals 
 
Male Wistar rats, 250-300g and 16 weeks aged were used (Harlan Interfauna 
Ibérica, Barcelona). Rats were sacrificed by decapitation, after anesthesia by 
inhalation of isoflurane (Esteve, Barcelona).  The removal of the thoracic aorta by 
thoracotomy, and the other procedures were approved by the Institutional Animal 
Care and Use Committee, and complied to the Spanish Guide for Care and Use of 
Laboratory Animals, following European Council Directive (86/609/EEC). 
 
 
5.5.2 The ex vivo “rat aortic ring” assay 
 
In vitro angiogenesis assays are essential for the identification of potential 
pro-angiogenic agents as well as for the screening of pharmacological inhibitors. 
Among them, the ex vivo “rat aortic ring" model, initially developed by Nicosia and 
Ottinetti (1990),
195
 bridges the gap between in vivo and in vitro models. Actually, by 
using intact vascular explants, the environment in which angiogenesis takes place 
results more accurately reproduced than those with isolated endothelial cells.
196
 
Considering that the organization of endothelial cells in capillary-like structures is a 
process that better occurs in a 3-dimensional extracellular matrix, the culture of rat 
aortic explants in a matrix of this type (TM Matrigel Basement Membrane Matrix, 
BD Bioscience, San Jose CA, USA: a tumor extract Englebreth-Holm-Swarm 
mouse) results one of the most effective ways for generating new capillaries in vitro. 
The assay was performed with some modifications of the method originally reported 
by Nicosia and Ottinetti. The artery was dissected from the aortic arch to the 
diaphragm, and the periaortic fibroadipose tissue was carefully removed keeping it in 
a Petri dish with nutrient Krebs solution (NaCl 118mM, KCl 4.7mM, CaCl2 1.8mM, 
KH2PO4 1.2mM, NaHCO3 25.0mM, glucose 11.0mM). One-millimetre length aortic 
rings were sectioned, and then transferred to a small Petri plate containing growth 
medium Endothelial cell basal medium MV2, (EBM MV2, Promocell, Heidelberg, 
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Germany), and added of antibiotics (gentamicin, amphotericin), to avoid possible 
contamination. The assay was performed in a 96-well flat-bottomed plate, which was 
kept on ice until use. All the materials that come in contact with Matrigel® would be 
cold in order to prevent its solidification, which takes place at room temperature. 
Likewise Matrigel® was kept on ice in cold chamber (4°C), for at least 4 hours 
before the experiment took place. 50µl of Matrigel® per well were added, and the 
aortic rings were randomized into wells. After 15 minutes at room temperature 
Matrigel® polymerized, and 200µl of EBM MV2 growth medium, preheated to 
37°C, were added. When required the growth medium was also enriched with the 
human basic Fibroblast Growth Factor (hbFGF), the human Vascular Endothelial 
Growth Factor (hVEGF), the human Recombinant Insuline-like Growth Factor-1 
(R3IGF-1), ascorbic acid and hydrocortisone. Finally 20µl of the drug, whose effect 
is intended to be studied, were added to the appropriate wells. The plate was 
incubated at 37°C and 5% CO2 for 7 days, renewing the medium, as well as the 
stimuli required the day after starting the experiment, and every two days. At the 7
th
 
day, once finished the experiment, the aortic samples were rapidly frozen in liquid 
nitrogen for the gene expression study. 
 
 
5.5.3 Image acquisition and analysis  
 
To daily monitoring the new vessels growth, an inverted microscope Nikon 
Eclipse TE2000-S Nikon camera (objective 2x) or an inverted microscope Leica DM 
IL LED Leica camera (objective 2.5x) were used. In addition, on the 7
th
 day, a final 
time fluorescence cell staining was also performed. For this purpose, 1µl of calcein 
(Molecular Probes Inc. InvitrogenTM Paisley, UK) was added, and after incubating 
for 15 minutes, the images visualized using a Nikon fluorescence microscope Eclipse 
E800 equipped with Nikon camera, with the 4x objective, were captured using the 
software Nikon ACT-1 and analyzed by SigmaScan Pro (Systat Software, Inc. 
Chicago IL). To determine the growth kinetic, it was measured in microns the 
distance in the x and y axis, taking as point source, in each case, the outer surface of 
the ring (Figure 16). 
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Figure 16. Visualization and quantification of the angiogenic growth at day 3 (Nikon Eclipse TE2000-S 
Nikon camera, objective 2x; SigmaScan Pro, Systat Software, Inc. Chicago IL). Fluorecence cell 
staining at day 7 (Nikon fluorescence microscope Eclipse E800 equipped with Nikon camera, 4x 
objective)      
 
 
 
5.5.4 RNA extraction 
 
Frozen tissues were shredded in a mortar, keeping the samples frozen with 
liquid nitrogen during all the process to prevent degradation. For this purpose also 
the mortar was pre-cooled with liquid nitrogen to always keep freezing temperatures. 
The samples were shredded one by one with pestle till they turned into a 
homogenized tissue powder, that was quickly dissolved and homogenized in 1ml of 
TriPure Isolation Reagent (Roche Group; U.S.), a lysis buffer containing a 
phenol/guanidine thiocyanate mix. A first centrifugation at 12,000 g for 10 min at 
4°C was conducted, and the supernatant separated from the pellet. After 5 minutes at 
room temperature, 200µl of chloroform per 1ml of Tripure were added to the sample, 
vigorously mixed by Vortex for 15 seconds, and then leaved at room temperature to 
separate the phases. To facilitate the separation and precipitation of genomic DNA, a 
second centrifugation at 12,000 g for 15 min at 4°C was performed. The upper 
aqueous phase, containing total RNA was collected and 500µl of Isopropanol were 
added and gently mixed, for the nucleic acids precipitation. After 10 minutes at room 
temperature and 10 minutes of centrifugation at 4°C, a pellet of total RNA was 
obtained. The supernatant was eliminated and the pellet washed with 1ml of ethanol 
70% diluted in diethyl pyrocarbonate (DEPC) treated water. Finally the ethanol was 
discarded, the pellet dried and then dissolved in a minimum volume of DEPC-treated 
water. The RNA samples were stored at -80°C until further use. 
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5.5.5 RNA quantification and qualitative analysis 
 
Total RNA quantification and qualitative analysis were performed using the 
Experion
TM
 automatic system (Bio-Rad), based on the Lab-on-a-chip Technology for 
separation, detection and analysis by microfluidics electrophoresis. The chips were 
loaded following the manufacture‟s conditions, as detailed below. The gel was 
filtered at 1,500 g for 10 min, and then stained with the specific RNA fluorochrome 
provided in the kit. The stained gel was loaded into the chip micro-channels through 
a compressed air filling system. 1ml of each sample of total RNA was denatured at 
70°C for 2 minutes and then loaded into the appropriate well containing loading 
buffer. The samples were separated through the microfluidic gel by voltage applying 
in each well, and the fluorescent dye excitation by laser finally produced the RNA 
bands visualization. The chip was analyzed by the Experion
TM
 V2.1 System (Bio-
Rad). The software gave us the RNA concentration values (ng/ml) per sample, and 
the ratio of the area between the ribosomal RNA peaks (ratio 28S/18S), which is 
representative of the sample quality (values close to 2). Results were visualized 
through an electropherogram and a virtual gel. 
 
 
5.5.6 Reverse Transcription (RT) 
 
For the reverse transcription reaction (RT) of the RNA extracted, 0,1-1μg of 
the RNA samples were mixed with the oligo(dT16) primer (250 ng), heated for 5 
minutes at 70°C, and then cooled on ice. The RT reaction for the synthesis of the 
cDNA was performed using a mix containing ImProm‐IITM reaction buffer, 3mM 
MgCl2, 2,5mM dNTP Mix (0,5mM each dNTP), 20 U of the recombinant 
ribonuclease inhibitor RNAsin® (Promega Corp. Madison, USA)   and 1µl of 
reverse transcriptase-II
TM
 ImProm (Promega Corp. Madison, USA) for a 20µl final 
volume. An annealing step of 5 min at 25°C was firstly conducted, before the 
extension reaction at 42° C during 60 minutes. After this period, the enzyme was 
inactivated by incubating for 15 minutes at 70° C. The synthesized cDNA was stored 
at -20° C until further use. 
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5.5.7 Real-Time Quantitative Reverse-Transcription Polymerase Chain 
Reaction (RT-PCR) 
 
The quantification of gene expression was performed by Real Time 
Polymerase Chain  Reaction (PCR), currently the most sensitive and accurate method 
for the detection and quantification of mRNA levels, through the use of compounds 
with fluorescent properties, as the Taqman® probes. Thus, the mRNA coding for 
each different subtypes of α1-AR (α1A, α1B and α1D), β-AR (β1, β2 and β3), G protein-
coupled receptor kinases (GRK2, GRK3, GRK5) and of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as internal control, were quantified by 
TaqMan® real-time RT-PCR with a GeneAmp 7500 Fast System (Applied 
Biosystems, USA). 1/10 dilutions of the reverse transcription reaction were analyzed 
in duplicate, using Taqman® Gene Expression Assays (Applied Biosystems Foster 
CA, USA), a 20X mixture of primers and MGB Taqman® probe (minor groove 
binder), labeled with the 6-FAM
TM
 fluorochrome at the 5' end of the probe and a no 
fluorescent quencher at the 3' end, designed for detection and quantification of 
specific gene sequences by two steps real time RT-PCR. The specific primer‐probes 
are described in Table 3. 
 
Table 3. Gene expression Taqman® assay 
Gene Sequence Assay Amplicon Lenght 
GAPDH (Gapdh) 
α1A‐AR (Adra1a) 
α1B‐AR (Adra1b) 
α1D‐AR (Adra1d) 
1‐AR (Adrb1) 
2‐AR (Adrb2) 
3‐AR (Adrb3) 
GRK2 (Adrbk1) 
GRK3 (Adrbk2) 
GRK5 (Grk5) 
NM_017008.3 
NM_017191.2 
NM_016991.2 
NM_024483.1 
NM_012701.1 
NM_012492.2 
NM_013108.1 
NM_012776.1 
NM_012897.2 
NM_030829.1 
Rn99999916_s1 
Rn00567876_m1 
Rn01471343_m1 
Rn00577931_m1 
Rn00824536_s1 
Rn00560650_s1 
Rn00565393_m1 
Rn00562822_m1 
Rn00563688_m1 
Rn00578086_m1 
87 pb 
67 pb 
125 pb 
51 pb 
65 pb 
61 pb 
58 pb 
82 pb 
128 pb 
83 pb 
 
The primer probes were pre‐designed and optimized to offer high sensitivity 
and specificity under universal thermal cycling conditions which provide high 
reproducibility. Probes were designed by crossing the exon‐exon junction, whenever 
possible, to eliminate the possibility of detecting genomic DNA contamination and to 
increase specific hybridization (TaqMan® Gene expression assays protocol, Applied 
Biosystems, US). The reactions were adjusted to a volume of 25µl with Taqman® 
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Universal Master Mix (AmpliTaq Gold® DNA Polymerase, Applied Biosystems, 
U.S.), including 5µl of the RT dilution and 1.2µl of the 20X mixture of probe (250 
nM) and primers (900 nM) (Taqman® Gene Expression Assays). cDNA was 
amplified following the manufacture‟s conditions; a first step for polymerase 
activation at 95°C during 10 minutes and 40 cycles composed of two steps: 
denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 minute. 
The threshold cycle (Ct) obtained for each gene were calculated using the sequence-
Fast program detection system 7500 (Applied Biosystems, U.S.). Ct values were 
standardized considering the difference (ΔCt) between Ct of the studied gene and the 
reference (GAPDH). The ΔCt value was finally converted into the linear form using 
the term 2‐
ΔCt
, as directly proportional to the number of copy of each gene.
197
  
 
5.5.8 Cell Culture and transfection 
 
HEK 293 cells were grown in Dulbecco‟s modified Eagle‟s minimum 
essential medium with L-Glutamine and 4,5g/L D-Glucose and Pyruvate (DMEM + 
GlutaMAX
TM
-I, Gibco BRL. Gaithersburg MD, USA.) supplemented with 10% 
newborn calf serum (Gibco BRL. Gaithersburg MD, USA.), 100μg/ml streptomycin 
and 100 U/ml penicillin, in a humid atmosphere at 5% CO2 and 37°C. The pcDNA3 
plasmid with the cDNA of the three α1-ARs subtypes inserted, was kindly provided 
by Dr. Milligan (University of Glasgow). To generate cell lines stably expressing the 
different α1-ARs subtypes, 5μg of plasmid cDNA for each AR-α1 were transfected 
into the HEK 293 cells (1x10
6
), by electroporation (300V, 50μs, 2mm gap ) with 
Multiporator (Eppendorf AG. Hamburg, Germany). The treated cells were suspended 
in 5 ml of DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 ug/ml 
streptomycin, transferred to a 60mm Petri dish and incubated in a humid atmosphere 
at 5% CO2 and 37°C. After 48 hours of electroporation, geniticina sulfate (G418, 
Sigma St Louis MO, USA) (400 mg/ml) was added to the medium for the cell 
selection, and the medium was renewed every 2-3 days. Cells were washed with 
phosphate buffered saline (phosphate buffered saline, PBS, Gibco BRL. 
Gaithersburg MD, USA), treated with trypsin (Gibco BRL. Gaithersburg MD, USA) 
and collected for the first time within 15-20 days after electroporation. 
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5.5.9 Western Blot 
 
HEK293 cells were seeded in 60mm diameter Petri dish and after reaching a 
75% confluence in about 48h, they were maintained for at least 4 hours in serum free 
medium. Cells were then stimulated with 1µM Isoprenaline or 1µM Carvedilol at 
37ºC over different times. When indicated, cells were treated for 15 minutes before 
the stimulation with an antagonist, 1μM Propranolol, and 0.005% DMSO was used 
as control when required. After stimulation, cells were washed with cold PBS 
(Phosphate Buffered Saline, Gibco BRL. Gaithersburg MD, USA) and lysed with 
300μl of RIPA buffer (50mM HEPES, 150mM NaCl, 10% glycerol, 1.5mM MgCl2, 
0.1% SDS, 1mM EGTA, 1% triton and 1% sodium deoxycholate) containing a 
protease inhibitor cocktail (Complete®, Roche Indianapolis IN, USA) and a 
phosphatase inhibitor cocktail (PhosSTOP®, Roche Indianapolis IN, USA). The 
sample sonication with a Microson™ XL 2000 Ultrasonic Liquid Processor was 
performed and after centrifugation (15 minutes at 4°C and 16100g) the supernatant 
was collected and frozen at -80°C. The protein content was measured by Bradford 
method 1976 (Bio-Rad Hercules CA, USA). 15μg of cellular extracts were incubated 
with SDS-sample buffer (2% SDS, 60 mM Tris buffer, 5% β-mercaptoethanol, 
0.01% bromophenol blue and 10% glycerol) at 40ºC for 30 minutes. Thus 
denaturalized proteins were separated by gel electrophoresis (10% polyacrylamide - 
sodium dodecyl sulphate) at 100V during 1-2 hours and then transferred (375mA, 2 
hours) to a Polyvinylidene fluoride membrane (PVDF, Bio-Rad Hercules CA, USA) 
previously activated by methanol, using the Mini-Trans-Blot ® Electrophoretic 
Transfer Cell System (Bio-Rad Hercules CA, USA). Before antibody incubation, 
membranes were blocked in phosphate-buffered saline with 0.1% Tween 20 (PBST) 
plus 3% BSA (Albumin from bovine serum, Sigma St Louis MO, USA). Anti 
phospho-ERK (anti-phospho-p44/42) and anti ERK (anti-p44/42) primary antibodies 
(Cell Signaling Technology. Beverly MA, USA) were incubated overnight at 4ºC, 
1/500 diluted. Membranes were then washed three times with PBST, incubated with 
an anti-rabbit antibody (Amersham International, Buckinghamshire,UK) at 1:2500, 
for 45 minutes at room temperature, and washed extensively with PBST before 
performing chemiluminescent detection using the ECL Western Blotting Detection 
Reagents (Amersham International, Buckinghamshire, UK). The image was captured 
with the AutoChemi System (uvp Bioimagin Systems. Cambridge. UK) and band 
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intensity was measured by densitometry using LabWorks Image acquisition and 
Analysis (Ver. 4.6 uvp Bioimagin Systems. Cambridge. UK). p-ERK levels were 
expressed in relation to the total ERK1/2. 
 
 
5.5.10 Antibodies, reagents and plasmids 
 
The antibodies used included phospho-p42/44 MAPK (Thr202/ Thr204), 
p42/44 MAPK (Cell Signaling Technology. Beverly, MA). Horseradish peroxidase-
labeled secondary antibodies and chemiluminiscent reagents were from Amersham 
(Amersham International, Buckinghamshire, UK). Carvedilol, Dobutamine, 
Phenylephrine, Isoprenaline, and antibiotic G418 were purchased from Sigma 
(Sigma St Louis MO, USA). Plasmids encoding human α1A-, α1B- and α1D-ARs were 
kindly provided by Dr. Milligan (University of Glasgow). 
 
5.5.11 Statistical Analysis 
 
Statistical analysis were performed using GraphPad Prism 4 software 
(GraphPad Software, Inc. San Diego CA, USA). The results were expressed as 
arithmetic mean values ± standard error of the mean (SEM) for n determinations 
obtained from different animals. The statistical analysis included the two way Anova 
method, followed by a Student‟s t‐test for unpaired samples. The difference between 
treated and control groups is significant (*) when the “P” obtained value is greater 
than the tabulated for a 95% confidence range (p <0.05), and very significant when 
greater than 99% (p <0.01 **) or 99.9% (p<0.001 ***). 
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5.6 Angiogenesis and Adrenoceptors role (Results) 
 
5.6.1 Growing conditions  
 
With the aim to analyze the possible role exerted in the angiogenic process by 
1 and  agonists, and in particular by Carvedilol, a non selective β-blocker/α1-
blocker, two parallel experiments, allowing different growing conditions, were 
performed: 
 
[1] The endothelial basal medium (EBM) was enriched with the human basic 
Fibroblast Growth Factor (hbFGF), the human Vascular Endothelial Growth 
Factor (hVEGF), the human Recombinant Insuline-like Growth Factor-1 (R3IGF-
1), ascorbic acid and hydrocortisone. 
 
[2] The endothelial basal medium (EBM) was lacking of additional growing factors. 
(Actually previous experiments, showed how the presence of additional growing 
factors, forcing the angiogenic process, might significantly influence the cell 
response). (Figure 17) 
 
    [1] Medium(EBM) + Growing Factors                            [2] Medium(EBM)              
                 
Figure 17. Day 7 fluorecence visualization of aortic explants cultivated in the presence [1] or absence 
[2] of additional growing factors.  
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5.6.2 DMSO as Control 
 
As Carvedilol needed a dimethylsulphoxide (DMSO) solution, DMSO at the 
appropriate concentration was used as control when it required. Therefore, we first 
verified if the used solvent, a well known toxic agent, might influence the angiogenic 
process. (Figure 18). 
 
 
Figure 18. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a simple medium (EBM). Quantification of angiogenic length growth 
of rat aortic rings cultured during 7 days, in the absence and presence of DMSO (0,005%). Data 
represent the mean ± SE of n=6-10 experiments.  
 
 
 
Figure 19. Aortic explants cultivated in the absence (a) or presence (b) of DMSO (0.005%) and 
visualized at day 7 with a Nikon fluorescence microscope Eclipse E800 equipped with Nikon camera, 
4x objective. Images relative to experiment [2].   
 
 
While in the first experiment [1], in presence of growing factors, the presence 
of DMSO didn‟t seem to influence the angiogenic growth, a different behaviour was 
showed in experiment [2], in absence of growing factors, where a greater angiogenic 
response was observed in the presence of the toxic agent DMSO.  
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A possible explanation for these results might be that additional growing 
factors, forcing the angiogenic growth, do not allow to evidence the pro-angiogenic 
response exerted by DMSO which is observed at the milder growing conditions 
experiment [2].  
 
 
5.6.3 α1-Adrenoceptor (α1-AR) 
 
To verify if an α1-AR selective agonist is able to induce a pro-angiogenic 
phenotype in rat aorta endothelial cells, rat aortic explants were cultivated in the 
presence of Phenylephrine (10
-6
 mol/L). 
 
 
Figure 20. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the absence (control) and presence of Phenylephrine (10
-6
 
mol/L). Data represent the mean ± SE of n=6 experiments. 
 
 
 
Figure 21. Aortic explants cultivated in the absence (a) or presence (b) of Phenylephrine (10
-6
 mol/L) 
and visualized at day 7 with a Nikon fluorescence microscope Eclipse E800 equipped with Nikon 
camera, 4x objective. Images relative to experiment [2]. 
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As it resulted from the statistical analysis (Figure 20),  the α1-AR selective 
agonist Phenylephrine, both in the presence [1] or absence [2] of additional growing 
factors, significantly increased the longitudinal growth compared with controls. 
Using the fluorescent marker calcein, Figure 21 shows the length and density of new 
vessels obtained on day 7 in presence or absence of Phenylephryne. 
On the other hand, when the rat aortic explants were incubated with 
Phenylephrine (10
-6
 mol/L) in the presence of DMSO (0,005%), the pro-angiogenic 
effect demonstrated in the absence of DMSO was confirmed in experiment [1] but 
seemed to be lacking in experiment [2] (Figure 22). As already hypothesized, the 
presence of DMSO, probably do not allow us to see the pro-angiogenic effect exerted 
by Phenylephryne, that clearly appeared in the absence of DMSO. (Figure 20) 
 
 
Figure 22. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the absence (control: DMSO 0.005%) and presence of 
Phenylephrine (10
-6
 mol/L). Data represent the mean ± SE of n=5-10 experiments. 
 
 
Figure 23. Aortic explants cultivated in the absence (a) or presence (b) of Phenylephrine (10
-6
 mol/L), 
using DMSO (0.005%) as control,  and visualized at day 7 with a Nikon fluorescence microscope 
Eclipse E800 equipped with Nikon camera, 4x objective. Images relative to experiment [2]. 
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5.6.4 β1-Adrenoceptor (β1-AR) 
 
To verify the angiogenic activity of a selective β1 agonist, we used 
Dobutamine (10
-5
 mol/L) in the presence of DMSO (0,005%). (Figure 24) 
 
 
Figure 24. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the absence (control: DMSO 0.005%) or presence of 
Dobutamine (10
-5
 mol/L). Data represent the mean ± SE of n=3-5 experiments. 
 
 
Figure 25. Aortic explants cultivated in the absence (a) or presence (b) of Dobutamine (10
-5
 mol/L), 
using DMSO (0.005%) as control, and visualized at day 7 with a Nikon fluorescence microscope 
Eclipse E800 equipped with Nikon camera, 4x objective. Images relative to experiment [2]. 
 
 
The results obtained indicated the capacity of the selective β1-agonist 
Dobutamine, to significantly inhibit the angiogenic longitudinal growth. However, 
the Dobutamine inhibitory properties, that clearly resulted from the first 
experiment[1], were less evident in the absence of additional growing factors[2]. 
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5.6.5 β2-Adrenoceptor (β2-AR) 
 
To verify the angiogenic activity of a selective β2 agonist, we used 
Salbutamol (10
-5
 mol/L) in the presence of DMSO (0,005%). (Figure 26) 
 
 
Figure 26. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the absence (control: DMSO 0.005%) or presence of 
Salbutamol (10
-5
 mol/L). Data represent the mean ± SE of n=3-5 experiments. 
 
When we applied the selective 2-agonist Salbutamol, we found contradictory 
or no significative results. 
 
 
5.6.6 Carvedilol (non-selective β-blocker/α1-blocker) 
 
In order to study the possible influence of Carvedilol on the angiogenic 
growth, rat aortic explants were incubated with Carvedilol (10
-6
 mol/L) in the 
presence of DMSO (0,005%) (Figure 27) 
Despite the numerous experiments, we were not able to assign to Carvedilol a 
clear role in the angiogenic process. Even if some assays seemed to indicate for 
Carvedilol a pro-angiogenic activity, the growth increase finally didn‟t result 
statistically significant. As in the case of Phenylephryne in DMSO, the use of 
DMSO, which is already promoting the process, might possibly be hiding the 
Carvedilol activity. However further experiments will be required to clarify this 
issue. 
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Figure 27. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the absence (control: DMSO 0.005%) and presence of 
Carvedilol (10
-6
 mol/L). Data represent the mean ± SE of n=8-10 experiments. 
 
 
 
Figure 28. Aortic explants cultivated in the absence (a) or presence (b) of Carvedilol (10
-6
 mol/L), 
using DMSO (0.005%) as control, and visualized at day 7 with a Nikon fluorescence microscope 
Eclipse E800 equipped with Nikon camera, 4x objective. Images relative to experiment [2]. 
 
 
While Carvedilol in DMSO (Figure 27), and Phenylephrine in DMSO (Figure 
22), didn‟t showed a clear angiogenic activity, we found in both experiment [1] and 
[2], that the angiogenic response significantly increased when incubating rat aortic 
explants with Phenylephrine (10
-6
 mol/L) together with Carvedilol (10
-6
 mol/L) in the 
presence of DMSO (0.005%), compared with Phenylephrine or Carvedilol alone 
(Figure 29), suggesting a possible relationship between α1- and β-ARs.  
     5.6 Angiogenesis and Adrenoceptors role (Results) 
 
259 
 
 
Figure 29. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the presence of Phenylephrine (10
-6
 mol/L), of Carvedilol (10
-6
 
mol/L), or Carvedilol + Phenylephrine. DMSO (0.005%) was used as control. Data represent the mean 
± SE of n=6-10 experiments.  
 
 
Finally the activity of Carvedilol (10
-6
 mol/L) incubated with the selective β1-
agonist Dobutamine (10
-5
 mol/L)  in the presence of DMSO was also investigated. 
The results clearly indicated that Carvedilol was not able to reverse the angiogenic 
inhibition produced by Dobutamine (Figure 30). 
 
 
Figure 30. Comparison of the results obtained from experiment [1], using a medium enriched with 
growing factors,  and [2], using a poor medium. Quantification of angiogenic length growth of rat 
aortic rings cultured during 7 days, in the presence of Carvedilol (10
-6
 mol/L), of Dobutamine (10
-5
 
mol/L), or Carvedilol + Dobutamine. DMSO (0.005%) was used as control. Data represent the mean ± 
SE of n=6-10 experiments 
 
 
     5.7 Gene expression studies (Results) 
 
260 
 
5.7 Gene expression studies (Results) 
 
The aortic samples used for the angiogenic study [2], at the 7
th
 day, once 
finished the experiment, were rapidly frozen. Total RNA was extracted, quantified 
and qualified, and cDNA was obtained by reverse transcription as previously 
described. Finally a real-time quantitative RT‐PCR was performed to quantify the 
mRNA expression levels of α1- and β-ARs (α1A, α1B, α1D ; β1, β2, β3) and of the G 
protein–coupled receptor kinases (GRK2, GRK3 and GRK5). To obtain sufficient 
RNA amount for the RT-PCR, two samples from the angiogenic assay were mixed 
during RNA extraction. Considering that every angiogenic sample included two 
aortic rings, four aortic rings relative to two different rats were required to have an 
n=1 in the gene expression study. This presupposed a huge work which is still in 
place, and those here reported are only preliminary results. 
 
5.7.1 Changes in the α1-AR expression 
mRNA of α1A- and α1B-AR subtypes resulted not sufficiently expressed to 
highlight any changes. On the other hand, the α1D-AR subtype, which is known to be 
the most expressed in aorta, allowed us to quantify and compare the mRNA levels 
related to the different samples (Figure 31). 
In the presence of the α1-AR agonist Phenylephrine (10
-6
 mol/L), the β1-AR 
agonist Dobutamine (10
-5
 mol/L), the non-selective β-blocker/α1-blocker Carvedilol 
(10
-6
 mol/L), or even when they were applied together, we could evidence a general 
decrease in the mRNA expression levels of the α1D-AR subtype compared with 
control (DMSO) but it did not result statistically significant. 
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Figure  31. mRNA expression levels for the α1D-AR subtype in rat aortic samples cultivated in the 
presence or absence of Phenylephrine, Dobutamine, Carvedilol, Carvedilol with Phenylephrine, and 
Carvedilol with Dobutamine. DMSO was added and used as control when it requiered. (Values were 
normalized using GAPDH as a housekeeping gene and expressed as the average of 2
‐ΔCt
 ± S.E.M. of 
n=2‐5.  
 
5.7.2 Changes in the β1-AR expression 
 
mRNA of β1-AR subtype was quantified and the expression levels were 
compared as illustrated below (Figure 32) 
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Figure 32. mRNA expression levels for the β1 - AR subtype in rat aortic samples cultivated in the 
presence or absence of Phenylephrine, Dobutamine, Carvedilol, Carvedilol with Phenylephrine, or 
Carvedilol with Dobutamine. DMSO 0,005% was added and used as control when it requiered. 
(Values were normalized using GAPDH as a housekeeping gene and expressed as the average of 2
‐ΔCt
 
± S.E.M. of n=2‐5 different animals. 
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Our preliminary results on the β1 mRNA expression levels, didn‟t allow 
significant changes for the single α1- and β1-agonists, Phenylephrine and Dobutamine 
respectively, when compared with control (DMSO). Curiously, the use of Carvedilol 
in combination with Phenylephrine seemed to produce a decrease in the β1 gene 
expression, which is not observed by Phenylephrine or Carvedilol alone. 
 
 
5.7.3 Changes in the β2-AR expression   
 
The results relative to the β2-AR mRNA levels are still incomplete, and more 
experiments are required to verify possible changes in the β2-AR expression. Our 
preliminary results (Figure 33) didn‟t allow significant differences but indicate a 
slight increase in the β2-AR expression when the aortic explants were cultivated with 
Carvedilol, alone or mixed with Phenylephrine. 
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Figure 33. mRNA expression levels for the β2-AR subtype in rat aortic samples cultivated in the 
presence or absence of Phenylephrine, Carvedilol, and Carvedilol with Phenylephrine. DMSO was 
added and used as control. (Values were normalized using GAPDH as a housekeeping gene and 
expressed as the average of 2
‐ΔCt
 ± S.E.M. of n=2‐5 different animals). 
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5.7.4 Changes in the G protein–coupled receptor kinases (GRK2, GRK3, 
GRK5) 
 
The GRK3 gene resulted not enough expressed to be detected, while for the 
GRK2 we couldn‟t achieve sufficient data. Our preliminary results are related to the 
GRK5 gene expression and show that either Carvedilol, Dobutamine, nor their mix, 
seemed to modify the GRK5 mRNA expression levels that resulted quite similar in 
each value (Figure 34). 
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Figure 34. mRNA expression levels for GRK5 in rat aortic samples cultivated in the presence or 
absence of Dobutamine, Carvedilol, and Carvedilol with Dobutamine. DMSO was added and used as 
control. (Values were normalized using GAPDH as a housekeeping gene and expressed as the 
average of 2
‐ΔCt
 ± S.E.M. of n=2‐5 different animals). 
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5.8 Analysis of intracellular signals coupled to 
α1/β-ARs (Results) 
 
  
5.8.1 ERK 1/2 Activation 
 
With the aim to investigate the unclear intracellular signaling pathways 
activated by Carvedilol, Western Blotting experiments were performed to quantify 
the ERK 1/2 activation. Actually, although previous works already demonstrated that 
Carvedilol also allows a partial agonist activity on β-ARs by producing ERK 1/2 
stimulation via β-arrestin,187 it was still not analyzed if α1-ARs subtypes are also 
involved in this activity. Therefore we started investigating a possible role exerted by 
the α1-ARs, and to this purpose HEK 293 cells, not-transfected or stably transfected 
with the three different α1-AR subtypes (α1A, α1B, α1D) were used as model and 
treated at different times with Carvedilol (10
-6
 M), or the non selective β-agonist 
Isoprenaline (10
-5
 M). DMSO was used as control when it required and the non-
selective β-blocker Propranolol (10-6 M) was eventually applied before Carvedilol or 
Isoprenaline. Finally the ERK 1/2 activation was detected using specific antibodies 
for the ERK 1/2 phosphorylated form (p-ERK). 
We started investigating if Carvedilol were able to activate the ERK 1/2 
pathway in HEK 293 cells not transfected and stably transfected with the three α1-
ARs subtypes (α1A;α1B;α1D), with a simple kinetic of the ERK 1/2 activation (Figure 
35).  
 
 
Figure 35. Immunoblot of pERK1/2 signal elicited by Carvedilol (10
-6
 mol/L) in HEK293 cells 
transfected with the three α1-ARs subtypes (α1A; α1B; α1D) and incubated at 5, 15 and 20min with the 
agent (n=1). 
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The results indicated a similar profile for the HEK293 cells transfected with 
the α1A and α1B subtypes, with Carvedilol activating the ERK 1/2, which was found 
mostly phosphorilated after 15 minutes of incubation, and at 20 minutes when the 
signal started to decrease, or 5‟ and 15‟ in the HEK293 cells not-transfected. These 
similarities suggest that ERK1/2 signal mediated by β-AR is not markedly 
influenced by α1A nor the α1B subtype. A different behavior was observed with the 
α1D-AR: the α1D transfected cells showed a basal level of ERK 1/2 activation, which 
is in agreement with the constitutive activity of this subtype previously described,
25
 
and then a weak signal after 5 minutes of incubation. The differences founded by 
comparing the not-transfected cells with the α1D-transfected cells suggested that the 
overexpression of α1D-AR subtype might influence the ERK1/2 activation mediated 
by Carvedilol. Therefore, with the aim to clarify this point, we carried out new 
experiments focusing on the differences between not-transfected and α1D transfected 
HEK293 cells. To verify the presence and the responsiveness of the β-ARs in both 
cell types, the β-agonist Isoprenaline was applied (Figure 36).  
 
 
 
Figure 36. Immunoblot of pERK1/2 signal elicited by Isoprenaline in HEK293 cells transfected or not 
with the α1D-AR subtype and incubated at 5, 15 and 20min with the agent (representative 
immunoblots of n=3 experiments). 
 
Both in not-transfected as well as in α1D-transfected HEK293 cells, at minute 
5 of the experiment, the β-agonist Isoprenaline produced an evident phosphorylation 
of ERK 1/2 and then the signal rapidly decreased. The β-AR transductional role 
seemed to be clear, but to verify any possible implication by the α1D-AR subtype, in 
some cases cells were pre-treated with the β-blocker Propranolol 15 minutes before 
applying Isoprenaline: the complete inhibition of the ERK 1/2 phosphorylation in 
both cells types, dropped the hypothesis of an α1D-AR transductional role for 
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Isoprenaline. Furthermore the same experiment showed how the β-blocker 
Propranolol was unable to activate the ERK 1/2 pathway. Therefore the same kind of 
experiment was conducted by treating not-transfected and α1D transfected HEK293 
cells with Carvedilol. We obtained results in agreement with the profile showed 
before (Figure 37), allowing a faster ERK 1/2 activation in the α1D transfected cells, 
and a complete inhibition by pre-treatment with Propranolol, but unfortunately, these 
results were not sufficiently reproducible to assess a clear profile. 
 
 
 
Figure 37. Immunoblot of pERK1/2 signal elicited by Isoprenaline in HEK293 cells transfected or not 
with the α1D-AR subtype and incubated at 5, 15 and 20min with the agent (representative 
immunoblot of n=3 experiments). 
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5.9 Discussion 
 
5.9.1 Evaluation of adrenoceptors (ARs) role in Angiogenesis by ex-vivo rat 
aortic rings assay. 
 
As previously described, little is known about the role of ARs in 
Angiogenesis. Actually if recent literature reported evidence of a relationship 
between ARs and vascular remodeling, the subtypes as well as the signalization 
pathways involved still remain to be clarified. To this purpose, we analyzed the 
effect exerted by selective α1- and β-AR agonists, or by Carvedilol, a non-selective 
β-blocker/α1-blocker, in the angiogenic process, by culturing rat aortic explants in a 
tridimensional extracellular matrix (Matrigel
®
) in the presence [1], or absence [2], of 
additional growing factors. The angiogenic response resulted much more remarkable 
when forcing the process with growing factors[1], even in the absence of any 
stimulus, but a close correlation between the results of the two parallel experiments 
was observed when different stimuli were employed.    
The selective α1-agonist Phenylephrine was found to significantly increase 
the angiogenic growth along the seven days experiment in the absence of DMSO. 
This result is in agreement with previous studies indicating that α1-mediated 
stimulation is responsible for trophic effects on vascular endothelium as well as for 
the outgrowth of tubular structures from fragments of mature human vessels.
125
 It 
agrees also with the findings that 1-AR antagonists (doxazosin, terazosin and 
prazosin) suppressed angiogenesis, in vitro (HUVEC model) and in a number of in 
vivo models.
127
 The lack of the same Phenylephrine pro-angiogenic activity observed 
in the presence of DMSO, might be due, as already hypothesized, to the increased 
angiogenic response promoted by this solvent. Actually we needed to add DMSO in 
order to compare the Phenylephrine or also the Dobutamine activity with that exerted 
by Carvedilol, which required DMSO to be solved. When we analyzed the effect of 
this well known toxic agent, as discussed above, we found that it was already 
promoting an angiogenic response, and this has to be considered as a limitation to 
our studies. The selective β1-agonist Dobutamine significantly inhibited the 
angiogenic growth, and this result could be related to the pro-apoptotic activity 
observed as a consequence of a β1 sustained stimulation.
69
 It is also in agreement 
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with another study revealing that chronic β1-blockade promotes arteriolar growth and 
preserves coronary perfusion in post-infarcted heart.
133
 As concern the β2-AR, 
although recent works showed how an overexpression of the β2-AR in mice, 
enhanced the adaptive pro-angiogenic response to ischaemia,
135
 and the gene 
removal of this receptor altered the intracellular signal transduction pathways, 
allowing impaired angiogenesis,
136
 our investigation do not show a clear angiogenic 
profile for the selective β2-agonist Salbutamol in our angiogenic model, where 
neither ischemia nor hypoxia were involved. Then, further studies will be required to 
elucidate the exact role of β2–ARs in the angiogenic process mediated by different 
stimuli. 
 
The activity of the vasodilating β-blocker Carvedilol, non-selective β-blocker 
and α1-blocker, was finally investigated, in order to verify if the unique clinical 
Carvedilol effectiveness could be related to the angiogenic process. In our ex vivo 
study Carvedilol did not seem to have a significant influence  on the angiogenic 
growth, but curiously, when culturing aortic explants with both Carvedilol and 
Phenylephrine, we observed a greater increase if compared with the results obtained 
by culturing Carvedilol or Phenylephrine alone. The finding that Carvedilol, non-
selective β-blocker/α1-blocker, did not inhibit but even increased the pro-angiogenic 
effect exerted by the α1-agonist Phenylephrine, could be not so amazing, considering 
the paradoxical capacities of Carvedilol to improve the signaling pathways mediated 
by α1-ARs
198
 or its ability to stabilize a 2-AR conformation, which is unable to 
couple to the Gs protein and therefore initiate this signaling pathway, but can activate 
the -arrestin mediated signaling pathway187 that directly stimulates MAPKs, 
including ERK 1/2,
199
 thus influencing the angiogenic process even in the absence of 
an agonist. However by culturing aortic explants with Carvedilol and Dobutamine, 
we found that Carvedilol was not able to reverse the anti-angiogenic activity exerted 
by the β1-agonist Dobutamine. 
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5.9.2 Analysis and quantification of the mRNA expression levels of α1- and 
β-ARs and of the G protein–coupled receptor kinases (GRK2, GRK3 and 
GRK5) by real-time Quantitative RT-PCR. 
 
 
Among the several properties showed by Carvedilol, a possible mechanism of 
action could be the modulation of the ARs expression and internalization. With the 
aim to quantify the possible changes in the mRNA expression levels of α1- and β-
ARs, and of the G protein-coupled receptor kinases (GRK2, GRK3 and GRK5), a 
real-time quantitative RT-PCR was performed after RNA extraction from the aortic 
explants used for the angiogenesis assay. As previously reported this part of the work 
is currently under study and more experiments will be required for an exhaustive 
analysis.  
The collected preliminary results illustrated above, did not allow significant 
changes in the expression of the ARs and the GRKs, by comparing Carvedilol or the 
α1- and β1 agonists Phenylephrine and Dobutamine with control (DMSO). The only 
curious significant change was noticed for the β1 gene expression study: the use of 
Carvedilol in combination with Phenylephrine seemed to produce a decrease in the 
β1 gene expression, which is not observed by Phenylephrine or Carvedilol alone. 
Keeping in mind that these are only preliminary results, a concrete explanation 
appears complicated, but considering the same unique behavior showed by the 
Carvedilol-Phenilephrine mix in the angiogenesis assay, we might hypothesize a 
relationship between the observed greater pro-angiogenic response and the decrease 
in the β1 gene expression.  
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5.9.3 Analysis by Western Blot of intracellular signals coupled to α1/β-ARs: 
ERK 1/2 activation 
 
MAPK have been studied for their relevance in essential cellular processes 
such as proliferation and cell differentiation, and their activation was proved to be 
triggered by mitogenic stimuli, phorbol esters, stress or cytokines.
200
 (Aouadi et al., 
2006). Recently GPCRs have been also involved in the process, finding that the 
PTH1R receptor (parathyroid hormone receptor type 1),
201,202
 the β2-AR,
108
 and the 
AT1AR (angiotensin II 1A receptor),
107
 were able to activate the Extracellular 
signal-Regulated Kinase (ERK). Likewise ERK activation was also found to be 
promoted by α1-ARs stimulation,
20
 although the kinetic of ERK phosphorylation and 
the mechanisms involved for each α1-AR subtype have only started to be studied by 
our group of investigation. Actually it was recently demonstrated that the stimulation 
of α1-AR mediated by an agonist, promoted ERK activation, with a spatiotemporal 
pattern that varied depending on the α1-AR subtype.
203
 The α1A and α1B-ARs 
subtypes displayed an early transient PKC-dependent activation phase, with a 
distribution of the ERK in cytosol and nucleus, while the α1D-AR subtype showed a 
PKC-independent early phase with the ERK distribution limited to the cytosol. 
Moreover the α1A subtype allowed a late and sustained phase, which depends on the 
receptor internalization, and with the ERK limited to the cytosol. Otherwise ERK 
activation, mediated by α1B and α1D subtypes didn‟t present the late phase. It was also 
found that the α1D subtype constitutively activated the ERK.  
Considering this pattern described by the use of an α1-AR agonist, we started 
studying on the same HEK293 cells trasfected with the three α1-AR subtypes, the 
ERK activation profile exerted by the non-selective β-blocker and α1-blocker 
Carvedilol. Actually the β-arrestin-mediated ERK activation by Carvedilol was 
already proved
187
 suggesting the β2-AR as responsible for the transductional role, but 
considering the paradoxical capacities of Carvedilol to improve the signaling 
pathways mediated by α1-ARs,
198 
and also the particular profile showed in our 
angiogenesis study, by culturing explants with both Phenylephrine and Carvedilol, a 
possible α1 transductional role was also hypothesized. In a first experiment, a kinetic 
of activation showed the capacity of Carvedilol to produce the ERK phosphorylation 
in HEK293 α1-transfected cells at different times but the kinetic of this activity 
changes when α1D-AR is sobreexpressed. However, when we applied the β-agonist 
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Isoprenaline, the presence and responsiveness of the β-ARs was not influenced by 
the overexpression of the α1-AR subtypes, as no differences with the not-transfected 
cells were found in the ERK activation, whose signal was completely abolished by 
pre-treatment with the β-blocker Propranolol.  
Unfortunately we were not able to assess if the ERK activation produced by 
Carvedilol was even partially modulated by the presence of α1D-ARs because we 
could only collect preliminary results, but the differences observed in the ERK 
signaling in α1D transfected cells suggests a possible relationship between the β and 
the α1D-AR at the level of MAPK pathway that future work could clarify. 
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6.1 Cáncer: aspectos generales 
 
6.1.1 Estadísticas 
La carga global de cáncer sigue aumentando en gran medida debido al 
envejecimiento y el crecimiento de la población mundial, junto a una creciente 
adopción de comportamientos que causan cáncer, especialmente el tabaquismo, en 
los países en vías de desarrollo económico. Según las estimaciones de GLOBOCAN 
2008, se estima que en el año 2008 hayan ocurrido alrededor de 12,7 millones de 
casos de cáncer y 7,6 millones de muertes por cáncer, de los cuales, el 56% de los 
casos y el 64% de las muertes ocurrieron en el mundo en desarrollo económico. 
(Figuras 1 y 2, Capítulo 1).  
Parte del aumento se debe sin duda, a las características ambientales de la 
vida industrializada, tales como la contaminación atmosférica, el tabaquismo y la 
dieta. Hay grandes variaciones en la incidencia y prevalencia del cáncer en sitios 
anatómicos diferentes, sexos, edades y grupos raciales, étnicos y geográficos. 
El cáncer de mama es el cáncer más frecuente y la principal causa de muerte 
por cáncer entre las mujeres, representando el 23% del total de casos y el 14% de las 
muertes por cáncer. El cáncer de pulmón es el más común en los hombres, y 
representa el 17% del total de nuevos casos y el 23% de las muertes totales por 
cáncer. (Figura 3.1-3.2 Capítulo 1) 
A pesar de los enormes esfuerzos y los notables progresos en la tasa de 
supervivencia, se estima (GLOBOCAN 2008) que la carga futura de cáncer aumente 
llegando a una incidencia de hasta 20 millones de casos en el año 2030. (Figura 4, 
Capítulo 1). 
 
6.1.2 Patología del cáncer 
El tumor es una lesión presente en un órgano o tejido, con características de 
crecimiento incontrolado y estructura aberrante, que no puede explicarse con los 
mecanismos conocidos relacionados con las enfermedades. Sin embargo, la 
característica común de todos los tumores es que sus células parecen eludir algunos, 
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si no todos, los mecanismos de control del crecimiento y la organización anatómica 
de las células normales. Por lo tanto, el tumor se define esencialmente como la 
enfermedad de la célula caracterizada por una desviación patológica en los 
mecanismos que regulan su crecimiento y proliferación; cuando estos mecanismos se 
hacen insuficientes ocurre una proliferación celular excesiva y por lo tanto, el 
crecimiento autónomo, que ha perdido la capacidad de control y la inhibición de 
contacto.  
Una primera clasificación consiste en la división de los tumores en malignos 
y benignos, en relación con el comportamiento clínico. Células cancerosas bien 
diferenciadas similares a las de los tejidos de origen son esencialmente benignas. 
Cuanto más se alejan las células de las características originales (es decir desarrollan 
formas menos diferenciadas), mayor es el riesgo de anaplasia  y luego malignidad. El 
tamaño de la célula, las características del núcleo y otras estructuras internas, el 
número de mitosis, la arquitectura del tejido formado y la capacidad de realizar las 
funciones normales son las características que orientan hacia una mayor o menor 
diferenciación. Los tumores benignos generalmente tienen una estructura coherente y 
están rodeados por una cápsula fibrosa. Los tumores malignos tienden en cambio a 
infiltrar y erosionar el tejido que les rodea, penetrando en las estructuras adyacentes. 
Ellos no reconocen límites anatómicos y pueden penetrar en la sangre y los vasos 
linfáticos diseminándose en las cavidades. Estas células se encuentran en otros 
órganos y tejidos y causan tumores secundarios (metástasis). 
 
6.1.3 Terapias actuales 
El método de tratamiento en gran medida está determinado por una 
evaluación de los objetivos terapéuticos. Las técnicas utilizadas incluyen: 
 La cirugía (extirpación del tumor primario). 
 Radioterapia 
 Tratamiento farmacológico (quimioterapia citotóxica, tratamiento hormonal, 
terapia biológica, inmunoterapia, terapia génica) 
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- Tratamiento Farmacológico: 
Se suele distinguir entre agentes citotóxicos tradicionales relativamente 
selectivos, que actúan en el núcleo, y nuevos agentes biológicos que actúan 
principalmente en la señalización celular y citoquinas, en el citoplasma o en la 
superficie celular. Los primeros producen muerte celular, de ahí el nombre 
citotóxicos; los segundos  actúan más como citostáticos, inhibiendo el crecimiento 
pero no necesariamente matando a la célula. 
 
6.1.4 Enfoque del trabajo de síntesis 
El trabajo realizado en esta tesis en el departamento de Química Farmacéutica 
de la Facultad de Farmacia, Universidad de Pisa, ha sido dedicado a la síntesis de 
nuevos sistemas policíclicos con potencial actividad antitumoral. Las nuevas 
moleculas sintetizadas pueden dividirse, por estructura y diana terapéutica en dos 
clases diferentes:  
 La primera clase incluye compuestos tetracíclicos, pertenecientes a la 
"tradicional" quimioterapia citotóxica, que se intercalan en el ADN, e inhiben 
las topoisomerasas I y II. 
 La segunda clase incluye compuestos que pertenecen a la categoría de 
"terapia biológica". En este caso el objetivo son las señales de crecimiento 
que están sobre-activadas en las células tumorales, y en particular los 
receptores del factor de crecimiento endotelial vascular (VEGFRs). 
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6.2 Nuevos agentes intercalantes en el ADN inhibidores de las 
Topoisomerasas I/II 
 
6.2.1 Interacciónes ligando-ADN 
 
Los agentes que se asocian con el ADN suelen dividirse en dos categorías: los 
que se intercalan entre los pares de bases, y los que se encuentran en los surcos, en 
particular el surco menor, de la doble hélice. La interacción puede implicar la 
formación de enlaces covalentes entre grupos reactivos del ligando y el ADN, o el 
reconocimiento puede ser a través de interacciones no covalentes (Figura 2, Capítulo 
2). Pequeños compuestos orgánicos que no se unen covalentemente a los ácidos 
nucleicos pueden producir modificaciones estructurales que conduzcan a cambios 
funcionales, como la inhibición de los procesos de transcripción y replicación, que 
culminan con la muerte celular. 
Las características estructurales del surco de ADN críticas para el 
reconocimiento de moléculas pequeñas son las siguientes: 
 amplitud  
 profundidad  
 funcionalidad  
 potencial electrostático 
y todas ellas son dependientes de la secuencia de nucleótidos. 
El ancho del surco varía de 3-4 Å para los tramos ricos en AT, a más de 8 Å 
para los ricos en GC. La profundidad del surco es menor para las secuencias de GC 
que en tramos de AT debido a la presencia de la amina exocíclica en la guanina. De 
hecho, el grupo amino tiene carácter nucleofílico y actúa como sitio de 
reconocimiento y de alquilación a través de la formación de enlaces de hidrógeno. A 
diferencia de la intercalación, donde la unión de moléculas induce cambios 
importantes en la conformación del ADN, la unión al surco menor se caracteriza por 
la leve distorsión del ADN, acompañada por cambios en la conformación de la 
molécula. 
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En la actualidad sólo hay unos pocos ejemplos de compuestos que se unen 
selectivamente con el surco mayor: la mayoría de los compuestos se unen por 
intercalación y establecen, además, enlaces de hidrógeno con el surco mayor. En 
general, las interacciones con el surco mayor proporcionan un cierto grado de 
especificidad de la secuencia, pero la afinidad de unión se debe, principalmente, a la 
intercalación. 
Una amplia gama de moléculas se une al ADN por intercalación y la mayoría 
de los que se definen como ligandos del surco menor o mayor se estabilizan por la 
intercalación de un grupo cromóforo. Desde el punto de vista químico, los agentes 
intercalantes, se caracterizan básicamente por la presencia de: 
 una estructura policíclica aromática o heteroaromática plana, que forma un 
complejo molecular con las bases de ADN, estabilizado por enlaces de 
hidrógeno, fuerzas de van der Waals e interacciones hidrofóbicas. 
 grupos o cadenas laterales, en posiciones adecuadas del sistema planar, 
capaces de colocarse en uno o ambos surcos de la doble hélice del ADN, 
favoreciendo la formación del complejo de intercalación. 
Las lesiones que pueden resultar de la intercalación en el ADN son numerosas: 
cambios estructurales en el ADN, separación del ADN, o inhibición de las 
topoisomerasas del ADN, las enzimas que constituyen un nuevo objetivo de la 
terapia antiblásticas. 
 
 
6.2.2 Topoisomerasas I/II 
 
Las topoisomerasas del ADN son enzimas del nucleo, esenciales para el 
metabolismo de los ácidos nucleicos. Su principal función es la de regular el estado 
topológico del ADN, y esta capacidad las hace indispensables en los procesos de 
replicación, transcripción, recombinación y reparación, así como en la formación y la 
segregación de los cromosomas durante la mitosis. Las topoisomerasas se dividieron 
inicialmente según el mecanismo de acción, en topoisomerasa I y topoisomerasa II; 
actualmente, en los eucariotas mayores se han encontrado al menos cuatro 
topoisomerasas diferentes: las topoisomerasas IA y IB  y las topoisomerasas IIA y 
IIB. 
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Su acción consiste en cortar una (topoisomerasa I) o ambas hebras 
(topoisomerasa II) de ADN, dejar pasar otro filamento, o una doble hélice, 
respectivamente, y luego volver a unir el ADN. (Figuras 17, 22, 25 Capítulo 2). 
Las topoisomerasas determinan el aumento o disminución del grado de 
superhelicidad del ADN actuando sobre el número de enlace (Lk) que indica el 
número de veces que un filamento gira en torno al otro (Figuras 11, 12, 13 Capítulo 
2). Las topoisomerasas son capaces de relajar la superhelicidad del ADN tanto 
negativamente como positivamente, en el primer caso desenredando el ADN, y en el 
segundo enredándolo para permitir que se almacene de manera más compacta. 
Durante el ciclo de reacción, se forma un complejo escindible entre el ADN y 
la enzima, en el que el grupo fosfato de las bases del ADN resulta unido 
covalentemente a la proteína a través de un residuo de tirosina (Figuras 14,26 
Capítulo 2). 
 
6.2.3 Inhibidores de las Topoisomerasas I/II 
 
Los complejos escindibles con el ADN son de naturaleza transitoria y su 
concentración celular està estrictamente regulada. Las condiciones que alteran de 
manera significativa la concentración fisiológica de estas rupturas, son responsables 
de alteraciones del ADN que desempeñan un papel crucial en la inhibición de la 
progresión del ciclo celular. Aunque las funciones biológicas de las topoisomerasas 
sean importantes para la integridad genómica, la capacidad de interferir con las 
enzimas o generar daño mediado por la enzima es una estrategia eficaz para el 
tratamiento del cáncer. En este sentido,  inhibidores de la topoisomerasa I y II 
representan una clase importante de agentes antitumorales, y constituyen la base de 
muchas combinaciones de quimioterapia ampliamente utilizadas en un amplio 
espectro de tumores.  
Los medicamentos que actúan como inhibidores de las topoisomerasas se 
clasifican según el mecanismo utilizado para alterar la función fisiológica de las 
enzimas, en "venenos" e "inhibidores propiamente dichos": 
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- "Venenos": estabilizan el enlace covalente del complejo ADN-enzima, y por 
lo tanto producen la ruptura de la cadena de ADN. 
 
- "Inhibidores propiamente dichos": no provocan un aumento en los complejos 
escindibles, ya que inhiben la actividad de las enzimas actuando sobre otras 
etapas del ciclo catalítico. 
 
Entre los inhibidores de la topoisomerasa I, ha despertado un considerable 
interés la camptotecina, un alcaloide que bloquea el complejo escindible entre la 
topoisomerasa I y el ADN. La utilidad clínica de este compuesto, sin embargo, está 
limitada por su toxicidad y baja solubilidad, por lo que se han llevado a cabo 
modificaciones para la obtención de derivados solubles en agua (topotecan e 
irinotecan), que se han introducido en el tratamiento del cáncer de ovario, pulmón, 
colon y recto. Recientemente, se han estudiado algunos compuestos con estructura 
diferente a los derivados de la camptotecina; entre ellos indenoisoquinolinas e 
indolocarbazoles que parecen muy prometedores, sobre todo debido a su mejor 
índice terapéutico (Figuras 31-34, Capítulo 2).  
Aunque los inhibidores de la topoisomerasa II conocidos hasta ahora 
pertenecen a clases químicas diferentes, casi todos tienen una parte aromática 
policíclica que se puede intercalar en el ADN y una o más cadenas laterales con 
diferentes sustituyentes que se alojan en el surco menor de la doble hélice y pueden 
interactuar directamente con la enzima.  
Los inhibidores catalíticos de la topoisomerasa II son un grupo de sustancias 
heterogéneas del punto de vista químico, que pueden interferir con la unión entre el 
ADN y la topoisomerasa (Aclarubicina, Suramina), estabilizar el complejo covalente 
ADN-topoisomerasa II (Merbarone, ICRF-I87) o inhibir la unión del ATP 
(novobiocina) (Figuras 36, Capítulo 2). 
Los venenos de la topoisomerasa II tambièn representan una clase 
heterogénea de compuestos; entre ellos se encuentran las epipodofilotoxinas, las 
antraciclinas, las antracenodionas y la amsacrina. (Figuras 35, Capítulo 2). 
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Considerando la naturaleza multifactorial de muchas enfermedades, 
particularmente el cáncer, cuando la monoterapia no resulta suficientemente eficaz, 
se puede utilizar un tratamiento con múltiples fármacos, o administrar una 
especialidad única que contenga más principios activos diferentes. Por esta razón, el 
desarrollo de fármacos con actividad dual, o mejor, "multitarget" parece una 
estrategia terapéutica prometedora. 
En este contexto han adquirido una importancia considerable, algunos 
compuestos recientemente descritos en literatura, que además de exponer 
importantes propiedades antiproliferativas, se han demostrado inhibidores eficaces de  
las dos topoisomerasas. La primera categoría comprende compuestos que se unen al 
ADN por intercalación, e incluye derivados de la acridina (DACA), piridocarbazoles 
(intoplicina), y derivados de antraciclinas (aclarubicina). Una segunda clase se 
compone de moléculas híbridas preparadas combinando inhibidores de la 
topoisomerasa I con los de la topoisomerasa II, como los híbridos camptotecina-
epipodofillotoxina, y ellipticina-distamicina. Una tercera clase incluye compuestos 
como tafluposide (F11782), obtenidos por modificaciones estructurales de 
compuestos con actividad selectiva en contra de una u otra clase de enzimas (Figuras 
37, Capítulo 2). 
 
6.2.4 Nuevos agentes intercalantes en el ADN inhibidores de las 
Topoisomerasas I/II 
 
El grupo de investigación en el que desarrollo mi trabajo, ha estudiado varios 
cromóforos policíclicos estructuralmente relacionados con las clases de agentes 
intercalantes del ADN, que efectivamente han mostrado la capacidad para 
intercalarse en el ADN y en algunos casos, para inhibir las topoisomerasas I/II. Entre 
ellos se sintetizaron nuevos compuestos que incorporan el núcleo de la purina (I), del 
benzimidazol (II), y del indol (III), y más recientemente se ha desarrollado un amplio 
estudio sobre la serie de benzotiopirano-indoles de fórmula general (IV). (Figura 38, 
Capítulo 2). 
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Los nuevos compuestos mostraron actividad antiproliferativa a concentración 
micromolar en células tumorales humanas HeLa y HL-60. Estudios de dicroismo 
lineal en flujo revelaron la capacidad de tales compuestos para intercalarse con el 
ADN, y modelos computacionales permitieron el análisis de las interacciones 
ligando-ADN. Por otra parte también se demostró el efecto “veneno” de la 
topoisomerasa II y la capacidad para inhibir la topoisomerasa I, (Figuras 39-43, 
Capítulo 2).  
Los resultados prometedores conseguidos, han sugerido modificaciones 
estructurales para la síntesis de nuevos compuestos con el fin de mejorar la actividad 
antitumoral e identificar los grupos farmacofóricos responsables. Las modificaciones 
que he aportado incluyen, la introducción de heteroátomos y grupos ricos en 
electrones, en diferentes posiciones del cromóforo, así como la funcionalización con 
cadenas polares hidrófilas o básicas, que no sólo estabilizan significativamente el 
complejo, sino que también podrían jugar un papel importante en el anclaje del 
ligando al dúplex de ADN, facilitando la inserción de la parte plana de la molécula 
en el sitio de intercalación del ADN. 
En particular, se llevó a cabo la síntesis de los nuevos benzotiopirano-indoles 
(2a-h) y de los isosteros piridotiopirano-indoles (3a-f).  
La vía de síntesis para la obtención de los derivados benzotiopirano- 
indólicos 2a-h requiere la preparación de los nuevos sistemas tetracíclicos 4a-d, que 
se caracterizan por la presencia o la ausencia de un sustituyente cloro en la posición 7 
y de un grupo metoxi adicional en la posición 2. Los compuestos 4a-d se realizaron 
siguiendo el procedimiento de síntesis ya descrito en literatura, e ilustrado en el 
Esquema 1 (Capítulo 2).  El producto comercial benzotiopiranona y el derivado 7-
cloro substituido 5c, se formilaron con buenos rendimientos para dar 6a,b, por 
reacción con formiato de etilo en presencia de metóxido de sodio, en una proporción 
de 1:2:2, respectivamente, en solución de tolueno anhidro. Los derivados 
hidroximetileno 6a,b, que contienen un grupo activo metino, llevaron a los 
intermediarios 3-fenilhidrazonas 7a-d, por acoplamiento con la sal de diazonio 
adecuadamente sustituida, según la reacción de Japp-Klingemann. Los compuestos 
obtenidos 7a-d se convierten directamente en los indoles deseados 4a-d con la 
ciclación de Fischer, por reflujo en solución etanólica de cloruro de hidrógeno. 
Finalmente la alquilación de los compuestos 4a-d se llevó a cabo en DMF anhidro 
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utilizando NaH para catalizar la reacción con el apropiado dialquilaminoalquilyoduro 
hidroyoduro (Esquema 3, Capítulo 2). Mientras que benzotiopiranona es comercial, 
el derivado 7-cloro sustituido 5c, fue sintetizado por reacción de 3-cloro-3-tiofenol 
con ácido bromopropiónico en una solución de hidróxido de sodio, para obtener el 
ácido 3-(2-carboxi-5-cloro-1-feniltio) propiónico 10c; la ciclación a 2,3-dihidro-7-
cloro-tiopirano-4 (4H)-ona 5c fue llevada a cabo por reacción de 10c con ácido 
sulfúrico durante 24 horas a temperatura ambiente (Esquema 2, Capítulo 2). 
El procedimiento experimental que conduce a la síntesis de los nuevos 
compuestos 3a-f, que se caracterizan por el sistema piridotiopiranoindolo, es similar 
al procedimiento descrito anteriormente para los análogos benzotiopiranoindoles. En 
este caso, el producto clave es el derivado carbonilo 2,3-dihidrothiopirano [2,3-b] 
piridin-4(4H)-one 11, que fue obtenido por un procedimiento ya descrito en la 
literatura. Ácido 2-mercaptonicotínico, producto comercial, se hace reaccionar con 
ácido bromopropiónico en una solución de hidróxido de sodio, para obtener el 
intermedio ácido 3-(3-carboxi-2-piridiltio) propiónico 15. La ciclación posterior para 
obtener el 2,3-dihidrotiopirano [2,3-b] piridin-4(4H)-one 11 se llevó a cabo por 
calentamiento de 15 en exceso de anhídrido acético y en presencia de acetato de 
sodio anhidro a una temperatura de 150 ° C (esquema 4, Capítulo 2). 
La evaluación biológica de los compuestos sintetizados fue realizada en la 
Facultad de Farmacia de la Universidad de Padua, dentro de un proyecto de 
colaboración. En particular, se evaluó primero la actividad citotóxica, y 
posteriormente, los mecanismos celulares que podrían estar involucrados. La 
actividad antiproliferativa fue evaluada en líneas celulares tumorales humanas, 
representantes de los diferentes tipos de tejido: HeLa (adenocarcinoma cervical), A-
431 (carcinoma de células escamosas) y MSTO-211H (mesotelioma bifásico). Los 
datos de toxicidad se expresan como valores de IC50, es decir, la concentración (M) 
de un compuesto capaz de producir 50% de muerte celular con respecto al control; 
elipticina fue utilizado como compuesto de referencia (Tabla II Capítulo 2, reportada 
abajo).   
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 Y X X’ X” R HeLa A431 MSTO-211H 
2a CH H OCH3 H (CH2)2N(CH3)2 n.d. n.d. n.d. 
2b CH H OCH3 H (CH2)2N(C2H5)2 n.d. n.d. n.d. 
2c CH Cl OCH3 H (CH2)2N(CH3)2 n.d. n.d. n.d. 
2d CH Cl OCH3 H (CH2)2N(C2H5)2 n.d. n.d. n.d. 
2e CH H OCH3 OCH3 (CH2)2N(CH3)2 n.d. n.d. n.d. 
2f CH H OCH3 OCH3 (CH2)2N(C2H5)2 2.4±0.04 0.16±0.01 0.75±0.06 
2g CH Cl OCH3 OCH3 (CH2)2N(CH3)2 n.d. n.d. n.d. 
2h CH Cl OCH3 OCH3 (CH2)2N(C2H5)2 3.5±0.3 1.68±0.3 n.d. 
3a N H H H (CH2)2N(CH3)2 1.55±0.05 0.54±0.04 1.08±0.07 
3b N H H H (CH2)2N(C2H5)2 2.6±0.2 0.47±0.02 1.63±0.06 
3c N H Cl H (CH2)2N(CH3)2 n.d. n.d. n.d. 
3d N H Cl H (CH2)2N(C2H5)2 4.2±0.3 1.80±0.05 1.42±0.09 
3e N H OCH3 OCH3 (CH2)2N(CH3)2 1.7±0.1 0.71±0.10 0.35±0.03 
3f N H OCH3 OCH3 (CH2)2N(C2H5)2 6.9±1.2 2.7±0.7 0.62±0.01 
Ellipticine 0.320.01 0.430.02 0.460.08 
 
Todos los compuestos ensayados ejercen una actividad antiproliferativa 
significativa en las líneas celulares consideradas, mostrando valores de IC50 en 
algunos casos comparables a los obtenidos por la elipticina. 
Para investigar el mecanismo de acción responsable de la actividad citotóxica 
de los nuevos derivados pyridothiopyranoindole 3a-f, se realizaron experimentos de 
dicroísmo lineal de flujo (LD) en presencia de una solución de ADN de salmón y dos 
diferentes concentraciones de los compuestos de prueba. Los resultados mostraron 
que todos los compuestos son capaces de intercalarse en el ADN, tal y como aparece 
en el espectro LD de soluciones de derivados a dos coeficientes de concentración 
[ADN]/[compuesto] (Figuras 47 y 48, Capítulo 2 relativo a los compuestos 3e y 3f). 
Finalmente, se investigó la actividad de los nuevos derivados en el proceso de 
relajación de ADN superenrollado de plásmido pBR322, mediada por la 
topoisomerasa I y II, así como el potencial efecto "veneno" sobre las enzimas. Los 
resultados preliminares indican que los derivados benzotiopiranoindoles son 
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potenciales inhibidores duales de la topoisomerasa I y II, mientras que el sistema 
piridotiopiranoindolo parece ser adecuado para la obtención de venenos eficaces de 
la topoisomerasa I (Figuras 49-51, Capítulo 2). 
 
6.3 Nuevas pequeñas moléculas inhibidoras de la fosforilación 
de tirosina quinasa 
 
La segunda clase de compuestos sintetizados pertenece a la categoría de 
"terapia biológica". En este caso el objetivo son las señales de crecimiento que están 
sobre-activadas en las células tumorales, y en particular los receptores del factor de 
crecimiento endotelial vascular (VEGFRs) que forman parte de la familia de 
receptores de tirosina quinasas. 
 
6.3.1 Receptores de Tirosina Quinasas: VEGF/VEGFR  
Las proteínas tirosina quinasas representan una amplia familia de enzimas 
homólogas, tanto localizadas en la membrana como citoplasmáticas, que catalizan la 
transferencia del grupo γ-fosfato del ATP a un grupo hidroxi de residuos de tirosina 
de proteínas diana. En condiciones fisiológicas, la fosforilación de la tirosina 
representa un mecanismo de transducción de señales fundamental, que precede 
jerárquicamente en una secuencia ordenada de interacciones de proteínas, lo que 
garantiza la diafonía entre las células y la regulación de aspectos clave de la vida 
celular como la proliferación, la diferenciación, el metabolismo, y la apoptosis. 
Los receptores de tirosina quinasas (RTKs) de la membrana, son proteínas 
que se localizan en la doble capa de fosfolípidos de membrana, y todos comparten 
una estructura similar caracterizada por tres regiones: una citosólica, una 
extracelular, y una porción intramembranaria.  La región extracelular expone el 
dominio N-terminal al fluido intersticial y preside el reconocimiento y la interacción 
con el ligando. La porción hidrófila intracelular, C-terminal, presenta sitios que 
gobiernan la transducción de señales mediados por la interacción ligando-receptor. 
Esta porción se caracteriza por residuos de tirosina en posiciones específicas que a 
consecuencia de la interacción con el ligando se autofosforilan. Es el mecanismo 
específico que determina la interacción con las proteínas citoplasmáticas y su 
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fosforilación, porque los dominios expuestos de esas proteínas reconocen secuencias 
específicas de aminoácidos fosforilados del dominio catalítico de la porción 
intracelular del receptor. Se han identificado aproximadamente 20 clases de RTKs 
por sus diferentes características estructurales de dominios; entre ellos, la familia de 
receptores del factor de crecimiento endotelial vascular (VEGFRs). La familia del 
VEGF humano se compone de cinco miembros: VEGF (o VEGF-A), el VEGF-B, 
VEGF-C, VEGF-D, y el factor de crecimiento placentario (PlGF). VEGFs son 
homodímeros que contienen residuos de cistina, esenciales para el establecimiento de 
la estructura terciaria.  
La familia de VEGFs y sus receptores juegan un papel primordial en la 
angiogénesis, linfangiogénesis, y la vasculogénesis. El miembro predominante de 
esta familia es el VEGF-A, una glicoproteína de 45 kDa compuesta por 165 
aminoácidos que interactúa con dos receptores transmembrana tirosina quinasa: 
VEGFR-1 y VEGFR-2. La proteína VEGF-B a través de la unión a VEGFR-1 ejerce 
un efecto mitogénico sobre las células endoteliales. VEGF-C y VEGF-D son 
estructuralmente similares y pueden ser considerados como miembros de una 
subfamilia. Estas proteínas, por interacción con el VEGFR-2, inducen un ligero 
efecto mitógeno sobre las células endoteliales, mientras que a través de la unión a 
VEGFR-3 regulan el proceso de linfangiogénesis. 
Los receptores humanos VEGFR-1 y VEGFR-2 consisten en 1338 y 1356 
aminoácidos, respectivamente. Son proteínas estructuralmente similares que estàn 
formadas por cuatro regiones: el dominio extracelular, un dominio transmembrana, 
un dominio intracelular con actividad quinasa, que se compone de un dominio 
regulador y un dominio catalítico, unidos por una región bisagra, y una región 
carboxi-terminal. Los dominios quinasa de VEGFR-1 y VEGFR-2 son las regiones 
más conservadas, con cerca el 70% de homología, mientras que el extremo carboxi-
representa la región más diferenciada. Tanto el VEGFR-1 y VEGFR-2 se encuentran 
en la superficie de las células endoteliales vasculares, y se unen con el VEGF con 
alta afinidad. Más recientemente se ha descubierto un tercer receptor, VEGFR-3, que 
resulta activado por VEGF, pero su acción se limita al proceso de linfangiogénesis. 
El mecanismo por el cual VEGFR-1, VEGFR-2  y VEGFR-3 traducen la señal del 
VEGF ha sido estudiado extensamente a nivel molecular. La unión del VEGF a dos 
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receptores proximales VEGFR provoca su dimerización y en consecuencia, la 
activación y autofosforilación del dominio quinasa intracelular, que cataliza la 
fosforilación de proteínas sustrato citosólicas y eventos celulares posteriores que 
modulan los procesos de angiogénesis, linfangiogénesis, y vasculogénesis. 
 
6.3.2 Terapia anti-angiogénica en el manejo del cáncer: 
           Inhibidores de Tirosina Quinasa 
 
Angiogénesis es el proceso de formación de nuevos vasos sanguíneos a partir 
de redes vasculares preexistentes por germinación de los capilares. Durante este 
proceso, las células endoteliales maduras se dividen y se incorporan nuevos 
capilares. La terapia anti-angiogénica en el manejo del cáncer se basa en la 
suposición de que la prevención del crecimiento de nuevos vasos sanguíneos 
perjudicaría la supervivencia y la proliferación de las células tumorales. Sin 
embargo, el concepto inicial, de privar radicalmente al tumor de los nutrientes 
bloqueando el aporte sanguíneo, ha sido modificado, teniendo en cuenta que una 
inhibición agresiva de la angiogénesis podría empeorar el metabolismo del tumor y 
promover la diseminación metastásica. Parece claro que la eficacia de la inhibición 
de la angiogénesis dependa del contexto celular, de la dosis y del momento de 
administración del fármaco. 
A pesar de que son muchos los factores que controlan el proceso angiogénico, 
los ligandos y los receptores de VEGFs siguen constituyendo el principal objetivo de 
la terapia anti-angiogénica en la práctica clínica. De hecho las estrategias actuales 
para la inhibición de la señalización de VEGFs incluyen agentes que se unen al 
VEGF, y por lo tanto bloquean su interacción con los receptores (anticuerpos, 
péptidos, ribozimas y los receptores solubles), asì como compuestos capaces de 
bloquear los receptores en forma directa (anticuerpos o pequeñas moléculas 
inhibidoras de la tirosina quinasa). 
El enfoque más avanzado para la inhibición de la angiogénesis VEGF-
dependiente es el anticuerpo monoclonal humanizado dirigido contra el VEGF-A, 
bevacizumab (Genentech). Los resultados obtenidos en los ensayos clínicos en 
diferentes tumores malignos, en combinación con 5-fluorouracilo e irinotecán por el 
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tratamiento del cáncer colorrectal metastásico, o en asociación con paclitaxel en el 
cáncer de mama metastásico, llevaron a su aprobación por la FDA como tratamiento 
de primera línea en combinación con quimioterapicos para el cáncer colorrectal 
metastásico.  
Aunque el bevacizumab se haya demostrado eficaz, la focalización en una 
única vía tumorigénica parece llevar a fenómenos de resistencia. Por otro lado 
pequeñas moléculas inhibidoras tienen la ventaja de estar disponibles por vía oral, 
actuar sobre diferentes vías y presentar menores costos. Basándose en estas ventajas 
terapéuticas, muchos inhibidores de tirosina quinasa (TKIs) se han desarrollado y 
sometido a ensayos clínicos. La mayoría de los RTKIs incluyen compuestos que se 
unen al dominio quinasa y compiten por la unión del sustrato normal, ATP. 
Inhibidores de tirosina quinasa de VEGFRs son generalmente inhibidores de 
multiquinasas (MKIs). Fármacos que pertenecen a esta clase, aprobados o en fase de 
ensayo clínico, incluyen Sunitinib (Pfizer), Sorafenib (Bayer and Onyx 
Pharmaceuticals), Axitinib (Pfizer), Cediranib (AstraZeneca), Pazopanib (GSK), 
Vandetanib (AstraZeneca), Vatalanib (Bayer Shering and Novartis)  
 
6.3.3 Nuevas moleculas inhibidoras del VEGFR 
 
Por medio de estudios de cribado virtual basados en la interacción ligando-
receptor, varias moléculas han sido acopladas a la estructura cristalizada de la 
proteína VEGFR, llevando a la identificación de diferentes clases de derivados. Entre 
ellos, se describieron las propiedades de derivados pirimidínicos, caracterizados por 
un anillo de pirimidina sustituido de diversas formas, ya sea aislado o fusionado para 
formar diferentes estructuras heterocíclicas, como pirrolo-pirimidinas, pirazolo-
pirimidinas, tieno-y furo-pirimidinas, pirimido-pirimidinonas o pirido-pirimidonas. 
La aplicación de modificaciónes a las estructuras mencionadas, llevó a la 
síntesis de una serie de pirimidinas fusionadas con el núcleo benzotiopirano y 
piridotiopirano de fórmula general I. En realidad los nuevos productos podrían 
cumplir con los requisitos farmacofóricos adecuados para el anclaje al sitio de unión 
del ATP, en particular el grupo NH de los derivados 2-anilino sustituidos 26a-q y 
29a-f y los átomos N1 y N3 de la pirimidina. 
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Con el objetivo de realizar estudios de relación estructura-actividad (SAR), se 
sintetizaron los derivados 2-aril- (compuestos 25a-i y 28a-c) y 2-bencilamino-
sustituidos (compuestos 27a-i y 30a-f). Además se evaluó también la influencia de 
sustituyentes donadores o aceptores de electrones, en diferentes posiciones del 
cromóforo. Finalmente, con el objetivo de comprobar  la importancia del grupo NH-
de los derivados 2-anilino sustituidos, se realizó la síntesis del derivado homólogo N-
metil-anilino sustituido 31. 
La vía sintética empleada en la preparación de todos los compuestos 
benzopiránicos 25a-i, 26a-q y 27a-i ( 25a, 25d y 26a ya han sido descritos) requiere 
como primer paso, la preparación del 7-cloro-2,3-dihidro-1-benzotiopiran-4(4H)-one 
5b (Esquema 1 Capítulo 3) y el ya descrito 7-metoxi-2 ,3-dihidro-1-benzotiopiran-
4(4H)-one 5c (véase el Esquema 2, Capítulo 2), mientras que el tiocroman-4-one 5a 
es un producto comercial. Un exceso de ácido 3-bromopropiónico en una solución 
saturada de carbonato de sodio hidrógeno se añadió a una solución del tiofenol 3-
sustituido adecuado en una solución de hidróxido de potasio acuoso al 10%. La 
mezcla de reacción se agitó a 100° C durante 3 horas, y una vez enfriada se acidificó 
con ácido clorhídrico concentrado a pH 4. El precipitado sólido se recogió por 
filtración y se lavó con agua para dar los correspondientes ácidos benzotiopropiónico 
10b, c con un buen rendimiento; luego por tratamiento con ácido metanosulfónico o 
H2SO4 concentrado se formaron respectivamente los 2,3-dihidro-1-benzotiopiran-
4(4H)-one 5b,c, que fueron purificados por cristalizaión.  
El procedimiento que conduce a la síntesis de 25a-i y 27a-i se aprovecha de 
la reactividad 1,3-bielectrófila de los intermedios 3-dimetilaminometilénicos 33a-c 
en la reacción binucleófila con la adecuada amidina (36a-c) y bencil-guanidina (37b-
c), en presencia de etóxido de sodio en etanol (Esquema 2 Capítulo 3). La 
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preparación de los compuestos 33a-c se logró, con buenos rendimientos, utilizando 
como compuestos iniciales los benzotiopiranones 5a-c, por reacción con un exceso 
de dimetilformamida dimetilacetal (DMF-DMA) en tolueno a reflujo (Esquema 2 
Capítulo 3). Sin embargo, cualquier intento de sintetizar ls compuestos  2-anilino-
sustituido 26a-q haciendo reaccionar los derivados 3-dimetilaminometileno 33a-c 
con fenilguanidinas apropiadas, fracasó.  
La preparación de compuestos 26a-q se logró, por tanto, mediante una ruta 
sintética diferente: derivados 3-dimetilaminometilénicos 33a-c se dejaron reaccionar 
con clorhidrato de guanidina, produciendo los intermedios 2-aminopirimidinicos 
34a-c, que por reacción bajo nitrógeno con fenilyoduro p- o m-sustituido, en dioxano 
anhidro y en presencia de K2CO3, N ',N'-dimetiletilendiamina y CuI, proporcionó los 
compuestos deseados 26a-q (Esquema 4, Capítulo 3) purificados mediante 
cromatografía flash usando éter de petróleo 60-80 ° C/acetato de etilo 5:5  como 
sistema eluyente. 
El procedimiento experimental que condujo a la síntesis de los análogos 
piridotiopiranoindólicos 28a-c, 29a-f, 30a-f y 31, es similar al procedimiento 
descrito anteriormente para los análogos benzotiopiranoindólicos. En este caso, el 
producto clave es el derivado 2,3-dihidrotiopiran[2,3-b]piridin-4(4H)-one 11 que fue 
obtenido por el procedimiento ilustrado en el esquema 5, Capítulo 3. 
La evaluación biológica de los compuestos sintetizados fue realizada en la 
Facultad de Farmacia de la Universidad de Padua. La capacidad de los nuevos 
derivados de inhibir el dominio catalítico de la proteína quinasa VEGFR-2, el subtipo 
que ejerce un papel fundamental en el proceso de neo-angiogénesis, se determinó 
mediante un ensayo bioquímico con un receptor recombinante humano (Tablas 5-8 y 
Figuras 22a-c y 23 Capítulo 3). La actividad antiproliferativa se demostró en líneas 
célulares tumorales HeLa (adenocarcinoma de cuello uterino), A-431 (carcinoma 
epidermoide) y MSTO-211H (mesotelioma bifásico) y los resultados se expresaron 
como valores de IC50, es decir, la concentración (M) de un compuesto capaz de 
producir el 50% de muerte celular con respecto al control; SU5416 se utilizó como 
compuesto de referencia (Tabla 9 Capítulo 3, reportada abajo).  
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Comp. Y Z X R1 R2 KDR HeLa A-431 MSTO-211H 
25a CH - H H H n.d >20 >20 >20 
25b CH - H OCH3 H 31 >20 >20 >20 
25c CH - H Cl H n.d >20 >20 >20 
25d CH - OCH3 H H n.d >20 6.51.2 11.91.1 
25e CH - OCH3 OCH3 H 11 >20 >20 >20 
25f CH - OCH3 Cl H n.d >20 >20 >20 
25g CH - Cl H H n.d >20 >20 >20 
25h CH - Cl OCH3 H 41 >20 >20 >20 
25i CH - Cl Cl H n.d >20 >20 >20 
26a CH NH H H H 83 10.22.1 >20 11.71.3 
26b CH NH H OCH3 H 73 0.70.5 0.960.25 1.080.04 
26c CH NH H Cl H 71 15.62.2 >20 11.51.5 
26d CH NH OCH3 H H 58 20.1 >20 15.01.6 
26e CH NH OCH3 OCH3 H 60 0.830.14 0.960.2 1.080.2 
26f CH NH OCH3 Cl H 22 >20 >20 >20 
26g CH NH Cl H H 21 >20 >20 >20 
26h CH NH Cl OCH3 H 18 2.10.2 5.80.4 20 
26i CH NH Cl Cl H 80 1.50.4 2.20.4 1.60.3 
26l CH NH H H OCH3 92 n.d n.d n.d 
26m CH NH H H Cl 13 n.d n.d n.d 
26n CH NH H H Br 17 n.d n.d n.d 
26o CH NH OCH3 H OCH3 n.d n.d n.d n.d 
26p CH NH OCH3 H Cl n.d n.d n.d n.d 
26q CH NH OCH3 H Br n.d n.d n.d n.d 
27a CH NHCH2 H H H n.d >20 >20 >20 
27b CH NHCH2 H OCH3 H 17 >20 >20 >20 
27c CH NHCH2 H Cl H n.d >20 >20 >20 
27d CH NHCH2 OCH3 H H n.d >20 >20 >20 
27e CH NHCH2 OCH3 OCH3 H 13 >20 >20 >20 
27f CH NHCH2 OCH3 Cl H n.d >20 >20 >20 
27g CH NHCH2 Cl H H n.d >20 >20 >20 
27h CH NHCH2 Cl OCH3 H 35 >20 >20 >20 
27i CH NHCH2 Cl Cl H n.d >20 >20 >20 
28a N - H H H n.d n.d n.d n.d 
28b N - H OCH3 H 20 >20 >20 >20 
28c N - H Cl H n.d >20 >20 >20 
29a N NH H H H 92 n.d n.d n.d 
29b N NH H OCH3 H 98 0.0840.022 0.120.02 0.130.02 
29c N NH H Cl H 60 n.d n.d n.d 
29d N NH H H OCH3 88 n.d n.d n.d 
29e N NH H H Cl 21 n.d n.d n.d 
29f N NH H H Br 53 n.d n.d n.d 
30a N NHCH2 H H H 10 n.d n.d n.d 
30b N NHCH2 H OCH3 H 38 2.70.2 >20 8.60.2 
30c N NHCH2 H Cl H 11 5.40.7 8.30.8 7.80.3 
30d N NHCH2 H H OCH3 n.d n.d n.d n.d 
30e N NHCH2 H H Cl n.d n.d n.d n.d 
30f N NHCH2 H H Br n.d n.d n.d n.d 
SU5416      67 38.50.5 37.20.4 27.31.8 
Table 9. 
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En cuanto a los compuestos benzotiopiranicos, los resultados obtenidos en 
los ensayos enzimáticos indican un porcentaje de inhibición generalmente alto para 
la mayoria de los derivados 2-anilino sustituidos (serie 26) mientras que tanto la 
adición de un grupo metileno (serie 27) como la supresión del grupo espaciador 
amino (serie 25) reducen la inhibición de la tirosina quinasa, indicando claramente 
que la longitud de la cadena lateral ejerce un papel crucial.  
Además parece que jueguen un papel importante los sustituyentes tanto en 
el cromóforo como en el arilo. Entre los derivados 2-anilino-sustituidos 26, cuando el 
arilo no está sustituido (26 a,d,g), o lleva un grupo p-metoxi (26 b,e,h), los valores 
de inhibición se reducen progresivamente en presencia de sustituyentes metoxi o 
cloro en  posición 8 del cromóforo. A la inversa, cuando se introduce el grupo p-
cloro (26 c,f,i), el valor más alto resulta lo del compuesto 8-cloro sustituido 26i. En 
el grupo de derivados m-anilino-sustituidos, los resultados preliminares, en relación a 
los compuestos 26 l-n, indican el grupo metoxi (comp. 26l) como el más eficaz, 
mientras que un halógeno (ambos Cl y Br) parece ser perjudicial.  
Por lo que respecta a los derivados 2-fenil (25 a-i) o 2-bencilamino (27 a-i) 
sustituidos, los resultados ahora disponibles indican los análogos 8-cloro sustituidos 
25h y 27h como los más activos, y lo que sorprende, es que muestran valores de 
inhibición del enzima más altos que el derivado 2-anilino sustituido 26h. Por último, 
la drástica disminución de la inhibición de KDR (2%) observada con el compuesto 
N-metil anilino sustituido 31, confirma el papel clave desempeñado por el grupo NH-
en la posición 2. 
Los resultados de la evaluación de algunos de los derivados isosteros 
pyridothiopyranicos, muestran la eficacia de la introducción del heteroátomo 
piridinico, que efectivamente condujo a una mejora en la actividad enzimática. En 
realidad, los homólogos 2-anilino sustituidos (serie 29) confirmaron una notable 
actividad y entre ellos, el derivado p-metoxi-anilino sustituido (29b) produjo el 
máximo de inhibición (98%) del actividad de tirosina quinasa. 
Considerando la actividad antiproliferativa de la colección de compuestos 
benzothiopyranicos 25, 26 y 27, el papel crucial para la longitud de la cadena lateral 
se confirmó, ya que sólo los derivados 2-anilino sustituidos (serie 26) mostraron un 
efecto citotóxico significativo. Ademas, un efecto notable también podría ser 
atribuible al sustituyente p-metoxi en el anillo fenilo colgante, siendo 26b,e los 
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derivados más activos. Por otro lado la sustitución p-cloro parece perjudicial, con la 
excepción de 26i que curiosamente llevó a una actividad notable, mediante la 
introducción de un átomo de cloro en la posición 8. 
Nuestros resultados preliminares parecen indicar una relación entre la 
inhibición de la actividad enzimática de VEGFR-2 y el efecto citotóxico observado, 
siendo que los valores más bajos de IC50 están generalmente relacionados con el 
porcentaje mayor de inhibición (26b, 26e, 29b). Sin embargo, las excepciones a esta 
tendencia general (por ejemplo, la falta de actividad antiproliferativa observada por 
el compuesto 25h (KDR inh. 41%), o por otra parte, la notable actividad ejercida por 
el compuesto 30c (KDR inh. 11%), sugieren la participación de vías de señalización 
adicionales, que aún se desconocen. En este contexto, se ha planeado la evaluación 
de la inhibición enzimática de otras tirosina quinasas. 
Dentro de un proyecto de colaboración con la Universidad de Valencia, 
donde he realizado esayos biológicos de angiogénesis, se decidió verificar también si 
los derivados 2-anilino sustituidos (26b, 26e y 29b), que ya habían demostrado su 
capacidad para bloquear la actividad tirosina quinasa del VEGFR-2, eran realmente 
capaces de inhibir la angiogénesis in vitro. Con este propósito, se evaluó la actividad 
de los compuestos seleccionados en el ensayo ex-vivo con anillos aórticos de rata 
(“rat aortic ring assay”). Explantes aórticos se incubaron durante 7 días, con los 
compuestos 26b, 26e y 29b en concentraciones diferentes (10μM; 5μM; 1µm; 100 
nM), utilizando DMSO como control, y Semaxanib (SU5416) como compuesto de 
referencia. Las muestras fueron controladas diariamente y a día 7 se realizó una 
tinción de fluorescencia. 
Los ensayos in vitro confirmaron la capacidad de los compuestos 
seleccionados para inhibir el proceso angiogénico, y el uso de diferentes 
concentraciones permitió identificar el rango en el que la inhibición se realizaba. En 
particular, los derivados benzotiopiránicos 26b y 26e, inhibían el proceso en 
concentraciones desde 1 a 5μM, mostrando un perfil similar al de SU5416. El  
derivado piridotiopiránico 29b, capaz de inhibir totalmente el VEGFR-2 en el ensayo 
enzimático, producía ahora una completa inhibición de la angiogénesis a una 
concentración inferior a 1µm (Figura 24 Capítulo 3). 
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Figure 24. Anti-angiogenic activity of compounds 26b, 26e, 29b at [10µM]; [5µM]; [1µM]; [100nM] 
compared with DMSO and SU5416 at the same concentration. Images are visualized using a Nikon 
fluorescence microscope Eclipse E800 equipped with Nikon camera, with the 4x objective, after 
fluorescence cell staining at day 7
th
 of the experiment. All experiment were conducted in duplicate 
and at least on two different animals. 
 
6.4 Parte Experimental 
 
6.4.1 Métodos generales (síntesis orgánica)  
Todos los disolventes y reactivos para la síntesis orgánica se obtuvieron de 
proveedores comerciales y se usaron sin purificación adicional. Reacciones que 
necesitaban condiciones anhidras se llevaron a cabo bajo atmósfera de N2 seco 
utilizando disolventes anhidros, recién destilados.  
Las reacciones fueron monitorizadas por cromatografía en capa fina (TLC) 
usando hojas de aluminio precubiertas de gel de sílice (60 F-254) de 0,2 mm 
(Merck). Gel de sílice 60 (malla 230-400) fue utilizado para cromatografía en 
columna. Las evaporaciones se hicieron a vacío (rotavapor). El sulfato de magnesio 
fue utilizado siempre como agente de secado. Los rendimientos se refieren a 
materiales homogéneos cromatográficamente y espectroscópicamente (1H-RMN).  
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Los espectros de resonancia magnética nuclear (1H-RMN) se registraron en 
solución DMSO-d6 en un espectrómetro Varian Gemini de 200 MHz, usando 
(CH3)4Si(TMS) como el estándar interno. Los puntos de fusión se determinaron 
utilizando un aparato Reichert Kofler y figuran sin corregir. Los análisis elementales 
fueron realizados por nuestro laboratorio de análisis y de acuerdo con los valores 
teóricos de ± 0,4%. (véase el Capítulo 4 para los valores) 
* Por el ensayo de angiogénesis Ver 6.5.3 o Capítulo 5.5 
  
 
6.5 Estudio del mecanismo de acción de los fármacos beta-
bloqueantes vasodilatadores: papel de los adrenoceptores α/β 
en el proceso de Angiogénesis 
 
6.5.1 Introducción 
 
- Adrenoceptores (ARs): 
Los adrenoceptores (ARs) pertenecen a la familia de receptores de 7 dominios 
transmembrana acoplados a proteínas G (GPCRs) y son los mediadores de las 
acciones, tanto centrales como periféricas, de las principales catecolaminas 
endógenas: el neurotransmisor Noradrenalina (NA), y la hormona y neurotransmisor 
Adrenalina (A). Ambas catecolaminas juegan un papel importante en el control de 
procesos fisiológicos tales como la presión arterial, la frecuencia cardiaca, la fuerza 
de contracción cardiaca o la reactividad de las vías aéreas, además de otros procesos 
metabólicos y del sistema nervioso central. Su importancia y relevancia en la práctica 
clínica actual se reflejan en la gran cantidad de fármacos que tienen como diana estos 
receptores. Los receptores adrenérgicos están subdivididos en tres subfamilias: α1, α2 
y β según su estructura, farmacología y mecanismos de señalización. Al menos tres 
subtipos han sido identificados dentro de cada subfamilia. Así los AR-α1 se 
subdividen en AR-α1A, α1B y α1D, los AR-α2 se subdividen en AR-α2A, α2B y α2C, 
mientras que entre los AR-β se encuentran los subtipos AR-β1, β2 y β3. Los tres 
subtipos de AR-α1 comparten la vía de señalización intracelular. La proteína G que 
resulta activada, en el caso de estos receptores, se conoce como proteína Gq/11. El 
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intercambio de GDP (difosfato de guanosina) por GTP (trifosfato de guanosina) 
provoca la disociación de la subunidad α que activa la fosfolipasa C (PLC). La PLC 
hidroliza el fosfolípido de membrana fosfatidilinositol 4,5-bifosfato (PIP2) llevando 
a un aumento en inositol trifosfato (IP3) y diacilglicerol (DAG). El DAG promueve 
además la activación de la proteína cinasa C (PKC), mientras que el IP3 determina 
un aumento de los niveles de Ca
2+
 intracelulares, responsable de muchas actividades 
esenciales. Por otro lado, en caso de ser activados los AR-β, se promoverá su 
acoplamiento con la proteína Gs, que conduce a la activación de la adenilil ciclasa 
(AC) y acumulación del AMPc, seguido por la activación de la proteína quinasa A 
(PKA), que es capaz de fosforilar proteínas diferentes. Además, dependiendo del 
subtipo y/o ubicación, los adrenoceptores β pueden acoplarse a otra proteína G (Gi), 
que determina la inhibición de la adenilil ciclasa, produciendo el efecto contrario a la 
proteína Gs. El efecto resultante variará dependiendo del tipo de célula y la función 
de la proteína fosforilada. La actividad de receptores acoplados a proteínas G está 
regulada por quinasas de receptores acoplados a proteínas G (GRKs) que fosforilan 
receptores activados y estimulan la interacción del receptor con ß-arrestinas, 
produciendo así desacoplamiento de la proteína G e internalización del receptor. Por 
otra parte los GPCRs, bien a través de su interacción con proteínas G o bien 
directamente, cuando son internalizados gracias a la interacción con ß-arrestinas, 
pueden promover la señalización celular a través de proteínquinasas activadas por 
mitógenos (MAPK). MAPKs representan una vasta red que regula una variedad de 
procesos fisiológicos tales como el crecimiento celular, la diferenciación o la muerte 
celular programada (apoptosis). De forma general, las cascadas de MAPK están 
organizadas como módulos en los que la activación de un receptor de la superficie 
celular promueve una activación secuencial de un módulo MAPK. Es decir: una 
quinasaquinasaquinasa fosforila una quinasaquinasa que a su vez fosforila una 
quinasa (MAPKKK→MAPKK→MAPK). Después de que una MAPK (ERK, JNK, 
p38) sea activada ya en el citoplasma o en el núcleo, modulará la función de un 
factor de transcripción al que fosforilará. Por otro lado, se ha visto que las cascadas 
de señalización MAPK pueden ser también iniciadas a través de una proteína 
andamio (scaffolding protein). En particular se demostró que la β-arrestina no sólo 
promueve la internalización de GPCR, sino que también puede actuar como 
andamiaje multiproteico y regular una multitud de moléculas de señalización, 
incluyendo la quinasa regulada por señales extracelulares (ERK). 
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- Papel de los ARs en el proceso de Angiogénesis 
La angiogénesis es un proceso que comienza con la proliferación y migración 
de células endoteliales, que llevan a la formación de nuevos capilares a partir de 
vasos sanguíneos preexistentes. Este fenómeno es esencial para el crecimiento de 
diversos órganos durante el desarrollo embrionario, en el ciclo reproductivo 
femenino y para la cicatrización de heridas. Por el contrario un desequilibrio en el 
crecimiento de nuevos vasos puede contribuir a la patogénesis de muchas 
enfermedades. En realidad, una excesiva estimulación angiogénica se ha señalado en 
el desarrollo de enfermedades inflamatorias o tumores. Sin embargo, para otros 
desórdenes, tales como la isquemia, puede resultar útil promover el crecimiento de 
nuevos vasos (angiogénesis terapéutica). Puesto que la angiogénesis es un aspecto 
clave de la función endotelial, ya que se ha visto que importantes modelos de 
disfunción endotelial muestran angiogénesis dañadas, la presencia de adrenoceptores 
α1 y β en el endotelio vascular sugiere que estos receptores podrían participar en 
dicho fenómeno regenerativo mediante la regulación de las respuestas de las células 
endoteliales implicadas. De hecho, evidencias previas sugieren una actividad pro-
angiogénica de los adrenoceptores α1, aunque se desconocen el subtipo y el 
mecanismo responsable de la misma. El papel de los ARs β en la angiogénesis 
apenas se conoce y los resultados obtenidos recientemente son contradictorios. 
 
- Beta-bloqueantes vasodilatadores: Carvedilol 
Tradicionalmente, los antagonistas de adrenoceptores α1 o β se han utilizado 
con éxito en la hipertensión. Sin embargo, aunque su eficacia a corto plazo es 
innegable, estudios clínicos recientes han cuestionado su utilidad a largo plazo. A 
pesar de ello, los nuevos betabloqueantes como Carvedilol o Nebivolol, llamados 
vasodilatadores (BBV), porque combinan su actividad sobre los adrenoceptores 
(ARs) β con otros mecanismos como bloqueo α1 o liberación de oxido nítrico, son en 
este momento el tratamiento de elección en insuficiencia cardiaca porque han 
demostrado un beneficio superior al de los bloqueantes selectivos β1. Parece que este 
perfil farmacodinámico mixto resulta favorable en terapéutica pero no se conoce con 
precisión. El carvedilol es un β-bloqueante/α1-bloqueante, vasodilatador, no-
cardioselectivo de tercera generación. Numerosas evidencias sugieren que el 
carvedilol puede poseer ventajas únicas frente a otros β-antagonistas. Los 
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mecanismos de dichas ventajas son actualmente desconocidos pero han sido 
atribuidos a la capacidad del carvedilol de actuar como antioxidante, anti-
inflamatorio, antiproliferativo, y antiarrítmico. Además, en un estudio reciente entre 
16 antagonistas de adrenoceptores β, se observaron espectros de eficacia diferentes 
tanto en la señalización celular dependiente de proteínas G como en la dependiente 
de β-arrestina, indicando para el Carvedilol un perfil de señalización único, de 
eficacia negativa para la activación de la AC GS-dependiente, y de eficacia positiva 
para la activación de ERK 1/2  β-arrestina-dependiente. 
 
6.5.2 Objetivos 
El grupo de investigación de la Facultad de Farmacia, Universidad de 
Valencia, con el cual he colaborado, ha iniciado recientemente un amplio estudio 
sobre la actividad de los β-bloqueantes vasodilatadores. En este contexto, con el 
presente trabajo nos proponemos analizar el perfil farmacológico del Carvedilol, 
antagonista de ARs 1 y con diferentes enfoques: 
 Evaluación de la relación entre adrenoceptores y crecimiento angiogénico. 
 Análisis de los cambios en la expresión génica de ARs y GRKs inducidos por 
Carvedilol y/o por agonistas de ARs α1 y β. 
 Análisis de señales intracelulares acopladas a ARs α1/β: activación de ERK 1/2 
 
6.5.3 Material y métodos 
 
- Obtención de muestras: 
Para llevar a cabo el presente trabajo se emplearon ratas Wistar macho de 
250-300g procedentes del animalario de la Facultad de Farmacia de Valencia. El 
cuidado de los animales se realizó siguendo el Real Decreto 223/1998, del 14 de 
Marzo, sobre “Protección de los animales utilizados para experimentación y otros 
propósitos científicos”, el cual incorpora las normas de la Unión Europea (D.O. nº 
2358/1 del 18/12/1986). Los protocolos utilizados han sido aprobados por el Comité 
Ético de Experimentación Animal de la Universidad de Valencia. Dichas ratas fueron 
sacrificadas por decapitación tras anestesiarlas por inhalación con isofluorano 
(Esteve, Barcelona). La extracción de la aorta torácica por toracotomía, así como el 
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resto de procedimientos necesarios para los ensayos de angiogénesis, se llevaron a 
cabo en campana de flujo laminar en condiciones de máxima esterilidad. Dicha 
arteria fue diseccionada desde el cayado aórtico hasta el diafragma y limpiada de 
tejido adiposo perivascular conservándola en una placa Petri con solución nutricia de 
Krebs (NaCl, 118 mM; KCl, 4.7 mM; CaCl2 1.8 mM; KH2PO4 1.2 mM; NaHCO3 
25.0 mM; Glucosa 11.0 mM). Tras lo cual la arteria fue cortada en anillos de 1 mm 
de grosor empleando un escalpelo teniendo la precaución de no producir daños. Estos 
anillos se transfirieron a una placa Petri pequeña que contenía medio de cultivo EBM 
MV2 (Endotelial cell basal medium MV2, Promocell, Heidelberg, Alemania) al que 
adicionamos antibióticos (gentamicina, anfotericina) para evitar posibles 
contaminaciones y albúmina 0.1%. 
 
- Ensayo de angiogénesis: 
 El ensayo de angiogénesis se realizó en una placa de 96 pocillos de fondo 
plano, la cual junto con las puntas de pipeta necesarias, se mantuvo en hielo hasta su 
uso. Así mismo, también se depositó el Matrigel
®
 (Matrigel 
TM
 Basement Membrane 
Matrix, BD Bioscience, San Jose CA, USA) en hielo en cámara fría (4ºC) durante un 
mínimo de 4 horas para su descongelación. Manteniendo la placa en hielo se 
pipetean 50μl de Matrigel® en los distintos pocillos y se sembraron en ellos los 
anillos aórticos. Transcurridos 15 minutos a temperatura ambiente, para que 
solidificara el Matrigel
®
, se adicionan 200 μl de medio de cultivo (EBM MV2, 
Promocell, Heidelberg, Germany) previamente calentado en baño a 37ºC. Cuando 
fue necesario, el medio se enriqueció con factores de crecimiento: hbFGF, hVEGF, 
R3IGF-1, ácido ascórbico, hidrocortisona, FCS-25. Además se adicionaron en los 
pocillos correspondientes, 20 μl del tratamiento cuyo efecto en el proceso 
angiogénico se deseaba estudiar: Fenilefrina (10
-6 M) agonista adrenérgico α1; 
Carvedilol (10
-6 M) antagonista adrenérgico selectivo α1 y antagonista adrenérgico 
no selectivo β; Dobutamina (10-5 M) agonista adrenérgico β1; Salbutamol (10
-5 
M) 
agonista adrenérgico β2. Los compuestos se obtuvieron de Sigma-Aldrich Co (Saint 
Louis MO, USA). Por último, la placa se incubó en estufa a 37º C y 5% CO2 durante 
7 días, renovando tanto el medio como el fármaco al día siguiente de la siembra y 
posteriormente cada dos días. 
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- Obtención y análisis de imágenes: 
Para llevar a cabo el seguimiento diario del crecimiento se tomaron imágenes 
empleando un microscopio invertido Nikon Eclipse TE2000-S con cámara 
fotográfica Nikon (objetivo 2x) o Leica DM IL LED con cámara fotográfica Leica 
(objectivo 2.5x). Además, al séptimo día también se llevó a cabo una tinción celular 
de fluorescencia a tiempo final. Para lo cual se añadió al medio 1 μl de calceína 
(InvitrogenTM Molecular Probes Inc. Paisley, UK). Tras incubar durante 15 minutos 
en estufa se visualizó la placa mediante un microscopio de fluorescencia Nikon 
Eclipse e800 equipado con cámara fotográfica Nikon, empleando el objetivo 4x. Las 
imágenes observadas al microscopio fueron capturadas empleando el programa 
informático Nikon ACT-1 y analizadas mediante el SigmaScan Pro (Systat Software, 
Inc. Chicago IL). Para determinar la cinética de crecimiento se midió la distancia en 
μm de los ejes x e y tomando como punto origen en cada caso la superficie externa 
del anillo. 
 
- Extracción y análisis cuantitativo y cualitativo de RNA: 
Una vez finalizado el ensayo de angiogénesis, los anillos de aorta fueron 
congelados en nitrógeno líquido y mantenidos a  -80º C hasta la extracción del RNA 
de las células endoteliales. Para ello las muestras congeladas fueron trituradas en 
mortero y posteriormente solubilizadas empleando el reactivo Tripure Isolation 
Reagent (Roche Group; U.S.). La extracción del RNA total solubilizado previamente 
con cloroformo, se llevó a cabo por precipitación con isopropanol (según protocolo 
del fabricante), y se resuspendió finalmente con agua tratada con DEPC 
(dietilpirocarbonato). Para su cuantificación y análisis se empleó el procedimiento 
RNA ExperionTM (Biorad). 
 
- Retrotranscripción: 
Posteriormente se llevó a cabo la reacción de retrotranscripción para la 
síntesis del ADNc a partir del ARN total aislado, adicionando a dicho ARN (1μg), el 
cebador oligodT (250 μg) y el tampón de reacción Improm-II que contiene MgCl2 
3mM, 0,5 mM de cada desoxinucleósido trifosfato, 20U del inhibidor de 
ribonucleasas RNAsin® (Promega Corp., Madison USA) y 1μl de Transcriptasa 
reversa ImProm-II TM (Promega Corp. Madison, USA) hasta un volumen final de 20 
                                                                                       6. Resúmen (Español)                                             
 
 
316 
 
μl. Tras la hibridación a 25ºC durante 5 min, la reacción de extensión transcurrió a 
42º C durante 60 min. Finalmente, la enzima se inactivó incubando a 70º C durante 
15 min. 
 
- Determinación cuantitativa a tiempo real de la reacción en cadena de la 
polimerasa (RT-PCR): 
El ADNc sintetizado se almacenó a -20º C hasta la realización de la PCR 
cuantitativa, para la cual se usó el sistema GeneAmp 7500 Fast system (Applied 
Biosystems, US). La amplificación de GAPDH sirvió de control interno. Diluciones 
1/10 de la reacción de la transcripción reversa previa, se analizaron por duplicado 
mediante ensayos Taqman de expresión génica (Taqman Gene Expression Assays, 
Applied Biosystems), consistentes en una mezcla 20X de cebadores y sonda 
Taqman® MGB, diseñados para la detección y cuantificación de secuencias génicas 
específicas por RT-PCR a tiempo real de dos pasos. Las reacciones se ajustaron a un 
volumen de 25μl con Taqman® Universal master mix (AmpliTaq Gold® ADN 
Polymerase; Applied Biosystems, US), incluyendo 5 μl de la dilución de la reacción 
de transcripción reversa y 1,2 μl de la mezcla 20X Taqman® Gene Expresión Assays 
(sonda 250nM y cebadores 900nM). El ADNc fue amplificado según las condiciones 
del fabricante: un primer paso de activación de la polimerasa a 95º C durante 10 
minutos y 40 ciclos compuestos de dos pasos, desnaturalización a 95º C durante 15 
segundos e hibridación/extensión a 60º C durante 1 minuto. Los valores del ciclo 
umbral (Ct) obtenidos para cada gen en cada reacción fueron calculados mediante el 
programa Gene Amp 7500 Sequence Detection Fast System (Applied Biosystems, 
US). Los valores Ct se normalizaron usando como gen de referencia el GAPDH, 
siendo ΔCt la diferencia entre Ct del gen estudiado y el de referencia (GAPDH). El 
valor ΔCt se transformó matemáticamente mediante la expresión 2-ΔCt, directamente 
proporcional al número inicial de copias de cada gen. 
 
- Cultivo celular: Línea celular HEK 293 
El plásmido pcADN3 con el ADNc de los tres subtipos de AR-α1 insertado, 
fue amablemente proporcionado por el Dr. Milligan (University of Glasgow). Para la 
generación de líneas celulares de expresión estable de los diferentes subtipos de 
ARs-α1, se transfectaron 5μg del plásmido con el ADNc correspondiente a cada AR-
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α1, en las células HEK 293 (1x106) mediante electroporación (300V, 50μs, 2mm 
gap) con Multiporator (Eppendorf AG. Hamburg, Germany). La línea celular HEK 
293 (Human Embryonic Kidney 293; ATCC CRL-1573) fue cultivada en medio 
DMEM (Dulbecco‟s modified Eagle‟s minimun essential medium, Sigma St Louis 
MO, USA) suplementado con suero NBCS (newborn calf serum, Sigma St Louis 
MO, USA) al 10%, 100 U/ml de penicilina, 100 μg/ml de estreptomicina, e incubada 
en atmósfera húmeda al 5% de CO2 y 37ºC. Las células crecen adheridas formando 
una monocapa. Los pases se realizaron en frascos de 25cm2 cada 2-3 días llegando a 
una confluencia de entre 70 y 80%. 
 
- Western Blot: 
Las células HEK 293 tanto transfectadas de forma estable con cada subtipo de 
AR-α1, así como las no transfectadas, fueron sembradas en placas Petri de 60mm de 
diámetro alcanzando una confluencia del 75%. Una vez obtenida dicha confluencia, 
las células se mantuvieron en medio sin suero durante 4h. Tras la privación de suero 
se realizó la incubación a diferentes tiempos con Isoprenalina 1µM o Carvedilol 
1µM. Cuando se indica, las células fueron tratadas durante 15 minutos antes de la 
estimulación con un antagonista β, Propranolol (1µM), y DMSO 0,005% se utilizó 
como control cuando fue necesario. Tras el estímulo, las células fueron lavadas con 
PBS frío e incubadas 30 minutos a 4ºC y en rotación suave con 500μl de la solución 
de lisis RIPA [50mM HEPES pH=7.5 (Panreac Barcelona, España), 150mM NaCl 
(J.T.Baker, Deventer, Holland) 10% glicerol (MERCK Darmstadt, Germany) 1.5mM 
MgCl2 (Panreac Barcelona, España), 0.1% SDS (Sodium Dodecyl Sulfate Sigma St 
Louis MO, USA), 1mM EGTA (Ethylene glicol-bis(2-aminoethylether)-N,N,N‟,N‟-
tetraacetic acid; Sigma St Louis MO, USA), 100mM NaF (Sigma St Louis MO, 
USA), 1% Tritón (Sigma St Louis MO, USA), 1% deoxicolato sódico (Sigma St 
Louis MO, USA)] a la que se añadieron inhibidores de proteasas (Protease inhibitor 
cocktail tablets, Roche Indianapolis IN, USA) con una dilución 1/10 y de fosfatasas 
(Phosphatase inhibitor cocktail tablets, Roche Indianapolis IN, USA) dilución 1/25. 
Transcurridos los 30 minutos los lisados se sonicaron (MicrosoTM ultrasonic cell 
disruptor, USA) se centrifugaron 20 minutos a 4ºC y 16100g. El sobrenadante fue 
congelado a -80ºC. Una alícuota de 10μl se reservó para la determinación de 
proteínas mediante el método de Bradford. A 15μg de proteína se le añadió tampón 
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de carga (concentraciones finales: tris-HCl pH 6.8 60mM; glicerol 10%; SDS 2%; β-
mercaptoetanol 5%; azul de bromofenol 0.01%) y se calentaron a 40ºC durante 30 
minutos. Posteriormente se realizó una electroforesis en gel (10% poliacrilamida – 
sodio dodecil sulfato) a 150V durante 60 minutos y se transfirieron (375mA, 2 horas) 
a una membrana de polivinildiedina fluoride (PVDF, Bio-Rad Hercules CA, USA) 
previamente activada con metanol, utilizando el Mini-Trans-Blot® Electrophoretic 
Transfer Cell System (Bio-Rad Hercules CA, USA) Después la membrana fue 
bloqueada durante 1 hora con BSA 3% (Albúmina de Suero Bovino) disuelto en 
PBS-tween 1%, tras lo cual se inició la incubación con el anticuerpo anti ERK 
fosforilado (phospho-p44/42 MAP Kinase; Cell Signaling Technology. Beverly MA, 
USA) de conejo, con una dilución de 1/500 que duró toda la noche y se realizó en 
rotación a 4ºC en presencia de BSA 3%. En el siguiente paso, se lavó 15 minutos 3 
veces el anticuerpo primario con PBS-tween 1%, y luego se incubó con el anticuerpo 
secundario anti-rabbit (Amersham International, Buckinghamshire, UK) 1/2500 en 
BSA 3%, durante 45 minutos en oscuridad. Se repitieron los lavados y finalmente se 
reveló utilizando el reactivo ECL® (Amersham International, Buckinghamshire, 
UK). Las imágenes fueron capturadas utilizando AutoChemi System (uvp Bioimagin 
Systems. Cambridge, UK). La intensidad de las bandas específicas fue cuantificada 
mediante el programa LabWorks Image Acquisition and Analysis (Ver. 4.6 uvp 
Bioimagin Systems. Cambridge, UK). Posteriormente la membrana se reincubó con 
el anticuerpo anti-ERK total (Cell Signaling Technology. Beverly MA, USA) de 
conejo, con una dilución 1/500, o con el anticuerpo anti actina (Sigma St Louis MO, 
USA) y se prosiguió según el mismo procedimiento anteriormente descrito. 
 
- Análisis estadístico: 
El análisis estadístico de los resultados obtenidos se realizó empleando el 
software GraphPad Prism 4 (GraphPad Software, Inc. San Diego CA, USA). Los 
resultados se expresaron como media aritmética de los valores ± error estándar de la 
media (eem) y se sometieron al tratamiento estadístico empleando un análisis de 
varianza (Anova) y el método t de Student para muestras independientes cuando se 
comparan dos muestras. Se considera que la diferencia entre los grupos tratados y el 
control es significativa (*) cuando el valor de p obtenido es mayor que el tabulado 
para un margen de confianza del 95% (p<0.05), y muy significativa cuando es mayor 
del 99% (p<0.01, **) o del 99.9% (p<0.001, ***). 
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6.5.4 Resultados y discusión 
 
- Ensayos de Angiogénesis: 
Para analizar el papel de Carvedilol en el proceso angiogénico se llevaron a 
cabo dos experimentos paralelos, empleando diferentes condiciones de cultivo. En el 
primer caso los explantes aórticos fueron cultivados con un medio endotelial basal 
enriquecido con factores de crecimiento adicionales (hbFGF, hVEGF, R3IGF-1, 
ácido ascórbico e hidrocortisona) mientras que en el segundo caso utilizamos medio 
basal endotelial sin forzar el crecimiento angiogénico (Figura 17, Capítulo 5.6). 
El uso del agonista α1-selectivo fenilefrina, aumentó significativamente el 
crecimiento angiogénico longitudinal en comparación con los controles, tanto en 
presencia como en ausencia de factores adicionales de crecimiento (Figuras 20,21 
Capítulo 5.6). Estos resultados coinciden con estudios previos que indican la 
estimulación α1 mediada por la fenilefrina, como responsable de los efectos tróficos 
sobre el endotelio vascular, así como para el desarrollo de estructuras tubulares a 
partir de fragmentos de vasos maduros humanos. También está de acuerdo con la 
observación de que el uso de antagonistas 1 (doxazosina, terazosina y prazosina) 
suprima la angiogénesis in vitro (modelo HUVEC) y en modelos in vivo. Por otro 
lado, cuando los explantes de aorta de rata se incubaron con fenilefrina en presencia 
de DMSO, este efecto pro-angiogénico fue confirmado en el experimento [1] pero no 
aparecía en el experimento [2] (Figuras 22,23 Capítulo 5.6). La presencia de DMSO, 
que en otros ensayos demostró  promover el proceso, probablemente no permite ver 
el efecto pro-angiogénico ejercido por fenilefrina, y que se observa claramente en 
ausencia de DMSO. 
El agonista β1-selectivo dobutamina inhibió significativamente el crecimiento 
angiogénico (Figuras 24,25, Capítulo 5.6). Este resultado podría estar relacionado 
con la actividad pro-apoptótica observada como consecuencia de una estimulación 
sostenida del AR β1. Nuestros resultados también concuerdan con la observación de 
que el bloqueo crónico del AR β1 promueve el crecimiento arteriolar y preserva la 
perfusión coronaria en el corazón postinfartado. Por otro lado, aunque se haya 
demostrado que la sobreexpresión de ARs 2 en el endotelio de la arteria femoral de 
rata favorece la neoangiogénesis tras un proceso de isquemia, y que este mismo 
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proceso está alterado en los ratones deficientes en el gen del AR 2, nuestros 
experimentos no clarifican este punto pues cuando utilizamos el agonista selectivo 2 
salbutamol, encontramos resultados contradictorios (Figura 26, Capítulo 5.6). A 
pesar de los numerosos experimentos, no conseguimos atribuir al carvedilol un perfil 
claro en el proceso angiogénico. Aunque algunos ensayos parecían indicar una 
actividad pro-angiogénica, al final este incremento no resultó estadísticamente 
significativo (Figuras 27,28, Capítulo 5.6). Como en el caso de la fenilefrina en 
DMSO, el uso de esto disolvente capaz de producir un efecto pro-angiogenico “per 
se”, podría estar ocultando la actividad del carvedilol. Sin embargo, otros 
experimentos serán necesarios para aclarar esta cuestión. 
Cuando se incubaron explantes de aorta de rata con fenilefrina en presencia 
de carvedilol, se encontró que el carvedilol, antagonista no selectivo β  y α1, no solo 
no inhibía, sino incluso aumentaba el efecto pro-angiogénico ejercido por el agonista 
α1 fenilefrina (Figura 29, Capítulo 5.6), lo que sugiere una posible relación entre los 
ARs α1 y β. Esta observación podria explicarse considerando acciones paradójicas 
que se han descrito para el carvedilol, como su capacidad para mejorar las vías de 
señalización mediadas por ARs β1 o su capacidad para estabilizar una conformación 
del AR β2 que, aunque incapaz de acoplarse a la proteína Gs y por tanto iniciar esta 
vía de señalización, si es capaz de estimular la vía de señalización mediada por β-
arrestina que directamente estimula MAPKs, entre ellas ERK 1/2. A través de estas 
vías podría ejercer una acción sobre el proceso angiogénico que no se observa en 
ausencia de los agonistas de estos receptores. Sin embargo, cultivando explantes de 
aorta con dobutamina en presencia de carvedilol, se encontró que el carvedilol no era 
capaz de revertir la actividad anti-angiogénica ejercida por la dobutamina, agonista 
β1 (Figura 30, Capítulo 5.6). 
 
- Análisis de expresión génica: 
Con respecto al análisis de los cambios de expresión génica, nuestros 
resultados preliminares indican una disminución general de la expresión génica del 
subtipo α1D (Figura 31, Capítulo 5.7) y un ligero aumento en la expresión génica del 
receptor β2 inducido por carvedilol solo o en combinación con fenilefrina (Figura 33, 
Capítulo 5.7), pero los cambios no resultaron estadísticamente significativos. Un 
cambio significativo curioso fue detectado en el estudio de expresión genica de β1: el 
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uso de carvedilol en combinación con fenilefrina parecía producir una disminución 
en la expresión génica de β1, que no se observaba con fenilefrina o carvedilol solo 
(Figura 32, Capítulo 5.7). Teniendo en cuenta que se trata de resultados preliminares, 
una explicación concreta parece complicada, pero si consideramos también el 
comportamiento único mostrado por el mix carvedilol-fenilefrina en el ensayo de 
angiogénesis, podríamos hipotetizar una relación entre la respuesta pro-angiogénica 
observada y la disminución en la expresión génica de β1. 
 
- Western Blot: activación de ERK 1/2  
En un primer experimento (Figura 35, Capítulo 5.8), una cinética de 
activación de ERK mostró la capacidad de carvedilol para producir fosforilación de 
la ERK a diferentes tiempos, en células HEK293 no transfectadas o transfectadas con 
los distintos subtipos α1, indicando un perfil particular cuando el subtipo α1D era 
sobre-expresado. Sin embargo, cuando se aplicó el agonista β, isoprenalina, la 
presencia y capacidad de respuesta de los ARs β no resultaba influenciada por la 
sobreexpresión de subtipos α1, ya que no se encontraron diferencias con las células 
no transfectadas en la activación de ERK, cuya señal era completamente abolida por 
pre-tratamiento con el β-bloqueante propranolol (Figura 36, Capítulo 5.8). 
Desafortunadamente, pudiendo elaborar tan solo resultados preliminares, no 
conseguimos aclarar si la activación de ERK producida por el carvedilol está 
modulada por la presencia de ARs α1D. Sin embargo, las diferencias observadas en la 
señalización de ERK en células transfectadas α1D (Figura 37, Capítulo 5.8) sugieren 
una posible relación entre los receptores β y el subtipo α1D, a nivel de la vía MAPK, 
que futuros trabajos podrían aclarar. 
 
 
